| Cell No. |
Cell Name |
|
| RCB0002 |
| ARM193 |
| Comment | Anti-recA protein mAb. |
|---|
| Comment from the depositor | |
|---|
| RCB0005 |
| BALB/3T3 clone A31 |
| Comment | A subline of BALB/3T3 cell line. Contact inhibition is well observed. |
|---|
| Comment from the depositor | |
|---|
| RCB0007 |
| HeLa |
| Comment | Human cell line derived from cervical cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB0008 |
| V79 |
| Comment | Chinese hamster lung fibroblast |
|---|
| Comment from the depositor | |
|---|
| RCB0009 |
| PC-12 |
| Comment | Pheochromocytoma, differentiate by NGF stimulation. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0012 |
| M227 |
| Comment | Infected with ts mutant of Kirsten sarcoma virus |
|---|
| Comment from the depositor | |
|---|
| RCB0016 |
| CCRF-HSB-2 |
| Comment | T cell leukemia |
|---|
| Comment from the depositor | |
|---|
| RCB0026 |
| PAb1400 |
| Comment | Anti-SV40 large T antigen mAb. |
|---|
| Comment from the depositor | |
|---|
| RCB0027 |
| K562 |
| Comment | Human cell line derived from chronic myelogenous leukemia. Can be a target of NK cells (reference). Can produce hemoglobin in the presence of NaB. |
|---|
| Comment from the depositor | |
|---|
| RCB0032 |
| FM3A FT-101 |
| Comment | Temperature-sensitive, forms multiple nuclei |
|---|
| Comment from the depositor | |
|---|
| RCB0033 |
| FM3A tscl.T85 Tsai |
| Comment | Temperature-sensitive at chromosome condensation |
|---|
| Comment from the depositor | |
|---|
| RCB0034 |
| FM3A ts T244 |
| Comment | Temperature-sensitive at DNA polymerase |
|---|
| Comment from the depositor | |
|---|
| RCB0035 |
| WEHI-3 |
| Comment | Mouse cell line derived from leukemia. Secretes cytokines for hematopoietic cells. |
|---|
| Comment from the depositor | |
|---|
| RCB0036 |
| C127 |
| Comment | Host for bovine papiloma virus |
|---|
| Comment from the depositor | |
|---|
| RCB0041 |
| HL60 |
| Comment | Human cell line derived from promyelocytic leukemia. Differentiates to granulocytes and macrophages. |
|---|
| Comment from the depositor | |
|---|
| RCB0043 |
| NRK |
| Comment | Contact-inhibited semi-normal, original of NRK49F |
|---|
| Comment from the depositor | |
|---|
| RCB0056 |
| NIH3T3/14-1 |
| Comment | Spontaneous transformant of NIH3T3 |
|---|
| Comment from the depositor | |
|---|
| RCB0057 |
| NIH3T3/13C7 |
| Comment | SV40 large T (tsA58)-pBR322 transformed NIH3T3. |
|---|
| Comment from the depositor | |
|---|
| RCB0063 |
| JTC-15 |
| Comment | Subclone of AH-66, lost transplantability in rats. |
|---|
| Comment from the depositor | |
|---|
| RCB0065 |
| JTC-27 |
| Comment | Ascites hepatoma. |
|---|
| Comment from the depositor | |
|---|
| RCB0067 |
| M |
| Comment | Capable to form collagen network |
|---|
| Comment from the depositor | |
|---|
| RCB0069 |
| RLC-16 |
| Comment | Epithelial cell from rat liver |
|---|
| Comment from the depositor | |
|---|
| RCB0070 |
| RLC-18 |
| Comment | Non tumorigenic in nude mice |
|---|
| Comment from the depositor | |
|---|
| RCB0072 |
| RLC-27 |
| Comment | Liver-derived cell, tumorigenic in nude mice |
|---|
| Comment from the depositor | |
|---|
| RCB0074 |
| JTC-19 |
| Comment | Rat lung fibroblast once said interferon-producing. Serum-& protein-free culturable. |
|---|
| Comment from the depositor | |
|---|
| RCB0075 |
| RCR-1 |
| Comment | Astroglia cell line |
|---|
| Comment from the depositor | |
|---|
| RCB0076 |
| LYM-1 |
| Comment | Sticky cell from lymph node. |
|---|
| Comment from the depositor | |
|---|
| RCB0083 |
| HLC-1 |
| Comment | Lung adenocarcinoma |
|---|
| Comment from the depositor | |
|---|
| RCB0086 |
| FM3A |
| Comment | Mammary carcinoma, grow in vitro and in vivo |
|---|
| Comment from the depositor | |
|---|
| RCB0095 |
| P3/NSI/1-AG4-1 |
| Comment | Mouse myeloma cell line. Utilized for genration of hybridoma. Reported in the literature to synthesize kappa chain, but do not secrete free light chain. |
|---|
| Comment from the depositor | |
|---|
| RCB0096 |
| Don(D-6) |
| Comment | Pseudodiploid, two marker chromosomes |
|---|
| Comment from the depositor | |
|---|
| RCB0097 |
| CHL |
| Comment | Widely used in chromosome aberration test |
|---|
| Comment from the depositor | |
|---|
| RCB0098 |
| A549 |
| Comment | Human cell line derived from lung cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB0101 |
| L·P3 |
| Comment | Protein- & lipid-free medium growing |
|---|
| Comment from the depositor | |
|---|
| RCB0102 |
| IC-2 |
| Comment | Mast cell precursor, respond to IL-3. Conditioned medium. |
|---|
| Comment from the depositor | |
|---|
| RCB0112 |
| NRK49F |
| Comment | Contact-inhibited semi-normal cell line |
|---|
| Comment from the depositor | |
|---|
| RCB0115 |
| ARM321 |
| Comment | Anti-recA protein mAb. |
|---|
| Comment from the depositor | |
|---|
| RCB0116 |
| 7501 |
| Comment | S. cerevisiae Endo.Sce I large subunit mAb. |
|---|
| Comment from the depositor | |
|---|
| RCB0120 |
| LT4Tr |
| Comment | Spontaneous transformant of LT4 |
|---|
| Comment from the depositor | |
|---|
| RCB0135 |
| L5178Y |
| Comment | Rapidly growing lymphoma |
|---|
| Comment from the depositor | |
|---|
| RCB0136 |
| M10 |
| Comment | Highly sensitive to X-ray irradiation |
|---|
| Comment from the depositor | |
|---|
| RCB0137 |
| M10^(-) |
| Comment | Resistant to 6TG, isolated from M10 |
|---|
| Comment from the depositor | |
|---|
| RCB0138 |
| LX830 |
| Comment | Highly sensitive to X-ray irradiation |
|---|
| Comment from the depositor | |
|---|
| RCB0142 |
| Ehrlich |
| Comment | Ehrlich's ascite tumor |
|---|
| Comment from the depositor | |
|---|
| RCB0153 |
| HUC-F |
| Comment | Normal umbilical cord fibroblast, female |
|---|
| Comment from the depositor | |
|---|
| RCB0156 |
| 305M |
| Comment | Normal human skin fibroblast |
|---|
| Comment from the depositor | |
|---|
| RCB0159 |
| HS-K |
| Comment | Normal diploid fibroblast from Japanese |
|---|
| Comment from the depositor | |
|---|
| RCB0162 |
| NHSF46 |
| Comment | Diploid fibroblast from normal Japanese skin. |
|---|
| Comment from the depositor | |
|---|
| RCB0163 |
| RGB3T3-1 |
| Comment | Original cloned line from RCB, just like BALB/3T3 |
|---|
| Comment from the depositor | |
|---|
| RCB0164 |
| RGB3T3-5 |
| Comment | Siblings of RGB3T3-1, contact-inhibited |
|---|
| Comment from the depositor | |
|---|
| RCB0165 |
| REF-RGB |
| Comment | Suitable as feeders for hybridoma cloning |
|---|
| Comment from the depositor | |
|---|
| RCB0169 |
| M1 |
| Comment | Differentiate to macrophage and granulocyte |
|---|
| Comment from the depositor | |
|---|
| RCB0171 |
| 7T1 |
| Comment | Contact inhibited, may transform spontaneously |
|---|
| Comment from the depositor | |
|---|
| RCB0174 |
| SUSM-1 |
| Comment | Transformed in vitro with carcinogen |
|---|
| Comment from the depositor | |
|---|
| RCB0180 |
| MDBK |
| Comment | BSL2. A cell line derived from kidney of bovine. Information about BVDV (ATCC) . Information about BVDV (ECACC) . Information about BVDV (DSMZ) . |
|---|
| Comment from the depositor | |
|---|
| RCB0183 |
| RK13 |
| Comment | BSL2. A cell line derived from kidney of rabbit. Susceptible to viruses such as rubella virus. A cell line derived from kidney of bovine. Information about BVDV (ATCC) . Information about BVDV (ECACC) . |
|---|
| Comment from the depositor | |
|---|
| RCB0184 |
| OLF-136 |
| Comment | Fish (medaka) fin fibroblast. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0185 |
| CAEP |
| Comment | Gold fish erythrophoroma with 4n chromosomal mode |
|---|
| Comment from the depositor | |
|---|
| RCB0186 |
| CAF |
| Comment | Pinna fibroblast |
|---|
| Comment from the depositor | |
|---|
| RCB0187 |
| OLHE-131 |
| Comment | H04C medaka hepatoma pretreated with MAM-acetate. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0188 |
| OLME-104 |
| Comment | HB32C medaka treated with MNNG. From peritoneum. Amelanotic. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0191 |
| HeLa.S3 |
| Comment | Most famous cultured human cell line |
|---|
| Comment from the depositor | |
|---|
| RCB0193 |
| KMM-1 |
| Comment | Human myeloma. Lambda- chain producing. |
|---|
| Comment from the depositor | |
|---|
| RCB0195 |
| PAb419 |
| Comment | Anti-SV40 large T antigen mAb. |
|---|
| Comment from the depositor | |
|---|
| RCB0197 |
| HUC-Fm |
| Comment | Normal umbilical cord fibroblast, male |
|---|
| Comment from the depositor | |
|---|
| RCB0202 |
| A431 |
| Comment | Human cell line derived from epidermoid carcinoma. Expressing EGF receptor. |
|---|
| Comment from the depositor | |
|---|
| RCB0205 |
| BU25 TK- |
| Comment | Thymidine kinase defective HeLa. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 85022104 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0206 |
| MOLT-4 |
| Comment | T cell leukemia, the same patient as RCB1164 MOLT-3. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 85011413 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0207 |
| MRC-5 SV1 TG1 |
| Comment | SV40-transformed, 6TG-resistant and HAT-sensitive. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 85042501 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0208 |
| LTK- |
| Comment | Thymidine kinase defective L cell. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 85011432 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0209 |
| SP2/0-Ag14 |
| Comment | Mouse myeloma cell line. Utilized for generation of hybridoma. This is a non-Ig-secreting or synthesising line. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to the ECACC 85072401 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0210 |
| HF19 |
| Comment | Normal human lung fibroblast. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 85011418 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0211 |
| MRC-5 |
| Comment | Distribution terminated. Normal embryonic lung fibroblast. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to the website of ECACC prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0218 |
| MRC-5 |
| Comment | Normal embryonic lung fibroblast with accurate PDL |
|---|
| Comment from the depositor | |
|---|
| RCB0222 |
| NB1RGB |
| Comment | Normal human skin fibroblast, RCB original |
|---|
| Comment from the depositor | |
|---|
| RCB0224 |
| ST2 |
| Comment | Bone marrow stroma cell-derived |
|---|
| Comment from the depositor | |
|---|
| RCB0243 |
| Nil2C2 |
| Comment | A fibroblastic cell line derived from a fetus of Syrian hamster. Transformed cells. Tumor formation and metastasis can be observed after transplantation. |
|---|
| Comment from the depositor | |
|---|
| RCB0244 |
| Nil2C1 |
| Comment | A fibroblastic cell line derived from a fetus of Syrian hamster. Transformed cells. Tumor formation and metastasis can be observed after transplantation, but these abilities are lower than Nil2C2. |
|---|
| Comment from the depositor | |
|---|
| RCB0245 |
| Nil1C1 |
| Comment | A fibroblastic cell line derived from a fetus of Syrian hamster. Transformed cells. Tumor formation and metastasis can be observed after transplantation, but these abilities are much lower than Nil2C2. |
|---|
| Comment from the depositor | |
|---|
| RCB0247 |
| 10T1/2 |
| Comment | Fibroblast-like cells derived from mouse embryo. Can be used for experiments regarding cell transformation. |
|---|
| Comment from the depositor | |
|---|
| RCB0248 |
| 3T6 |
| Comment | Non-contact inhibited |
|---|
| Comment from the depositor | |
|---|
| RCB0249 |
| CKT-1 |
| Comment | Very flat and thin kidney epithelial cell |
|---|
| Comment from the depositor | |
|---|
| RCB0251 |
| VA-13 |
| Comment | SV40-transformed WI-38. |
|---|
| Comment from the depositor | |
|---|
| RCB0252 |
| W-V |
| Comment | SV40-transformed Werner's syndrome fibroblast |
|---|
| Comment from the depositor | |
|---|
| RCB0256 |
| BALL-1 |
| Comment | Human cell line derived from B cell leukemia. |
|---|
| Comment from the depositor | |
|---|
| RCB0266 |
| CLA1RGB |
| Comment | Pseudo congenital lactic acidosis. |
|---|
| Comment from the depositor | |
|---|
| RCB0270 |
| KG-1-C |
| Comment | Glioma, S-100 Protein producing. |
|---|
| Comment from the depositor | |
|---|
| RCB0271 |
| HeLa S3 (SC) |
| Comment | Suspension culturable. Useful for JIS medium inspection |
|---|
| Comment from the depositor | |
|---|
| RCB0273 |
| BRL |
| Comment | ES cell differentiation inhibitory activity (DIA) |
|---|
| Comment from the depositor | |
|---|
| RCB0275 |
| SES-MaBr-1 |
| Comment | Cabbage armyworm cell line applicable to large scale insect virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB0276 |
| SES-MaBr-3 |
| Comment | Cabbage armyworm cell line applicable to large scale production of insect virus. |
|---|
| Comment from the depositor | |
|---|
| RCB0278 |
| NIAS-MB-25 |
| Comment | Show finely branched cytoplasmic processes |
|---|
| Comment from the depositor | |
|---|
| RCB0279 |
| NIAS-MaBr-92 |
| Comment | Susceptible to nuclear polyhedrosis virus |
|---|
| Comment from the depositor | |
|---|
| RCB0282 |
| NFSa Y83 |
| Comment | A subline of NFSa which is a mouse cell line derived from fibrosarcoma. Transplantable. |
|---|
| Comment from the depositor | |
|---|
| RCB0283 |
| C-1300 |
| Comment | Highly metastatic neuroblastoma |
|---|
| Comment from the depositor | |
|---|
| RCB0284 |
| Sq-1979 |
| Comment | Metastatic epithelial cell |
|---|
| Comment from the depositor | |
|---|
| RCB0285 |
| CHO-K1 |
| Comment | A cell line derived from ovary of Chinese hamster. Frequently used for production of recombinant proteins etc. |
|---|
| Comment from the depositor | |
|---|
| RCB0286 |
| tk^(-)ts13 |
| Comment | Thymidine kinase-defective mutant of ts13 |
|---|
| Comment from the depositor | |
|---|
| RCB0288 |
| 3Y1-B clone 1-6-2 |
| Comment | Subclone of 3Y1-B clone 1. |
|---|
| Comment from the depositor | |
|---|
| RCB0289 |
| 3Y1-B cl 1-6-K5-4-2 |
| Comment | Subclone of 3Y1-B clone 1-6. |
|---|
| Comment from the depositor | |
|---|
| RCB0290 |
| 3Y1-B clone 1 |
| Comment | Mother clone of 3Y1 series. |
|---|
| Comment from the depositor | |
|---|
| RCB0291 |
| 3Y1ts-101 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0292 |
| 3Y1tsC102 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0293 |
| 3Y1ts-103 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0294 |
| 3Y1ts-104 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0295 |
| 3Y1ts-105 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0296 |
| 3Y1tsA106 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0297 |
| 3Y1tsB107 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0298 |
| 3Y1ts-108 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0299 |
| 3Y1ts-109 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0301 |
| 3Y1ts-111 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0302 |
| 3Y1tsC112 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0303 |
| 3Y1tsC113 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0304 |
| 3Y1ts-114 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0305 |
| 3Y1ts-115 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0306 |
| 3Y1tsC116 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0307 |
| 3Y1ts-117 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0308 |
| 3Y1ts-118 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0309 |
| 3Y1tsC119 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0310 |
| 3Y1ts-120 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0311 |
| 3Y1tsF121 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0312 |
| 3Y1ts-122 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0313 |
| 3Y1tsD123 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0314 |
| 3Y1tsD124 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0315 |
| 3Y1tsG125 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0316 |
| 3Y1tsF126 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0317 |
| 3Y1ts-201 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0318 |
| 3Y1ts-202 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0319 |
| 3Y1tsH203 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0320 |
| 3Y1tsE204 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0321 |
| 3Y1tsC205 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0322 |
| 3Y1tsD206 |
| Comment | A subline of 3Y1 cell line. Temperature-sensitive mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0323 |
| 3Y1-SB-15 |
| Comment | A subline of 3Y1 cell line. Tetraploid clone. |
|---|
| Comment from the depositor | |
|---|
| RCB0324 |
| 3Y1-SB-16 |
| Comment | A subline of 3Y1 cell line. Tetraploid clone. |
|---|
| Comment from the depositor | |
|---|
| RCB0325 |
| 3Y1BU^(r-1) |
| Comment | A subline of 3Y1 cell line. Thymidine kinase-defective. |
|---|
| Comment from the depositor | |
|---|
| RCB0326 |
| 3Y1BU^(r-2) |
| Comment | A subline of 3Y1 cell line. Thymidine kinase-defective. |
|---|
| Comment from the depositor | |
|---|
| RCB0327 |
| 3Y1BU^(r-3) |
| Comment | A subline of 3Y1 cell line. Thymidine kinase-defective. |
|---|
| Comment from the depositor | |
|---|
| RCB0328 |
| Ad12-3Y1-Z11 |
| Comment | A subline of 3Y1 cell line. Transformed by adenovirus type 12. |
|---|
| Comment from the depositor | |
|---|
| RCB0329 |
| Ad12-3Y1-Z13 |
| Comment | A subline of 3Y1 cell line. Transformed by adenovirus type 12. |
|---|
| Comment from the depositor | |
|---|
| RCB0330 |
| Ad12-3Y1-Z19 |
| Comment | A subline of 3Y1 cell line. Transformed by adenovirus type 12. |
|---|
| Comment from the depositor | |
|---|
| RCB0331 |
| Ad12-3Y1-W5 |
| Comment | A subline of 3Y1 cell line. Transformed by adenovirus type 12. |
|---|
| Comment from the depositor | |
|---|
| RCB0332 |
| E1A-3Y1-1 |
| Comment | A subline of 3Y1 cell line. Transformed by adenovirus type 12 E1A gene. |
|---|
| Comment from the depositor | |
|---|
| RCB0333 |
| E1A-3Y1-2 |
| Comment | A subline of 3Y1 cell line. Transformed by adenovirus type 12 E1A gene. |
|---|
| Comment from the depositor | |
|---|
| RCB0334 |
| E1A-3Y1-3 |
| Comment | A subline of 3Y1 cell line. Transformed by adenovirus type 12 E1A gene. |
|---|
| Comment from the depositor | |
|---|
| RCB0335 |
| in203-3Y1-7 |
| Comment | A subline of 3Y1 cell line. Transformed by adenovirus in203. |
|---|
| Comment from the depositor | |
|---|
| RCB0336 |
| in203-3Y1-19 |
| Comment | A subline of 3Y1 cell line. Transformed by adenovirus in203. |
|---|
| Comment from the depositor | |
|---|
| RCB0337 |
| in203-3Y1-23 |
| Comment | A subline of 3Y1 cell line. Transformed by adenovirus in203. |
|---|
| Comment from the depositor | |
|---|
| RCB0338 |
| Ad2-3Y1-1 |
| Comment | A subline of 3Y1 cell line. Transformed by adenovirus type 2. |
|---|
| Comment from the depositor | |
|---|
| RCB0339 |
| Ad2-3Y1-2 |
| Comment | A subline of 3Y1 cell line. Transformed by adenovirus type 2. |
|---|
| Comment from the depositor | |
|---|
| RCB0340 |
| Ad2-3Y1-3 |
| Comment | A subline of 3Y1 cell line. Transformed by adenovirus type 2. |
|---|
| Comment from the depositor | |
|---|
| RCB0343 |
| SV-3Y1-C66 |
| Comment | A subline of 3Y1 cell line. Transformed by SV40 virion. |
|---|
| Comment from the depositor | |
|---|
| RCB0344 |
| A640-3Y1-1 |
| Comment | A subline of 3Y1 cell line. Transformed by SV40 tsA640. |
|---|
| Comment from the depositor | |
|---|
| RCB0347 |
| dl-884-3Y1-KO1 |
| Comment | A subline of 3Y1 cell line. Transformed by SV40 dl-884. |
|---|
| Comment from the depositor | |
|---|
| RCB0350 |
| Py-3Y1-S2 |
| Comment | A subline of 3Y1 cell line. Transformed by mouse polyoma virus. |
|---|
| Comment from the depositor | |
|---|
| RCB0353 |
| SR-3Y1-1 |
| Comment | A subline of 3Y1 cell line. Transformed by Rous sarcoma virus. |
|---|
| Comment from the depositor | |
|---|
| RCB0354 |
| SR-3Y1-2 |
| Comment | A subline of 3Y1 cell line. Transformed by Rous sarcoma virus. |
|---|
| Comment from the depositor | |
|---|
| RCB0356 |
| HR-3Y1-1 |
| Comment | A subline of 3Y1 cell line. Transformed by v-Ha-ras oncogene. |
|---|
| Comment from the depositor | |
|---|
| RCB0357 |
| HR-3Y1-2 |
| Comment | A subline of 3Y1 cell line. Transformed by v-Ha-ras oncogene. |
|---|
| Comment from the depositor | |
|---|
| RCB0359 |
| NG-3Y1-D303 |
| Comment | A subline of 3Y1 cell line. Transformed by nitrosoguanidine. |
|---|
| Comment from the depositor | |
|---|
| RCB0371 |
| NG-3Y1-T18D |
| Comment | A subline of 3Y1 cell line. Transformed by nitrosoguanidine. |
|---|
| Comment from the depositor | |
|---|
| RCB0379 |
| mos-3Y1-10 |
| Comment | A subline of 3Y1 cell line. Transformed by v-mos oncogene. |
|---|
| Comment from the depositor | |
|---|
| RCB0380 |
| mos-3Y1-16 |
| Comment | A subline of 3Y1 cell line. Transformed by v-mos oncogene. |
|---|
| Comment from the depositor | |
|---|
| RCB0381 |
| V12S-3Y1-2 |
| Comment | A subline of 3Y1 cell line. Transformed by adenovirus type 12 12S-E1A. |
|---|
| Comment from the depositor | |
|---|
| RCB0384 |
| V13S-3Y1-4 |
| Comment | A subline of 3Y1 cell line. Transformed by adenovirus type 12 12S-E1A. |
|---|
| Comment from the depositor | |
|---|
| RCB0388 |
| NCU-F1 |
| Comment | Ehlers-Danlos syndrome |
|---|
| Comment from the depositor | |
|---|
| RCB0389 |
| NCU-F2 |
| Comment | Morquio syndrome |
|---|
| Comment from the depositor | |
|---|
| RCB0390 |
| NCU-F3 |
| Comment | Wilson's disease |
|---|
| Comment from the depositor | |
|---|
| RCB0391 |
| NCU-F4 |
| Comment | Wilson's disease |
|---|
| Comment from the depositor | |
|---|
| RCB0393 |
| NCU-F6 |
| Comment | Citrullinemia |
|---|
| Comment from the depositor | |
|---|
| RCB0394 |
| NCU-F7 |
| Comment | Citrullinemia |
|---|
| Comment from the depositor | |
|---|
| RCB0395 |
| NCU-F8 |
| Comment | Wilson's disease |
|---|
| Comment from the depositor | |
|---|
| RCB0397 |
| NCU-F10 |
| Comment | Cockayne's syndrome |
|---|
| Comment from the depositor | |
|---|
| RCB0402 |
| HeLa·P3 |
| Comment | Protein- free, serm- free, lipid-free medium growing |
|---|
| Comment from the depositor | |
|---|
| RCB0403 |
| CHO-K1 (SC) |
| Comment | A subline of CHO-K1 (RCB0285). Suspension culture is possible. |
|---|
| Comment from the depositor | |
|---|
| RCB0404 |
| SES-MaBr-4 |
| Comment | Sensitive to nuclear polyhedrosis virus. Possible to grow in sea-water based low-cost medium. |
|---|
| Comment from the depositor | |
|---|
| RCB0405 |
| NIAS-LeSe-11 |
| Comment | Susceptible to insect viruses. |
|---|
| Comment from the depositor | |
|---|
| RCB0407 |
| WS2TKB |
| Comment | Werner's syndrome |
|---|
| Comment from the depositor | |
|---|
| RCB0409 |
| WS1TKB |
| Comment | Werner's syndrome, the same patient as RCB0433 WS1TKB2. |
|---|
| Comment from the depositor | |
|---|
| RCB0410 |
| MEN1RGB |
| Comment | Fibroblasts from multiple endocrine neoplasia |
|---|
| Comment from the depositor | |
|---|
| RCB0411 |
| HaP-T1 |
| Comment | Mucin producing, BHP-induced pancreatic tumor |
|---|
| Comment from the depositor | |
|---|
| RCB0412 |
| NIAS-PX-64 |
| Comment | Pupal ovary. |
|---|
| Comment from the depositor | |
|---|
| RCB0413 |
| NIAS-MB-32 |
| Comment | Show finely branched cytoplasmic processes. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0414 |
| NIAS-MaBr-93 |
| Comment | larval hemocyte |
|---|
| Comment from the depositor | |
|---|
| RCB0417 |
| KU-1 |
| Comment | Bovine B cell leukemia cell line. It is described in the paper that bovine leukaemia virus (BLV) particles and BLV antigen are both negative. In relation to the production of virus, RIKEN Cell Bank has not confirmed it. |
|---|
| Comment from the depositor | |
|---|
| RCB0418 |
| KU-17 |
| Comment | BSL2. Bovine leukemia cell line. It is described in the paper that this cell line produces bovine leukosis virus (BLV). In relation to the production of virus, RIKEN Cell Bank has not confirmed it. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0420 |
| BHK-21C13-2P |
| Comment | Culturable in suspension, cf. ECACC ( BHK-21C13-3P). Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 84111301 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0421 |
| MEN2RGB |
| Comment | Fibroblasts from multiple endocrine neoplasia |
|---|
| Comment from the depositor | |
|---|
| RCB0423 |
| BL312 |
| Comment | BSL2. Bovine derived lymphocyte. It is described in the paper that this cell line produces bovine leukemia virus (BLV). Syncytium formation assay performed in RIKEN Cell Bank also suggested production of BLV (Figure). |
|---|
| Comment from the depositor | |
|---|
| RCB0429 |
| SES-MaBr-5 |
| Comment | Larval fat body hemocyte. |
|---|
| Comment from the depositor | |
|---|
| RCB0431 |
| T24 |
| Comment | Bladder transitional-cell carcinoma |
|---|
| Comment from the depositor | |
|---|
| RCB0432 |
| MT-5 |
| Comment | MNNG-initiated clone of BALB/c 3T3 clone A31 |
|---|
| Comment from the depositor | |
|---|
| RCB0433 |
| WS1TKB2 |
| Comment | Werner's syndrome, the same patient as RCB0409 WS1TKB. |
|---|
| Comment from the depositor | |
|---|
| RCB0434 |
| J774.1 |
| Comment | Macrophage-like cell |
|---|
| Comment from the depositor | |
|---|
| RCB0435 |
| U-937 DE-4 |
| Comment | Cloned U-937, differentiate with TNF |
|---|
| Comment from the depositor | |
|---|
| RCB0436 |
| HUC-F2 |
| Comment | Normal umbilical cord fibroblast, female |
|---|
| Comment from the depositor | |
|---|
| RCB0437 |
| HUC-Fm2 |
| Comment | Normal umbilical cord fibroblast, male |
|---|
| Comment from the depositor | |
|---|
| RCB0438 |
| LC-1/sq-SF |
| Comment | Human cell line derived from lung cancer. Squamous cell carcinoma. A subline of LC-1/sq (RCB0455) able to be cultured in serum-free conditions. LC-1/sq-SF (RCB0438), LC-1F (RCB0439), and LC-1/sq (RCB0455) are derived from the same patient. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0439 |
| LC-1F |
| Comment | Human cell line derived from lung cancer. Squamous cell carcinoma. Floating cells (non-adherent cells). LC-1/sq-SF (RCB0438), LC-1F (RCB0439), and LC-1/sq (RCB0455) are derived from the same patient. |
|---|
| Comment from the depositor | |
|---|
| RCB0440 |
| LC-2/ad |
| Comment | Adenocarcinoma, moderately differentiated. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0441 |
| SCCKN |
| Comment | Highly sensitive to bleomycin |
|---|
| Comment from the depositor | |
|---|
| RCB0443 |
| TC-YIK |
| Comment | Integrating HPV16, neurosecretory granules(+) |
|---|
| Comment from the depositor | |
|---|
| RCB0444 |
| RERF-LC-AI |
| Comment | Japanese lung squamous carcinoma. |
|---|
| Comment from the depositor | |
|---|
| RCB0447 |
| ARLJ301-3 |
| Comment | Diploid rat liver epithelial cell line |
|---|
| Comment from the depositor | |
|---|
| RCB0448 |
| ARLJ301-3TR1 |
| Comment | Spontaneous transformant of ARLJ301-3 |
|---|
| Comment from the depositor | |
|---|
| RCB0449 |
| Anr4 |
| Comment | EJ-ras oncogene transformed ARLJ301-3 |
|---|
| Comment from the depositor | |
|---|
| RCB0450 |
| Anr9-1 |
| Comment | EJ-ras oncogene transformed ARLJ301-3 |
|---|
| Comment from the depositor | |
|---|
| RCB0451 |
| Anr13-1 |
| Comment | EJ-ras oncogene transformed ARLJ301-3 |
|---|
| Comment from the depositor | |
|---|
| RCB0452 |
| HTC/C3 |
| Comment | Secretes IL-1,TGFα,GM-CSF but not thyroglobulin |
|---|
| Comment from the depositor | |
|---|
| RCB0453 |
| SHOK |
| Comment | Contact-inhibited hamster embryonal cell line |
|---|
| Comment from the depositor | |
|---|
| RCB0455 |
| LC-1/sq |
| Comment | Human cell line derived from lung cancer. Squamous cell carcinoma. The parental cell line of LC-1/sq-SF (RCB0438). LC-1/sq-SF (RCB0438), LC-1F (RCB0439), and LC-1/sq (RCB0455) are derived from the same patient. |
|---|
| Comment from the depositor | |
|---|
| RCB0457 |
| BM-N |
| Comment | Useful for recombinant BmNPV expression. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0466 |
| Lu-134-A |
| Comment | Small cell carcinoma, classic type. See Lu-134-B. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0467 |
| Lu-134-B |
| Comment | Small cell carcinoma, classic type. See Lu-134-A. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0468 |
| Lu-135 |
| Comment | Small cell carcinoma, variant type. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0469 |
| Lu-139 |
| Comment | Small cell carcinoma, classic type. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0470 |
| Lu-140 |
| Comment | Small cell carcimoma, classic type. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0471 |
| CYNOM-K1 |
| Comment | CITES. Cynomolgus monkey embryo skin, early passage.Monkey cell lines require import and export permits according to the Convention on International Trade in Endangered Species (CITES). |
|---|
| Comment from the depositor | |
|---|
| RCB0473 |
| DD762 |
| Comment | Mammary tumor cell line without C-type virus |
|---|
| Comment from the depositor | |
|---|
| RCB0474 |
| K562/MTX-2 |
| Comment | Methotrexate(MTX)-resistant K562 cell line |
|---|
| Comment from the depositor | |
|---|
| RCB0475 |
| ILT-Mat |
| Comment | BSL2.IL-2 dependent ATL cell line. Based on the information by depositor; this cell line possesses HTLV-1 pro-virus DNA. We don't know whether virus particles are produced or not. |
|---|
| Comment from the depositor | |
|---|
| RCB0476 |
| Had-1 |
| Comment | A subline of FM3A (mouse breast cancer cell line). Resistant to Newcastle virus and Sendai virus. Dye by GS-II lectin. The revertant cells (parent cell-like cells) dye by WGA lectin. |
|---|
| Comment from the depositor | |
|---|
| RCB0477 |
| NB9 |
| Comment | Human cell line derived from Neuroblastoma. N-myc gene is amplified. Another name is CHP-212 (PMID: 6871857). Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0478 |
| NB16 |
| Comment | Human cell line derived from Neuroblastoma. N-myc gene is amplified. |
|---|
| Comment from the depositor | |
|---|
| RCB0480 |
| NB69 |
| Comment | Human cell line derived from Neuroblastoma. N-myc gene is not amplified. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0481 |
| TNB1 |
| Comment | Human cell line derived from Neuroblastoma. N-myc gene is amplified. Another name is TGW (PMID: 2335222). Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0482 |
| MC-NB-1 |
| Comment | Human cell line derived from Neuroblastoma. Possess N-myc gene amplicon. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0483 |
| LA-N-1 |
| Comment | Human cell line derived from Neuroblastoma. N-myc gene is amplified. Derived from metastatic tumor in bone marrow. |
|---|
| Comment from the depositor | |
|---|
| RCB0484 |
| LA-N-2 |
| Comment | Human cell line derived from Neuroblastoma. N-myc gene is amplified. |
|---|
| Comment from the depositor | |
|---|
| RCB0485 |
| LA-N-5 |
| Comment | Human cell line derived from Neuroblastoma. N-myc gene is amplified. |
|---|
| Comment from the depositor | |
|---|
| RCB0486 |
| CHP-126 |
| Comment | Human cell line derived from Neuroblastoma. N-myc gene is amplified. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0487 |
| CHP-134 |
| Comment | Human cell line derived from Neuroblastoma. N-myc gene is amplified. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0488 |
| 3Y1-B clone 1-6 |
| Comment | Standard clone of 3Y1 series. So called 3Y1 |
|---|
| Comment from the depositor | |
|---|
| RCB0489 |
| NEC8 |
| Comment | Embryonal carcinoma, testis. |
|---|
| Comment from the depositor | |
|---|
| RCB0490 |
| NEC14 |
| Comment | Embryonal carcinoma, testis. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0492 |
| OTCD1TKB |
| Comment | Human adherent cells derived from skin of a patient suffering from ornithine transcarbamylase deficiency. |
|---|
| Comment from the depositor | |
|---|
| RCB0494 |
| NEC15 |
| Comment | Embryonal carcinoma, testis. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0495 |
| KU812 |
| Comment | Chronic myelogeneous leukemia, Ph1 chromosome (+), basophil-like cells. |
|---|
| Comment from the depositor | |
|---|
| RCB0496 |
| KU812E |
| Comment | Chronic myelogenous leukemia , subclone of RCB0495 KU812. |
|---|
| Comment from the depositor | |
|---|
| RCB0497 |
| KU812F |
| Comment | Chronic myelogeneous leukemia, subclone of RCB0495 KU812. |
|---|
| Comment from the depositor | |
|---|
| RCB0500 |
| HGC-27 |
| Comment | Human cell line derived from metastatic lymph node of gastric cancer (undifferentiated carcinoma). |
|---|
| Comment from the depositor | |
|---|
| RCB0503 |
| HeLa.S3(Mer^(-)) |
| Comment | Repair deficient (mer-) |
|---|
| Comment from the depositor | |
|---|
| RCB0504 |
| MR1-3 |
| Comment | MNNG-reistant HeLa.S3(Mer-) cells |
|---|
| Comment from the depositor | |
|---|
| RCB0505 |
| MR6 |
| Comment | MNNG-resistant HeLa.S3(Mer-) cells |
|---|
| Comment from the depositor | |
|---|
| RCB0507 |
| MR10-1 |
| Comment | MNNG-resistant HeLa.S3(Mer-) cells |
|---|
| Comment from the depositor | |
|---|
| RCB0508 |
| H-EMC-SS |
| Comment | Extraskeletal myxoid chondrosarcoma |
|---|
| Comment from the depositor | |
|---|
| RCB0510 |
| ACL-15 |
| Comment | Metastasis to liver, lung |
|---|
| Comment from the depositor | |
|---|
| RCB0511 |
| RCN-9 |
| Comment | Metastasis to liver, lung |
|---|
| Comment from the depositor | |
|---|
| RCB0512 |
| RCN-H-4 |
| Comment | Metastasis to liver |
|---|
| Comment from the depositor | |
|---|
| RCB0513 |
| SKN |
| Comment | Human cell line derived from uterine leiomyosarcoma. Sensitive to estradiol-17 beta. Metastasis to kidney was observed in the clinic. |
|---|
| Comment from the depositor | |
|---|
| RCB0515 |
| HSKTC |
| Comment | Human cell line derived from Krukenberg tumor. Metastasis to ovary of gastric signet ring cell carcinoma. Producing mucin. Expressing CA19-9, CEA, and TPA. |
|---|
| Comment from the depositor | |
|---|
| RCB0520 |
| WR216 |
| Comment | APRT(-) EB transformed B cell line |
|---|
| Comment from the depositor | |
|---|
| RCB0521 |
| HFL-I |
| Comment | Human fibroblasts derived from fetal lung (11 weekly age). |
|---|
| Comment from the depositor | |
|---|
| RCB0522 |
| HFL-II |
| Comment | Human fibroblasts derived from fetal lung (14 weekly age). |
|---|
| Comment from the depositor | |
|---|
| RCB0523 |
| HFL-III |
| Comment | Human fibroblasts derived from fetal lung (11 weekly age). |
|---|
| Comment from the depositor | |
|---|
| RCB0524 |
| HFL-AE-I |
| Comment | Human fibroblasts derived from lung of anencephalic fetus. 46XY,17p+ or 17ph+ |
|---|
| Comment from the depositor | |
|---|
| RCB0525 |
| HFL-AE-II |
| Comment | Human fibroblasts derived from lung of anencephalic fetus. 46XX, inv(9p+,q-) |
|---|
| Comment from the depositor | |
|---|
| RCB0526 |
| Jyg-MC(A) |
| Comment | murine mammary tumor cell lines. High level MMTV producer line. |
|---|
| Comment from the depositor | |
|---|
| RCB0527 |
| Jyg-MC(B) |
| Comment | Murine mammary tumor cell lines. Higher incidence in lung metastasis. |
|---|
| Comment from the depositor | |
|---|
| RCB0528 |
| MtT/S |
| Comment | Rat cell line derived from pituitary tumor. Estrogen-induced tumor. Producing growth hormone. Able to induce the cells producing prolactin. Four cell lines (MtT/E, MtT/S, MtT/SM, MtT/Se) were established simultaneously.Application consideration. |
|---|
| Comment from the depositor | |
|---|
| RCB0529 |
| MtT/Se |
| Comment | Rat cell line derived from pituitary tumor. Estrogen-induced tumor. Estrogen-dependent cell line. Producing a small amount of growth hormone. Four cell lines (MtT/E, MtT/S, MtT/SM, MtT/Se) were established simultaneously.Application consideration. |
|---|
| Comment from the depositor | |
|---|
| RCB0530 |
| MtT/SM |
| Comment | Rat cell line derived from pituitary tumor. Estrogen-induced tumor. Producing prolactin and growth hormone. Four cell lines (MtT/E, MtT/S, MtT/SM, MtT/Se) were established simultaneously. Application consideration. |
|---|
| Comment from the depositor | |
|---|
| RCB0531 |
| TtT/M-87 |
| Comment | Mouse cell line derived from pituitary tumor (thyrotropin-producing tumor). Macrophage-like cells. Dependent on conditioned medium of L929 cells. Conditioned medium. |
|---|
| Comment from the depositor | |
|---|
| RCB0533 |
| Y1 |
| Comment | Mouse steroid hormone secreting adrenal cortex cell line. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 85062807 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0535 |
| RAW 264 |
| Comment | Mouse leukemic monocyte. Abelson leukemia virus induced. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 85062803 prior to order. Application consideration(PDF 580KB) |
|---|
| Comment from the depositor | |
|---|
| RCB0536 |
| STO |
| Comment | Tioguanine- and ouabain-resistant and HAT-sensitive fibroblasts. Suitable for ES cell feeder layer. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 86032003 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0537 |
| JM |
| Comment | Human cell line derived from T-cell leukemia. Isolated from the same patient as “Jurkat”. Has the ability to grow HIV. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 86010201 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0538 |
| PU5-18 |
| Comment | Mouse lymphoid tumor, macrophage like. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 85051501 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0540 |
| HAL-01 |
| Comment | Acute lymphatic leukemia |
|---|
| Comment from the depositor | |
|---|
| RCB0544 |
| MBT-2 |
| Comment | A mouse cell line derived from bladder cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB0545 |
| OHTA |
| Comment | Mouse embryonic carcinoma |
|---|
| Comment from the depositor | |
|---|
| RCB0546 |
| AT-PDH1TKB |
| Comment | Pyruvate dehydrogenase deficiency fibroblasts. |
|---|
| Comment from the depositor | |
|---|
| RCB0548 |
| IA-5 |
| Comment | Human cell line derived from lung cancer. Large cell carcinoma. Derived from skin metastasis. Transplantable in immuno-deficient mouse, but metastasis to lymph nodes is rarely observed. IA-5 (RCB0548) and IA-LM (RCB0554) were derived from the same patient. |
|---|
| Comment from the depositor | |
|---|
| RCB0549 |
| Cle-H3 |
| Comment | NIH3T3 transformant expressing human activated k-ras-2. |
|---|
| Comment from the depositor | |
|---|
| RCB0550 |
| Cle-H3^(neo+) |
| Comment | pSV2neo-introduced G418-resistant Cle-H3 mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0554 |
| IA-LM |
| Comment | Human cell line derived from lung cancer. Large cell carcinoma. Derived from skin metastasis. Transplantable in immuno-deficient mouse, and metastasis to lymph nodes can be observed. IA-5 (RCB0548) and IA-LM (RCB0554) were derived from the same patient. |
|---|
| Comment from the depositor | |
|---|
| RCB0555 |
| GCIY |
| Comment | Stomach cancer (Borrmann IV). Mucin, CA19-9, CEA, alphafetoprotein positive. |
|---|
| Comment from the depositor | |
|---|
| RCB0556 |
| NIAS-PX-58 |
| Comment | Pupal ovary hemocyte-like. |
|---|
| Comment from the depositor | |
|---|
| RCB0557 |
| B16 melanoma 4A5 |
| Comment | Melanin pigment producing mouse melanoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0558 |
| LLC |
| Comment | Highly metastatic and drug-resistant mouse tumor. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0559 |
| K-1.fl |
| Comment | SFFV producing Friend leukemia cell line. Non-differentiating. |
|---|
| Comment from the depositor | |
|---|
| RCB0560 |
| F5-5.fl |
| Comment | Friend leukemia. Differentiate to erythroblastoid cells with benzidine etc. |
|---|
| Comment from the depositor | |
|---|
| RCB0561 |
| T-3-Cl-2-0.fl |
| Comment | Friend leukemia. Differentiate to erythroblastoid cells with 1.5% DMSO etc. A clone of TSFAT-3.fl |
|---|
| Comment from the depositor | |
|---|
| RCB0562 |
| TSFAT-3.fl |
| Comment | Friend leukemia. Differentiate to erythroblastoid cells. |
|---|
| Comment from the depositor | |
|---|
| RCB0565 |
| ATDC5 |
| Comment | Differentiate to chondrocytes, unidentifiable pigment cells. Teratocarcinoma AT805 derived. |
|---|
| Comment from the depositor | |
|---|
| RCB0566 |
| CGM1 |
| Comment | EB transformed B cell line |
|---|
| Comment from the depositor | |
|---|
| RCB0568 |
| ULF-23 |
| Comment | Cold water fish cell line. Cultured at 25 C. Relatively large chromosomes (Mode 23). |
|---|
| Comment from the depositor | |
|---|
| RCB0569 |
| 707.fl |
| Comment | Friend leukemia cell line. High ability to differentiate to erythroblastoid cells. |
|---|
| Comment from the depositor | |
|---|
| RCB0570 |
| GM86.fl |
| Comment | Friend leukemia cell line from DBA/2 mouse. |
|---|
| Comment from the depositor | |
|---|
| RCB0571 |
| FVTCT.fl |
| Comment | Friend leukemia cell line from BALB/c mouse. Virusnon-producing. |
|---|
| Comment from the depositor | |
|---|
| RCB0580 |
| SF8402 |
| Comment | Control from a nonexposed individual with breast cancer, different specimen from RCB0635 |
|---|
| Comment from the depositor | |
|---|
| RCB0582 |
| SF8404 |
| Comment | Control from a nonexposed individual without cancer |
|---|
| Comment from the depositor | |
|---|
| RCB0583 |
| SF8405 |
| Comment | Control from a nonexposed individual without cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB0584 |
| SF8406 |
| Comment | Control from a nonexposed individual without cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB0585 |
| SF8657 |
| Comment | Control from a nonexposed individual with stomach cancer |
|---|
| Comment from the depositor | |
|---|
| RCB0587 |
| SF8759 |
| Comment | Atomic bomb survivor with breast cancer |
|---|
| Comment from the depositor | |
|---|
| RCB0588 |
| SF8760 |
| Comment | Atomic bomb survivor with breast cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB0589 |
| SF8761 |
| Comment | Control from a nonexposed individual without cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB0590 |
| SF8762 |
| Comment | Atomic bomb survivor with breast cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB0591 |
| HNS1A |
| Comment | Salamander cell line with large chromosomes. |
|---|
| Comment from the depositor | |
|---|
| RCB0592 |
| HNS2 |
| Comment | Larger epithelial cells than HNS1A. |
|---|
| Comment from the depositor | |
|---|
| RCB0593 |
| HNS3 |
| Comment | Salamander cell line. Fibroblast-like cells. |
|---|
| Comment from the depositor | |
|---|
| RCB0594 |
| HNS4 |
| Comment | Salamander cell line. Epithelial-like cells. |
|---|
| Comment from the depositor | |
|---|
| RCB0595 |
| HNS5 |
| Comment | Salamander cell line. Fibroblast-like cells. |
|---|
| Comment from the depositor | |
|---|
| RCB0596 |
| SF8758 |
| Comment | Atomic bomb survivor with breast cancer |
|---|
| Comment from the depositor | |
|---|
| RCB0597 |
| SF8656 |
| Comment | Control from a non-exposed individual without breast cancer but with thyroid & colon cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB0598 |
| SF8655 |
| Comment | Atomic bomb survivor without cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB0600 |
| SF8653 |
| Comment | Atomic bomb survivor without breast cancer but with thyroid cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB0602 |
| SF8650 |
| Comment | Atomic bomb survivor with breast cancer |
|---|
| Comment from the depositor | |
|---|
| RCB0603 |
| SF8649 |
| Comment | Atomic bomb survivor with breast cancer |
|---|
| Comment from the depositor | |
|---|
| RCB0604 |
| SF8647 |
| Comment | Atomic bomb survivor with breast cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB0605 |
| SF8546 |
| Comment | Control from a nonexposed individual without cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB0608 |
| SF8543 |
| Comment | Control from a nonexposed individual with breast cancer |
|---|
| Comment from the depositor | |
|---|
| RCB0610 |
| SF8541 |
| Comment | Control from a nonexposed individual with uterus cancer |
|---|
| Comment from the depositor | |
|---|
| RCB0614 |
| SF8536 |
| Comment | Atomic bomb survivor without cancer |
|---|
| Comment from the depositor | |
|---|
| RCB0617 |
| SF8433 |
| Comment | Atomic bomb survivor with breast cancer |
|---|
| Comment from the depositor | |
|---|
| RCB0620 |
| SF8429 |
| Comment | Atomic bomb survivor with breast cancer |
|---|
| Comment from the depositor | |
|---|
| RCB0621 |
| SF8428 |
| Comment | Atomic bomb survivor with breast cancer, different specimen from RCB0624 |
|---|
| Comment from the depositor | |
|---|
| RCB0624 |
| SF8425 |
| Comment | Atomic bomb survivor with breast cancer, different specimen from RCB0621. |
|---|
| Comment from the depositor | |
|---|
| RCB0631 |
| SF8416 |
| Comment | Atomic bomb survivor with breast cancer |
|---|
| Comment from the depositor | |
|---|
| RCB0633 |
| SF8414 |
| Comment | Control from a nonexposed individual with breast cancer |
|---|
| Comment from the depositor | |
|---|
| RCB0634 |
| SF8413 |
| Comment | Control from a nonexposed individual with chest cancer |
|---|
| Comment from the depositor | |
|---|
| RCB0635 |
| SF8410 |
| Comment | Control from a nonexposed individual with breast cancer, different specimen from RCB0580. |
|---|
| Comment from the depositor | |
|---|
| RCB0637 |
| CTLL-2 |
| Comment | Cytotoxic T-cell line. IL-2 dependent. |
|---|
| Comment from the depositor | |
|---|
| RCB0638 |
| TCS |
| Comment | Human cell line derived from uterine cervix cancer. Keratinizing squamous carcinoma. Said producing CEA. |
|---|
| Comment from the depositor | |
|---|
| RCB0641 |
| EoL-1 cell |
| Comment | Eosinophilic leukemia. Differenciate by n-butylate treatment. |
|---|
| Comment from the depositor | |
|---|
| RCB0644 |
| D134 |
| Comment | MoAb IgM to sea urchin sperm dynein alpha-heavy chain. |
|---|
| Comment from the depositor | |
|---|
| RCB0646 |
| D264 |
| Comment | MoAb IgM to sea urchin sperm dynein beta-heavy chain. |
|---|
| Comment from the depositor | |
|---|
| RCB0648 |
| D308 |
| Comment | MoAb IgM to sea urchin sperm dynein beta-heavy chain. |
|---|
| Comment from the depositor | |
|---|
| RCB0649 |
| D52 |
| Comment | MoAb IgM to sea urchin sperm dynein IC1. |
|---|
| Comment from the depositor | |
|---|
| RCB0650 |
| D9 |
| Comment | MoAb IgM to sea urchin sperm dynein IC2. |
|---|
| Comment from the depositor | |
|---|
| RCB0651 |
| D58 |
| Comment | MoAb IgG1 to sea urchin sperm dynein IC2. |
|---|
| Comment from the depositor | |
|---|
| RCB0654 |
| D16 |
| Comment | MoAb IgG1 to sea urchin sperm dynein IC3. |
|---|
| Comment from the depositor | |
|---|
| RCB0657 |
| HOKUG |
| Comment | Human cell line derived from uterine cervix cancer. Glassy cell carcinoma. |
|---|
| Comment from the depositor | |
|---|
| RCB0658 |
| HHUA |
| Comment | Human cell line derived from endometrial cancer. HHUA (RCB0658) was derived from the same patient of SNG-M (JCRB0179), another “human endometrial cancer-derived cell line” distributed from another cell repository, JCRB cell bank in Japan (precise explanation).
|
|---|
| Comment from the depositor | |
|---|
| RCB0659 |
| HOUA-I |
| Comment | Human cell line derived from uterine cancer (endometrial cancer). |
|---|
| Comment from the depositor | |
|---|
| RCB0660 |
| HTMMT |
| Comment | Human cell line derived from malignant mixed mesodermal tumor found in uterus (malignant mixed Müllerian tumor). |
|---|
| Comment from the depositor | |
|---|
| RCB0662 |
| HOTHC |
| Comment | Human cell line derived from undifferentiated carcinoma of thyroid (pleomorphous). Expressing tumor angiogenesis factor (TAF) and G-CSF. |
|---|
| Comment from the depositor | |
|---|
| RCB0665 |
| HFWT |
| Comment | Human cell line derived from Wilms' tumor. Expressing CA125 and TPA. |
|---|
| Comment from the depositor | |
|---|
| RCB0666 |
| HSNB |
| Comment | Human cell line derived from Neuroblastoma. N-myc gene is amplified. Producing neuron specific enolase.Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0669 |
| PCH42-63 |
| Comment | Hybridoma against differentiated PC-12 cell surface |
|---|
| Comment from the depositor | |
|---|
| RCB0673 |
| PCH41-43 |
| Comment | Hybridoma against differentiated PC-12 cell surface |
|---|
| Comment from the depositor | |
|---|
| RCB0674 |
| PCH41-44 |
| Comment | Hybridoma producing monoclonal antibody against differentiated PC-12 cell surface molecules. |
|---|
| Comment from the depositor | |
|---|
| RCB0676 |
| PCH42-58 |
| Comment | Hybridoma producing monoclonal antibody against differentiated PC-12 cell surface molecules. |
|---|
| Comment from the depositor | |
|---|
| RCB0678 |
| PCH54-37 |
| Comment | Hybridoma against differentiated PC-12 cell surface |
|---|
| Comment from the depositor | |
|---|
| RCB0679 |
| HDC |
| Comment | Human fibroblasts derived from uterine. 46XX,t(2/q2/q). The first child of this donor suffers from Down's syndrome, 46XX,t(2/q2/q). |
|---|
| Comment from the depositor | |
|---|
| RCB0680 |
| HKBMM |
| Comment | Human cell line derived from malignant meningioma. |
|---|
| Comment from the depositor | |
|---|
| RCB0684 |
| HFL-AE-III |
| Comment | Human fibroblasts derived from lung of anencephalic fetus (15 weekly age). |
|---|
| Comment from the depositor | |
|---|
| RCB0685 |
| SKG-II-SF |
| Comment | A subline of SKG-II (human cell line derived from uterine cervix cancer, large cell non-keratinizing squamous cell carcinoma). Serum-free culture is possible. HPV type 18 integrated. |
|---|
| Comment from the depositor | |
|---|
| RCB0687 |
| KP-N-NS |
| Comment | Adrenal neuroblastoma derived from brain metastasis |
|---|
| Comment from the depositor | |
|---|
| RCB0688 |
| QG-U |
| Comment | Japanese cervix carcinoma. |
|---|
| Comment from the depositor | |
|---|
| RCB0689 |
| TCO-2 |
| Comment | Human cell line derived from uterine cervix cancer. Adenocarcinoma. Said producing CEA, CA125, TPA. |
|---|
| Comment from the depositor | |
|---|
| RCB0690 |
| HOTHC-SF |
| Comment | A subline of HOTHC. Serum-free and protein-free culture is possible. |
|---|
| Comment from the depositor | |
|---|
| RCB0697 |
| GM2-1TKB |
| Comment | Tay-Sachs' disease |
|---|
| Comment from the depositor | |
|---|
| RCB0698 |
| HFSKF-II |
| Comment | Human fibroblasts derived from fetal skin (11 weekly age). |
|---|
| Comment from the depositor | |
|---|
| RCB0700 |
| HTMM |
| Comment | Human cell line derived from malignant melanoma. Established from a metastasis to a lymph node. The origin is unknown. |
|---|
| Comment from the depositor | |
|---|
| RCB0701 |
| 143B/TK^(-)neo^(R) |
| Comment | v-Ki-ras transformant TE85 cell line. HAT sensitive, neo resistant. |
|---|
| Comment from the depositor | |
|---|
| RCB0702 |
| WI-38 |
| Comment | The most famous normal human fibroblast. Obtained directly from L. Hayflick. Younger PDL than RCB704 at time of deposit. |
|---|
| Comment from the depositor | |
|---|
| RCB0704 |
| WI-38 |
| Comment | The most famous normal human fibroblast. Obtained directly from L. Hayflick. |
|---|
| Comment from the depositor | |
|---|
| RCB0705 |
| 10H |
| Comment | Anti poly(ADP-ribose) IgG3 kappa producing. |
|---|
| Comment from the depositor | |
|---|
| RCB0708 |
| HF10B4 |
| Comment | Anti-human lung carcinoma mAb (IgM). Possible to culture in serum-free medium. |
|---|
| Comment from the depositor | |
|---|
| RCB0709 |
| HyLDH·YK-1 |
| Comment | Anti-rabbit muscle lactate dehydrogenase (LDH) mAb (IgG1). Possible to culture in serum-free medium. |
|---|
| Comment from the depositor | |
|---|
| RCB0710 |
| HyLDH·YK-2 |
| Comment | Anti-rabbit muscle lactate dehydrogenase (LDH) mAb (IgG2b). Possible to culture in serum-free medium |
|---|
| Comment from the depositor | |
|---|
| RCB0711 |
| HyGPD·YK-1-1 |
| Comment | Anti-rabbit muscle glyceraldehyde-3-phosphate dehydrogenase mAb (IgG). Serum-free culturable. |
|---|
| Comment from the depositor | |
|---|
| RCB0713 |
| HTUD1 |
| Comment | Large cells with large chromosomes. |
|---|
| Comment from the depositor | |
|---|
| RCB0715 |
| CHAUT-G |
| Comment | Smooth muscle cell sarcoma from Chinese hamster. |
|---|
| Comment from the depositor | |
|---|
| RCB0721 |
| GOTO·P3 |
| Comment | Subline of GOTO. Protein-free medium adapted. |
|---|
| Comment from the depositor | |
|---|
| RCB0725 |
| MS-1 |
| Comment | Small lung carcinoma. PTHrP producing. |
|---|
| Comment from the depositor | |
|---|
| RCB0733 |
| NLS-6-5 |
| Comment | Nalidixic acid sensitive mutant. Also sensitive toVP-16 and VM-26 Topo II inhibitors. |
|---|
| Comment from the depositor | |
|---|
| RCB0735 |
| OS-RC-2 |
| Comment | Renal tumor cell from a Japanese. Transplantable to nude mice. |
|---|
| Comment from the depositor | |
|---|
| RCB0736 |
| DJM-1 |
| Comment | Malignant trichilemmal cyst cells. Strongly laminin positive on cell surface. Serum-free culturable. |
|---|
| Comment from the depositor | |
|---|
| RCB0738 |
| MTHC-1 |
| Comment | Rat thymoma cell line without mouse chromosome contamination. Compare to MTHC-2 and -3. |
|---|
| Comment from the depositor | |
|---|
| RCB0739 |
| MTHC-2 |
| Comment | Rat thymoma cell line fused to mouse cells during nude-mouse transplantation. Mouse chr. 5, 15, 17. |
|---|
| Comment from the depositor | |
|---|
| RCB0740 |
| MTHC-3 |
| Comment | Rat thymoma cell line fused to mouse cells during nude-mouse transplantation. Mouse chr. 5,7,15,17. |
|---|
| Comment from the depositor | |
|---|
| RCB0748 |
| Mm1 |
| Comment | Spontaneouly differentiated cell line derived from M1. Non-tumorigenic. |
|---|
| Comment from the depositor | |
|---|
| RCB0749 |
| MFH-ino |
| Comment | Human fibrous histiocytoma. Showing fibroblastic- and histiocytic features. |
|---|
| Comment from the depositor | |
|---|
| RCB0750 |
| TLR2 |
| Comment | Hepatocytes containing temperature sensitive SV40 large T antigen. P450IA1 inducible. |
|---|
| Comment from the depositor | |
|---|
| RCB0752 |
| TKD2 |
| Comment | Mouse kidney cell line. Derived from a transgenic mouse expressing temperature sensitive SV40 large T antigen (SV40tsA58). |
|---|
| Comment from the depositor | |
|---|
| RCB0753 |
| OMC-1 |
| Comment | Japanese cervix squamous cell carcinoma. Once said TA-4 positive. |
|---|
| Comment from the depositor | |
|---|
| RCB0755 |
| OMC-3 |
| Comment | Mucinous cystadenocarcinoma. Said CA125,CA19-9 (+). |
|---|
| Comment from the depositor | |
|---|
| RCB0760 |
| MT-8 |
| Comment | Rat cell line derived from malignant fibrous histiocytoma. Characteristics of histiocytes are lacking. The tumor formed by this cell line consists of immature cells. |
|---|
| Comment from the depositor | |
|---|
| RCB0761 |
| 505-05-01 |
| Comment | Methylcholanthrene-induced fibrosarcoma. Metastatic to lung. |
|---|
| Comment from the depositor | |
|---|
| RCB0762 |
| MT-9 |
| Comment | Rat cell line derived from malignant fibrous histiocytoma. Possessing characteristics of histiocytes. |
|---|
| Comment from the depositor | |
|---|
| RCB0763 |
| GI-1 |
| Comment | Human glioma separated from gliosarcoma. |
|---|
| Comment from the depositor | |
|---|
| RCB0764 |
| Fvp^(r)B350 |
| Comment | Topoisomerase II inhibitor VP-16 resistant FM3A mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB0768 |
| HP50-2 |
| Comment | Hydrogen peroxide resistant HL60-derived clone. |
|---|
| Comment from the depositor | |
|---|
| RCB0769 |
| HP100-1 |
| Comment | Hydrogen peroxide resistant HL60-derived clone. More resistant than HP50-2. |
|---|
| Comment from the depositor | |
|---|
| RCB0770 |
| XTY |
| Comment | Frog (Xenopus laevis) cell line derived from subcutaneous tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB0771 |
| XTC-YF |
| Comment | Frog (Xenopus laevis) cell line derived from tadpole. |
|---|
| Comment from the depositor | |
|---|
| RCB0772 |
| A6 |
| Comment | Frog (Xenopus laevis) cell line derived from kidney. |
|---|
| Comment from the depositor | |
|---|
| RCB0773 |
| A8 |
| Comment | Frog (Xenopus laevis) cell line derived from liver. |
|---|
| Comment from the depositor | |
|---|
| RCB0774 |
| EC-GI-10 |
| Comment | Produce hypercalcemia in nude mice. PTH-related protein, IL-1alpha producing. |
|---|
| Comment from the depositor | |
|---|
| RCB0775 |
| F-36P |
| Comment | GM-CSF- or IL-3-dependent cell line. Differentiate to erythoid cells with erythropoietin. |
|---|
| Comment from the depositor | |
|---|
| RCB0776 |
| F-36E |
| Comment | Subline of F-36P. Erythropoietin-dependent |
|---|
| Comment from the depositor | |
|---|
| RCB0777 |
| HMV-II |
| Comment | Melanin producing. Originated from the same site of HMV-I. |
|---|
| Comment from the depositor | |
|---|
| RCB0778 |
| CW-2 |
| Comment | Colon carcinoma. CEA-positive, nude mouse-transplantable. |
|---|
| Comment from the depositor | |
|---|
| RCB0782 |
| RC4 |
| Comment | Normal rabbit cornea cells. Usually transform spontaneously during serial culture. |
|---|
| Comment from the depositor | |
|---|
| RCB0783 |
| FCP-S1M |
| Comment | Skin fibroblasts from a familial colon polyposis patient. |
|---|
| Comment from the depositor | |
|---|
| RCB0784 |
| FCP-S2H |
| Comment | Skin fibroblasts from a familial colon polyposis patient at Hiroshima. |
|---|
| Comment from the depositor | |
|---|
| RCB0785 |
| FCP-S3H |
| Comment | Skin fibroblasts from a familial colon polyposis patient at Hiroshima. |
|---|
| Comment from the depositor | |
|---|
| RCB0786 |
| FCP-S4H |
| Comment | Skin fibroblasts from a familial colon polyposis patient at Hiroshima. |
|---|
| Comment from the depositor | |
|---|
| RCB0787 |
| FCP-S5H |
| Comment | Skin fibroblasts from a familial colon polyposis patient at Hiroshima. |
|---|
| Comment from the depositor | |
|---|
| RCB0788 |
| FCP-S6H |
| Comment | Skin fibroblasts from a familial colon polyposis patient at Hiroshima. |
|---|
| Comment from the depositor | |
|---|
| RCB0789 |
| HSQ-89 |
| Comment | Japanese maxillary simus squamous carcinoma |
|---|
| Comment from the depositor | |
|---|
| RCB0792 |
| T88-M |
| Comment | IL-5 dependent early B-cell line. Also grows on IL-3. The population contain non-IL-5-dependent cell |
|---|
| Comment from the depositor | |
|---|
| RCB0793 |
| B151K12 |
| Comment | IL-5 producing T-cell hybridoma. Culture sup is useful for T88-M cell culture. |
|---|
| Comment from the depositor | |
|---|
| RCB0794 |
| 2C6 |
| Comment | Human cell line derived from embryonic pancreas. Four cell lines (RCB0794,RCB0795,RCB0796,RCB0797) were derived from the same individual. |
|---|
| Comment from the depositor | |
|---|
| RCB0795 |
| 1B2C6 |
| Comment | Human cell line derived from embryonic pancreas. Four cell lines (RCB0794,RCB0795,RCB0796,RCB0797) were derived from the same individual. |
|---|
| Comment from the depositor | |
|---|
| RCB0796 |
| 1C3D3 |
| Comment | Human cell line derived from embryonic pancreas. Four cell lines (RCB0794,RCB0795,RCB0796,RCB0797) were derived from the same individual. |
|---|
| Comment from the depositor | |
|---|
| RCB0797 |
| 1C3IKEI |
| Comment | Human cell line derived from embryonic pancreas. Four cell lines (RCB0794,RCB0795,RCB0796,RCB0797) were derived from the same individual. |
|---|
| Comment from the depositor | |
|---|
| RCB0803 |
| NBsusSR |
| Comment | Isolated from a patient with hiper dopaminemia andnorepinephrinemia. |
|---|
| Comment from the depositor | |
|---|
| RCB0804 |
| BRF41 |
| Comment | Zebrafish fin fibroblast. |
|---|
| Comment from the depositor | |
|---|
| RCB0805 |
| Ba/F3 |
| Comment | IL-3 dependent pro B cell line. Conditioned medium. Information. |
|---|
| Comment from the depositor | |
|---|
| RCB0806 |
| Jurkat |
| Comment | Human T cell line, the same patient as JM. IL-2 productivity of this line was undetermined. |
|---|
| Comment from the depositor | |
|---|
| RCB0808 |
| MMAc |
| Comment | Human melanoma, spindle-shaped. Said DOPA (+). |
|---|
| Comment from the depositor | |
|---|
| RCB0819 |
| HMMME |
| Comment | Human cell line derived from malignant mesothelioma. |
|---|
| Comment from the depositor | |
|---|
| RCB0820 |
| HKBML |
| Comment | Human cell line derived from malignant lymphoma occurred in brain. Epstein-Barr virus positive. |
|---|
| Comment from the depositor | |
|---|
| RCB0844 |
| 8C9 |
| Comment | Producing anti-human CD36 MoAb. |
|---|
| Comment from the depositor | |
|---|
| RCB0867 |
| 3-2H3 |
| Comment | Anti-human-myeloperoxidase MoAb producing. |
|---|
| Comment from the depositor | |
|---|
| RCB0868 |
| 4-2C11 |
| Comment | Anti-human-myeloperoxidase MoAb producing. |
|---|
| Comment from the depositor | |
|---|
| RCB0869 |
| 9-1A11 |
| Comment | Anti-human-myeloperoxidase MoAb producing. |
|---|
| Comment from the depositor | |
|---|
| RCB0870 |
| 12-1B6 |
| Comment | Anti-human-myeloperoxidase MoAb producing. |
|---|
| Comment from the depositor | |
|---|
| RCB0871 |
| LLC-GA5-CoL150 |
| Comment | Pig kidney (LLC-PK1) cells expressing human P-glycoproteins. |
|---|
| Comment from the depositor | |
|---|
| RCB0872 |
| LLC-GA5-CoL300 |
| Comment | Pig kidney (LLC-PK1) cells expressing human P-glycoproteins. |
|---|
| Comment from the depositor | |
|---|
| RCB0875 |
| Chab1KMM |
| Comment | Chromosomal aberration; 46XX + (11;12)(q23.3, q15). Need confirmation. |
|---|
| Comment from the depositor | |
|---|
| RCB0876 |
| RGM1 |
| Comment | So called clear cells from rat stomach mucosa. |
|---|
| Comment from the depositor | |
|---|
| RCB0881 |
| OCUB-M |
| Comment | Same as OCUB-1, OCUB-F. |
|---|
| Comment from the depositor | Chromosome = pseudotetraploid. |
|---|
| RCB0882 |
| OCUB-F |
| Comment | Same as OCUB-1, OCUB-M. |
|---|
| Comment from the depositor | Chromosome = pseudodiploid |
|---|
| RCB0959 |
| HH13-1 |
| Comment | Producing IgG MoAb against human 29 kDa lectin detectable in many human tumors. Also see HH17-4. |
|---|
| Comment from the depositor | |
|---|
| RCB0960 |
| HH17-4 |
| Comment | Producing IgG MoAb against human 29 kDa lectin detectable in many human tumors. Also see HH13-1. |
|---|
| Comment from the depositor | |
|---|
| RCB0966 |
| HGRT |
| Comment | Human cell line derived from retroperitoneal teratoma. |
|---|
| Comment from the depositor | |
|---|
| RCB0967 |
| HTST |
| Comment | Human cell line derived from sacrococcygeal teratoma. |
|---|
| Comment from the depositor | |
|---|
| RCB0978 |
| HIRS-BM |
| Comment | Human cell line derived from malignant mixed mesodermal tumor found in uterus (malignant mixed Müllerian tumor). Established from metastasis in bone marrow. |
|---|
| Comment from the depositor | |
|---|
| RCB0980 |
| Sa3 |
| Comment | Squamous carcinoma cells derived from human oral cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB0982 |
| ECC4 |
| Comment | Human cell line derived from rectum cancer (small cell cancer). Expressing creatinine kinase of brain isoenzyme etc. ( PubMed ID: 8392984). |
|---|
| Comment from the depositor | |
|---|
| RCB0983 |
| ECC10 |
| Comment | Human cell line derived from stomach cancer (small cell cancer). Expressing creatinine kinase of brain isoenzyme etc. ( PubMed ID: 8392984). |
|---|
| Comment from the depositor | |
|---|
| RCB0985 |
| Ae |
| Comment | Worm cell line established by Grace. Culturable in MGM-450-10%FBS. |
|---|
| Comment from the depositor | |
|---|
| RCB0987 |
| C2C12 |
| Comment | Said differentiate to myotubes, but need confirmation. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 91031101 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0988 |
| CACO-2 |
| Comment | Human colon carcinoma. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 86010202 prior to order. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB0989 |
| COLO 679 |
| Comment | Melanoma from a 47 year old female. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 87061210 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0990 |
| CPAE |
| Comment | BSL2. Bovine pulmonary artery endothelial cells producing angiotensin-converting enzyme. Bovine Viral Diarrhea Virus (BVDV) positive. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 86111401 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0991 |
| G-361 |
| Comment | Human melanoma producing melanin up to 50 PDL. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 88030401 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0992 |
| HOS |
| Comment | Sensitive to further transformation with both virus and chemicals. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 87070202 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0993 |
| IEC 6 |
| Comment | Rat small intestine epithelial cells. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 88071401 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0995 |
| MDCK |
| Comment | Canine kidney epithelial. Sensitive to wide range of viruses. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 84121903 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0996 |
| Mv.1.Lu(NBL-7) |
| Comment | Aleutian mink cells. Used for focus forming assays for murine and ferine sarcoma viruses. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 88050503 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB0998 |
| 117-13 |
| Comment | Anti-lactotetraosylceramide antibody producing. Discriminates metastatic cells from mesothelial cell |
|---|
| Comment from the depositor | |
|---|
| RCB0999 |
| MKN7 |
| Comment | c-erbB-2 expressing gastric adenocarcinoma. Differentiated type. |
|---|
| Comment from the depositor | |
|---|
| RCB1001 |
| MKN45 |
| Comment | Poorly differentiated gastric adenocarcinoma. Producing high level of CEA. |
|---|
| Comment from the depositor | |
|---|
| RCB1002 |
| MKN74 |
| Comment | Moderately differentiated adenocarcinoma. Once they were hypodiploids. |
|---|
| Comment from the depositor | |
|---|
| RCB1003 |
| MKN1 |
| Comment | Potentially differentiatable to both direction of adenomatous and squamous epithelial cells. |
|---|
| Comment from the depositor | |
|---|
| RCB1005 |
| KP4 |
| Comment | Pancreatic ductal cell carcinoma. Mother cell line of KP4-1, -2, and -3. |
|---|
| Comment from the depositor | |
|---|
| RCB1006 |
| KP4-1 |
| Comment | Pancreatic ductal cell carcinoma. PTHrP producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1007 |
| KP4-2 |
| Comment | Pancreatic ductal cell carcinoma. PTHrP producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1008 |
| KP4-3 |
| Comment | Pancreatic ductal cell carcinoma. PTHrP producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1009 |
| ECC12 |
| Comment | Stomach cancer (small cell cancer + glandular cancer)-derived cell line. Expressing creatinine kinase of brain isoenzyme etc. ( PubMed ID: 8392984). Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1010 |
| HOEF |
| Comment | Human fibroblasts derived from endometrium. The donor was suffering from infertility. 47,XX,+X (analyzed by the depositor).
|
|---|
| Comment from the depositor | |
|---|
| RCB1011 |
| H-AE-IV |
| Comment | Human fibroblasts derived from anencephalic fetus (11 weekly age). |
|---|
| Comment from the depositor | |
|---|
| RCB1012 |
| T3M-5 |
| Comment | G-CSF producing thyroidal squamous carcinoma. |
|---|
| Comment from the depositor | |
|---|
| RCB1015 |
| T3M-1 Clone2 |
| Comment | G-CSF producing oral squamous cell carcinoma, the same patient as T3M-1 Cl-10 and CJM. |
|---|
| Comment from the depositor | |
|---|
| RCB1017 |
| T3M-1 Cl-10 |
| Comment | G-CSF and IL-1 producing oral squamous cell carcinoma, the same patient as T3M-1 Clone2 and CJM. |
|---|
| Comment from the depositor | |
|---|
| RCB1018 |
| T3M-3 |
| Comment | Trophoblastic cell. Producing chorionic gonadotropin, estrogen, progesterone. |
|---|
| Comment from the depositor | |
|---|
| RCB1020 |
| T3M-10 |
| Comment | Lung large cell carcinoma producing CSF. |
|---|
| Comment from the depositor | |
|---|
| RCB1021 |
| T3M-4 |
| Comment | Pancreatic adenocarcinoma producing CEA. K-ras activated. |
|---|
| Comment from the depositor | |
|---|
| RCB1022 |
| T3M-11 |
| Comment | Human cell line derived from lung cancer (small cell carcinoma). Expressing insulin-like growth factor II (IGF-II). |
|---|
| Comment from the depositor | |
|---|
| RCB1024 |
| IMR-90-SV |
| Comment | SV40 transformed human lung fibroblast. |
|---|
| Comment from the depositor | |
|---|
| RCB1025 |
| RTH33 |
| Comment | SV40-Adeno Vector transformed hepatocytes. Albumin secretion and urea synthesis were reported. |
|---|
| Comment from the depositor | |
|---|
| RCB1026 |
| GM95 |
| Comment | Glucosylceramide synthetase-deficient B16 melanoma mutant. |
|---|
| Comment from the depositor | |
|---|
| RCB1027 |
| MEB4 |
| Comment | Not expressing melanoma antigen. Control for GM-95(RCB1026) cell line. |
|---|
| Comment from the depositor | |
|---|
| RCB1032 |
| NOS-1 |
| Comment | Osteoid producing in vitro and in nude mice. |
|---|
| Comment from the depositor | |
|---|
| RCB1033 |
| NOS-2 |
| Comment | Human osteosarcoma producing osteoid in vitro and in vivo(mouse). |
|---|
| Comment from the depositor | |
|---|
| RCB1034 |
| CJM |
| Comment | Human cell line derived from metastasis of cancer occurred in oral cavity, the same patient as T3M-1 Clone2 and T3M-1 Cl-10. |
|---|
| Comment from the depositor | |
|---|
| RCB1035 |
| CJM Cl4 |
| Comment | Human cell line derived from metastasis of cancer occurred in oral cavity, the same patient as T3M-1 Clone2 and T3M-1 Cl-10. |
|---|
| Comment from the depositor | |
|---|
| RCB1036 |
| CJM Cl5 |
| Comment | Human cell line derived from metastasis of cancer occurred in oral cavity, the same patient as T3M-1 Clone2 and T3M-1 Cl-10. |
|---|
| Comment from the depositor | |
|---|
| RCB1037 |
| CJM Cl6 |
| Comment | Human cell line derived from metastasis of cancer occurred in oral cavity, the same patient as T3M-1 Clone2 and T3M-1 Cl-10. |
|---|
| Comment from the depositor | |
|---|
| RCB1038 |
| CJM Cl7 |
| Comment | Human cell line derived from metastasis of cancer occurred in oral cavity, the same patient as T3M-1 Clone2 and T3M-1 Cl-10. |
|---|
| Comment from the depositor | |
|---|
| RCB1039 |
| CJM Cl8 |
| Comment | Human cell line derived from metastasis of cancer occurred in oral cavity, the same patient as T3M-1 Clone2 and T3M-1 Cl-10. |
|---|
| Comment from the depositor | |
|---|
| RCB1062 |
| LMSU |
| Comment | Human cell line derived from lymph node metastasis of gastric cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB1088 |
| ψCRIP-P131 |
| Comment | High-titer producer of MoMLV-derived retrovirus. A subline of ψCRIP. |
|---|
| Comment from the depositor | |
|---|
| RCB1089 |
| ψCRIP-MFGmGM-CSF |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse GM-CSF. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1090 |
| ψCRIP-MFGmIL-1α |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse IL-1alpha. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1091 |
| ψCRIP-MFGmIL-1RA |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse IL-1 receptor antagonist. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1092 |
| ψCRIP-MFGmIL-2 |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse IL-2. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1093 |
| ψCRIP-MFGmIL-3 |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse IL-3. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1094 |
| ψCRIP-MFGmIL-4 |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse IL-4. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1095 |
| ψCRIP-MFGmIL-6 |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse IL-6. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1096 |
| ψCRIP-MFGmIL-7 |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse IL-7. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1097 |
| ψCRIP-MFGmIL-10 |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse IL-10. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1098 |
| ψCRIP-MFGmIL-12p40 |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse IL-12 (p40 subunit). Refer to RCB1099. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1099 |
| ψCRIP-MFGmIL-12p35 |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse IL-12 (p35 subunit). Refer to RCB1098. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1100 |
| ψCRIP-MFGmTNF-α |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse TNF-alpha. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1101 |
| ψCRIP-MFGhTNF-α |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express human TNF-alpha. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1102 |
| ψCRIP-MFGmLT |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse lymphotoxin. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1103 |
| ψCRIP-MFGmG-CSF |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse G-CSF. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1104 |
| ψCRIP-MFGhM-CSF |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express human M-CSF. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1105 |
| ψCRIP-MFGmIFN-γ |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse IFN-gamma. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1106 |
| ψCRIP-MFGhMIF |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express human MIF. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1107 |
| ψCRIP-MFGmLIF |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse leukemia inhibitory factor (LIF). Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1108 |
| ψCRIP-MFGmKitLigand |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse kit ligand (SCF). Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1109 |
| ψCRIP-MFGhOncost-M |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express human oncostatin M. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1110 |
| ψCRIP-MFGmB7 |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse B7 (CD80). Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1111 |
| ψCRIP-MFGmB7-2 |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse B7-2 (CD86). Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1112 |
| ψCRIP-MFGtrγIFNR |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express a truncated form of mouse IFN-gamma. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1113 |
| ψCRIP-MFGrab-IL1RA |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express rabbit IL-1 receptor antagonist. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1114 |
| ψCRIP-MFGratGM-CSF |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express rat GM-CSF. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1115 |
| ψCRIP-MFGneo |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express neomycin. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1116 |
| ψCRIP-MFGHSVtk |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express HSV thymidine kinase. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1117 |
| ψCRE-MFGts-c-src |
| Comment | Cartagena Protocol on Biosafety.Producer of MoMLV-derived retrovirus including mouse c-src cDNA with ts mutation. |
|---|
| Comment from the depositor | |
|---|
| RCB1118 |
| ψCRIP-MFGts-c-src |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse c-src possessing ts mutation. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1119 |
| ψCRE-MFGtsT |
| Comment | Cartagena Protocol on Biosafety.High-titer producer of MoMLV-derived retrovirus including SV40 large T temperature-sensitive cDNA. |
|---|
| Comment from the depositor | |
|---|
| RCB1120 |
| ψCRIP-MFGtsT |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express temperature-sensitive SV40 large T. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1124 |
| OP9 |
| Comment | Support hematpoietic stem cell and ES cell differentiation to blood cells and lymphocytes. |
|---|
| Comment from the depositor | |
|---|
| RCB1125 |
| TOM-2 |
| Comment | Glassy cell carcinoma from cervix. |
|---|
| Comment from the depositor | |
|---|
| RCB1126 |
| MC3T3-E1 |
| Comment | Differentiate to osteoblasts. Collagen producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1127 |
| MC3T3-G2/PA6 |
| Comment | Support hematpoietic stem cell and osteoclast differentiation. Pre-adipocyte. |
|---|
| Comment from the depositor | |
|---|
| RCB1129 |
| TGBC1TKB |
| Comment | Japanese gallbadder carcinoma metastated to lymph node from the same patient of TGBC2TKB. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1130 |
| TGBC2TKB |
| Comment | Japanese gallbladder carcinoma from the same patient of TGBC1TKB. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1139 |
| HFSKF-AE-V |
| Comment | Human fibroblasts derived from fetal skin (31 weekly age). |
|---|
| Comment from the depositor | |
|---|
| RCB1142 |
| 10H-2 |
| Comment | Anti poly(ADP-ribose) IgG3 kappa producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1143 |
| DA-1 |
| Comment | IL-3 dependent mouse myeloid cells. MoLV induced. |
|---|
| Comment from the depositor | |
|---|
| RCB1144 |
| DA-3 |
| Comment | IL-3 dependent mouse myeloid cells. MoLV induced. |
|---|
| Comment from the depositor | |
|---|
| RCB1145 |
| 32D |
| Comment | IL-3 dependent cells from Friend leukemia virus-infected mouse bone marrow. |
|---|
| Comment from the depositor | |
|---|
| RCB1148 |
| TGBC11TKB |
| Comment | Stopped distribution temporarily. Japanese gastric cancer, lymph node metastated. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1151 |
| RCC10RGB |
| Comment | Kidney carcinoma from a Japanese patient. |
|---|
| Comment from the depositor | |
|---|
| RCB1152 |
| Sawano |
| Comment | Human cell line derived from endometrial adenocarcinoma of uterus. Resistant to cisplatin. |
|---|
| Comment from the depositor | |
|---|
| RCB1153 |
| S2 (Drosophila) |
| Comment | Fruit fly Oregon-R derived cell line. Highly sensitive in RNA interference compared with CHO-K1. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1154 |
| KGN |
| Comment | Human cell line derived from ovarian granulosa cell tumor. Aromatase activity is increased by stimulation of FSH and hMG. |
|---|
| Comment from the depositor | |
|---|
| RCB1155 |
| Hepa-E1 |
| Comment | Eel hepatocyte. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1157 |
| UV-P3U1-B8 |
| Comment | Anti-thymine dimer antibody producing. Serum-free cultured hybridoma. |
|---|
| Comment from the depositor | |
|---|
| RCB1158 |
| B16F10/mGM |
| Comment | Mouse GM-CSF producing B16 melanoma. |
|---|
| Comment from the depositor | |
|---|
| RCB1164 |
| MOLT-3 |
| Comment | Human T cell leukemia, the same patient as RCB0206 MOLT-4. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ACC 84 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB1165 |
| YAC-1 |
| Comment | Natural killer cell-sensitive mouse lymphoma.Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ACC 96 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB1166 |
| KG-1 |
| Comment | Human acute myeloid leukemia. The variant subline (RCB1928 KG-1a) CD3-,CD13+,CD14-,CD15+,CD19-,CD33+. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ACC 14 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB1167 |
| P-815 |
| Comment | Mouse mastocytoma. Used as a target cells for cytotoxic T cell assays. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ACC 1 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB1168 |
| SKW-3 |
| Comment | Human cell line derived from acute lymphoblastic leukemia (ALL). A subline of KE-37. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ACC 53 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB1169 |
| TGBC18TKB |
| Comment | Papillotubular adenocarcinoma of the Vater's papilla. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1171 |
| HOUFXXX |
| Comment | Stopped distribution. This cell line has been distributed as “Human fibroblasts derived from vagina. 47,XX,+X” until August 2023. It was proved that this cell line was a misidentified cell line of HOEF (RCB1010), human fibroblasts derived from endometrium with 47,XX,+X, deposited from the same scientist. |
|---|
| Comment from the depositor | |
|---|
| RCB1174 |
| GEM-81 |
| Comment | Tumor cells derived from Gold Fish red pigment cells. |
|---|
| Comment from the depositor | |
|---|
| RCB1175 |
| GEM-199 |
| Comment | Tumor cells derived from Gold Fish red pigment cells. |
|---|
| Comment from the depositor | |
|---|
| RCB1176 |
| GEM-218 |
| Comment | Tumor cells derived from Gold Fish red pigment cells. |
|---|
| Comment from the depositor | |
|---|
| RCB1178 |
| HuG1-PI |
| Comment | Human cell line derived from ascites of a gastric cancer patient. Expressing hybrid type of alkaline phosphatase. HuG1-N is another cell line derived from the same patient. |
|---|
| Comment from the depositor | |
|---|
| RCB1179 |
| HuG1-N |
| Comment | Human cell line derived from ascites of a gastric cancer patient. Expressing Nagao-type alkaline phosphatase. HuG1-PI is another cell line derived from the same patient. |
|---|
| Comment from the depositor | |
|---|
| RCB1180 |
| Tanoue |
| Comment | B-lineage acute lymphoblastic leukemia. |
|---|
| Comment from the depositor | |
|---|
| RCB1181 |
| ST |
| Comment | A subclone of RCB1180 Tanoue. |
|---|
| Comment from the depositor | |
|---|
| RCB1182 |
| GR-ST |
| Comment | RCB1181 ST cells transformed with human G-CSF receptor cDNA. Responds to G-CSF. |
|---|
| Comment from the depositor | |
|---|
| RCB1184 |
| Lu-165 |
| Comment | Producing high level of anti-diuretic hormone. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1185 |
| TT1TKB |
| Comment | Rectal carcinoma from a Japanese patient. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1186 |
| TGBC14TKB |
| Comment | Japanese gallbladder tumor passed through a nude mouse. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1187 |
| TUHR3TKB |
| Comment | Japanese kidney carcinoma cells. RCB original. |
|---|
| Comment from the depositor | |
|---|
| RCB1188 |
| NRS-1 |
| Comment | Human rhabdomyosarcoma showing myogenic differentiation. TGFbeta inhibits it. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1189 |
| THP-1 |
| Comment | Human cell line derived from acute monocytic leukemia. Differentiate to macrophage-like cells by treatment of phorbol ester. The characteristics are somewhat different from THP-1 distributed from ATCC such as in cell size and drug sensitivities. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ACC 16 prior to order.Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1190 |
| 7-TD-1 |
| Comment | Responding to IL-6 in the bioassay. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ACC 23 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB1191 |
| 5637 |
| Comment | Described to produce SCF, IL-1, IL-3, IL-6, G-CSF, GM-CSF, etc. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ACC 35 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB1192 |
| MDA-MB-453 |
| Comment | Human breast carcinoma established from an effusion. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ACC 65 prior to order.Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1193 |
| COLO-320 |
| Comment | Described to produce serotonin, epinephrine. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ACC 144 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB1196 |
| TGBC24TKB |
| Comment | Japanese gallbladder carcinoma established from metastated ascite. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1197 |
| P2UR/K-562 |
| Comment | Expressing P2U receptor acting in signal transduction pathway. |
|---|
| Comment from the depositor | |
|---|
| RCB1198 |
| TUHR4TKB |
| Comment | Japanese renal carcinoma cells. |
|---|
| Comment from the depositor | |
|---|
| RCB1200 |
| MMAc·SF |
| Comment | Serum-free medium-adapted MMAc cells. For SF culture, + insulin, hEGF, hydrocortisone, bovine pituit |
|---|
| Comment from the depositor | |
|---|
| RCB1205 |
| Anti-PT-S1-1B7 |
| Comment | Anti-pertussis toxin subunit S-1 MoAb (IgG2a) producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1208 |
| Anti-PT-S1-10D6 |
| Comment | Anti-pertussis toxin subunit S-1 MoAb (IgG1) producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1209 |
| Anti-PT-S1-8G4 |
| Comment | Anti-pertussis toxin subunit S-1 MoAb (IgG1) producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1212 |
| Anti-PT-S1-3F10 |
| Comment | Anti-pertussis toxin subunit S-1 MoAb (IgG1) producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1214 |
| Anti-PT-S1-4D10 |
| Comment | Anti-pertussis toxin subunit S-1 MoAb (IgG1) producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1215 |
| Anti-PT-S23-11E6 |
| Comment | Anti-pertussis toxin subunit S-2,3 MoAb (IgG1) producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1220 |
| Anti-PT-S2-3A12 |
| Comment | Anti-pertussis toxin subunit S-2 MoAb (IgG1) producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1222 |
| Anti-PT-S2-9G8 |
| Comment | Anti-pertussis toxin subunit S-2 MoAb (IgG1) producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1223 |
| Anti-PT-S3-7E10 |
| Comment | Anti-pertussis toxin subunit S-3 MoAb (IgG1) producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1229 |
| Anti-PT-S4-7F2 |
| Comment | Anti-pertussis toxin subunit S-4 MoAb (IgG1) producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1233 |
| Anti-PT-S4-1H2 |
| Comment | Anti-pertussis toxin subunit S-4 MoAb (IgG1) producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1238 |
| Anti-FHA(2)2E9 |
| Comment | Anti-pertussis filamentous hemagglutinin (FHA) MoAb producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1239 |
| Anti-FHA(1)1C6 |
| Comment | Anti-pertussis filamentous hemagglutinin (FHA) MoAb producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1240 |
| Anti-α(1)1C6F4 |
| Comment | MoAb to Clostridium perfringens alpha-toxin (phospholipase C). |
|---|
| Comment from the depositor | |
|---|
| RCB1243 |
| Anti-α(4)11D9G5 |
| Comment | MoAb to Clostridium perfringens alpha-toxin (phospholipase C). |
|---|
| Comment from the depositor | |
|---|
| RCB1244 |
| Anti-α(5)11D10B6 |
| Comment | MoAb to Clostridium perfringens alpha-toxin (phospholipase C). |
|---|
| Comment from the depositor | |
|---|
| RCB1246 |
| Anti-α(7)7C9A10 |
| Comment | MoAb to Clostridium perfringens alpha-toxin (phospholipase C). |
|---|
| Comment from the depositor | |
|---|
| RCB1247 |
| Anti-α(8)9F3A6 |
| Comment | MoAb to Clostridium perfringens alpha-toxin (phospholipase C). |
|---|
| Comment from the depositor | |
|---|
| RCB1248 |
| Anti-α(9)12G8B11 |
| Comment | MoAb to Clostridium perfringens alpha-toxin (phospholipase C). |
|---|
| Comment from the depositor | |
|---|
| RCB1250 |
| Anti-θ(1)3H10 |
| Comment | MoAb to Clostridium perfringens theta-toxin. |
|---|
| Comment from the depositor | |
|---|
| RCB1264 |
| tsBN2 |
| Comment | Temperature-sensitive mutant of BHK-21. Causing premature chromosome condensation. |
|---|
| Comment from the depositor | |
|---|
| RCB1267 |
| tsBN7 |
| Comment | Temperature-sensitive mutant of BHK-21 with mutated DAD1 gene. Causing apoptosis at 39.5 C. |
|---|
| Comment from the depositor | |
|---|
| RCB1268 |
| tsBN462 |
| Comment | Temperature-sensitive mutant of BHK-21. Complemented with human X-linked CCG1 gene. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1269 |
| tsBN75 |
| Comment | Temperature-senstive mutant of BHK-21. Complemented with ubiquitin-activating enzyme E1 cDNA. |
|---|
| Comment from the depositor | |
|---|
| RCB1270 |
| tsBN51 |
| Comment | Temperature-sensitive mutant of BHK-21 with defect in RNA polymerase III subunit. |
|---|
| Comment from the depositor | |
|---|
| RCB1271 |
| tsBN67 |
| Comment | Temperature-sensitive mutant of BHK-21. Stop growth after 2-day culture at 39.5 C. |
|---|
| Comment from the depositor | |
|---|
| RCB1272 |
| tsBN250 |
| Comment | Temperature-sensitive mutant of BHK-21. Complementation group A. Dye rapidly at 39.5 C. |
|---|
| Comment from the depositor | |
|---|
| RCB1273 |
| tsBN269 |
| Comment | Temperature-sensitive mutant of BHK-21 selected after MNNG treatment. |
|---|
| Comment from the depositor | |
|---|
| RCB1275 |
| TUHR10TKB |
| Comment | Japanese renal carcinoma cells expressing HLA-A2402. |
|---|
| Comment from the depositor | |
|---|
| RCB1278 |
| MtT/E |
| Comment | Rat cell line derived from pituitary tumor. Estrogen-induced tumor. Producing no pituitary hormone. Four cell lines (MtT/E, MtT/S, MtT/SM, MtT/Se) were established simultaneously.Application consideration. |
|---|
| Comment from the depositor | |
|---|
| RCB1279 |
| TtT/GF |
| Comment | Mouse cell line derived from pituitary tumor (thyrotropin-producing tumor). Pituitary folliculo-stellate-like cells. FGF-dependent cell line. GFAP positive. S-100 positive. Said producing IL-6. |
|---|
| Comment from the depositor | |
|---|
| RCB1280 |
| TGBC50TKB |
| Comment | 3 cell lines from different metastases were established from the same patient. See TGBC51TKB. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1281 |
| TGBC51TKB |
| Comment | 3 cell lines from different metastases were established from the same patient. See TGBC52TKB. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1282 |
| TGBC52TKB |
| Comment | 3 cell lines from different metastases were established from the same patient. See TGBC50TKB. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1283 |
| B16 melanoma |
| Comment | Mouse melanoma producing melanin. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1284 |
| B16 melanoma/lacZ |
| Comment | Mouse melanoma expressing E.coli lac Z. Strongly positive with beta-galactosidase. |
|---|
| Comment from the depositor | |
|---|
| RCB1285 |
| 3A21 |
| Comment | Anti-ribonuclease A antibody producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1286 |
| ECPC-3 |
| Comment | Choroid plexus carcinoma cell line transfected with IgH enhancer-SV40 T fusion gene. |
|---|
| Comment from the depositor | |
|---|
| RCB1287 |
| ECPC-4 |
| Comment | Choroid plexus carcinoma cell line transfected with IgH enhancer-SV40 T fusion gene. Different shape |
|---|
| Comment from the depositor | |
|---|
| RCB1290 |
| OIH-1 |
| Comment | A human cell line derived from acute myeloid leukemia (AML). AML was originated from MDS. Possessing a mutation in DCC gene. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1292 |
| RBE |
| Comment | Human intrahepatic cholangiocarcinoma.Please read carefully this information before use. |
|---|
| Comment from the depositor | |
|---|
| RCB1293 |
| SSP-25 |
| Comment | Human intrahepatic cholangiocarcinoma. Please read carefully this information before use. |
|---|
| Comment from the depositor | |
|---|
| RCB1294 |
| HRC-17 |
| Comment | Hybridoma producing anti-E antigen of the human Rh blood group system |
|---|
| Comment from the depositor | |
|---|
| RCB1296 |
| HNT-34 |
| Comment | A human cell line derived from acute myeloid leukemia (AML). AML was originated from CMMoL. Possessing Philadelphia chromosome and t(3;3)(q21;q26). Expressing EVI1 and BCR/ABL. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1297 |
| HYT-1 |
| Comment | A human cell line derived from acute myeloid leukemia (AML). Secondary AML. Able to differentiate to megakaryocyte-like cells. |
|---|
| Comment from the depositor | |
|---|
| RCB1303 |
| anti-αA-crystallin |
| Comment | Anti-chick αA-crystallin MoAb producing. Bacteria(+), therefore, must add penicillin+streptomycin. |
|---|
| Comment from the depositor | |
|---|
| RCB1304 |
| anti-αB-crystallin |
| Comment | Anti-chick αB-crystallin MoAb producing. Bacteria(+), therefore, must add penicillin+streptomycin. |
|---|
| Comment from the depositor | |
|---|
| RCB1305 |
| anti-β5-crystallin |
| Comment | Anti-chick β5-crystallin MoAb producing. Bacteria(+), therefore, must add penicillin+streptomycin. |
|---|
| Comment from the depositor | |
|---|
| RCB1306 |
| anti-β6-crystallin |
| Comment | Anti-chick β6-crystallin MoAb producing. Bacteria(+), therefore, must add penicillin+streptomycin. |
|---|
| Comment from the depositor | |
|---|
| RCB1307 |
| anti-γ1-crystallin |
| Comment | Anti-newt γ1-crystallin MoAb producing. Bacteria(+), therefore, must add penicillin+streptomycin. |
|---|
| Comment from the depositor | |
|---|
| RCB1308 |
| anti-δ-crystallin |
| Comment | Anti-chick δ-crystallin MoAb producing. Bacteria(+), therefore, must add penicillin+streptomycin. |
|---|
| Comment from the depositor | |
|---|
| RCB1311 |
| C3H/HeN-emb |
| Comment | Mouse(C3H/HeN Jcl) embryonic fibroblasts cultured under the 3T3 schedule. |
|---|
| Comment from the depositor | |
|---|
| RCB1312 |
| C57BL/6J-emb |
| Comment | Mouse(C57BL/6J) embryonic fibroblasts cultured under the 3T3 schedule. |
|---|
| Comment from the depositor | |
|---|
| RCB1313 |
| RERF-LC-KJ |
| Comment | Japanese lung adenocarcinoma, highly metastatic in SCID mice. Also refer to RCB0444 RCRF-LC-AI. |
|---|
| Comment from the depositor | |
|---|
| RCB1316 |
| CTB-1 |
| Comment | Fas-antigen expressing. Ligation with anti-Fas mAb does not induce apoptosis. |
|---|
| Comment from the depositor | |
|---|
| RCB1317 |
| KU-SN |
| Comment | Rare peripheral neuroectodermal tumor cells. Use collagen-coated dish. |
|---|
| Comment from the depositor | |
|---|
| RCB1366 |
| HuH-7 |
| Comment | Said producing alpha-fetoprotein, alpha-antitrypsin, ceruloplasmin, fibrinogen, fibronectin, etc. |
|---|
| Comment from the depositor | |
|---|
| RCB1367 |
| HuH-6 |
| Comment | Hepatoblastoma. Said albumin and alpha-fetoprotein producing. |
|---|
| Comment from the depositor | |
|---|
| RCB1369 |
| NBT-T1 |
| Comment | A subline of NBT-II. Low invasive bladder carcinoma. Relatively high cadherin expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1370 |
| NBT-T2 |
| Comment | A subline of NBT-II. Almost non-invasive bladder carcinoma. Relatively high cadherin expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1371 |
| NBT-L1 |
| Comment | A subline of NBT-II. Invasive bladder carcinoma. Relatively low cadherin expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1372 |
| NBT-L2a |
| Comment | A subline of NBT-II. Highly invasive bladder carcinoma. Relatively low cadherin expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1373 |
| NBT-L2b |
| Comment | A subline of NBT-II. The most invasive bladder carcinoma. Relatively low cadherin expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1374 |
| 1-8 |
| Comment | CITES. CAG-loxP-neopA-loxP-LacZ(incomplete) was inserted. Control cell line for 2-2 and 2-7 cells. Monkey cell lines require import and export permits according to the Convention on International Trade in Endangered Species (CITES). Origin animal species details |
|---|
| Comment from the depositor | |
|---|
| RCB1375 |
| 2-2 |
| Comment | CITES. 35 copies of CAG-loxP-neopA-loxP-LacZ were tandemly inserted. Cre will delete neopA and induce LacZ. Monkey cell lines require import and export permits according to the Convention on International Trade in Endangered Species (CITES). Origin animal species details |
|---|
| Comment from the depositor | |
|---|
| RCB1376 |
| 2-7 |
| Comment | CITES. A copy of CAG-loxP-neopA-loxP-LacZ was inserted. Cre will delete neopA and induce LacZ. Monkey cell lines require import and export permits according to the Convention on International Trade in Endangered Species (CITES). Origin animal species details |
|---|
| Comment from the depositor | |
|---|
| RCB1377 |
| 32Dcl3 |
| Comment | Mouse IL-3 dependent cells cloned from 32D. Differentiate with G-CSF stimulation. Conditioned medium. |
|---|
| Comment from the depositor | |
|---|
| RCB1378 |
| MuSS |
| Comment | A-Jackson mouse-derived histiocyte-like cells from spontaneous sarcoma. |
|---|
| Comment from the depositor | |
|---|
| RCB1382 |
| CF1TKB |
| Comment | Japanese cystic fibrosis fibroblast. |
|---|
| Comment from the depositor | |
|---|
| RCB1383 |
| TUHR14TKB |
| Comment | Japanese renal carcinoma cells. |
|---|
| Comment from the depositor | |
|---|
| RCB1422 |
| L929 |
| Comment | TNFalpha-sensitive L929. Do not confuse with RCB0081 L929 that is insensitive to TNFalpha. |
|---|
| Comment from the depositor | |
|---|
| RCB1423 |
| BHK-21 |
| Comment | The parent cell line used for the temperature sensitive cell line series of BN. |
|---|
| Comment from the depositor | |
|---|
| RCB1425 |
| LCAM1 |
| Comment | Human lung cancer derived cell. |
|---|
| Comment from the depositor | |
|---|
| RCB1426 |
| PMF-ko14 |
| Comment | Stopped distribution.. Until September 2023, we have distributed this cell line as “Japanese colon carcinoma cell line. Family of the patient also exhibited high risk, but not so-called HNPCC.” This cell line was a mix-up of KM12, a colon carcinoma cell line registered in the National Cancer Institute of USA. |
|---|
| Comment from the depositor | |
|---|
| RCB1429 |
| SN-512 |
| Comment | A human cell line derived from acute myeloid leukemia (AML, M2). |
|---|
| Comment from the depositor | |
|---|
| RCB1433 |
| TEN |
| Comment | Human cell line derived from endometrial cancer. Clear cell carcinoma. Said c-erb-2(+), cathepsin D(+), CA125(+) in a part of cells. |
|---|
| Comment from the depositor | |
|---|
| RCB1434 |
| KE-39 |
| Comment | Human cell line derived from gastric cancer |
|---|
| Comment from the depositor | |
|---|
| RCB1435 |
| KE-97 |
| Comment | Stopped distribution. Until 2022, this cell line has been distributed as “Human cell line derived from intraperitoneal metastasis of gastric cancer”. However, this cell line was proved to be derived from B cells, and thus we stopped the distribution. |
|---|
| Comment from the depositor | |
|---|
| RCB1437 |
| AW-EBV-LCL |
| Comment | B95-8 EB virus transformed B cell line (derived from B cells present in a patient suffering from leukemia). |
|---|
| Comment from the depositor | |
|---|
| RCB1438 |
| TW-EBV-LCL |
| Comment | B95-8 EB virus transformed (originally normal) B cell line. |
|---|
| Comment from the depositor | |
|---|
| RCB1440 |
| ATN-1 |
| Comment | BSL2. Adult T-cell leukemia. HTLV-1 pro-virus DNA(+). Based on the information by depositor; this cell line possesses HTLV-1 pro-virus DNA. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | |
|---|
| RCB1444 |
| MBHL-2 |
| Comment | Insect cell line derived from Mamestra brassicae. |
|---|
| Comment from the depositor | |
|---|
| RCB1445 |
| MBHL-3 |
| Comment | Insect cell line derived from Mamestra brassicae |
|---|
| Comment from the depositor | |
|---|
| RCB1449 |
| C7 |
| Comment | p53 deficient mouse bone marrow derived cell. Useful for study of p53 suppressor oncogene. |
|---|
| Comment from the depositor | |
|---|
| RCB1450 |
| LM8 |
| Comment | A highly metastatic cell line derived from Dunn's osteosarcoma (C3H mouse origin). |
|---|
| Comment from the depositor | |
|---|
| RCB1451 |
| L929 |
| Comment | Sanford's original, brought by Katsuta at 7/5/1955. Insensitive to TNFalpha. Possible to culture in MEM medium. |
|---|
| Comment from the depositor | |
|---|
| RCB1456 |
| RCR-1 |
| Comment | Astroglia cell line. Possible to culture in DMEM medium. See RCB0075. |
|---|
| Comment from the depositor | |
|---|
| RCB1460 |
| PCM6 |
| Comment | Human myeloma cell. |
|---|
| Comment from the depositor | |
|---|
| RCB1464 |
| DT40 |
| Comment | Chicken B cell line transformed by avian leukosis virus. c-myc and IgM expressing. |
|---|
| Comment from the depositor | |
|---|
| RCB1465 |
| SHIP^(-) DT40 |
| Comment | SHIP deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1466 |
| SHP1^(-) DT40 |
| Comment | SHP1 deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1467 |
| IP3R^(-) DT40 |
| Comment | IP3R(type1,type2,type3) deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1468 |
| Btk^(-) DT40 |
| Comment | Btk deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1469 |
| PLC-γ2^(-) DT40 |
| Comment | PLC-γ2 deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1470 |
| Syk^(-) DT40 |
| Comment | Syk deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1471 |
| Lyn^(-) DT40 |
| Comment | Lyn deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1472 |
| M |
| Comment | Capable to form collagen network. Possible to culture in DMEM medium. See RCB0067. |
|---|
| Comment from the depositor | |
|---|
| RCB1473 |
| LYM-1 |
| Comment | Sticky cell from lymph node. Possible to culture in DMEM medium. |
|---|
| Comment from the depositor | |
|---|
| RCB1474 |
| RLC-16 |
| Comment | Epithelial cell from rat liver. Possible to culture in DMEM medium. |
|---|
| Comment from the depositor | |
|---|
| RCB1477 |
| CHO-RD |
| Comment | Subline of CHO cells. Derived from CHO-K1 cell line. Serum-free medium adapted. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1483 |
| OV2944-HM-1 |
| Comment | Lymphnode-metastatic ovarian tumor. So called HM-1 cells. |
|---|
| Comment from the depositor | |
|---|
| RCB1484 |
| RLC-18 |
| Comment | Non tumorigenic in nude mice. Possible to culture in DMEM medium. |
|---|
| Comment from the depositor | |
|---|
| RCB1486 |
| JTC-19 |
| Comment | Rat lung fibroblast once said interferon-producing. Possible to culture in DMEM medium. See RCB0074 . |
|---|
| Comment from the depositor | |
|---|
| RCB1487 |
| MY-EBV-LCL |
| Comment | B95-8 EB virus transformed (originally normal) B cell line. |
|---|
| Comment from the depositor | |
|---|
| RCB1489 |
| RLC-27 |
| Comment | Liver-derived cell, tumorigenic in nude mice. Possible to culture in DMEM medium. |
|---|
| Comment from the depositor | |
|---|
| RCB1495 |
| FU-RPNT-1 |
| Comment | Scarcely found primitive neuroectodermal tumor from a Japanese kidney. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1498 |
| Grap^(-) DT40 |
| Comment | Grap deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1499 |
| Grb2^(-) DT40 |
| Comment | Grb2 deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1500 |
| Lyn^(-)/Syk^(-) DT40 |
| Comment | Lyn and Sky deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1501 |
| SHP1^(-)/SHP2^(-) DT40 |
| Comment | SHP1 and SHP2 deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1502 |
| SHP2^(-) DT40 |
| Comment | SHP2 deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1503 |
| Shc^(-) DT40 |
| Comment | Shc deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1506 |
| clone YP1N25 |
| Comment | Subline of mouse C127 cell line. Inducible expression of influenza virus protein (PB1, NP) is possible. |
|---|
| Comment from the depositor | |
|---|
| RCB1507 |
| clone YP1N27 |
| Comment | A subline of C127. PB1 RNA polymerase subunit and nucleoprotein are inducible by dexamethasone. |
|---|
| Comment from the depositor | |
|---|
| RCB1508 |
| clone 76 |
| Comment | Subline of mouse C127 cell line. Inducible expression of influenza virus protein (PB1, NP, PA, PB2) is possible. |
|---|
| Comment from the depositor | |
|---|
| RCB1509 |
| clone 64 |
| Comment | Subline of mouse C127 cell line. Inducible expression of influenza virus protein (PB1, NP, PA) is possible. |
|---|
| Comment from the depositor | |
|---|
| RCB1510 |
| BLNK^(-) DT40 |
| Comment | BLNK deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1512 |
| MH7A |
| Comment | Rheumatoid fibroblast-like synoviocyte transformed with SV40 T antigen. Respond to IL-1beta. |
|---|
| Comment from the depositor | |
|---|
| RCB1513 |
| HOMM |
| Comment | Human cell line derived from melanoma occurred in uterine cervix. Possessing melanin granules. |
|---|
| Comment from the depositor | |
|---|
| RCB1514 |
| HOCE |
| Comment | Stopped distribution due to the limited proliferation capacity. Human cell line derived from choriocarcinoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1517 |
| A-6(ES derived) |
| Comment | Mouse ES ( AES0001 H-1 ) cell derived cell, useful for study of hematopoiesis. |
|---|
| Comment from the depositor | |
|---|
| RCB1518 |
| SS-A3-1 |
| Comment | F344 male rat fibrosarcoma cells, but with histiocytic and/or myofibroblastic characteristics. |
|---|
| Comment from the depositor | |
|---|
| RCB1520 |
| JHOC-5 |
| Comment | Human cell line derived from ovarian clear cell adenocarcinoma. Said CA125 and CA72-4 producing. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1521 |
| JHOS-2 |
| Comment | Human cell line derived from ovarian serous adenocarcinoma. Said CA125 and CA15-3 producing. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1525 |
| HeLa.S3 |
| Comment | RCB0191 HeLa.S3, that has been cultured in MEM(susp.). This line is cultured in MEM. |
|---|
| Comment from the depositor | |
|---|
| RCB1528 |
| CCP-2 |
| Comment | Bone marrow stroma cell line, depositing calcified matrix on the culture surface. TRAP-positive. |
|---|
| Comment from the depositor | |
|---|
| RCB1530 |
| CCP-7 |
| Comment | Bone marrow stroma cell line, depositing calcified matrix on the culture surface. TRAP-positive. |
|---|
| Comment from the depositor | |
|---|
| RCB1531 |
| CCP-8 |
| Comment | Bone marrow stroma cell line, depositing calcified matrix on the culture surface. TRAP-positive. |
|---|
| Comment from the depositor | |
|---|
| RCB1534 |
| MLC-1-B |
| Comment | Bone marrow stroma cell line, depositing calcified matrix on the culture surface. |
|---|
| Comment from the depositor | |
|---|
| RCB1535 |
| MLC-2-4 |
| Comment | Bone marrow stroma cell line, depositing calcified matrix on the culture surface. |
|---|
| Comment from the depositor | |
|---|
| RCB1536 |
| MLC-6 |
| Comment | Osteoclast-like cell line derived from mouse (C3H/He). |
|---|
| Comment from the depositor | |
|---|
| RCB1537 |
| MLC-7 |
| Comment | Bone marrow stroma cell line, depositing calcified matrix on the culture surface. |
|---|
| Comment from the depositor | |
|---|
| RCB1538 |
| 32Dcl3 |
| Comment | Subclone of 32D cell line. Differentiate to mature granulocytes by G-CSF. Conditioned medium. |
|---|
| Comment from the depositor | |
|---|
| RCB1539 |
| P19.CL6 |
| Comment | Mouse cell line derived from embryonal carcinoma. C3H strain. Following differentiation, beating cardiomyocytes appear. The efficiency of differentiation is lower compared to RCB 2318. |
|---|
| Comment from the depositor | |
|---|
| RCB1541 |
| HFL9t |
| Comment | Human fibroblasts derived from fetal lung (19 weekly age). 47,+del(9)(q12). RCB1542 is derived from the same fetus. |
|---|
| Comment from the depositor | |
|---|
| RCB1542 |
| HFSK9t |
| Comment | Human fibroblasts derived from fetal skin (19 weekly age). 47,+del(9)(q12). RCB1541 is derived from the same fetus. |
|---|
| Comment from the depositor | |
|---|
| RCB1543 |
| JHTKI-col-L |
| Comment | Human B cell-like cell line derived from colon cancer tissue. |
|---|
| Comment from the depositor | |
|---|
| RCB1544 |
| JHUAS-1 |
| Comment | Human cell line derived from uterine adenosquamous carcinoma. Said CEA and CA125 producing. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1545 |
| JHUAS-2-L |
| Comment | Human B cell-like cell line derived from uterine cancer tissue (Adenosquamous carcinoma). |
|---|
| Comment from the depositor | |
|---|
| RCB1546 |
| JHOS-3 |
| Comment | Human cell line derived from ovarian serous adenocarcinoma. Said CA125 producing. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1547 |
| JHUCS-1 |
| Comment | Human cell line derived from uterine carcinosarcoma. Nude mouse transplantable. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1548 |
| JHUEM-1 |
| Comment | Human cell line derived from uterine endometrioid adenocarcinoma. Said CA125 and CEA producing. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1549 |
| YSCCC |
| Comment | Human cell line derived from cholangiocellular carcinoma. |
|---|
| Comment from the depositor | |
|---|
| RCB1550 |
| HL-60-R2 |
| Comment | Variant of HL60. Resistant to retinoic acid and active Vit. D derivatives. |
|---|
| Comment from the depositor | |
|---|
| RCB1551 |
| JHUEM-2 |
| Comment | Human cell line derived from uterine endometrioid adenocarcinoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1552 |
| JHUEM-3 |
| Comment | Human cell line derived from uterine endometrioid adenocarcinoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1555 |
| F9 |
| Comment | Said to differentiate to parietal endoderm with retinoic acid and dibutyryl cAMP. |
|---|
| Comment from the depositor | |
|---|
| RCB1558 |
| JHUS-nk1 |
| Comment | Human cell line derived from uterine cervix cancer. Squamous cell carcinoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1560 |
| PWS-Yamaguchi |
| Comment | Prader-Willi syndrome with obesity. del(15) was found in lymphocytes of the patient. |
|---|
| Comment from the depositor | |
|---|
| RCB1561 |
| RML-Yoshi |
| Comment | Severe insulin-resistance by uncleaved insulin proreceptor. G->T mutation in interconnecting region. |
|---|
| Comment from the depositor | |
|---|
| RCB1564 |
| ψCRIP-RxnZ |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express LacZ possessing nuclear localization signal. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1572 |
| ψCRIP-hBax-i-hCD25-CS |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express human Bax. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1573 |
| ψCRIP-ATR-bsr |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express angiotensin receptor and blasticidin S deaminase. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1574 |
| ψCRIP-RxhCD82 |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express human CD82. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1575 |
| ψCRIP-Rx-crmA-bsr |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express anti-apoptotic crmA and blasticidin S deaminase. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1576 |
| ψCRIP-Rx-ETBR-bsr |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express human endothelin receptor and blasticidin S deaminase. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1577 |
| ψCRIP-mPCNF1-bsr |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse calcineurin and blasticidin S deaminase. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1579 |
| ψCRIP-MFG-Z |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express lac Z. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1580 |
| ψCRIP-MFG-T37 |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express SV40 large T antigen. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1581 |
| ψCRIP-MSHR |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express human MSH receptor. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1582 |
| ψCRIP-NCre |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express Cre recombinase. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1583 |
| ψCRIP-hp53-bsr |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express human p53 and blasticidin S deaminase. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1584 |
| ψCRIP-RxBcl-XL-i-bsr |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express human Bcl-xL and blasticidin S deaminase. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1585 |
| ψCRIP-RxhFAS-i-CD80 |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express human FAS and human CD80. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1587 |
| ψCRIP-RxhSecR-bsr |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express human secretin receptor and blasticidin S deaminase. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1588 |
| ψCRIP-hSSR-bsr |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express human somatostatin receptor and blasticidin S deaminase. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1589 |
| ψCRIP-RxmPCNT1-i-bsr |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express a truncated form of mouse calcineurin and blasticidin S deaminase. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1590 |
| ψCRIP-RxhVIPR-bsr |
| Comment | Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express human VIP receptor and blasticidin S deaminase. Long term culture results in decrease of virus production. |
|---|
| Comment from the depositor | |
|---|
| RCB1591 |
| SRA 01/04 |
| Comment | alpha, beta-crystaline expressing human lense epithelial cell line. plasmid DNA: pRSV-B-T Ag. |
|---|
| Comment from the depositor | |
|---|
| RCB1593 |
| OS3 |
| Comment | ori- SV40 DNA transformed C3H mouse brain-derived cells. GFAP+ astrocytes and GFAP- oligodendrocytes |
|---|
| Comment from the depositor | |
|---|
| RCB1597 |
| KKC |
| Comment | Mouse T cell line transformed by Gross leukemia virus. |
|---|
| Comment from the depositor | |
|---|
| RCB1598 |
| NCKA |
| Comment | Mouse T cell line transformed by Gross leukemia virus. |
|---|
| Comment from the depositor | |
|---|
| RCB1600 |
| KKF |
| Comment | Mouse T cell line transformed by Gross leukemia virus. |
|---|
| Comment from the depositor | |
|---|
| RCB1601 |
| KKB |
| Comment | Mouse T cell line transformed by Gross leukemia virus. |
|---|
| Comment from the depositor | |
|---|
| RCB1604 |
| DHA3-1 |
| Comment | Mouse T cell hybridoma expressing double HA-tag alone. |
|---|
| Comment from the depositor | |
|---|
| RCB1605 |
| DHA3-26 |
| Comment | Mouse T cell hybridoma (DO-11.10) expressing double HA-tagged HS1BP3 (HS1 SH3 domain binding protein)-C2. |
|---|
| Comment from the depositor | |
|---|
| RCB1606 |
| DMyc3-45 |
| Comment | Mouse T cell hybridoma (DO-11.10) expressing double Myc-tagged HS1BP3 (HS1 SH3 domain binding protein)-C2 . |
|---|
| Comment from the depositor | |
|---|
| RCB1607 |
| DHA9-3 |
| Comment | Mouse T cell hybridoma (DO-11.10) expressing double HA-tagged HS1BP3 (HS1 SH3 domain binding protein). |
|---|
| Comment from the depositor | |
|---|
| RCB1608 |
| DHA9-13 |
| Comment | Mouse T cell hybridoma (DO-11.10) expressing double HA-tagged HS1BP3 (HS1 SH3 domain binding protein). |
|---|
| Comment from the depositor | |
|---|
| RCB1609 |
| DHA9-15 |
| Comment | Mouse T cell hybridoma (DO-11.10)expressing double HA-tagged HS1BP3 (HS1 SH3 domain binding protein). |
|---|
| Comment from the depositor | |
|---|
| RCB1610 |
| DMyc9-36 |
| Comment | Mouse T cell hybridoma (DO-11.10) expressing double Myc-tagged HS1BP3 (HS1 SH3 domain binding protein). |
|---|
| Comment from the depositor | |
|---|
| RCB1611 |
| M4 |
| Comment | Anti-chicken IgM antibody secreting. Able to stimulate DT40 cell surface antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB1613 |
| HFL-AE-VI |
| Comment | Human fibroblasts derived from lung of anencephalic fetus (18 weekly age). |
|---|
| Comment from the depositor | |
|---|
| RCB1615 |
| HFSKF-AE-VII |
| Comment | Human fibroblasts derived from skin of anencephalic fetus (17 weekly age). RCB1617 and RCB1618 are derived from the same fetus. |
|---|
| Comment from the depositor | |
|---|
| RCB1617 |
| HFL-AE-VII |
| Comment | Human fibroblasts derived from lung of anencephalic fetus (17 weekly age). RCB1615 and RCB1618 are derived from the same fetus. |
|---|
| Comment from the depositor | |
|---|
| RCB1618 |
| HFLI-AE-VII |
| Comment | Human fibroblasts derived from liver of anencephalic fetus (17 weekly age). RCB1615 and RCB1617 are derived from the same fetus. |
|---|
| Comment from the depositor | |
|---|
| RCB1620 |
| ΔDNAPK-DT40 |
| Comment | DNA PK gene deleted DT40 (chicken B cell line). |
|---|
| Comment from the depositor | |
|---|
| RCB1621 |
| ΔKu70-DT40 |
| Comment | Ku70 gene deleted DT40 (chicken B cell line). |
|---|
| Comment from the depositor | |
|---|
| RCB1622 |
| ΔRad51B-DT40 |
| Comment | Rad51B gene deleted DT40 (chicken B cell line). |
|---|
| Comment from the depositor | |
|---|
| RCB1623 |
| ΔRad51C-DT40 |
| Comment | Rad51C gene deleted DT40 (chicken B cell line). |
|---|
| Comment from the depositor | |
|---|
| RCB1624 |
| ΔRad51D-DT40 |
| Comment | Rad51D gene deleted DT40 (chicken B cell line). |
|---|
| Comment from the depositor | |
|---|
| RCB1625 |
| ΔXRCC2-DT40 |
| Comment | XRCC2 gene deleted DT40 (chicken B cell line). |
|---|
| Comment from the depositor | |
|---|
| RCB1626 |
| ΔXRCC3-DT40 |
| Comment | XRCC3 gene deleted DT40 (chicken B cell line). |
|---|
| Comment from the depositor | |
|---|
| RCB1627 |
| ΔRad52-DT40 |
| Comment | Rad52 gene deleted DT40 (chicken B cell line). |
|---|
| Comment from the depositor | |
|---|
| RCB1628 |
| ΔRad54-DT40 |
| Comment | Rad54 gene deleted DT40 (chicken B cell line). |
|---|
| Comment from the depositor | |
|---|
| RCB1629 |
| ΔMre11-DT40(#190) |
| Comment | Mre11 gene deleted DT40 (chicken B cell line), subclone of RCB1630. |
|---|
| Comment from the depositor | |
|---|
| RCB1630 |
| ΔMre11-DT40(#194) |
| Comment | Mre11 gene deleted DT40 (chicken B cell line), subclone of RCB1629. |
|---|
| Comment from the depositor | |
|---|
| RCB1631 |
| ΔRad51+hRad51-DT40 |
| Comment | Rad51 gene deleted and human Rad51 gene inserted DT40 (chicken B cell line). |
|---|
| Comment from the depositor | |
|---|
| RCB1632 |
| ΔKu70ΔRad54B-DT40 |
| Comment | Ku70 and Rad54B gene double-deleted DT40 (chicken B cells). |
|---|
| Comment from the depositor | |
|---|
| RCB1633 |
| ΔMre11ΔKu70-DT40 |
| Comment | Mre11 and Ku70 gene double-deleted DT40 (chicken B cells). |
|---|
| Comment from the depositor | |
|---|
| RCB1634 |
| ΔRad54ΔRad54B-DT40 |
| Comment | Rad54 and Rad54B gene double-deleted DT40 (chicken B cells). |
|---|
| Comment from the depositor | |
|---|
| RCB1635 |
| K-562 |
| Comment | Human cell line derived from chronic myelogenous leukemia. Can produce hemoglobin in the presence of NaB. Directly deposited from the institution that has established this cell line. |
|---|
| Comment from the depositor | |
|---|
| RCB1637 |
| 293 |
| Comment | A human cell line derived from kidney of a fetus. Transformed with sheared human Ad5 DNA. Sensitive to human adenoviruses and adenovirus DNA. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 85120602 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB1638 |
| Hepa 1-6 |
| Comment | Mouse cell line derived from hepatoma. Derived from BW7756 tumour in a C57L mouse. Secretes several products such as albumin, alpha-fetoprotein, alpha 1-antitrypin and amylase. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 92110305 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB1639 |
| LoVo |
| Comment | CEA-producing colon adenocarcinoma. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 87060101 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB1640 |
| DAUDI |
| Comment | Burkitt's lymphoma. Sensitive to lymphokine-activated killer cells but resistant to natural killer cells. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 85011437 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB1641 |
| EL4 |
| Comment | 9,10-dimethyl-1,2benzanthracene induced lymphoma. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 85023105 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB1642 |
| 3T3 Swiss Albino |
| Comment | Contact inhibition. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 85022108 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB1644 |
| BeWo |
| Comment | It was initiated from a malignant gestational choriocarcinoma of the fetal placenta. Need to check response to hormones before use. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 86082803 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB1645 |
| Y79 |
| Comment | Caucasian retinoblastoma. May have reverse transcriptase. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 86093003 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB1647 |
| RAJI |
| Comment | Burkitt's lymphoma. Sensitive to LAK cells but resistant to NK cells. Back up of culture ECA2673. Resistant to VSV. This cell line carries the latent Epstein-Barr Virus (EBV) genome and is positive for EBNA. RAJI is sometimes referred to as a 'non-producer'; the EBV genome carries deletions attributed to preventing the formation of virus particles. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 85011429 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB1648 |
| Hep G2 |
| Comment | Human cell line derived from hepatoblastoma. Secretes several products such as albumin, alpha2-macroglobulin, alpha 1-antitrypsin, transferrin and plasminogen. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECACC 85011430 prior to order. Information |
|---|
| Comment from the depositor | |
|---|
| RCB1649 |
| ΔAtm-DT40 |
| Comment | ATM gene deleted DT40 (chicken B cells). |
|---|
| Comment from the depositor | |
|---|
| RCB1650 |
| ΔAtmΔKu70-DT40 |
| Comment | ATM and Ku70 gene double-deleted DT40 (chicken B cells). |
|---|
| Comment from the depositor | |
|---|
| RCB1651 |
| ΔAtmΔRad54+hRad54-DT40 |
| Comment | ATM and Rad54 gene double-deleted DT40 (chicken B cells). Inducible expression of human Rad54 is possible. |
|---|
| Comment from the depositor | |
|---|
| RCB1652 |
| G1MF285D |
| Comment | Hybridoma that produce anti-human G1MF (allotype of IgG1) antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB1668 |
| 293/CrmA |
| Comment | A subline of 293. Expressing caspase-inhibiting CrmA gene. |
|---|
| Comment from the depositor | |
|---|
| RCB1672 |
| ΔRad54+hRad54-DT40 |
| Comment | Rad54 gene deleted DT40 (chicken B cells). Inducible expression of human Rad54 is possible. |
|---|
| Comment from the depositor | |
|---|
| RCB1675 |
| Cbl^(-) DT40 |
| Comment | Cbl deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1676 |
| JHOM-1 |
| Comment | Human cell line derived from ovarian mucinous adenocarcinoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1677 |
| JHUEM-7 |
| Comment | Human cell line derived from uterine endometrioid adenocarcinoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1678 |
| JHOS-4 |
| Comment | Human cell line derived from ovarian serous cyst adenocarcinoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1680 |
| TUHR25TKB |
| Comment | Human cell line derived from kidney cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB1681 |
| GS-HepG2 |
| Comment | A subline of Hep G2. Expressing abundant glutamine synthetase. Information |
|---|
| Comment from the depositor | |
|---|
| RCB1682 |
| JHOM-2B |
| Comment | Human cell line derived from ovarian mucinous tubular adenocarcinoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1687 |
| ΔRad54ΔKu70-DT40 |
| Comment | Rad54 and Ku70 gene double-deleted DT40 (chicken B cells). |
|---|
| Comment from the depositor | |
|---|
| RCB1688 |
| JHOC-7 |
| Comment | Human cell line derived from ovarian clear cell carcinoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1690 |
| CPN4B |
| Comment | Cell line derived from embryo of Cynops pyrrhogaster. |
|---|
| Comment from the depositor | |
|---|
| RCB1691 |
| Tpit/F1 |
| Comment | Pituitary folliculo-stellate-like cell line. Derived from a transgenic mouse expressing temperature sensitive SV40 large T antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB1692 |
| Tpit/E |
| Comment | Vascular endothelial cell-like cell line derived from an anterior pituitary gland of a transgenic mouse expressing temperature sensitive SV40 large T antigen. Producing endothelin. |
|---|
| Comment from the depositor | |
|---|
| RCB1695 |
| RMS-YM |
| Comment | Embryonal rhabdomyosarcoma cell line derived from human. Transplantable in nude mouse. |
|---|
| Comment from the depositor | |
|---|
| RCB1696 |
| SPB-1 |
| Comment | Serine-palmitoyl transferase deficient (temperature-sensitive) cells derived from CHO-K1 cell line. |
|---|
| Comment from the depositor | |
|---|
| RCB1697 |
| SPB-1/cLCB1 |
| Comment | SPB-1 derivative complemented the Serine-palmitoyl transferase deficiency. |
|---|
| Comment from the depositor | |
|---|
| RCB1698 |
| LY-B |
| Comment | Serine-palmitoyl transferase (LCB1 subunit) deficient cells derived from CHO-K1 cell line. |
|---|
| Comment from the depositor | |
|---|
| RCB1699 |
| LY-B/cLCB1 |
| Comment | LY-B derivative complemented the Serine-palmitoyl transferase (LCB1 subunit) deficiency. |
|---|
| Comment from the depositor | |
|---|
| RCB1701 |
| MY |
| Comment | Human cell line derived from p180-BCR-ABL dependent leukemia. |
|---|
| Comment from the depositor | |
|---|
| RCB1702 |
| SLVL |
| Comment | Human cell line derived from splenic B cell lymphoma. |
|---|
| Comment from the depositor | |
|---|
| RCB1704 |
| BLNK^(-)/Syk^(-) DT40 |
| Comment | BLNK and Syk deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1705 |
| JHCA-ov |
| Comment | Human cell line derived from metastasis at ovary of colon cancer. Moderately differentiated adenocarcinoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1706 |
| JHCOLOYI |
| Comment | Human cell line derived from rectal cancer. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1708 |
| JHTSK-col-L |
| Comment | Human B cell-like cell line derived from colon cancer tissue. |
|---|
| Comment from the depositor | |
|---|
| RCB1709 |
| GE1 |
| Comment | Mouse-derived gingival epithelial cell line. Derived from SV40-Large T antigen transgenic mouse. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1716 |
| BCAP^(-) DT40 |
| Comment | BCAP deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1717 |
| IP3R type1^(-)/2^(-) DT40 |
| Comment | IP3R type1 and IP3R type2 deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1718 |
| IP3R type1^(-)/3^(-) DT40 |
| Comment | IP3R type1 and IP3R type3 deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1719 |
| IP3R type2^(-)/3^(-) DT40 |
| Comment | IP3R type2and IP3R type3 deficient DT40 |
|---|
| Comment from the depositor | |
|---|
| RCB1721 |
| JHUCS-3 |
| Comment | Human cell line derived from uterine cervix cancer. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1723 |
| JHOC-8 |
| Comment | Human cell line derived from ovarian clear cell adenocarcinoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1724 |
| JHSK-rec |
| Comment | Human cell line derived from rectal cancer. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1728 |
| Hpr-4 |
| Comment | H2O2 resistant Chinese Hamster V79 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1731 |
| TM-31 |
| Comment | Human cell line derived from astrocytoma developed in a patient with NF-1 (neurofibromatosis type 1) |
|---|
| Comment from the depositor | |
|---|
| RCB1734 |
| LAH3 |
| Comment | Melanophore derived cell line. Derived from Rana porosa brevipoda (albino). |
|---|
| Comment from the depositor | |
|---|
| RCB1741 |
| NHOS |
| Comment | Mouse osteosarcoma cell line. Transplantable to mouse and form bone tissue in mouse. |
|---|
| Comment from the depositor | |
|---|
| RCB1747 |
| ΔNBS1-DT40 |
| Comment | Subline of DT40 (chicken B cell line), lacking Nbs1 expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1749 |
| ΔDinB-DT40 |
| Comment | Subline of DT40 cell line, lacking DinB expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1750 |
| ΔRad18-DT40 |
| Comment | Subline of DT40 cell line, lacking Rad18 expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1752 |
| BS-SHI-4M |
| Comment | Human cell line derived from Bloom syndrome patient. Transformed by EBV. Can express certain antigen on the cell surface, such as cancer-specific antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB1753 |
| KMY-J |
| Comment | Meningioma derived cell line. Derived from rat F344. |
|---|
| Comment from the depositor | |
|---|
| RCB1754 |
| KMY-1 |
| Comment | Subline of KMY-J. Fibroblast-like. |
|---|
| Comment from the depositor | |
|---|
| RCB1755 |
| KMY-2 |
| Comment | Subline of KMY-J. Epithelial-like. |
|---|
| Comment from the depositor | |
|---|
| RCB1756 |
| KMY-3 |
| Comment | Subline of KMY-J. Polyploidy. |
|---|
| Comment from the depositor | |
|---|
| RCB1757 |
| HS-P |
| Comment | Rat cell line derived from histiocytic sarcoma. Possessing characteristics of macrophage. |
|---|
| Comment from the depositor | |
|---|
| RCB1759 |
| ΔDNAPKΔKu70-DT40 |
| Comment | Subline of DT40 cell line, lacking both of DNAPK and Ku70 expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1764 |
| ΔRev3-DT40 |
| Comment | Subline of DT40 cell line, lacking Rev3 expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1766 |
| ΔligIV-DT40 |
| Comment | Subline of DT40 cell line, lacking ligase IV expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1767 |
| ΔRad52ΔXRCC3-DT40 |
| Comment | Subline of DT40 cell line, lacking both of Rad52 and XRCC3 expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1768 |
| ΔXRCC3-cond1-DT40 |
| Comment | Subline of DT40 cell line, which lacks XRCC3 inducibly by tamoxifen. |
|---|
| Comment from the depositor | |
|---|
| RCB1769 |
| ΔXRCC3-cond2-DT40 |
| Comment | Subline of DT40 cell line, which lacks XRCC3 inducibly by tamoxifen. |
|---|
| Comment from the depositor | |
|---|
| RCB1770 |
| XRCC3+/--DT40 |
| Comment | Subline of DT40 cell line, lacking XRCC3 only in one allele. |
|---|
| Comment from the depositor | |
|---|
| RCB1771 |
| Lu-24 |
| Comment | Human cell line derived from lung cancer. Oat cell type. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1772 |
| Lu-141 |
| Comment | Human cell line derived from lung cancer. Small cell carcinoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1773 |
| Lu-143 |
| Comment | Human cell line derived from lung cancer. Small cell carcinoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1785 |
| Lu-138 |
| Comment | Human cell line derived from lung cancer. Small cell carcinoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1788 |
| AT805 |
| Comment | Mouse teratoma-derived cell line. Parent cell line of ATDC5. |
|---|
| Comment from the depositor | |
|---|
| RCB1790 |
| P19C6 |
| Comment | Embryonal carcinoma cell line derived from mouse C3H. Differentiate to nervous system. |
|---|
| Comment from the depositor | |
|---|
| RCB1791 |
| PCC3/A/1 |
| Comment | Mouse teratoma-derived cell line. |
|---|
| Comment from the depositor | |
|---|
| RCB1792 |
| SIL-6/1 |
| Comment | Subline of A-6. Dependent on SCF and IL-6 for proliferation. Differentiate to erythroid cells by IL-3. |
|---|
| Comment from the depositor | |
|---|
| RCB1794 |
| ΔRad18ΔXPA-DT40 |
| Comment | Subline of DT40 cell line, lacking both of Rad18 and XPA expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1795 |
| ΔRad18ΔDinB-DT40 |
| Comment | Subline of DT40 cell line, lacking both of Rad18 and DinB expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1797 |
| BP7(R80) |
| Comment | Rat renal tumor derived cell line. |
|---|
| Comment from the depositor | |
|---|
| RCB1798 |
| BP11(R2) |
| Comment | Rat (Wistar) cell line derived from renal (kidney) tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB1799 |
| BP11(R100) |
| Comment | Rat (Wistar) cell line derived from renal (kidney) tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB1800 |
| BP13(R2) |
| Comment | Rat cells derived from kidney carcinoma. After passage 2. Wistar rat. |
|---|
| Comment from the depositor | |
|---|
| RCB1801 |
| BP13(R100) |
| Comment | Rat cell line derived from kidney carcinoma. After passage 100. Wistar rat. |
|---|
| Comment from the depositor | |
|---|
| RCB1802 |
| BP26(R2) |
| Comment | Rat cells derived from kidney carcinoma. After passage 2. Wistar rat. |
|---|
| Comment from the depositor | |
|---|
| RCB1803 |
| BP26(R80) |
| Comment | Rat cell line derived from kidney carcinoma. After passage 80. Wistar rat. |
|---|
| Comment from the depositor | |
|---|
| RCB1804 |
| BP30(R2) |
| Comment | Rat cells derived from kidney carcinoma. After passage 2. Wistar rat. |
|---|
| Comment from the depositor | |
|---|
| RCB1805 |
| BP30(R100) |
| Comment | Rat cell line derived from kidney carcinoma. After passage 100. Wistar rat. |
|---|
| Comment from the depositor | |
|---|
| RCB1806 |
| BP36B(R2) |
| Comment | Rat cells derived from kidney carcinoma. After passage 2. Wistar rat. |
|---|
| Comment from the depositor | |
|---|
| RCB1807 |
| BP36B(R100) |
| Comment | Rat cell line derived from kidney carcinoma. After passage 100. Wistar rat. |
|---|
| Comment from the depositor | |
|---|
| RCB1809 |
| Vav3^(-) DT40 |
| Comment | Vav3 deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1810 |
| PI3Kp110α^(-) DT40 |
| Comment | PI3Kp110α deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1811 |
| ΔBLM-DT40 |
| Comment | Subline of DT40 cell line, lacking BLM (Bloom syndrome gene) expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1812 |
| ΔWRN-DT40 |
| Comment | Subline of DT40 cell line, lacking WRN (Werner syndrome gene) expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1813 |
| ΔWRNΔBLM-DT40 |
| Comment | Subline of DT40 cell line, lacking both of WRN (Werner syndrome gene) and BLM (Bloom syndrome gene) expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1814 |
| ΔDinBΔXPA-DT40 |
| Comment | Subline of DT40 cell line, lacking both of DinB and XPA expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1817 |
| DT40(v-myb^+)WT |
| Comment | A subline of avian cell line, DT40, expressing v-myb exogenously. |
|---|
| Comment from the depositor | |
|---|
| RCB1818 |
| DT40(v-myb^+)Δpolβ |
| Comment | A subline of avian cell line, DT40, expressing v-myb exogenously and lacking polβ gene. |
|---|
| Comment from the depositor | |
|---|
| RCB1819 |
| DT40(v-myb^+)Δpolλ |
| Comment | A subline of avian cell line, DT40, expressing v-myb exogenously and lacking polλ gene. |
|---|
| Comment from the depositor | |
|---|
| RCB1820 |
| DT40(v-myb^+)Δpolλβ |
| Comment | A subline of avian cell line, DT40, expressing v-myb exogenously and lacking both polβ and polλ gene. |
|---|
| Comment from the depositor | |
|---|
| RCB1821 |
| CHO-FLAG-hBLT1 |
| Comment | Subline of CHO-K1 that expresses human leukotriene B4 receptor (BLT1). |
|---|
| Comment from the depositor | |
|---|
| RCB1822 |
| CHO-HA-hBLT2 |
| Comment | Subline of CHO-K1 that expresses human leukotriene B4 receptor (BLT2). |
|---|
| Comment from the depositor | |
|---|
| RCB1823 |
| CHO·1F8 |
| Comment | Subline of CHO-K1 that expresses human platelet activating factor receptor. |
|---|
| Comment from the depositor | |
|---|
| RCB1824 |
| TRP1^(-) DT40 |
| Comment | TRP1 deficient DT40 |
|---|
| Comment from the depositor | |
|---|
| RCB1829 |
| SC-1 |
| Comment | Embryonal cell line derived from wild mouse. Sensitive to leukemia viruses. |
|---|
| Comment from the depositor | |
|---|
| RCB1830 |
| Rat-1 |
| Comment | Rat fibroblast-like cell line that can be transformed by oncogenes. |
|---|
| Comment from the depositor | |
|---|
| RCB1831 |
| XC |
| Comment | Cell line for titration of murine leukemia virus. |
|---|
| Comment from the depositor | |
|---|
| RCB1832 |
| THK |
| Comment | SV40 transformed hamster cell line. Fibroblast-like cells. |
|---|
| Comment from the depositor | |
|---|
| RCB1833 |
| Mink |
| Comment | Lung epithelial cell line derived from mink. Useful for focus forming assays for murine leukemia virus. |
|---|
| Comment from the depositor | |
|---|
| RCB1834 |
| S+L-Mink |
| Comment | Mink (RCB1833) cells transformed by Moloney murine sarcoma virus. |
|---|
| Comment from the depositor | |
|---|
| RCB1835 |
| Sirc |
| Comment | Fibroblast-like cell line derived from rabbit. |
|---|
| Comment from the depositor | |
|---|
| RCB1836 |
| Grb2^(-)/Grap^(-) DT40 |
| Comment | Grb2and Grap deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1837 |
| MVP1 |
| Comment | Hybridoma producing a monoclonal antibody against Medaka Vitellogenin. |
|---|
| Comment from the depositor | |
|---|
| RCB1838 |
| MVP25 |
| Comment | Hybridoma producing a monoclonal antibody against Medaka Vitellogenin. |
|---|
| Comment from the depositor | |
|---|
| RCB1839 |
| MVP47 |
| Comment | Hybridoma producing a monoclonal antibody against Medaka Vitellogenin. |
|---|
| Comment from the depositor | |
|---|
| RCB1840 |
| MVP49 |
| Comment | Hybridoma producing a monoclonal antibody against Medaka Vitellogenin. |
|---|
| Comment from the depositor | |
|---|
| RCB1841 |
| MVP51 |
| Comment | Hybridoma producing a monoclonal antibody against Medaka Vitellogenin. |
|---|
| Comment from the depositor | |
|---|
| RCB1845 |
| ΔUbc9+cUbc9-DT40 |
| Comment | Endogenous Ubc9 deficient DT40 cells but expressing Ubc9 exogenously |
|---|
| Comment from the depositor | |
|---|
| RCB1846 |
| HSC-F |
| Comment | CITES. T cell line derived from Cynomolgus Monkey (Macaca fascicularis). Monkey cell lines require import and export permits according to the Convention on International Trade in Endangered Species (CITES). |
|---|
| Comment from the depositor | |
|---|
| RCB1847 |
| ES-8040 20-2 |
| Comment | Erythroleukemia cell line derived from mouse C3H/He. TER119(+) cells. |
|---|
| Comment from the depositor | |
|---|
| RCB1848 |
| ES-8047 2-1 |
| Comment | Erythroleukemia cell line derived from mouse C3H/He. TER119(+) cells. |
|---|
| Comment from the depositor | |
|---|
| RCB1849 |
| C-8049 |
| Comment | Erythroleukemia cell line derived from mouse C3H/He. TER119(+) cells. |
|---|
| Comment from the depositor | |
|---|
| RCB1850 |
| C-8052 |
| Comment | Erythroleukemia cell line derived from mouse C3H/He. TER119(+) cells. |
|---|
| Comment from the depositor | |
|---|
| RCB1851 |
| DT40 Cre1 |
| Comment | A subline of avian cell line, DT40, expressing v-myb/pMerCreMer exogenously (see reference : BMC Biotechnol. 2001;1:7). |
|---|
| Comment from the depositor | |
|---|
| RCB1853 |
| MSH6-1-[ClX3.16]DT40 |
| Comment | A subline of avian cell line, DT40, lacking MSH6 (see reference : BMC Biotechnol. 2001;1:7). |
|---|
| Comment from the depositor | |
|---|
| RCB1854 |
| HSP-239 |
| Comment | CITES. T cell line derived from Chimpanzee (Pan troglodytes). Chimpanzee cell lines require import and export permits according to the Convention on International Trade in Endangered Species (CITES). |
|---|
| Comment from the depositor | |
|---|
| RCB1855 |
| HSP-250 |
| Comment | CITES. T cell line derived from Chimpanzee (Pan troglodytes). Chimpanzee cell lines require import and export permits according to the Convention on International Trade in Endangered Species (CITES). |
|---|
| Comment from the depositor | |
|---|
| RCB1856 |
| TX-7F (hybridoma) |
| Comment | Hybridoma producing a monoclonal antibody against tetrodotoxin. |
|---|
| Comment from the depositor | |
|---|
| RCB1857 |
| DA-3 (hybridoma) |
| Comment | Hybridoma producing a monoclonal antibody against domoic acid. |
|---|
| Comment from the depositor | |
|---|
| RCB1858 |
| GT-13A (hybridoma) |
| Comment | Hybridoma producing a monoclonal antibody against gonyautoxin. |
|---|
| Comment from the depositor | |
|---|
| RCB1859 |
| MDBK-NST |
| Comment | BSL2. A cell line derived from kidney of bovine. FBS independent for culture. A cell line derived from kidney of bovine. Information about BVDV (ATCC) . Information about BVDV (ECACC) . Information about BVDV (DSMZ) . |
|---|
| Comment from the depositor | |
|---|
| RCB1860 |
| BLNK^(-)Grb2^(-)DT40 |
| Comment | BLNK and Grb2 deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1861 |
| T-23 |
| Comment | CITES. Lung fibroblastic cell line derived from Tupaia belangeri. Tupaia cell lines require import and export permits according to the Convention on International Trade in Endangered Species (CITES). |
|---|
| Comment from the depositor | |
|---|
| RCB1862 |
| NIH3T3-3-4 |
| Comment | Subclone of NIH3T3. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1863 |
| GRP1^(-)DT40 |
| Comment | Ras GRP1 deficient DT40 cells |
|---|
| Comment from the depositor | |
|---|
| RCB1864 |
| GRP3^(-)DT40 |
| Comment | Subline of DT40 cell line, lacking RasGRP3 expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1865 |
| GRP1^(-)/GRP3^(-)DT40 |
| Comment | Subline of DT40 cell line, lacking both of RasGRP1 and RasGRP3 expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1866 |
| Sos1^(-)DT40 |
| Comment | Subline of DT40 cell line, lacking Sos1 expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1867 |
| Sos2^(-)DT40 |
| Comment | Subline of DT40 cell line, lacking Sos2 expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1868 |
| Sos1^(-)/Sos2^(-)DT40 |
| Comment | Subline of DT40 cell line, lacking both Sos1 and Sos2 expression. |
|---|
| Comment from the depositor | |
|---|
| RCB1869 |
| LY-A |
| Comment | Subline of CHO-K1 cell line in which trafficking of ceramide is deficient |
|---|
| Comment from the depositor | |
|---|
| RCB1870 |
| LY-A/hCERT |
| Comment | Subline of LY-A in which human CERT cDNA are expressed and trafficking of ceramide is recovered |
|---|
| Comment from the depositor | |
|---|
| RCB1871 |
| TL-1 |
| Comment | Human lymphoid cell line derived from Burkitt's lymphoma. Tumorigenic in nude mouse. TKG0607 (Deposited from Tohoku Univ.). Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1872 |
| A431 |
| Comment | Human cell line derived from epidermoid carcinoma. TKG0182 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1873 |
| JTK-LCL |
| Comment | Human B cell line transformed by Epstein-Barr Virus. HLA: A0206 and A2402. TKG0585 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1874 |
| KOIA-LCL |
| Comment | EBV-transformed cell line from a patient (male) with p53 germ line mutation. Mutation was noted at codon 242 (TGC→TAC) by FASAY. TKG0506 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1875 |
| XPL 5 |
| Comment | Lymphoblastoid cell line established by EBV infection from XP patient, variant type. TKG0309 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1876 |
| 211-LCL-MUC1 |
| Comment | Human B lymphoblastoid cell line (RCB2288 211-LCL) transformed with APR-MUC1 and PRC-MUC1 cDNAs. TKG0615 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1878 |
| RPMI1788 |
| Comment | IgM (lambda) secreting B cell line. Established from peripheral blood lymphocytes of apparently normal 33-y-o male. HLA profile: A2, Aw33, B7, B14. TKG0464 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1879 |
| PEER |
| Comment | Human T cell line derived from acute T cell leukemia. TKG0377 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1881 |
| TL-Mor |
| Comment | BSL2. Human derived T cell line. HTLV-1 pro-virus DNA(+). TKG0369 (Deposited from Tohoku Univ.). Based on the information by depositor; this cell line possesses HTLV-1 pro-virus DNA. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | |
|---|
| RCB1882 |
| BALL-1 |
| Comment | Human cell line derived from B cell leukemia. TKG0467 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1884 |
| H-111-TC |
| Comment | Human cell line derived from gastric cancer. TKG0411 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1886 |
| Hep G2 |
| Comment | Human cell line derived from hepatoblastoma. Secretes several products such as albumin, alpha2-macroglobulin, alpha 1-antitrypsin, transferrin and plasminogen. TKG0205 (Deposited from Tohoku Univ.). Information |
|---|
| Comment from the depositor | |
|---|
| RCB1889 |
| HEp-2 |
| Comment | Supports growth of arvovirus and measles virus. A subline of HeLa cell (HeLa contamination). TKG0403 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1890 |
| MG-63 |
| Comment | Osteosarcoma cell line derived from human. High yield of IFN production by induction with poly IC, cyclohexmide, actinomycin D. Antigenically, MG-63 IFN is closely related to human fibroblast IFN. TKG0294 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1891 |
| HeLa TG |
| Comment | A subline of HeLa. 6-thioguanine resistant. TKG0204 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1892 |
| SKG-IIIa |
| Comment | Cervical carcinoma cell line derived from human. TA-4, CA-4, TPA, placental ALP are positive. Regan isoenzyme producing. p53 normal, p51 mutation (+), HLA-A 2402/. TKG0462 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1894 |
| TE-1 |
| Comment | Human cell line derived from esophageal cancer. Squamous cell carcinoma. TKG0252 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1896 |
| TN-2 |
| Comment | Human cell line derived from neuroblastoma of adrenal gland. TKG0278 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1897 |
| K562 |
| Comment | Human cell line derived from chronic myelogenous leukemia. IMPORTANT NOTICE: Can NOT produce hemoglobin in the presence of NaB. Of note, K562 (RCB0027) and K-562 (RCB1635) can produce hemoglobin in the presence of NaB. TKG0210 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1898 |
| K562/Adr |
| Comment | Subline of K562. Resistant to adriamycin. TKG0211 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1900 |
| Lu99 |
| Comment | Lung giant cell carcinoma cell line derived from human. TKG0495 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1901 |
| PK-59 |
| Comment | Human cell line derived from pancreatic cancer. TKG0492 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1902 |
| HSC-4 |
| Comment | Human tongue squamous cell carcinoma derived cell line. TKG0489 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1903 |
| OVK18 |
| Comment | Human cell line derived from ovarial cancer, subclone of RCB2535. TKG0323 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1904 |
| MCF7 |
| Comment | Human cell line derived from breast adenocarcinoma. TKG0479 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1905 |
| Sq-1 |
| Comment | Human cell line derived from lung squamous cell carcinoma. Many granules are found in cytoplasma. HLA-A 11/24. TKG0301 (Deposited from Tohoku Univ.). Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1907 |
| TKKK |
| Comment | Human cell line derived from intrahepatic bile duct cancer. TKG0456 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1909 |
| 8305C |
| Comment | Human thyroid anaplastic carcinoma derived cell line. TKG0446 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1911 |
| CCD-IC |
| Comment | Rabbit kidney cell line transformed by SV40 large T antigen. Derived from renal cortical collecting tubules. |
|---|
| Comment from the depositor | |
|---|
| RCB1912 |
| CNT |
| Comment | Rabbit kidney cell line transformed by SV40 large T antigen. Derived from renal distal tubules. |
|---|
| Comment from the depositor | |
|---|
| RCB1913 |
| PST-S2 |
| Comment | Rabbit kidney cell line transformed by SV40 large T antigen. Derived from renal proximal tubules. |
|---|
| Comment from the depositor | |
|---|
| RCB1914 |
| BBWV-22K3-9B |
| Comment | Hybridoma producing a monoclonal antibody against Broad bean wilt virus 2 22-kDa coat protein. |
|---|
| Comment from the depositor | |
|---|
| RCB1915 |
| BBWV-22K5-12A |
| Comment | Hybridoma producing a monoclonal antibody against Broad bean wilt virus 2 22-kDa coat protein. |
|---|
| Comment from the depositor | |
|---|
| RCB1916 |
| BBWV-22K6-2A |
| Comment | Hybridoma producing a monoclonal antibody against Broad bean wilt virus 2 22-kDa coat protein. |
|---|
| Comment from the depositor | |
|---|
| RCB1918 |
| J#176-3.2 |
| Comment | Hybridoma producing a monoclonal antibody against mouse JDP2. |
|---|
| Comment from the depositor | |
|---|
| RCB1919 |
| J#214.2-2 |
| Comment | Hybridoma producing a monoclonal antibody against mouse JDP2. The antibody recognizes a truncated from of JDP2. |
|---|
| Comment from the depositor | |
|---|
| RCB1920 |
| J#249.1-1 |
| Comment | Hybridoma producing a monoclonal antibody against mouse JDP2. |
|---|
| Comment from the depositor | |
|---|
| RCB1921 |
| NRG |
| Comment | Mouse bone marrow derived fibroblast-like cells line. Differentiates to neuron. |
|---|
| Comment from the depositor | |
|---|
| RCB1922 |
| 1C7 |
| Comment | Hybridoma producing antibody against the purified basal apparatus of sperm of the an-1 strain of fern Lygodium. |
|---|
| Comment from the depositor | |
|---|
| RCB1923 |
| 13D10 |
| Comment | Hybridoma producing antibody against the purified basal apparatus of sperm of the an-1 strain of fern Lygodium. |
|---|
| Comment from the depositor | |
|---|
| RCB1924 |
| h1c |
| Comment | Hybridoma producing antibody against the purified basal apparatus of sperm of the an-1 strain of fern Lygodium. |
|---|
| Comment from the depositor | |
|---|
| RCB1925 |
| WA-mFib |
| Comment | Mouse stromal cell line for human lung small cell carcinoma cell line, WA-ht. |
|---|
| Comment from the depositor | |
|---|
| RCB1926 |
| OT11 |
| Comment | RBP-J deficient mouse fibroblasts |
|---|
| Comment from the depositor | |
|---|
| RCB1927 |
| OT13 |
| Comment | Control cell line for OT11 (normal fibroblasts derived from the same mouse strain) |
|---|
| Comment from the depositor | |
|---|
| RCB1928 |
| KG-1a |
| Comment | Human cell line derived from acute myelogenous leukemia. The variant subline of KG-1(RCB1166) cell line. TKG0402 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1932 |
| T2 |
| Comment | Human hybrid (T and B lymphoblast) cell line. Fusion cll line between 174 and CEM.T2. This hybrid cells do not express MHC class II. HLA-A2 positive. TKG0599 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1933 |
| NALM-6 |
| Comment | Human cell line derived from B cell leukemia. TKG0413 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1934 |
| HUT78 |
| Comment | Human cell line derived from T cell of a patient with Sezary syndrome. Producing IL-2. TKG0375 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1935 |
| HPB-ALL |
| Comment | Human cell line derived from T cell leukemia. TKG0199 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1936 |
| MOLT-4F |
| Comment | Human T leukemic cell line (CD4+). CR2 receptor (+). TKG0229 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1938 |
| P30/OHK |
| Comment | Human cell line derived from T cell leukemia. TKG0463 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1939 |
| NUGC-4 |
| Comment | Human cell line derived from signet ring cell carcinoma of stomach. TKG0449 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1940 |
| SH-10-TC |
| Comment | Human cell line derived from gastric cancer. Derived from nude mouse xenograft tumor (TKG 0338, SH-10). TKG0412 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1941 |
| Li-7 |
| Comment | Human hepatoma cell line. This cell line was established from nude mouse xenograft tumor (Dr. Hirohashi., National Cancer Center, Tokyo) by Tanno, H. (Tohoku Univ., 1st Surg). AFP producing. TKG0368 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1943 |
| HuH-28 |
| Comment | Human cell line derived from cholangiocellular carcinoma. TKG0438 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1945 |
| HSC-2 |
| Comment | Human cell line derived from oral squamous cell carcinoma occurred in 69-yo, male patient. HLA-A 24/. TKG0487 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1947 |
| Ca Ski |
| Comment | Human cell line derived from uterine cervical epidermoid carcinoma. TKG0366 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1949 |
| TE-5 |
| Comment | Human cell line derived from poorly differntiated esophageal squamous cell carcinoma. Not transplantable to nude mouse. TKG0256 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1950 |
| TE-6 |
| Comment | Highly differentiated squamous carcinoma (esophagus), not transplantable to nude mouse. Progeny were cured by Treatments with BM Cycline and MC210. TKG0257 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1951 |
| TE-15 |
| Comment | Human cell line derived from esophageal cancer (highly differentiated squamous cell carcinoma). Not transplantable to nude mouse. TKG0266 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1952 |
| SCCH-26 |
| Comment | Human neuroblastoma cell line. TKG0460 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1953 |
| NB-1 |
| Comment | Human cell line derived from neuroblastoma. Dibuty-cAMP (1 mM) induces differentiation. TKG0486 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1954 |
| T98G |
| Comment | Human cell line derived from glioblastoma multiforme (Caucasian). Hyperpentaploid chromosome count. TKG0471 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1955 |
| KMST-6 |
| Comment | Human cell line derived from embryonic fibroblasts. Characteristics Embryonal fibroblast immortalized by 60-Co irradiation (400 Rad x 1 time and 200 rad x 12 times). Non-tumorigenic. TKG0482 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1960 |
| HuCCT1 |
| Comment | Human bile duct carcinoma. This cell line produces carbohydrate antigen 19/9 in serum-free medium. TKG0389 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1963 |
| VMRC-RCW |
| Comment | Human renal cell carcinoma cell line. TKG0447 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1965 |
| EBC-1 |
| Comment | Human lung squamous cell carcinoma cell line. TKG0481 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1966 |
| S1 |
| Comment | Human cell line derived from lung cancer. Small cell carcinoma. TKG0244 (Deposited from Tohoku Univ.). Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB1967 |
| LU65 |
| Comment | Human lung carcinoma cell line. TKG0442 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1970 |
| LK-2 |
| Comment | Human lung squamous cell carcinoma cell line. TKG0494 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1971 |
| Lu99B |
| Comment | Human lung giant cell carcinoma cell line. TKG0496 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1972 |
| PK-1 |
| Comment | Human pancreatic carcinoma cell line. RCB2138 was derived from the same patient. TKG0239 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1973 |
| PK-45H |
| Comment | Human pancreatic carcinoma cell line, the same patient as RCB2141. TKG0491 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1974 |
| SAS |
| Comment | Human cell line derived from tongue cancer. Squamous cell carcinoma. TKG0470 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1975 |
| HSC-3 |
| Comment | Human tongue squamous cell carcinoma cell line. HLA-A 2/24. TKG0484 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1976 |
| Ca9-22 |
| Comment | Human gingival carcinoma cell line. Expressing remarkable EGF receptor. HLA-A 2/24. TKG0485 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1980 |
| CCRF-CEM |
| Comment | Human cell line derived from T cell leukemia. TKG0563 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1981 |
| HD-Mar2 |
| Comment | A cell line derived from the pleural effusion of a patient with a recurrent T-lymphoblastic lymphoma after treatment of the originally diagnosed Hodgkin's lymphoma. The characteristics is T cell lymphoma. TKG0198 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1988 |
| TE-9 |
| Comment | Human esophageal squamous cell carcinoma (poorly differentiated) cell line. Not transplantable to nude mouse. TKG0260 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB1990 |
| KUSA-H1 |
| Comment | Mouse bone marrow-derived stromal cells. |
|---|
| Comment from the depositor | |
|---|
| RCB1991 |
| KUSA-O |
| Comment | Mouse multipotent mesenchymal cells. Derived from bone marrow. |
|---|
| Comment from the depositor | |
|---|
| RCB1992 |
| UV♂1d |
| Comment | Mouse cell line derived from UV-induced fibroblast sarcome. |
|---|
| Comment from the depositor | |
|---|
| RCB1993 |
| UV♀1A |
| Comment | Mouse cell line derived from UV-induced fibroblast sarcome. |
|---|
| Comment from the depositor | |
|---|
| RCB1994 |
| UV♀2 |
| Comment | Mouse cell line derived from UV-induced angioendothelioma-like tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB1995 |
| UV·BAL-1.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB1996 |
| UV·BAL-2.1D |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB1997 |
| UV·B6-1.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB1998 |
| UV·B6-2.1A |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB1999 |
| UV·B6-4.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2000 |
| UV·B6-5.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2013 |
| GMR3 |
| Comment | Hybridoma producing a monoclonal antibody against N-glycolylneuraminic acid-containing gangliosides (GD3 gangliosides). |
|---|
| Comment from the depositor | |
|---|
| RCB2014 |
| GMB7 |
| Comment | Hybridoma producing a monoclonal antibody against GD2 gangliosides (b-pathway gangliosides). |
|---|
| Comment from the depositor | |
|---|
| RCB2015 |
| GMR8 |
| Comment | Hybridoma producing a monoclonal antibody against N-glycolylneuraminic acid-containing gangliosides (GM3 gangliosides). |
|---|
| Comment from the depositor | |
|---|
| RCB2016 |
| AMR19 |
| Comment | Hybridoma producing a monoclonal antibody against ganglioside lactones. |
|---|
| Comment from the depositor | |
|---|
| RCB2021 |
| GGR41 |
| Comment | Hybridoma producing a monoclonal antibody against GQ1ba gangliosides. |
|---|
| Comment from the depositor | |
|---|
| RCB2024 |
| UV·BAL-3.3 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2025 |
| UV·BAL-5.4G |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2026 |
| UV·BAL-6.1E |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2027 |
| UV·BAL-7.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2028 |
| UV·BAL-8.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2029 |
| UV·BAL-8.1C |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2030 |
| UV·BAL-12.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2031 |
| UV·BAL-13.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2032 |
| UV·BAL-14.2 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2033 |
| UV·BAL-15.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2034 |
| UV·BAL-16.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2035 |
| UV·BAL-17.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2036 |
| UV·BAL-18.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2037 |
| NGR54 |
| Comment | Hybridoma producing a monoclonal antibody against 2-3NeuAca-nLc4Cer gangliosides. |
|---|
| Comment from the depositor | |
|---|
| RCB2039 |
| NMR52 |
| Comment | Hybridoma producing a monoclonal antibody against nLc4Cer. |
|---|
| Comment from the depositor | |
|---|
| RCB2040 |
| NGR50 |
| Comment | Hybridoma producing a monoclonal antibody against SGPG. |
|---|
| Comment from the depositor | |
|---|
| RCB2041 |
| AMR20 |
| Comment | Hybridoma producing a monoclonal antibody against GalCer. |
|---|
| Comment from the depositor | |
|---|
| RCB2042 |
| AGB43 |
| Comment | Hybridoma producing a monoclonal antibody against Sulfatide. |
|---|
| Comment from the depositor | |
|---|
| RCB2046 |
| BMR26 |
| Comment | Hybridoma producing a monoclonal antibody against Globoside. |
|---|
| Comment from the depositor | |
|---|
| RCB2048 |
| OMB4 |
| Comment | Hybridoma producing a monoclonal antibody against N-linked neutral oligosaccharides of glycoproteins. |
|---|
| Comment from the depositor | |
|---|
| RCB2049 |
| OMR5 |
| Comment | Hybridoma producing a monoclonal antibody against F1-linked neutral oligosaccharides of glycoproteins. |
|---|
| Comment from the depositor | |
|---|
| RCB2050 |
| OMR6 |
| Comment | Hybridoma producing a monoclonal antibody against M1-linked neutral oligosaccharides of glycoproteins. |
|---|
| Comment from the depositor | |
|---|
| RCB2053 |
| UV·C3H-3.3 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2056 |
| UV·C3H-8.2 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2057 |
| UV·BAL-19.1A |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2058 |
| UV·BAL-20.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2059 |
| UV·BAL-21.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2060 |
| UV·BAL-23.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2061 |
| UV·C3B6-1.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2062 |
| UV·C3B6-1.1C |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2065 |
| UV·CB6-2.1F |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2066 |
| UV·CB6-3.4B |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2067 |
| UV·CB6-4.1D |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2068 |
| UV·CB6-4.1F |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2070 |
| UV·CB6-5.2 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2071 |
| UV·CB6-5.2B |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2072 |
| UV·CB6-6.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2073 |
| UV·CB6-6.1B |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2074 |
| UV·CC3-11.1 |
| Comment | Mouse cell line derived from UV-induced skin tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2076 |
| Has |
| Comment | Chinese hamster cell line. Epithelial-like adherent cells. |
|---|
| Comment from the depositor | |
|---|
| RCB2078 |
| FU-RPNT-2 |
| Comment | Human primitive neuroectodermal tumor cell line derived from kidney. |
|---|
| Comment from the depositor | |
|---|
| RCB2079 |
| UCB-TERT-21 |
| Comment | Human mesenchymal cell line derived from umbilical cord blood. Immortalized by hTERT. |
|---|
| Comment from the depositor | |
|---|
| RCB2080 |
| UCB408E6E7TERT-33 |
| Comment | Human mesenchymal cell line derived from umbilical cord blood. Immortalized by HPV E6, E7, and hTERT. |
|---|
| Comment from the depositor | |
|---|
| RCB2081 |
| KUSA-A1 |
| Comment | Mesenchymal stem cell line derived from C3H/He mouse strain. |
|---|
| Comment from the depositor | |
|---|
| RCB2082 |
| 103-LCL |
| Comment | Human B cell line transformed by Epstein-Barr Virus. TKG0614 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2083 |
| 141-LCL |
| Comment | Human B cells transformed by Epstein-Barr virus. RCB2541 was derived from the same patient. TKG0611 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2084 |
| TALL-1 |
| Comment | Human T-cell line derived from acute lynphblastic leukemia. TKG0251 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2088 |
| Kato III |
| Comment | Human cell line derived from gastric cancer. Signet ring carcinoma. TKG0213 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2092 |
| 87-5 |
| Comment | Human cell line derived from lung cancer. Small cell carcinoma. TKG0503 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2093 |
| II-18 |
| Comment | Human cell line derived from lung cancer. Adenocarcinoma. TKG0177 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2094 |
| MIA Paca2 |
| Comment | Human cell line derived from pancreatic cancer. TKG0227 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2095 |
| PANC-1 |
| Comment | Human cell line derived from pancreatic cancer. Ductal origin. TKG0606 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2097 |
| TE-4 |
| Comment | Human cell line derived from esophageal cancer. Highly differentiated squamous cell carcinoma. TKG0255 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2098 |
| TE-8 |
| Comment | Human cell line derived from esophageal cancer. Moderately differentiated squamous cell carcinoma. TKG0259 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2099 |
| TE-10 |
| Comment | Human cell line derived from esophageal cancer. Highly differentiated squamous cell carcinoma. TKG0261 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2100 |
| TE-11 |
| Comment | Human cell line derived from esophageal cancer. Moderately differentiated squamous cell carcinoma. TKG0262 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2101 |
| TE-14 |
| Comment | Human cell line derived from esophageal cancer. Moderately differentiated squamous cell carcinoma. TKG0265 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2102 |
| HO-1-u-1 |
| Comment | Human cell line derived from squamous cell carcinoma at mouth floor. TKG0455 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2103 |
| 8505C |
| Comment | Human cell line derived from thyroid cancer. Poorly differentiated papillary adenocarcinoma. TKG0439 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2104 |
| HuO-3N1 |
| Comment | Human cell line derived from osteosarcoma. TKG0452 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2105 |
| D98-AH2 |
| Comment | Human cell line derived from cervical cancer. The cells were converted to HGPRT(-). A subline of HeLa cell. TKG0191 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2106 |
| ME-180 |
| Comment | Human cell line derived from cervical cancer. TKG0437 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2107 |
| TN-1 |
| Comment | Human cell line derived from neuroblastoma formed at adrenal gland. TKG0277 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2108 |
| NH-12 |
| Comment | Human cell line derived from neuroblastoma. TKG0448 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2109 |
| NH-6 |
| Comment | Human cell line derived from neroblastoma of adrenal gland. TKG0468 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2110 |
| YKG1 |
| Comment | Human cell line derived from glioblastoma. TKG0453 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2111 |
| K562/Vin |
| Comment | Subline of K562 cell line. Resistant to vincristine. TKG0212 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2112 |
| KUM4 |
| Comment | Mouse mesenchymal cell line derived from bone marrow. C3H/He |
|---|
| Comment from the depositor | |
|---|
| RCB2113 |
| KUM6 |
| Comment | Mouse mesenchymal cell line derived from bone marrow. C3H/He |
|---|
| Comment from the depositor | |
|---|
| RCB2114 |
| KUM7 |
| Comment | Mouse mesenchymal cell line derived from bone marrow. C3H/He |
|---|
| Comment from the depositor | |
|---|
| RCB2115 |
| KUM9 |
| Comment | Mouse mesenchymal cell line derived from bone marrow. C3H/He |
|---|
| Comment from the depositor | |
|---|
| RCB2116 |
| TSt-4 |
| Comment | Murine mesenchymal cell line derived from fetal thymus tissue. Can support the generation of myeloid cells and B cells from muirne hematopietic stem/progenitors. |
|---|
| Comment from the depositor | |
|---|
| RCB2117 |
| TSt-4/G |
| Comment | Murine mesenchymal cell line derived from fetal thymus tissue. Can support the generation of myeloid cells and B cells from muirne hematopietic stem/progenitors. Established originally as a cotrol cells for TSt-4/G-DLL1. By retorviral transduction, EGFP is expressed. |
|---|
| Comment from the depositor | |
|---|
| RCB2118 |
| TSt-4/G-DLL1 |
| Comment | Original murine mesenchymal cell line was derived from fetal thymus tissue. DLL1 gene was retrovirally introduced. Can support the generation of T cells (up to DP stage) from muirne hematopietic stem/progenitors. EGFP was also introduced, and is expressed as a marker. |
|---|
| Comment from the depositor | |
|---|
| RCB2119 |
| TSt-4/N |
| Comment | Original murine mesenchymal cell line was derived from fetal thymus tissue. Can support the generation of myeloid cells and B cells from muirne hematopietic stem/progenitors. Established originally as a cotrol cells for TSt-4/N-DLL1. By retorviral transduction, huma NGF receptor is expressed. |
|---|
| Comment from the depositor | |
|---|
| RCB2120 |
| TSt-4/N-DLL1 |
| Comment | Original murine mesenchymal cell line was derived from fetal thymus tissue. By retrovirally introducing DLL1 gene, this cell line can support the generation of T cells (up to DP stage) from muirne hematopietic stem/progenitors. Human NGF receptor is also introduced, and is expressed as a marker on cell surface. |
|---|
| Comment from the depositor | |
|---|
| RCB2125 |
| BmN4-DR |
| Comment | Silkworm (Bombyx mori) cell line derived from ovary. Useful for the identification and analysis of homologous recombination-related genes in the silkworm. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB2126 |
| BmN4-IR |
| Comment | Silkworm (Bombyx mori) cell line derived from ovary. Useful for the identification and analysis of homologous recombination-related genes in the silkworm. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB2127 |
| COLO205 |
| Comment | Human cell line derived from colon cancer. Derived from ascites metastasis. TKG0457 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2133 |
| S2 |
| Comment | Human cell line derived from lung cancer. Small cell carcinoma. TKG0245 (Deposited from Tohoku Univ.).Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB2134 |
| 86-2 |
| Comment | Human cell line derived from lung cancer. Large cell carcinoma. TKG0181 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2135 |
| NIH:OVCAR-3 |
| Comment | Human cell line derived from adenocarcinoma of ovary. TKG0602 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2136 |
| YST-1 |
| Comment | Human cell line derived from schwannoma. TKG0454 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2138 |
| KLM-1 |
| Comment | Human cell line derived from pancreatic cancer. RCB1972 was derived from the same patient. TKG0490 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2141 |
| PK-45P |
| Comment | Human cell line derived from pancreatic carcinoma. RCB1973 was derived from the same patient. TKG0493 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2143 |
| DU145 |
| Comment | Human cell line derived from brain metastasis of prostate carcinoma. TKG0604 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2144 |
| LNCap.FGC |
| Comment | Human cell line derived from prostate adenocarcinoma. Derived from lymph node metastasis. TKG0603 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2145 |
| PC-3 |
| Comment | Human cell line derived from bone metastasis of prostatic cancer. TKG0600 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2146 |
| WERI-Rb-1 |
| Comment | Human cell line derived from retinoblastoma. TKG0601 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2147 |
| KUM3 |
| Comment | Mouse mesenchymal cell line derived from bone marrow. C3H/He |
|---|
| Comment from the depositor | |
|---|
| RCB2148 |
| KOP |
| Comment | Mouse fibroblast-like cell line lacking p38 MAP kinase expression. |
|---|
| Comment from the depositor | |
|---|
| RCB2149 |
| RKOP |
| Comment | Subline of KOP cell line, expressing FLAG-tagged p38 MAP kinase. Zeocin-resistant. |
|---|
| Comment from the depositor | |
|---|
| RCB2150 |
| EKOP |
| Comment | Subline of KOP cell line, expressing FLAG-tagged EXIP. Zeocin-resistant. |
|---|
| Comment from the depositor | |
|---|
| RCB2151 |
| ZKOP |
| Comment | Subline of KOP cell line. Zeocin-resistant. |
|---|
| Comment from the depositor | |
|---|
| RCB2153 |
| UE6E7T-2 |
| Comment | Human mesenchymal cell line derived from bone marrow. Immortalized by HPV E6, E7, and hTERT. RCB2152- RCB2163 are derived from the same bone marrow. |
|---|
| Comment from the depositor | |
|---|
| RCB2154 |
| UE6E7T-3 |
| Comment | Human mesenchymal cell line derived from bone marrow. Immortalized by HPV E6, E7, and hTERT. RCB2152- RCB2163 are derived from the same bone marrow. |
|---|
| Comment from the depositor | |
|---|
| RCB2156 |
| UBE6T-6 |
| Comment | Human mesenchymal cell line derived from bone marrow. Immortalized by bmi-1, HPV E6, and hTERT. RCB2152- RCB2163 are derived from the same bone marrow. |
|---|
| Comment from the depositor | |
|---|
| RCB2157 |
| UBE6T-7 |
| Comment | Human mesenchymal cell line derived from bone marrow. Immortalized by bmi-1, HPV E6, and hTERT. RCB2152- RCB2163 are derived from the same bone marrow. |
|---|
| Comment from the depositor | |
|---|
| RCB2158 |
| UE7T-9 |
| Comment | Human mesenchymal cell line derived from bone marrow. Immortalized by HPV E7 and hTERT. RCB2152- RCB2163 are derived from the same bone marrow. |
|---|
| Comment from the depositor | |
|---|
| RCB2159 |
| UE6E7T-11 |
| Comment | Human mesenchymal cell line derived from bone marrow. Immortalized by HPV E6, E7, and hTERT. RCB2152- RCB2163 are derived from the same bone marrow. |
|---|
| Comment from the depositor | |
|---|
| RCB2160 |
| UE6E7T-12 |
| Comment | Human mesenchymal cell line derived from bone marrow. Immortalized by HPV E6, E7, and hTERT. RCB2152- RCB2163 are derived from the same bone marrow. |
|---|
| Comment from the depositor | |
|---|
| RCB2161 |
| UE7T-13 |
| Comment | Human mesenchymal cell line derived from bone marrow. Immortalized by HPV E7 and hTERT. RCB2152- RCB2163 are derived from the same bone marrow. |
|---|
| Comment from the depositor | |
|---|
| RCB2162 |
| UBE6T-15 |
| Comment | Human mesenchymal cell line derived from bone marrow. Immortalized by bmi-1, HPV E6, and hTERT. RCB2152- RCB2163 are derived from the same bone marrow. |
|---|
| Comment from the depositor | |
|---|
| RCB2163 |
| UE6E7-16 |
| Comment | Human mesenchymal cell line derived from bone marrow. Immortalized by HPV E6 and E7. RCB2152- RCB2163 are derived from the same bone marrow. |
|---|
| Comment from the depositor | |
|---|
| RCB2202 |
| 293T |
| Comment | A subline of 293. Expressing SV40 large T antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB2203 |
| TFS-2 |
| Comment | Hybridoma producing monoclonal antibody against a surface antigen of small cell carcinoma of lung. |
|---|
| Comment from the depositor | |
|---|
| RCB2204 |
| TFS-4 |
| Comment | Hybridoma producing monoclonal antibody against a surface antigen of small cell carcinoma of lung. |
|---|
| Comment from the depositor | |
|---|
| RCB2205 |
| NCC-RbC-39 |
| Comment | Human retinoblastoma cell line. |
|---|
| Comment from the depositor | |
|---|
| RCB2206 |
| NCC-RbC-51 |
| Comment | Human retinoblastoma cell line derived from cervical lymph node metastasis. |
|---|
| Comment from the depositor | |
|---|
| RCB2208 |
| NCC-RbC-54 |
| Comment | Human cell line derived from retinoblastoma. |
|---|
| Comment from the depositor | |
|---|
| RCB2212 |
| NCC-RbC-59 |
| Comment | Human cell line derived from retinoblastoma. |
|---|
| Comment from the depositor | |
|---|
| RCB2213 |
| NCC-RbC-60 |
| Comment | Human cell line derived from retinoblastoma. |
|---|
| Comment from the depositor | |
|---|
| RCB2217 |
| NCC-RbC-83 |
| Comment | Human cell line derived from retinoblastoma. |
|---|
| Comment from the depositor | |
|---|
| RCB2218 |
| NCC-RbC-92 |
| Comment | Human cell line derived from retinoblastoma. |
|---|
| Comment from the depositor | |
|---|
| RCB2219 |
| NCC-RbC-T1 |
| Comment | Human cell line derived from retinoblastoma. |
|---|
| Comment from the depositor | |
|---|
| RCB2223 |
| NCC-OvC-K119 |
| Comment | Human cell line derived from ovarian cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB2224 |
| NCC-StC-K140 |
| Comment | Human cell line derived from stomach cancer. |
|---|
| Comment from the depositor | |
|---|
| RCB2225 |
| JHUEM-14 |
| Comment | Human cell line derived from uterine endometrioid adenocarcinoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB2226 |
| JHOC-9 |
| Comment | Human cell line derived from ovarian clear cell carcinoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB2227 |
| JMSU1 |
| Comment | Human cell line derived from urinary bladder carcinoma. Derived from ascites. |
|---|
| Comment from the depositor | |
|---|
| RCB2229 |
| HS-Os-1 |
| Comment | Human cell line derived from osteosarcoma. |
|---|
| Comment from the depositor | |
|---|
| RCB2230 |
| HS-Sch-2 |
| Comment | Human cell line derived from malignant peripheral nerve sheath tumor (MPNST). |
|---|
| Comment from the depositor | |
|---|
| RCB2231 |
| HS-SY-II |
| Comment | Human cell line derived from synovial sarcoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB2233 |
| HE12 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB2234 |
| HE13 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2237 |
| HE16 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2238 |
| HE18 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2239 |
| HE19 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2240 |
| HE21 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2241 |
| HE22 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2244 |
| HE27 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2245 |
| HE28 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2246 |
| HE29 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2247 |
| HE30 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2248 |
| HE31 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2249 |
| HE32 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2250 |
| HE33 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2251 |
| HE34 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2253 |
| HKb20 |
| Comment | A subline of 293. Expressing BtR175b (Cry 1Aa receptor). |
|---|
| Comment from the depositor | |
|---|
| RCB2254 |
| HE36 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2256 |
| HE37 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2257 |
| HE38 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2258 |
| HE39 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2259 |
| HE40 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2260 |
| HE41 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2261 |
| HE42 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2262 |
| HE46 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2263 |
| HE47 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2264 |
| HE48 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2265 |
| HE49 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2266 |
| HE50 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2267 |
| HE51 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2268 |
| HE52 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2269 |
| HE53 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2270 |
| HE54 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2271 |
| HE55 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2273 |
| HE57 |
| Comment | Human fibroblast-like cells derived from embryo. Not immortalized. |
|---|
| Comment from the depositor | |
|---|
| RCB2277 |
| GSS |
| Comment | Human gastric cancer cell line derived from metastasis at liver. |
|---|
| Comment from the depositor | |
|---|
| RCB2278 |
| GSU |
| Comment | Human cell line derived from gastric cancer. Established from the cells in ascites. |
|---|
| Comment from the depositor | |
|---|
| RCB2279 |
| WA-hT |
| Comment | Human cell line derived from lung cancer. Small cell carcinoma. Mouse WA-mFib cells are the stromal cells for this cell line. |
|---|
| Comment from the depositor | |
|---|
| RCB2280 |
| HCE-T |
| Comment | SV40-Adeno vector transformed cornea cells. 64kD keratin producing. Choleratoxin-free medium. To the users who purchased this cell line for OECD Test Guideline No. 494 (PDF 91KB) |
|---|
| Comment from the depositor | |
|---|
| RCB2281 |
| T3M-12 |
| Comment | Human lung small cell carcinoma cell line. ADH producing. |
|---|
| Comment from the depositor | |
|---|
| RCB2282 |
| 701-LCL |
| Comment | Human cell line derived from B cells of healthy volunteer. Transformed by EB virus. TKG0610 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2283 |
| 277-LCL |
| Comment | Human B cells transformed by Epstein-Barr virus. TKG0609 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2286 |
| XPL 17 |
| Comment | Human B cells derived from a patient of xeroderma pigmentosum. Transformed by Epstein-Barr virus. TKG0311 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2287 |
| XPL 20 |
| Comment | Human B cells derived from a patient of xeroderma pigmentosum. Transformed by Epstein-Barr virus. TKG0313 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2288 |
| 211-LCL |
| Comment | Human cell line derived from B cells of healthy volunteer. Transformed by EB virus. TKG0616 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2292 |
| ACC-MESO-1 |
| Comment | Human malignant pleural mesothelioma cell line. |
|---|
| Comment from the depositor | |
|---|
| RCB2293 |
| ACC-MESO-4 |
| Comment | Human malignant pleural mesothelioma cell line. |
|---|
| Comment from the depositor | |
|---|
| RCB2295 |
| KUM10 |
| Comment | Mouse mesenchymal cell line derived from bone marrow. C57/B6. |
|---|
| Comment from the depositor | |
|---|
| RCB2296 |
| CARMA1^(-)DT40 |
| Comment | Subline of DT40 cell line, lacking CARMA1 expression. |
|---|
| Comment from the depositor | |
|---|
| RCB2297 |
| PKCβ^(-)DT40 |
| Comment | Subline of DT40 cell line, lacking PKC-β expression. |
|---|
| Comment from the depositor | |
|---|
| RCB2298 |
| TAK1^(-)DT40 |
| Comment | Subline of DT40 cell line, lacking TAK1 expression. |
|---|
| Comment from the depositor | |
|---|
| RCB2299 |
| RMC-1 |
| Comment | Rat cell line derived from mammary gland carcinoma which is induced by DMBA in the transgenic rat expressing human prototype c-Ha-ras gene. |
|---|
| Comment from the depositor | |
|---|
| RCB2300 |
| RMC-2 |
| Comment | Rat cell line derived from mammary gland carcinoma which is induced by DMBA in the transgenic rat expressing human prototype c-Ha-ras gene. |
|---|
| Comment from the depositor | |
|---|
| RCB2301 |
| RMC-3 |
| Comment | Rat cell line derived from mammary gland carcinoma which is induced by DMBA in the transgenic rat expressing human prototype c-Ha-ras gene. |
|---|
| Comment from the depositor | |
|---|
| RCB2302 |
| RMC-6 |
| Comment | Rat cell line derived from mammary gland carcinoma which is induced by DMBA in the transgenic rat expressing human prototype c-Ha-ras gene. |
|---|
| Comment from the depositor | |
|---|
| RCB2303 |
| RMC-11 |
| Comment | Rat cell line derived from mammary gland carcinoma which is induced by DMBA in the transgenic rat expressing human prototype c-Ha-ras gene. |
|---|
| Comment from the depositor | |
|---|
| RCB2304 |
| RMC-17 |
| Comment | Rat cell line derived from mammary gland carcinoma which is induced by DMBA in the transgenic rat expressing human prototype c-Ha-ras gene. |
|---|
| Comment from the depositor | |
|---|
| RCB2305 |
| MIH5(GIT) |
| Comment | Hybridoma producing a monoclonal antibody against mouse B7-H1. |
|---|
| Comment from the depositor | |
|---|
| RCB2306 |
| PC3.1 |
| Comment | Hybridoma producing monoclonal antibody against latexin. |
|---|
| Comment from the depositor | |
|---|
| RCB2307 |
| T1.7 |
| Comment | Hybridoma producing monoclonal antibody against C-terminal peptide of rat GSK3-beta. |
|---|
| Comment from the depositor | |
|---|
| RCB2308 |
| 802C11 |
| Comment | Hybridoma producing monoclonal antibody against MuSc. |
|---|
| Comment from the depositor | |
|---|
| RCB2309 |
| JFP-J1 |
| Comment | Hybridoma producing monoclonal antibody against GFP. Rat IgG2a monoclonal antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB2310 |
| JFP-J5 |
| Comment | Hybridoma producing monoclonal antibody against GFP. Rat IgG2a monoclonal antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB2311 |
| JFP-K2 |
| Comment | Hybridoma producing monoclonal antibody against GFP. Rat IgG2a monoclonal antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB2312 |
| 859H5 |
| Comment | Hybridoma producing monoclonal antibody against bacterial unknown molecule. Rat IgG2a monoclonal antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB2313 |
| 884F11 |
| Comment | Hybridoma producing monoclonal antibody against mouse apolipoprotein E. |
|---|
| Comment from the depositor | |
|---|
| RCB2314 |
| F9/LM10 |
| Comment | Mouse cell line derived from embryonal carcinoma. Expressing laminin alpha-5 exogenously. |
|---|
| Comment from the depositor | |
|---|
| RCB2315 |
| F9/LM(1+10) |
| Comment | Mouse cell line derived from embryonal carcinoma. Expressing laminin alpha-5 exogenously. |
|---|
| Comment from the depositor | |
|---|
| RCB2316 |
| AB1 |
| Comment | Hybridoma producing monoclonal antibody against GD1b gangliosides. |
|---|
| Comment from the depositor | |
|---|
| RCB2317 |
| AC1 |
| Comment | Hybridoma producing monoclonal antibody against GD1c gangliosides. |
|---|
| Comment from the depositor | |
|---|
| RCB2318 |
| P19.CL6 |
| Comment | Mouse cell line derived from embryonal carcinoma. C3H strain. Following differentiation, beating cardiomyocytes appear efficiently. |
|---|
| Comment from the depositor | |
|---|
| RCB2321 |
| IP-B12 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Rat pulmonary carcinoma-derived cell line producing parathyroid hormone-related protein (PTHrP). |
|---|
| RCB2322 |
| KUM5 |
| Comment | Mouse mesenchymal cell line derived from bone marrow. C3H/He |
|---|
| Comment from the depositor | |
|---|
| RCB2323 |
| 9-15C |
| Comment | Mouse mesenchymal cell line derived from bone marrow. C3H/He |
|---|
| Comment from the depositor | |
|---|
| RCB2324 |
| MIH5(RPMI) |
| Comment | Hybridoma producing a monoclonal antibody against mouse B7-H1. Possible to culture in RPMI1640 medium. |
|---|
| Comment from the depositor | |
|---|
| RCB2326 |
| CHO-AA8 |
| Comment | A subline of the CHO-K1 cell line. Widely used for the isolation of repair-deficient mutants. Useful for gene mutation assays at the APRT and HPRT loci. |
|---|
| Comment from the depositor | |
|---|
| RCB2327 |
| EM-9 |
| Comment | A subline of the CHO-K1 cell line. X-ray-sensitive mutant derived from CHO-AA8 cell line. XRCC1 gene deficient. |
|---|
| Comment from the depositor | |
|---|
| RCB2328 |
| irs1SF |
| Comment | A subline of the CHO-K1 cell line. X-ray-sensitive mutant derived from CHO-AA8 cell line. XRCC3 gene deficient. |
|---|
| Comment from the depositor | |
|---|
| RCB2329 |
| V-3 |
| Comment | A subline of the CHO-K1 cell line. X-ray-sensitive mutant derived from CHO-AA8 cell line. XRCC7(DNA-PK) gene deficient. |
|---|
| Comment from the depositor | |
|---|
| RCB2330 |
| CHO-K1 |
| Comment | Chinese hamster ovary cell line. Widely used for the isolation of mutants by mutagenesis. |
|---|
| Comment from the depositor | |
|---|
| RCB2331 |
| XR-1 |
| Comment | A subline of the CHO-K1 cell line. X-ray-sensitive mutant. XRCC4 gene deficient. |
|---|
| Comment from the depositor | |
|---|
| RCB2332 |
| V79-4 |
| Comment | A subline of the V79 cell line following cloning. Widely used for radiation biology, mutagenesis and mammalian cell genetics. |
|---|
| Comment from the depositor | |
|---|
| RCB2335 |
| V-E5 |
| Comment | X-ray-sensitive mutant derived from the V79 cell line. XRCC8 gene deficient. |
|---|
| Comment from the depositor | |
|---|
| RCB2336 |
| V-G8 |
| Comment | A subline of the V79 cell line. X-ray-sensitive mutant. XRCC8 gene deficient. |
|---|
| Comment from the depositor | |
|---|
| RCB2337 |
| V79B |
| Comment | A subline of the V79 cell line. Widely used for radiation biology, mutagenesis and mammalian cell genetics. |
|---|
| Comment from the depositor | |
|---|
| RCB2338 |
| XR-V9B-4 |
| Comment | A subline of the V79B cell line. X-ray-sensitive mutant. XRCC5(ku80) gene deficient. |
|---|
| Comment from the depositor | |
|---|
| RCB2339 |
| XR-V15B |
| Comment | A subline of the V79 cell line. X-ray-sensitive mutant. XRCC5(ku80) gene deficient. |
|---|
| Comment from the depositor | |
|---|
| RCB2341 |
| NCR-G1 |
| Comment | Human cell line derived from embryonal carcinoma of testis. |
|---|
| Comment from the depositor | |
|---|
| RCB2342 |
| NCR-G2 |
| Comment | Human cell line derived from embryonal carcinoma of testis. |
|---|
| Comment from the depositor | |
|---|
| RCB2343 |
| NCR-G3 |
| Comment | Human cell line derived from embryonal carcinoma of testis.Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB2344 |
| NCR-G4 |
| Comment | Human cell line derived from embryonal carcinoma of testis. |
|---|
| Comment from the depositor | |
|---|
| RCB2345 |
| EEB |
| Comment | Human cell line derived from erythroblastic leukemia. |
|---|
| Comment from the depositor | |
|---|
| RCB2346 |
| NMFH-1 |
| Comment | Human cell line derived from myxofibrosarcoma. |
|---|
| Comment from the depositor | |
|---|
| RCB2347 |
| NMS-2 |
| Comment | Human cell line derived from malignant peripheral nerve sheath tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2348 |
| NOS-10 |
| Comment | Human cell line derived from osteosarcoma. |
|---|
| Comment from the depositor | |
|---|
| RCB2350 |
| StromaNKtert |
| Comment | Human cell line derived from bone marrow stromal cells. Useful to propagate hematopoietic stem cells. |
|---|
| Comment from the depositor | |
|---|
| RCB2351 |
| OGU1 |
| Comment | Human cell line derived from primary effusion lymphoma (PEL). Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB2352 |
| 633 |
| Comment | Human lung cancer cell line expressing capsid protein of human adenovirus. |
|---|
| Comment from the depositor | |
|---|
| RCB2354 |
| 293gp |
| Comment | A subline of 293. Expressing MoMLV (Moloney murine leukemia virus) gag/pol. A retroviral vector packaging cell line. |
|---|
| Comment from the depositor | |
|---|
| RCB2355 |
| HeLa CD4+Clone1022 |
| Comment | A subline of the HeLa cells. Expressing human CD4 and Neomycin-resistant gene. |
|---|
| Comment from the depositor | |
|---|
| RCB2356 |
| HeLa-CD4-LTR-β-gal |
| Comment | A subline of the HeLa cells. Expressing human CD4 and Neomycin-resistant gene. One copy of the HIV-1 LTR (nt-138 to +80) linked to the β-galactosidase gene is integrated. |
|---|
| Comment from the depositor | |
|---|
| RCB2358 |
| HLtat |
| Comment | A subline of the HeLa cells. HeLa cells contained stably integrated copies of the HIV-1 LTR promoter linked to a synthetic tat gene. |
|---|
| Comment from the depositor | |
|---|
| RCB2360 |
| HS-ES-2M |
| Comment | Human cell line derived from epithelioid sarcoma. RCB2360 and RCB2361 were derived from the same patient. HS-ES-1 (RCB2364) was derived from another patient. |
|---|
| Comment from the depositor | |
|---|
| RCB2361 |
| HS-ES-2R |
| Comment | Human cell line derived from epithelioid sarcoma. RCB2360 and RCB2361 were derived from the same patient. HS-ES-1 (RCB2364) was derived from another patient. |
|---|
| Comment from the depositor | |
|---|
| RCB2362 |
| HS-PSS |
| Comment | Human cell line derived from malignant peripheral nerve sheath tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2364 |
| HS-ES-1 |
| Comment | Human cell line derived from epithelioid sarcoma. RCB2360 and RCB2361 were derived from another different patient. |
|---|
| Comment from the depositor | |
|---|
| RCB2365 |
| JHONA |
| Comment | Human cell line derived from ovarian squamous cell carcinoma. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB2366 |
| Hu5/E18 |
| Comment | Human multipotent stem cell line able to differentiate into muscle, bone, and adipocytes. |
|---|
| Comment from the depositor | |
|---|
| RCB2367 |
| KT01 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on P-granule. |
|---|
| Comment from the depositor | |
|---|
| RCB2368 |
| KT02 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on P-granule. |
|---|
| Comment from the depositor | |
|---|
| RCB2369 |
| KT03 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on P-granule and body wall muscle. |
|---|
| Comment from the depositor | |
|---|
| RCB2372 |
| KT06 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on P-granule and body wall muscle. |
|---|
| Comment from the depositor | |
|---|
| RCB2375 |
| KT09 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on body wall muscle. |
|---|
| Comment from the depositor | |
|---|
| RCB2376 |
| KT10 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on body wall muscle. |
|---|
| Comment from the depositor | |
|---|
| RCB2377 |
| KT11 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on body wall muscle. |
|---|
| Comment from the depositor | |
|---|
| RCB2378 |
| KT12 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on body wall muscle. |
|---|
| Comment from the depositor | |
|---|
| RCB2379 |
| KT13 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that seam cell. |
|---|
| Comment from the depositor | |
|---|
| RCB2380 |
| KT14 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on pharynx basement membrane. |
|---|
| Comment from the depositor | |
|---|
| RCB2381 |
| KT16 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on pharynx. |
|---|
| Comment from the depositor | |
|---|
| RCB2382 |
| KT17 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on pharynx. |
|---|
| Comment from the depositor | |
|---|
| RCB2383 |
| KT18 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on pharynx. |
|---|
| Comment from the depositor | |
|---|
| RCB2386 |
| KT21 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on intestine. |
|---|
| Comment from the depositor | |
|---|
| RCB2388 |
| KT23 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on nuclear membrane. |
|---|
| Comment from the depositor | |
|---|
| RCB2389 |
| KT26 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on centrosome. |
|---|
| Comment from the depositor | |
|---|
| RCB2390 |
| KT27 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on hypodermis. |
|---|
| Comment from the depositor | |
|---|
| RCB2392 |
| KT29 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on egg shell. |
|---|
| Comment from the depositor | |
|---|
| RCB2393 |
| KT30 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on egg shell. |
|---|
| Comment from the depositor | |
|---|
| RCB2395 |
| KT32 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on P-granule and pharynx. |
|---|
| Comment from the depositor | |
|---|
| RCB2400 |
| KT54 |
| Comment | Hybridoma producing monoclonal antibody against an antigen of C. elegans embryo. Antigen is not determined but that on centrosome and P-granule. |
|---|
| Comment from the depositor | |
|---|
| RCB2402 |
| STIM1^(-)DT40 |
| Comment | Subline of DT40 cell line, lacking STIM1 expression. |
|---|
| Comment from the depositor | |
|---|
| RCB2403 |
| MG6 |
| Comment | Mouse microglial cell line immortalized by a replication-deficient retroviral vector containing human c-myc gene. No significant production of infectious viral particles from MG6 cells was confirmed by bioassay using SC-1 cells. |
|---|
| Comment from the depositor | |
|---|
| RCB2530 |
| A172 |
| Comment | Human cell line derived from glioblastoma. TKG0183 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2531 |
| CB-3512 |
| Comment | Human cell line derived from B cells in umbilical cord blood. Transformed by EB virus. TKG0305 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2532 |
| HuO 9N2 (O9N2) |
| Comment | Human cell line derived from osteosarcoma. TKG0451 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2534 |
| M-MOK |
| Comment | Human cell line derived from megakaryoblastic leukemia. TKG0458 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2535 |
| OVK18#102 |
| Comment | Human cell line derived from ovarian endometrioid carcinoma, subclone of RCB1903. TKG0357 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2536 |
| T24 |
| Comment | Human cell line derived from bladder cancer. Transitional cell carcinoma. TKG0443 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2537 |
| TFK-1 |
| Comment | Human cell line derived from extrahepatic bile duct carcinoma. TKG0367 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2539 |
| XPL 19 |
| Comment | Human B cell line derived from xeroderma pigmentosum (XP) patient and transformed by Epstein-Barr Virus. TKG0312 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2540 |
| XPL 24 |
| Comment | Human cell line derived from B cells of Xeroderma pigmentosum (XP) patient. Transformed by EB virus. TKG0314 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2541 |
| 141-LCL-MUC1 |
| Comment | Human cell line derived from B cells of healthy volunteer. Transformed by EB virus. RCB2083 was derived from the same patient. TKG0634 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2610 |
| FELV3281-AD |
| Comment | BSL2. Cat cell line derived from lymphoma. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | |
|---|
| RCB2611 |
| MDCK-AD |
| Comment | Dog cell line derived from kidney. |
|---|
| Comment from the depositor | |
|---|
| RCB2614 |
| KLN205-MUC1 |
| Comment | Mouse cell line derived from lung squamous cell carcinoma. TKG0473 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2618 |
| BCL1-B20 |
| Comment | Mouse cell line derived from B cell leukemia. TKG0435 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2619 |
| L929 |
| Comment | Mouse fibroblast-like cell line. TKG0217 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2620 |
| C-1300N18 |
| Comment | Mouse cell line derived from neuroblastoma. TKG0307 (Deposited from Tohoku Univ.). Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB2621 |
| M1(D+) |
| Comment | Mouse cell line derived from meyloid leukemia. TKG0319 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2623 |
| KLN205 |
| Comment | Mouse cell line derived from lung squamous cell carcinoma. TKG0214 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2627 |
| BOY-12E |
| Comment | Human cell line derived from urinary bladder carcinoma. TKG0641 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2630 |
| B16F10 |
| Comment | Mouse cell line derived from melanoma. TKG0348 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2633 |
| MM46 CEA1-2 |
| Comment | Mouse cell line derived from mammary carcinoma. TKG0597 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2634 |
| MM46-APR-MUC1 cl.1 |
| Comment | Mouse cell line derived from mammary carcinoma. Expressing human MUC1 (APR-MUC1) exogenously. TKG0595 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2637 |
| A4 |
| Comment | Subline of NIH/3T3 transformed with an active type c-erb B-2 (V-659 was changed to E659). c-erb B-2 prouct (+). G418 resistant. TKG0298 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2638 |
| B16/BL6 |
| Comment | Mouse cell line derived from melanoma. TKG0598 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2639 |
| NB2a |
| Comment | Mouse cell line derived from neuroblastoma. TKG0509 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2640 |
| G-415 |
| Comment | Human cell line derived from gallbladder carcinoma. TKG0642 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2642 |
| MUSS |
| Comment | Mouse cell line derived from spontaneous malignant fibrous histiocytoma. A/J strain. TKG0497 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2643 |
| F9 |
| Comment | Mouse cell line derived from embryonal carcinoma. 129 strain. TKG0519 (Deposited from Tohoku Univ.). Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB2648 |
| D4 |
| Comment | A subline of the NIH/3T3 cell line. NIH/3T3 cell line transfected with wild type c-erb B2 gene with carboxyl-terminal deletion. Swiss strain.TKG0300(Deposited from Tohoku Univ.). TKG0300 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2649 |
| B16F1 |
| Comment | Mouse cell line derived from melanoma. C57BL/6J strain. TKG0347 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2651 |
| JLS-V9 |
| Comment | Mouse cell line derived from bone marrow. Fibroblast-like cells. BALB/c strain. TKG0355 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2652 |
| J774-1 |
| Comment | Mouse cell line derived from ascites. Macrophage-like cells. BALB/c strain. TKG0208 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2657 |
| Colon-26 |
| Comment | Mouse cell line derived from colon cancer. BALB/c strain. TKG0518 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2660 |
| MEDEP-E14 |
| Comment | Mouse erythroid cell line able to differentiate into enucleated red blood cells. Derived from mouse ES cell line, E14TG2a. Epo(Erythropoietin) dependent. |
|---|
| Comment from the depositor | |
|---|
| RCB2686 |
| JTC-35 |
| Comment | Bovine granulosa cell line. |
|---|
| Comment from the depositor | |
|---|
| RCB2691 |
| MEDEP-E14 clone 4 |
| Comment | A subclone of MEDEP-E14(RCB2660) following cloning procedure. |
|---|
| Comment from the depositor | |
|---|
| RCB2692 |
| MEDEP-BRC4-1 |
| Comment | Mouse erythroid cell line able to differentiate into enucleated red blood cells. Derived from mouse ES cell line, BRC4 (AES0008). SCF(Stem cell factor) and Dex(dexamethasone) dependent. |
|---|
| Comment from the depositor | |
|---|
| RCB2693 |
| MEDMC-NT2 |
| Comment | Mouse cell line possessing the characteristics of mast cells. IL-3 (Interleukin-3) dependent. |
|---|
| Comment from the depositor | |
|---|
| RCB2694 |
| MEDMC-BRC6 |
| Comment | Mouse cell line derived from mouse ES cell line, BRC6 (AES0010). Mast cell-like cells. SCF (Stem cell factor) and IL-3 (Interleukin-3) dependent. C57BL/6 strain. |
|---|
| Comment from the depositor | |
|---|
| RCB2695 |
| RD-C2 |
| Comment | Mouse osteoblast-like cell line derived from Runx2 deficient mouse. |
|---|
| Comment from the depositor | |
|---|
| RCB2696 |
| RD-C6 |
| Comment | Mouse osteoblast-like cell line derived from Runx2 deficient mouse. |
|---|
| Comment from the depositor | |
|---|
| RCB2700 |
| PK-8 |
| Comment | Human cell line derived from liver metastasis of pancreas carcinoma. TKG0383 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2709 |
| 2F8 |
| Comment | Hybridoma producing monoclonal antibody against oxitocin receptor. |
|---|
| Comment from the depositor | |
|---|
| RCB2710 |
| Atg5^(+/+)MEF |
| Comment | Mouse embryonic fibroblasts. Wild type control for RCB2711. |
|---|
| Comment from the depositor | |
|---|
| RCB2711 |
| Atg5^(-/-)MEF |
| Comment | Mouse embryonic fibroblasts lacking Atg5 gene expression. |
|---|
| Comment from the depositor | |
|---|
| RCB2712 |
| MAEC |
| Comment | Vascular endothelial cell line derived from aorta of p53-deficient mouse. |
|---|
| Comment from the depositor | |
|---|
| RCB2718 |
| MT-7 |
| Comment | Rat cell line derived from fibrous histiocytoma. After cloning. |
|---|
| Comment from the depositor | |
|---|
| RCB2719 |
| MT-10 |
| Comment | Rat cell line derived from fibrous histiocytoma. After cloning. |
|---|
| Comment from the depositor | |
|---|
| RCB2720 |
| MT-R8 |
| Comment | A subline of MT-8, a rat cell line derived from malignant fibrous histiocytoma, which is resistant to cisplatin. |
|---|
| Comment from the depositor | |
|---|
| RCB2721 |
| MT-R9 |
| Comment | A subline of MT-9, a rat cell line derived from malignant fibrous histiocytoma, which is resistant to cisplatin. |
|---|
| Comment from the depositor | |
|---|
| RCB2722 |
| MT-10R |
| Comment | A subline of MT-10, a rat cell line derived from malignant fibrous histiocytoma, which is resistant to cisplatin. |
|---|
| Comment from the depositor | |
|---|
| RCB2723 |
| MT-PR |
| Comment | A subline of MT-P, a rat cell line derived from malignant fibrous histiocytoma, which is resistant to cisplatin. T |
|---|
| Comment from the depositor | |
|---|
| RCB2724 |
| KB-D8 |
| Comment | Rat cell line derived from dendritic cell carcinoma in thymus. |
|---|
| Comment from the depositor | |
|---|
| RCB2725 |
| KJ-A |
| Comment | Rat cell line derived from malignant fibrous histiocytoma. |
|---|
| Comment from the depositor | |
|---|
| RCB2726 |
| KE-F11 |
| Comment | Rat cell line derived from malignant schwannoma. |
|---|
| Comment from the depositor | |
|---|
| RCB2727 |
| RY-B-E3 |
| Comment | Rat cell line derived from endometrial stromal sarcoma. |
|---|
| Comment from the depositor | |
|---|
| RCB2728 |
| LY-H12 |
| Comment | Rat non-neoplastic cell line derived from malignant peripheral nerve sheath tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2729 |
| LY-PPB6 |
| Comment | Rat cell line derived from malignant peripheral nerve sheath tumor. |
|---|
| Comment from the depositor | |
|---|
| RCB2740 |
| 5A5-WASP |
| Comment | Hybridoma producing monoclonal antibody against WASP (Wiskott-Aldrich syndrome protein). TKG0631 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2745 |
| A20 |
| Comment | Mouse cell line derived from lymphoma. Balb/c strain. TKG0571 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2758 |
| LAG |
| Comment | Mouse cell line derived from connective tissue. Fibroblast-like. C3H strain. TKG0218 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2766 |
| Morris 5123D-TC |
| Comment | Rat (Buffalo) cell line derived from hepatoma. TKG0365 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2767 |
| NIH/3T3 |
| Comment | Mouse fibroblast-like cell line. TKG0299 (Deposited from Tohoku Univ.). Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB2776 |
| P388 |
| Comment | Mouse cell line derived from lymphoid tumor. DBA/2 strain. TKG0326 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2782 |
| RBL 2H3 |
| Comment | Rat cell line derived from basophilic leukemia cells. TKG0321 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2783 |
| RGC-6 |
| Comment | Rat cell line derived from glioma induced by N-nitrosomethylurea. TKG0242 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2784 |
| RL♂1(Gloria) |
| Comment | Mouse cell line derived from lymphoid tumor. BALB/c strain. TKG0292 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2799 |
| YAC-1 |
| Comment | Mouse cell line derived from lymphoma. A/Sn strain. TKG0387 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2800 |
| PC12-F7 |
| Comment | A subline of PC-12 lacking synaptotagmin-1. |
|---|
| Comment from the depositor | |
|---|
| RCB2801 |
| PC12-G11 |
| Comment | A subline of PC-12 expressing synaptotagmin-1, a control cell line for PC12-F7. |
|---|
| Comment from the depositor | |
|---|
| RCB2806 |
| MSK-C5.8G |
| Comment | Rat cell line derived from osteosarcoma. F344 strain. |
|---|
| Comment from the depositor | |
|---|
| RCB2808 |
| Odf2-deficient F9 cells |
| Comment | A subline of mouse ES cell line, F9 (129), lacking Odf2. |
|---|
| Comment from the depositor | |
|---|
| RCB2809 |
| CH12F3-2A |
| Comment | Mouse cell line derived from B cell lymphoma. |
|---|
| Comment from the depositor | |
|---|
| RCB2811 |
| 7F9 (hybridoma) |
| Comment | Hybridoma. Anti-Rat Carboxypeptidase M MoAb producing. |
|---|
| Comment from the depositor | |
|---|
| RCB2812 |
| HeLa/Fucci |
| Comment | A subline of the HeLa cell line expressing Fucci, a cell cycle marker. Cell line name : HeLa/Fucci #4.Important notice regarding nomenclature of Fucci. Research tools : Fucci – Fluorescent Ubiquitination-based Cell Cycle Indicator. |
|---|
| Comment from the depositor | |
|---|
| RCB2813 |
| NMuMG/Fucci |
| Comment | A subline of the NMuMG cell line expressing Fucci, a cell cycle marker. Cell line name : NMuMG/Fucci #1.Important notice regarding nomenclature of Fucci. Research tools : Fucci – Fluorescent Ubiquitination-based Cell Cycle Indicator. |
|---|
| Comment from the depositor | |
|---|
| RCB2815 |
| P20.1 |
| Comment | Hybridoma producing monoclonal antibody against a peptide, GYPGQV. |
|---|
| Comment from the depositor | |
|---|
| RCB2816 |
| A110L |
| Comment | Human cell line derived from lung adenocarcinoma cells. |
|---|
| Comment from the depositor | |
|---|
| RCB2817 |
| A529L |
| Comment | Human cell line derived from lung adenosquamous cell carcinoma. HLA A2402/, B5201/, Cw01201/. |
|---|
| Comment from the depositor | |
|---|
| RCB2818 |
| B1203L |
| Comment | Human cell line derived from lung squamous cell carcinoma. HLA A2402/2402, B5201/5401, C0102/1202. |
|---|
| Comment from the depositor | |
|---|
| RCB2819 |
| C831L |
| Comment | Human cell line derived from lung large cell carcinoma. HLA A0206/2601, B0702/3501, Cw0702/0801. |
|---|
| Comment from the depositor | |
|---|
| RCB2820 |
| N0003(<50) |
| Comment | Human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. RCB2820, RCB2821 were derived from the same patient. |
|---|
| Comment from the depositor | |
|---|
| RCB2821 |
| N0003(>300) |
| Comment | Human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. RCB2820, RCB2821 were derived from the same patient. |
|---|
| Comment from the depositor | |
|---|
| RCB2822 |
| N0005(<50) |
| Comment | Human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. RCB2822, RCB2823, RCB2824 were derived from the same patient. |
|---|
| Comment from the depositor | |
|---|
| RCB2823 |
| N0005(>500) |
| Comment | Human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. RCB2822, RCB2823, RCB2824 were derived from the same patient. |
|---|
| Comment from the depositor | |
|---|
| RCB2824 |
| N0005-A1 |
| Comment | Human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. RCB2822, RCB2823, RCB2824 were derived from the same patient. |
|---|
| Comment from the depositor | |
|---|
| RCB2825 |
| N0013(<50) |
| Comment | Human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. RCB2825, RCB2826 were derived from the same patient. |
|---|
| Comment from the depositor | |
|---|
| RCB2826 |
| N0013(>300) |
| Comment | Human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. RCB2825, RCB2826 were derived from the same patient. |
|---|
| Comment from the depositor | |
|---|
| RCB2827 |
| N6803(<50) |
| Comment | Human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. RCB2827, RCB2828 were derived from the same patient. |
|---|
| Comment from the depositor | |
|---|
| RCB2828 |
| N6803(>500) |
| Comment | Human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. RCB2827, RCB2828 were derived from the same patient. |
|---|
| Comment from the depositor | |
|---|
| RCB2830 |
| OMC-2 |
| Comment | Human cell line derived from endometrial adenocarcinoma. |
|---|
| Comment from the depositor | |
|---|
| RCB2831 |
| DEOC-1 |
| Comment | Human cell line derived from malignant melanoma. |
|---|
| Comment from the depositor | |
|---|
| RCB2832 |
| OMC-9 |
| Comment | Human cell line derived from endometrial stromal sarcoma. |
|---|
| Comment from the depositor | |
|---|
| RCB2833 |
| L23immo |
| Comment | Human immortalized cell line derived from MRC5 cells. |
|---|
| Comment from the depositor | |
|---|
| RCB2834 |
| L12.9-2(1) |
| Comment | Human immortalized cell line derived from MRC5 cells. |
|---|
| Comment from the depositor | |
|---|
| RCB2843 |
| 43L |
| Comment | Somatic tumor hybrid (fusion cell between C3H mammary tumor FM3A#2 and 8-Ag resistant L cell). This hybrid tumor cells induce resistance to MM Ag positive tumor cells. TKG0381 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2844 |
| L1210 TGR4 |
| Comment | Mouse cell line derived from leukemia. Resistant to 6TG (10 microgram/ml). DBA/2 strain. TKG0478 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2845 |
| L1210-5FU-R-TC |
| Comment | Mouse cell line derived from leukemia. Lymphoblastoid cells. DBA/2 strain. TKG0409 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2846 |
| LAG-MUC1 |
| Comment | A subline of LAG (RCB2758) expressing MUC1. 8-Ag resistant. TKG0466 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2848 |
| OTT6050(B) |
| Comment | Mouse cell line derived from testicular teratoma. This cell line was established by inoculation of tibia (6 days old) to A/He x 129/sv mouse testis. Primary tumor was developed in testis. TKG0330 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2852 |
| TSA8 |
| Comment | Mouse cell line derived from erythroleukemia cells transformed by Friend leukemia virus. TKG0370 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2853 |
| WEHI-3B |
| Comment | Mouse cell line derived from myelomonocytic leukemia cells. BALB/c strain. TKG0584 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2854 |
| C6 |
| Comment | Rat cell line derived from glial cell tumor induced by N-nitrosomethylurea. TKG0589 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2859 |
| K-251 |
| Comment | Rat cell line derived from hepatoma cells in ascites. TKG0130 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2860 |
| MRMT-1 |
| Comment | Rat cell line derived from mammary carcinoma. TKG0132 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2862 |
| SLC |
| Comment | Rat cell line derived from lung cancer. TKG0135 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2863 |
| N14.5 |
| Comment | Rat neuronal cell line derived from the ventrolateral region of the suprachiasmatic nucleus |
|---|
| Comment from the depositor | |
|---|
| RCB2864 |
| OLP6 |
| Comment | Rat neuronal cell line derived from the ventrolateral region of the suprachiasmatic nucleus |
|---|
| Comment from the depositor | |
|---|
| RCB2867 |
| HeLa/Fucci2 |
| Comment | A subline of the HeLa cell line expressing Fucci2, a cell cycle marker. Cell line name : HeLa/Fucci2 #3. Important notice regarding nomenclature of Fucci. Research tools : Fucci – Fluorescent Ubiquitination-based Cell Cycle Indicator. |
|---|
| Comment from the depositor | |
|---|
| RCB2868 |
| NMuMG/Fucci2 |
| Comment | A subline of the NMuMG cell line expressing Fucci2, a cell cycle marker. Cell line name : NMuMG/Fucci2 #5. Important notice regarding nomenclature of Fucci. Research tools : Fucci – Fluorescent Ubiquitination-based Cell Cycle Indicator. |
|---|
| Comment from the depositor | |
|---|
| RCB2869 |
| CHO-K1 |
| Comment | A subline of CHO cells. Require proline. TKG0328 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2896 |
| JLS-V9 6TG |
| Comment | Mouse cell line derived from bone marrow. Fibroblast-like. 6TG resistant. BALB/c strain. TKG0350 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2899 |
| S180-Kumamoto-TC |
| Comment | Mouse cell line derived from Swiss Webster Sarcoma 180. CFW strain. TKG0637 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2900 |
| S180-Meiji-TC |
| Comment | Mouse cell line derived from sarcoma cells in ascites. CFW strain. TKG0672 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2901 |
| S180-NCC-TC |
| Comment | Mouse cell line derived from sarcoma cells in ascites. CFW strain. TKG0638 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2904 |
| WEHI164R |
| Comment | Mouse cell line derived from fibrosarcoma. TNF resistant. BALB/c strain. TKG0281 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2905 |
| WEHI164S |
| Comment | Mouse cell line derived from fibrosarcoma. TNF sensitive. BALB/c strain. TKG0282 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2908 |
| AH272-TC |
| Comment | Rat cell line derived from hepatoma cells in ascites. TKG0535 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2909 |
| Walker256-TC |
| Comment | Rat cell line derived from mammary carcinoma. TKG0565 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2910 |
| LY-6-TC |
| Comment | Rat cell line derived from sarcoma cells in ascites. TKG0648 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB2911 |
| MEDEP-BRC5 |
| Comment | Mouse erythroid cell line able to differentiate into enucleated red blood cells. Derived from mouse ES cell line, BRC5 (AES0009). SCF(Stem cell factor) dependent. |
|---|
| Comment from the depositor | |
|---|
| RCB2924 |
| OP9/G |
| Comment | Subline of OP9 cell line, expressing EGFP. See RCB2117 TSt-4/G. |
|---|
| Comment from the depositor | |
|---|
| RCB2925 |
| OP9/G-DLL1 |
| Comment | Subline of OP9 cell line, expressing DLL1 and EGFP. See RCB2118 TSt-4/G-DLL1. |
|---|
| Comment from the depositor | |
|---|
| RCB2926 |
| OP9/N |
| Comment | Subline of OP9 cell line, expressing human NGF receptor. See RCB2119 TSt-4/N. |
|---|
| Comment from the depositor | |
|---|
| RCB2927 |
| OP9/N-DLL1 |
| Comment | Subline of OP9 cell line, expressing DLL1 and human NGF receptor. See RCB2120 TSt-4/N-DLL1. |
|---|
| Comment from the depositor | |
|---|
| RCB2931 |
| 6E2 |
| Comment | Hybridoma cell line expressing anti-human SSEA-4 monoclonal antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB2932 |
| MEDEP-BRC4-2 |
| Comment | Mouse erythroid cell line able to differentiate into enucleated red blood cells. Derived from mouse ES cell line, BRC4 (AES0008). SCF (Stem cell factor) and Dexamethasone dependent. C57BL/6 strain. |
|---|
| Comment from the depositor | |
|---|
| RCB2942 |
| OLHNI-2 |
| Comment | Medaka cell line derived from HNI strain. |
|---|
| Comment from the depositor | |
|---|
| RCB2943 |
| OLHdrR-e3 |
| Comment | Medaka cell line derived from HdrR strain. |
|---|
| Comment from the depositor | |
|---|
| RCB2944 |
| OLCAB-e31 |
| Comment | Medaka cell line. |
|---|
| Comment from the depositor | |
|---|
| RCB2945 |
| DIT29 |
| Comment | Medaka cell line derived from hepatoma cells. |
|---|
| Comment from the depositor | |
|---|
| RCB2946 |
| OLCAB-e3 |
| Comment | Medaka cell line. |
|---|
| Comment from the depositor | |
|---|
| RCB2979 |
| HCT116 |
| Comment | Human cell line derived from colon cancer. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2980 |
| HCT116-XRCC4(+/-) |
| Comment | Subline of HCT116 cell line lacking XRCC4 gene in one allele. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2981 |
| HCT116-XRCC4(-/-) |
| Comment | Subline of HCT116 cell line lacking XRCC4 gene in both alleles. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2982 |
| HCT116-RAD18(+/-) |
| Comment | Subline of HCT116 cell line lacking RAD18 gene in one allele. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2983 |
| HCT116-RAD18(-/-) |
| Comment | Subline of HCT116 cell line lacking RAD18 gene in both alleles. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2984 |
| HCT116-ARTEMIS(+/-) |
| Comment | Subline of HCT116 cell line lacking ARTEMIS gene in one allele. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2985 |
| HCT116-ARTEMIS(-/-) |
| Comment | Subline of HCT116 cell line lacking ARTEMIS gene in both alleles. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2986 |
| HCT116-MDC1(+/-) |
| Comment | Subline of HCT116 cell line lacking MDC1 gene in one allele. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2987 |
| HCT116-MDC1(-/-) |
| Comment | Subline of HCT116 cell line lacking MDC1 gene in both alleles. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2988 |
| HCT116-REV1(+/-) |
| Comment | Subline of HCT116 cell line lacking REV1 gene in one allele. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2989 |
| HCT116-REV1(-/-) |
| Comment | Subline of HCT116 cell line lacking REV1 gene in both alleles. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2990 |
| HCT116-REV3L(+/-) |
| Comment | Subline of HCT116 cell line lacking REV3L gene in one allele. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2991 |
| HCT116-KU70(+/-) |
| Comment | Subline of HCT116 cell line lacking Ku70 gene in one allele. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2992 |
| HCT116-DNAPKcs(+/-) |
| Comment | Subline of HCT116 cell line lacking DNAPKcs gene in one allele. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2993 |
| HCT116-POLM(+/-) |
| Comment | Subline of HCT116 cell line lacking DNA polymerase m gene in one allele. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2994 |
| HCT116-LIG3(+/-) |
| Comment | Subline of HCT116 cell line lacking Ligase 3 gene in one allele. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2995 |
| HCT116-LIG4(+/-) |
| Comment | Subline of HCT116 cell line lacking Ligase 4 gene in one allele. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2996 |
| HCT116-53BP1(+/-) |
| Comment | Subline of HCT116 cell line lacking 53BPI gene in one allele. |
|---|
| Comment from the depositor | Loss of the DNA mismatch repair gene (hMLH1). |
|---|
| RCB2997 |
| H414 |
| Comment | Subline of HCT116 cell line which has intact DNA mismatch repair gene (hMLH1). |
|---|
| Comment from the depositor | |
|---|
| RCB2998 |
| H414-RAD18(+/-) |
| Comment | Subline of H414 cell line lacking RAD18 gene in one allele. |
|---|
| Comment from the depositor | |
|---|
| RCB2999 |
| H414-RAD18(-/-) |
| Comment | Subline of H414 cell line lacking RAD18 gene in both alleles. |
|---|
| Comment from the depositor | |
|---|
| RCB3000 |
| H414-MDC1(+/-) |
| Comment | Subline of H414 cell line lacking MDC1 gene in one allele. |
|---|
| Comment from the depositor | |
|---|
| RCB3001 |
| H414-MDC1(-/-) |
| Comment | Subline of H414 cell line lacking MDC1 gene in both alleles. |
|---|
| Comment from the depositor | |
|---|
| RCB3002 |
| H414-LIG4(+/-) |
| Comment | Subline of H414 cell line lacking Ligase 4 gene in one allele. |
|---|
| Comment from the depositor | |
|---|
| RCB3007 |
| MOPC-70A |
| Comment | Mouse cell line derived from myeloma. This cell line was established from a cell line maintained by in vivo transplantation. TKG0167 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB3010 |
| RPMI8226 |
| Comment | Human cell line derived from myeloma. IgG producer. TKG0243 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB3052 |
| Jurkat |
| Comment | Human T cell leukemia. IL-2 receptor (-). Progeny were cured by Treatments with BM Cycline and MC210. TKG0209 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB3055 |
| C38 |
| Comment | |
|---|
| Comment from the depositor | |
|---|
| RCB3515 |
| JLS-V9 BudR |
| Comment | Mouse cell line derived from bone marrow. Fibroblast-like. BudR resistant. BALB/c strain. TKG0356 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB3516 |
| ASMF |
| Comment | A cell line derived from muscle of large japanese field mouse (Apodemus speciosus). |
|---|
| Comment from the depositor | |
|---|
| RCB3517 |
| LLKF |
| Comment | A cell line derived from kidney of steppe lemming. |
|---|
| Comment from the depositor | |
|---|
| RCB3518 |
| KM-Y |
| Comment | Burkitt lymphoma. |
|---|
| Comment from the depositor | |
|---|
| RCB3520 |
| KM-S |
| Comment | Lung cancer, Immature large cell type |
|---|
| Comment from the depositor | |
|---|
| RCB3521 |
| HAM1 |
| Comment | Human cell line derived from ameloblastoma. RCB3522 was derived from the same patient. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB3522 |
| HAM2 |
| Comment | Human cell line derived from ameloblastoma. RCB3521 was derived from the same patient. Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB3529 |
| G603L |
| Comment | Human cell line derived from lung large cell carcinoma cells. |
|---|
| Comment from the depositor | |
|---|
| RCB3530 |
| B901L |
| Comment | Human cell line derived from lung adenocarcinoma cells. |
|---|
| Comment from the depositor | |
|---|
| RCB3531 |
| A904L |
| Comment | Human cell line derived from lung large cell carcinoma cells. |
|---|
| Comment from the depositor | |
|---|
| RCB3532 |
| A129L |
| Comment | Human cell line derived from lung adenocarcinoma cells. |
|---|
| Comment from the depositor | |
|---|
| RCB3533 |
| ED-40515(+) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL patient derived leukemic cell line (IL-2 dependent). ED-40515, ED-40810, ED-41214, ED-50823, ED-70423C cell lines were established from the same patient's blood. |
|---|
| RCB3534 |
| ED-40515(-) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL patient derived leukemic cell line (IL-2 independent). ED-40515, ED-40810, ED-41214, ED-50823, ED-70423C cell lines were established from the same patient's blood. |
|---|
| RCB3535 |
| ATL-43T(+) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL patient derived leukemic cell line (IL-2 dependent). ATL-43T(+), ATL-43Tb(-) cell lines were established from the same patient's blood. |
|---|
| RCB3536 |
| ATL-43Tb(-) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL patient derived leukemic cell line (IL-2 independent). ATL-43T(+), ATL-43Tb(-) cell lines were established from the same patient's blood. |
|---|
| RCB3537 |
| ATL-55T(+) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL patient derived leukemic cell line (IL-2 dependent). ATL-55T(+), ATL-55T(-) cell lines were established from the same patient's blood. |
|---|
| RCB3538 |
| ATL-55T(-) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL patient derived leukemic cell line (IL-2 independent). ATL-55T(+), ATL-55T(-) cell lines were established from the same patient's blood. |
|---|
| RCB3539 |
| ED-50823(+) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL patient derived non-leukemic cell line (IL-2 dependent). ED-40515, ED-40810, ED-41214, ED-50823, ED-70423C cell lines were established from the same patient's blood. |
|---|
| RCB3540 |
| ED-50823(-) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL patient derived non-leukemic cell line (IL-2 independent). ED-40515, ED-40810, ED-41214, ED-50823, ED-70423C cell lines were established from the same patient's blood. |
|---|
| RCB3541 |
| ATL-72/2(+) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL patient derived non-leukemic cell line (IL-2 dependent). ATL-72/2(+), ATL-72/2(-), ATL-72b(+), ATL-72b(-), ATL-72T(+) cell lines were established from the same patient's blood. |
|---|
| RCB3542 |
| ATL-72/2(-) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL patient derived non-leukemic cell line (IL-2 independent). ATL-72/2(+), ATL-72/2(-), ATL-72b(+), ATL-72b(-), ATL-72T(+) cell lines were established from the same patient's blood. |
|---|
| RCB3543 |
| SezM3(+) |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Sezary syndrome like patient’s mother derived T cell line (IL-2 dependent). |
|---|
| RCB3544 |
| SezM3(-) |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Sezary syndrome like patient’s mother derived T cell line (IL-2 independent). |
|---|
| RCB3545 |
| ATL-2(+) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL patient derived non-leukemic cell line (IL-2 dependent). ATL-2(+), ATL-2(-) cell lines were established from the same patient's blood. |
|---|
| RCB3547 |
| Sez627(+) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Sezary syndrome like patient derived T cell line (IL-2 dependent). |
|---|
| RCB3548 |
| Sez627C(-) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Sezary syndrome like patient’s derived T cell line (IL-2 independent). |
|---|
| RCB3549 |
| ATL-72b(+) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL patient derived non-leukemic cell line (IL-2 dependent). ATL-72/2(+), ATL-72/2(-), ATL-72b(+), ATL-72b(-), ATL-72T(+) cell lines were established from the same patient's blood. |
|---|
| RCB3550 |
| ATL-72b(-) |
| Comment | BSL2. Important Notice : unidentified autonomous proliferative particles. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL patient derived non-leukemic cell line (IL-2 independent). ATL-72/2(+), ATL-72/2(-), ATL-72b(+), ATL-72b(-), ATL-72T(+) cell lines were established from the same patient's blood. |
|---|
| RCB3551 |
| ATL-21C(+) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line (IL-2 dependent). ATL-21C(+), ATL-21C(-)/2, ATL-21C(-)/8.9 cell lines were established from the same patient's blood. |
|---|
| RCB3552 |
| ATL-21C(-)/2 |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line (IL-2 independent). Cultured for 2-years without IL-2. ATL-21C(+), ATL-21C(-)/2, ATL-21C(-)/8.9 cell lines were established from the same patient's blood. |
|---|
| RCB3553 |
| ATL-21C(-)/8.9 |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line (IL-2 independent). Cultured for 8.9-years without IL-2. ATL-21C(+), ATL-21C(-)/2, ATL-21C(-)/8.9 cell lines were established from the same patient's blood. |
|---|
| RCB3554 |
| ATL-16T(-) |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line (IL-2 independent). |
|---|
| RCB3555 |
| ATL-35T(-) |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line (IL-2 independent). |
|---|
| RCB3556 |
| ED-40810(-) |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL patient derived leukemic cell line (IL-2 independent). ED-40515, ED-40810, ED-41214, ED-50823, ED-70423C cell lines were established from the same patient's blood. |
|---|
| RCB3557 |
| ED-41214(-) |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL patient derived leukemic cell line (IL-2 independent). ED-40515, ED-40810, ED-41214, ED-50823, ED-70423C cell lines were established from the same patient's blood. |
|---|
| RCB3558 |
| ED-70423C(-) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL patient derived leukemic cell line (IL-2 independent). ED-40515, ED-40810, ED-41214, ED-50823, ED-70423C cell lines were established from the same patient's blood. |
|---|
| RCB3559 |
| ATL-6(+) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line (IL-2 dependent). |
|---|
| RCB3560 |
| ATL-7(+) |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line (IL-2 dependent). |
|---|
| RCB3561 |
| ATL-11-6(+) |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line (IL-2 dependent). |
|---|
| RCB3562 |
| ATL-12A(+) |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line (IL-2 dependent). |
|---|
| RCB3563 |
| ATL-17C(+) |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line (IL-2 dependent). ATL-17C(+), ATL-17-2(+) cell lines were established from the same patient's blood. |
|---|
| RCB3564 |
| ATL-17-2(+) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line (IL-2 dependent). ATL-17C(+), ATL-17-2(+) cell lines were established from the same patient's blood. |
|---|
| RCB3565 |
| ATL-18C(+) |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line (IL-2 dependent). |
|---|
| RCB3566 |
| ATL-23(+) |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line (IL-2 dependent). |
|---|
| RCB3567 |
| ATL-26C(+) |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line (IL-2 dependent). |
|---|
| RCB3568 |
| ATL-42T(+) |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2.
|
|---|
| Comment from the depositor | Leukemic cell line (IL-2 dependent). |
|---|
| RCB3569 |
| ATL-46T(+) |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line (IL-2 dependent). |
|---|
| RCB3570 |
| ATL-48T(+) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Leukemic cell line (IL-2 dependent). |
|---|
| RCB3571 |
| ATL-67T(+) |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line (IL-2 dependent). |
|---|
| RCB3572 |
| ATL-72T(+) |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line (IL-2 dependent). ATL-72/2(+), ATL-72/2(-), ATL-72b(+), ATL-72b(-), ATL-72T(+) cell lines were established from the same patient's blood. |
|---|
| RCB3574 |
| CATL-3(+) |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | Non-leukemic cell line derived from healthy carrier of HTLV-1 (IL-2 dependent). |
|---|
| RCB3576 |
| Aska-SS |
| Comment | Human cell line derived from synovial sarcoma. |
|---|
| Comment from the depositor | |
|---|
| RCB3577 |
| Yamato-SS |
| Comment | Human cell line derived from synovial sarcoma. |
|---|
| Comment from the depositor | |
|---|
| RCB3579 |
| ASF-4-2 |
| Comment | Normal human skin fibroblast. RCB3579〜RCB3585 were derived from the same person. |
|---|
| Comment from the depositor | |
|---|
| RCB3580 |
| ASF-4-3L |
| Comment | Normal human skin fibroblast. RCB3579〜RCB3585 were derived from the same person. |
|---|
| Comment from the depositor | |
|---|
| RCB3582 |
| ASF-4-4L1 |
| Comment | Normal human skin fibroblast. RCB3579〜RCB3585 were derived from the same person. |
|---|
| Comment from the depositor | |
|---|
| RCB3583 |
| ASF-4-4L2 |
| Comment | Normal human skin fibroblast. RCB3579〜RCB3585 were derived from the same person. |
|---|
| Comment from the depositor | |
|---|
| RCB3585 |
| ASF-4-4R2 |
| Comment | Normal human skin fibroblast. RCB3579〜RCB3585 were derived from the same person. |
|---|
| Comment from the depositor | |
|---|
| RCB3588 |
| hPSC-5 |
| Comment | Human cell line derived from pacreatic cancer. Pancreatic stellate cells. |
|---|
| Comment from the depositor | |
|---|
| RCB3589 |
| hPSC-14 |
| Comment | Human cell line derived from pacreatic cancer. Pancreatic stellate cells. |
|---|
| Comment from the depositor | |
|---|
| RCB3600 |
| SDR-P-1D5 |
| Comment | Rat prolactin secreting cell line derived from anterior pituitary lacking growth hormone. |
|---|
| Comment from the depositor | |
|---|
| RCB3601 |
| SDRL-1 |
| Comment | Rat cell line derived from liver lacking growth hormone. |
|---|
| Comment from the depositor | |
|---|
| RCB3602 |
| SDRL-2 |
| Comment | Rat cell line derived from liver lacking growth hormone. |
|---|
| Comment from the depositor | |
|---|
| RCB3673 |
| Raji |
| Comment | Human cell line derived from Burkitt lymphoma. EBNA (EBV—nuclear antigen) positive. TKG0371 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB3675 |
| SCC-TC |
| Comment | Rectal carcinoma. Culture cell line of SCC (TKG 0340) . TKG0646 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB3676 |
| 5637 |
| Comment | Human cell line derived from bladder carcinoma. TKG0605 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB3677 |
| A549 |
| Comment | Human cell line derived from lung cancer. Epithelial-like cells. HLA-A 2603/3001. A culture submitted to the Cell Resource Center for Biomedical Research was found to be contaminated with mycoplasma. Progeny were cured by Treatments with BM Cycline and MC210. TKG0184 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB3678 |
| BeWo |
| Comment | Human cell line derived from choriocarcinoma. TKG0567 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB3680 |
| HeLa |
| Comment | Human cell line derived from cervical cancer. A culture submitted to the Cell Resource Center for Biomedical Research was found to be contaminated with mycoplasma. Progeny were cured by Treatments with BM Cycline and MC210. TKG0331 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB3681 |
| HeLa.P3(S) |
| Comment | Subline of HeLa cell line. Serum-free culture is possible. TKG0465 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB3682 |
| HeLa S3 |
| Comment | Human cell line derived from cervical cancer. TKG0444 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB3683 |
| HL-60 |
| Comment | Human cell line derived from promyelocytic leukemia cells. HL60 (RCB0041) can proliferate better than this HL-60 immediately after thawing. TKG0345 (Deposited from Tohoku Univ.). Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB3685 |
| HMV-II |
| Comment | Human cell line derived from melanotic melanoma (highly melanotic). TKG0318 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB3686 |
| THP-1 |
| Comment | Human cell line derived from monocytic leukemia. TKG0267 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB3687 |
| MKN-7 |
| Comment | Human cell line derived from stomach cancer (gastric cancer; highly differentiated tubular adenocarcinoma). TKG0228 (Deposited from Tohoku Univ.). |
|---|
| Comment from the depositor | |
|---|
| RCB3706 |
| Atg7 +/+ MEFs |
| Comment | Mouse embryonic fibroblasts derived from wild type mouse (C57BL/6). |
|---|
| Comment from the depositor | |
|---|
| RCB3707 |
| Atg7 -/- MEFs |
| Comment | Mouse embryonic fibroblasts derived from Atg-deficient mouse (C57BL/6). |
|---|
| Comment from the depositor | |
|---|
| RCB3708 |
| Atg3 +/+ MEFs |
| Comment | Mouse embryonic fibroblast cell line derived from wild type C57BL/6 strain. |
|---|
| Comment from the depositor | |
|---|
| RCB3709 |
| Atg3 -/- MEFs |
| Comment | Mouse embryonic fibroblast cell line derived from Atg3-deficient C57BL/6 strain. |
|---|
| Comment from the depositor | |
|---|
| RCB3710 |
| CRP2(A1311A) |
| Comment | Currently not ready. Hybridoma against CRP2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3711 |
| CDX2(A3701A) |
| Comment | Currently not ready. Hybridoma against CDX2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3712 |
| CDX2(A3707A) |
| Comment | Currently not ready. Hybridoma against CDX2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3713 |
| CDX2(A3715A) |
| Comment | Currently not ready. Hybridoma against CDX2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3714 |
| CDX2(A3719A) |
| Comment | Currently not ready. Hybridoma against CDX2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3715 |
| CDX2(A3722A) |
| Comment | Currently not ready. Hybridoma against CDX2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3716 |
| NNMT(A2402A) |
| Comment | Currently not ready. Hybridoma against NNMT (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3717 |
| NNMT(A2418A) |
| Comment | Currently not ready. Hybridoma against NNMT (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3718 |
| NNMT(A2433A) |
| Comment | Currently not ready. Hybridoma against NNMT (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3719 |
| NNMT(A2434A) |
| Comment | Currently not ready. Hybridoma against NNMT (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3720 |
| NNMT(A2438A) |
| Comment | Currently not ready. Hybridoma against NNMT (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3721 |
| NNMT(A2440A) |
| Comment | Currently not ready. Hybridoma against NNMT (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3722 |
| Olig1(A5501A) |
| Comment | Currently not ready. Hybridoma against Olig1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3723 |
| Olig1(A5507A) |
| Comment | Currently not ready. Hybridoma against Olig1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3724 |
| Olig1(A5508A) |
| Comment | Currently not ready. Hybridoma against Olig1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3725 |
| Olig1(A5515A) |
| Comment | Currently not ready. Hybridoma against Olig1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3726 |
| Olig1(A5518A) |
| Comment | Currently not ready. Hybridoma against Olig1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3727 |
| Olig2(A5618A) |
| Comment | Currently not ready. Hybridoma against Olig2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3728 |
| Olig2(A5628A) |
| Comment | Currently not ready. Hybridoma against Olig2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3729 |
| Olig2(A5629A) |
| Comment | Currently not ready. Hybridoma against Olig2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3730 |
| Olig2(A5643A) |
| Comment | Currently not ready. Hybridoma against Olig2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3731 |
| SFRP4(A7113A) |
| Comment | Currently not ready. Hybridoma against SFRP4 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3732 |
| SFRP4(A7116-2A) |
| Comment | Currently not ready. Hybridoma against SFRP4 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3733 |
| SFRP4(A7118A) |
| Comment | Currently not ready. Hybridoma against SFRP4 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3734 |
| SFRP4(A7123A) |
| Comment | Currently not ready. Hybridoma against SFRP4 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3735 |
| SFRP4(A7127-74A) |
| Comment | Currently not ready. Hybridoma against SFRP4 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3736 |
| EPST11(H9209) |
| Comment | Currently not ready. Hybridoma against EPST11 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3737 |
| EPST11(H9214) |
| Comment | Currently not ready. Hybridoma against EPST11 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3738 |
| EPST11(H9219) |
| Comment | Currently not ready. Hybridoma against EPST11 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3739 |
| EPST11(H9220) |
| Comment | Currently not ready. Hybridoma against EPST11 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3740 |
| EPST11(H9228) |
| Comment | Currently not ready. Hybridoma against EPST11 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3741 |
| C20-ORF102(H9613) |
| Comment | Currently not ready. Hybridoma against C20-0RF102 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3742 |
| C20-ORF102(H9615) |
| Comment | Currently not ready. Hybridoma against C20-0RF102 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3743 |
| C20-ORF102(H9616) |
| Comment | Currently not ready. Hybridoma against C20-0RF102 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3744 |
| C20-ORF102(H9625) |
| Comment | Currently not ready. Hybridoma against C20-0RF102 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3745 |
| C20-ORF102(H9627) |
| Comment | Currently not ready. Hybridoma against C20-0RF102 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3746 |
| C20-ORF102(H9638) |
| Comment | Currently not ready. Hybridoma against C20-0RF102 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3747 |
| C20-ORF102(H9645) |
| Comment | Currently not ready. Hybridoma against C20-0RF102 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3748 |
| SP-5AD5(N2901) |
| Comment | Currently not ready. Hybridoma against SP-5AD5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3749 |
| SP-5AD5(N2906) |
| Comment | Currently not ready. Hybridoma against SP-5AD5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3750 |
| SP-5AD5(N2922) |
| Comment | Currently not ready. Hybridoma against SP-5AD5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3751 |
| SP-5AD5(N2927) |
| Comment | Currently not ready. Hybridoma against SP-5AD5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3752 |
| SP-5AD5(N2931) |
| Comment | Currently not ready. Hybridoma against SP-5AD5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3753 |
| SP-5AD5(N2933) |
| Comment | Currently not ready. Hybridoma against SP-5AD5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3754 |
| SP-5AD5(N2935) |
| Comment | Currently not ready. Hybridoma against SP-5AD5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3755 |
| SP-5AD5(N2942) |
| Comment | Currently not ready. Hybridoma against SP-5AD5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3756 |
| PTCH1-2(N7333) |
| Comment | Currently not ready. Hybridoma against PTCH1-2 : Patched 1 (268-319(52aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3757 |
| PTCH1-2(N7346) |
| Comment | Currently not ready. Hybridoma against PTCH1-2 : Patched 1 (268-319(52aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3758 |
| PTCH1-2(N7357) |
| Comment | Currently not ready. Hybridoma against PTCH1-2 : Patched 1 (268-319(52aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3759 |
| PLCη2C(N8320) |
| Comment | Currently not ready. Hybridoma against PLCη2C : Phospholipase Cη2 (1065-1164(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3760 |
| PLCη2C(N8328) |
| Comment | Currently not ready. Hybridoma against PLCη2C : Phospholipase Cη2 (1065-1164(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3761 |
| PLCη2C(N8339) |
| Comment | Currently not ready. Hybridoma against PLCη2C : Phospholipase Cη2 (1065-1164(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3762 |
| PLCη2C(N8346) |
| Comment | Currently not ready. Hybridoma against PLCη2C : Phospholipase Cη2 (1065-1164(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3763 |
| PLCη2C(N8351) |
| Comment | Currently not ready. Hybridoma against PLCη2C : Phospholipase Cη2 (1065-1164(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3764 |
| PLCη2C(N8353) |
| Comment | Currently not ready. Hybridoma against PLCη2C : Phospholipase Cη2 (1065-1164(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3765 |
| PLCη2C(N8357) |
| Comment | Currently not ready. Hybridoma against PLCη2C : Phospholipase Cη2 (1065-1164(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3766 |
| PLCη2C(N8360) |
| Comment | Currently not ready. Hybridoma against PLCη2C : Phospholipase Cη2 (1065-1164(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3767 |
| PLCη2C(N8361) |
| Comment | Currently not ready. Hybridoma against PLCη2C : Phospholipase Cη2 (1065-1164(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3768 |
| Prdm14-2(N8028) |
| Comment | Currently not ready. Hybridoma against Prdm14-2 : PR domain containing 14 (181-280(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3769 |
| Prdm14-2(N8048) |
| Comment | Currently not ready. Hybridoma against Prdm14-2 : PR domain containing 14 (181-280(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3770 |
| Prdm14-2(N8070) |
| Comment | Currently not ready. Hybridoma against Prdm14-2 : PR domain containing 14 (181-280(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3771 |
| Prdm1-2(N6902) |
| Comment | Currently not ready. Hybridoma against Prdm1-2+AP75: PR domain containing1 (757-856(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3772 |
| Prdm1-2(N6915) |
| Comment | Currently not ready. Hybridoma against Prdm1-2+AP75: PR domain containing1 (757-856(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3773 |
| Prdm1-2(N6916) |
| Comment | Currently not ready. Hybridoma against Prdm1-2+AP75: PR domain containing1 (757-856(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3774 |
| Prdm1-2(N6917) |
| Comment | Currently not ready. Hybridoma against Prdm1-2+AP75: PR domain containing1 (757-856(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3775 |
| Prdm1-2(N6927) |
| Comment | Currently not ready. Hybridoma against Prdm1-2+AP75: PR domain containing1 (757-856(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3776 |
| HZF2(Y3701) |
| Comment | Currently not ready. Hybridoma against HZF2 : Hematopoietic zinc finger (1-50(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3777 |
| HZF2(Y3713) |
| Comment | Currently not ready. Hybridoma against HZF2 : Hematopoietic zinc finger (1-50(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3778 |
| HZF2(Y3716) |
| Comment | Currently not ready. Hybridoma against HZF2 : Hematopoietic zinc finger (1-50(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3779 |
| HZF3(Y3901) |
| Comment | Currently not ready. Hybridoma against HZF3 : Hematopoietic zinc finger (107-157(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3780 |
| HZF3(Y3916) |
| Comment | Currently not ready. Hybridoma against HZF3 : Hematopoietic zinc finger (107-157(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3781 |
| HZF3(Y3919) |
| Comment | Currently not ready. Hybridoma against HZF3 : Hematopoietic zinc finger (107-157(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3782 |
| HZF3(Y3921) |
| Comment | Currently not ready. Hybridoma against HZF3 : Hematopoietic zinc finger (107-157(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3783 |
| HZF3(Y3923) |
| Comment | Currently not ready. Hybridoma against HZF3 : Hematopoietic zinc finger (107-157(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3784 |
| HZF3(Y3924) |
| Comment | Currently not ready. Hybridoma against HZF3 : Hematopoietic zinc finger (107-157(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3785 |
| HZF3(Y3928) |
| Comment | Currently not ready. Hybridoma against HZF3 : Hematopoietic zinc finger (107-157(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3786 |
| HZF3(Y3932) |
| Comment | Currently not ready. Hybridoma against HZF3 : Hematopoietic zinc finger (107-157(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3787 |
| HZF3(Y3942) |
| Comment | Currently not ready. Hybridoma against HZF3 : Hematopoietic zinc finger (107-157(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3788 |
| HZF4(Y4006) |
| Comment | Currently not ready. Hybridoma against HZF4 : Hematopoietic zinc finger (294-365(72aa)+1amino acid [Ser]) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3789 |
| HZF4(Y4019) |
| Comment | Currently not ready. Hybridoma against HZF4 : Hematopoietic zinc finger (294-365(72aa)+1amino acid [Ser]) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3790 |
| tead2(Y3312) |
| Comment | Currently not ready. Hybridoma against tead2 : TEA domain family member 2 (140-216(77aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3791 |
| tead2(Y3321) |
| Comment | Currently not ready. Hybridoma against tead2 : TEA domain family member 2 (140-216(77aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3792 |
| tead2(Y3324) |
| Comment | Currently not ready. Hybridoma against tead2 : TEA domain family member 2 (140-216(77aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3793 |
| tead2(Y3325) |
| Comment | Currently not ready. Hybridoma against tead2 : TEA domain family member 2 (140-216(77aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3794 |
| tead2(Y3329) |
| Comment | Currently not ready. Hybridoma against tead2 : TEA domain family member 2 (140-216(77aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3795 |
| tead2(Y3331) |
| Comment | Currently not ready. Hybridoma against tead2 : TEA domain family member 2 (140-216(77aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3796 |
| tead2(Y3336) |
| Comment | Currently not ready. Hybridoma against tead2 : TEA domain family member 2 (140-216(77aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3797 |
| tead2(Y3339) |
| Comment | Currently not ready. Hybridoma against tead2 : TEA domain family member 2 (140-216(77aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3798 |
| tead2(Y3342) |
| Comment | Currently not ready. Hybridoma against tead2 : TEA domain family member 2 (140-216(77aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3799 |
| tead2(Y3343) |
| Comment | Currently not ready. Hybridoma against tead2 : TEA domain family member 2 (140-216(77aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3800 |
| SOCS1-1(Y9208) |
| Comment | Currently not ready. Hybridoma against SOCS1-1 : Suppressor of Cytokine Signaling1 (1-60(60aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3801 |
| SOCS1-1(Y9213) |
| Comment | Currently not ready. Hybridoma against SOCS1-1 : Suppressor of Cytokine Signaling1 (1-60(60aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3802 |
| SOCS1-1(Y9215) |
| Comment | Currently not ready. Hybridoma against SOCS1-1 : Suppressor of Cytokine Signaling1 (1-60(60aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3803 |
| Prdm14-1(N8902) |
| Comment | Currently not ready. Hybridoma against Prdm14-1 : PR domain containing14 (1-100(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3804 |
| CDK-11(Z0410) |
| Comment | Currently not ready. Hybridoma against CDK-11 : Cyclin dependent kinase-11 (378-456(79aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3805 |
| CDK-11(Z0418) |
| Comment | Currently not ready. Hybridoma against CDK-11 : Cyclin dependent kinase-11 (378-456(79aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3806 |
| CDK-11(Z0425) |
| Comment | Currently not ready. Hybridoma against CDK-11 : Cyclin dependent kinase-11 (378-456(79aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3807 |
| CDK-11(Z0430) |
| Comment | Currently not ready. Hybridoma against CDK-11 : Cyclin dependent kinase-11 (378-456(79aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3808 |
| CDK-11(Z0432) |
| Comment | Currently not ready. Hybridoma against CDK-11 : Cyclin dependent kinase-11 (378-456(79aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3809 |
| CDK-11(Z0441) |
| Comment | Currently not ready. Hybridoma against CDK-11 : Cyclin dependent kinase-11 (378-456(79aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3810 |
| Neurotonin3(Z0835) |
| Comment | Currently not ready. Hybridoma against Neurotonin3 : Neurotonin (409-507(99aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3811 |
| Neurotonin4(Z0901-265) |
| Comment | Currently not ready. Hybridoma against Neurotonin4 : Neurotonin (1-77(77aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3812 |
| Neurotonin4(Z0937) |
| Comment | Currently not ready. Hybridoma against Neurotonin4 : Neurotonin (1-77(77aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3813 |
| Neurotonin4(Z0953) |
| Comment | Currently not ready. Hybridoma against Neurotonin4 : Neurotonin (1-77(77aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3814 |
| Neurotonin4(Z0956(222)) |
| Comment | Currently not ready. Hybridoma against Neurotonin4 : Neurotonin (1-77(77aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3815 |
| AKAP15(Y0319) |
| Comment | Currently not ready. Hybridoma against AKAP15 : A kinase anchor protein15 (23-75(53aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3816 |
| AKAP15(Y0329) |
| Comment | Currently not ready. Hybridoma against AKAP15 : A kinase anchor protein15 (23-75(53aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3817 |
| AKAP15(Y0332) |
| Comment | Currently not ready. Hybridoma against AKAP15 : A kinase anchor protein15 (23-75(53aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3818 |
| AKAP15(Y0335) |
| Comment | Currently not ready. Hybridoma against AKAP15 : A kinase anchor protein15 (23-75(53aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3819 |
| AKAP15(Y0348) |
| Comment | Currently not ready. Hybridoma against AKAP15 : A kinase anchor protein15 (23-75(53aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3820 |
| mGli2-2(N9106) |
| Comment | Currently not ready. Hybridoma against mGli2-2 : GLI family zinc finger 2 (327-391(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3821 |
| mGli2-2(N9109) |
| Comment | Currently not ready. Hybridoma against mGli2-2 : GLI family zinc finger 2 (327-391(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3822 |
| mGli2-2(N9110) |
| Comment | Currently not ready. Hybridoma against mGli2-2 : GLI family zinc finger 2 (327-391(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3823 |
| mGli2-2(N9113) |
| Comment | Currently not ready. Hybridoma against mGli2-2 : GLI family zinc finger 2 (327-391(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3824 |
| mGli2-2(N9119) |
| Comment | Currently not ready. Hybridoma against mGli2-2 : GLI family zinc finger 2 (327-391(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3825 |
| mGli2-2(N9122) |
| Comment | Currently not ready. Hybridoma against mGli2-2 : GLI family zinc finger 2 (327-391(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3826 |
| mGli2-2(N9124) |
| Comment | Currently not ready. Hybridoma against mGli2-2 : GLI family zinc finger 2 (327-391(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3827 |
| mGli2-2(N9133) |
| Comment | Currently not ready. Hybridoma against mGli2-2 : GLI family zinc finger 2 (327-391(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3828 |
| mGli2-2(N9143) |
| Comment | Currently not ready. Hybridoma against mGli2-2 : GLI family zinc finger 2 (327-391(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3829 |
| mGli2-2(N9144) |
| Comment | Currently not ready. Hybridoma against mGli2-2 : GLI family zinc finger 2 (327-391(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3830 |
| mGli2-2(N9145) |
| Comment | Currently not ready. Hybridoma against mGli2-2 : GLI family zinc finger 2 (327-391(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3831 |
| SMO-2(B7115B) |
| Comment | Currently not ready. Hybridoma against SMO-2 : SMO (470-519 (50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3832 |
| Wnt4(N0716) |
| Comment | Currently not ready. Hybridoma against Wnt4 : Wnt4 (37-77 (41aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3833 |
| Gli1(N5510) |
| Comment | Currently not ready. Hybridoma against Gli1 : GLI family zinc finger 1 (2-68 (67aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3834 |
| Gli1(N5516-191) |
| Comment | Currently not ready. Hybridoma against Gli1 : GLI family zinc finger 1 (2-68 (67aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3835 |
| Gli1(N5537) |
| Comment | Currently not ready. Hybridoma against Gli1 : GLI family zinc finger 1 (2-68 (67aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3836 |
| SMO-1(N5813) |
| Comment | Currently not ready. Hybridoma against SMO-1 : SMO (90-172 (83aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3837 |
| Gli3(N6202) |
| Comment | Currently not ready. Hybridoma against gp64 fusion Gli3 : GLI family zinc finger 3 (2-60 (59aa)) antigen expressed by baculovirus. |
|---|
| Comment from the depositor | |
|---|
| RCB3838 |
| Calp7-1(Y0717) |
| Comment | Currently not ready. Hybridoma against Calp7-1 : Calpain7 (78-157(80aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3839 |
| Calp7-1(Y0737) |
| Comment | Currently not ready. Hybridoma against Calp7-1 : Calpain7 (78-157(80aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3840 |
| PEG10-1(H1805) |
| Comment | Currently not ready. Hybridoma against PEG10-1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3841 |
| PEG10-1(H1807) |
| Comment | Currently not ready. Hybridoma against PEG10-1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3842 |
| PEG10-1(H1812) |
| Comment | Currently not ready. Hybridoma against PEG10-1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3843 |
| PEG10-1(H1827) |
| Comment | Currently not ready. Hybridoma against PEG10-1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3844 |
| PEG10-1(H1829) |
| Comment | Currently not ready. Hybridoma against PEG10-1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3845 |
| PEG10-1(H1831) |
| Comment | Currently not ready. Hybridoma against PEG10-1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3846 |
| TFF1deltaN(H6110) |
| Comment | Currently not ready. Hybridoma against TFF1 deltaN : TFF1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3847 |
| TFF1deltaN(H6111) |
| Comment | Currently not ready. Hybridoma against TFF1 deltaN : TFF1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3848 |
| TFF1deltaN(H6112) |
| Comment | Currently not ready. Hybridoma against TFF1 deltaN : TFF1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3849 |
| TFF1deltaN(H6123) |
| Comment | Currently not ready. Hybridoma against TFF1 deltaN : TFF1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3850 |
| TFF1deltaN(H6134) |
| Comment | Currently not ready. Hybridoma against TFF1 deltaN : TFF1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3851 |
| STIP1(H3401) |
| Comment | Currently not ready. Hybridoma against STIP1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3852 |
| STIP1(H3408) |
| Comment | Currently not ready. Hybridoma against STIP1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3853 |
| STIP1(H3420) |
| Comment | Currently not ready. Hybridoma against STIP1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3854 |
| STIP1(H3425) |
| Comment | Currently not ready. Hybridoma against STIP1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3855 |
| STIP1(H3430) |
| Comment | Currently not ready. Hybridoma against STIP1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3856 |
| STIP1(H3444) |
| Comment | Currently not ready. Hybridoma against STIP1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3857 |
| STIP1(H3445) |
| Comment | Currently not ready. Hybridoma against STIP1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3858 |
| STIP1(H3454) |
| Comment | Currently not ready. Hybridoma against STIP1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3859 |
| STIP1(H3455) |
| Comment | Currently not ready. Hybridoma against STIP1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3860 |
| STIP1(H3456) |
| Comment | Currently not ready. Hybridoma against STIP1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3861 |
| STIP1(H1726) |
| Comment | Currently not ready. Hybridoma against STIP1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3862 |
| STIP1(H1731) |
| Comment | Currently not ready. Hybridoma against STIP1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3863 |
| Rab32(H3502) |
| Comment | Currently not ready. Hybridoma against Rab32 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3864 |
| Rab32(H3506) |
| Comment | Currently not ready. Hybridoma against Rab32 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3865 |
| Rab32(H3512) |
| Comment | Currently not ready. Hybridoma against Rab32 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3866 |
| Rab32(H3513) |
| Comment | Currently not ready. Hybridoma against Rab32 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3867 |
| Rab32(H3516) |
| Comment | Currently not ready. Hybridoma against Rab32 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3868 |
| Rab32(H3519) |
| Comment | Currently not ready. Hybridoma against Rab32 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3869 |
| Rab32(H3521) |
| Comment | Currently not ready. Hybridoma against Rab32 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3870 |
| GBR7(H4720) |
| Comment | Currently not ready. Hybridoma against GBR7 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3871 |
| GBR7(H4722) |
| Comment | Currently not ready. Hybridoma against GBR7 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3872 |
| GBR7(H4733) |
| Comment | Currently not ready. Hybridoma against GBR7 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3873 |
| GBR7(H4739) |
| Comment | Currently not ready. Hybridoma against GBR7 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3874 |
| GBR7(H4747) |
| Comment | Currently not ready. Hybridoma against GBR7 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3875 |
| GBR7(H4749) |
| Comment | Currently not ready. Hybridoma against GBR7 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3876 |
| GBR7(H4750) |
| Comment | Currently not ready. Hybridoma against GBR7 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3877 |
| GBR7(H4751) |
| Comment | Currently not ready. Hybridoma against GBR7 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3878 |
| GBR7(H4752) |
| Comment | Currently not ready. Hybridoma against GBR7 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3879 |
| GBR7(H4755) |
| Comment | Currently not ready. Hybridoma against GBR7 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3880 |
| FLJ20442(H5409) |
| Comment | Currently not ready. Hybridoma against FLJ20442 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3881 |
| FLJ20442(H5413) |
| Comment | Currently not ready. Hybridoma against FLJ20442 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3882 |
| FLJ20442(H5422) |
| Comment | Currently not ready. Hybridoma against FLJ20442 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3883 |
| FLJ20442(H5425) |
| Comment | Currently not ready. Hybridoma against FLJ20442 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3884 |
| FLJ20442(H5429) |
| Comment | Currently not ready. Hybridoma against FLJ20442 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3885 |
| FLJ20442(H5432) |
| Comment | Currently not ready. Hybridoma against FLJ20442 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3886 |
| FLJ20442(H5433) |
| Comment | Currently not ready. Hybridoma against FLJ20442 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3887 |
| Galectin4(H6004) |
| Comment | Currently not ready. Hybridoma against Galectin4 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3888 |
| Galectin4(H6005) |
| Comment | Currently not ready. Hybridoma against Galectin4 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3889 |
| Galectin4(H6006) |
| Comment | Currently not ready. Hybridoma against Galectin4 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3890 |
| Galectin4(H6007) |
| Comment | Currently not ready. Hybridoma against Galectin4 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3891 |
| Galectin4(H6009) |
| Comment | Currently not ready. Hybridoma against Galectin4 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3892 |
| Galectin4(H6013) |
| Comment | Currently not ready. Hybridoma against Galectin4 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3893 |
| Galectin4(H6015) |
| Comment | Currently not ready. Hybridoma against Galectin4 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3894 |
| Galectin4(H6024) |
| Comment | Currently not ready. Hybridoma against Galectin4 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3895 |
| Galectin4(H6026) |
| Comment | Currently not ready. Hybridoma against Galectin4 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3896 |
| Galectin4(H6034) |
| Comment | Currently not ready. Hybridoma against Galectin4 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3897 |
| Galectin4(H6038) |
| Comment | Currently not ready. Hybridoma against Galectin4 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3898 |
| Galectin4(H6043) |
| Comment | Currently not ready. Hybridoma against Galectin4 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3899 |
| PAEP(H7001) |
| Comment | Currently not ready. Hybridoma against PAEP (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3900 |
| PAEP(H7005) |
| Comment | Currently not ready. Hybridoma against PAEP (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3901 |
| PAEP(H7006) |
| Comment | Currently not ready. Hybridoma against PAEP (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3902 |
| PAEP(H7011) |
| Comment | Currently not ready. Hybridoma against PAEP (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3903 |
| PAEP(H7015A) |
| Comment | Currently not ready. Hybridoma against PAEP (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3904 |
| PAEP(H7020A) |
| Comment | Currently not ready. Hybridoma against PAEP (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3905 |
| PAEP(H7026) |
| Comment | Currently not ready. Hybridoma against PAEP (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3906 |
| PAEP(H7033) |
| Comment | Currently not ready. Hybridoma against PAEP (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3907 |
| PGC-1(H5953) |
| Comment | Currently not ready. Hybridoma against PGC-1 (2-81(80aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3908 |
| STK15(H5701) |
| Comment | Currently not ready. Hybridoma against STK15 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3909 |
| STK15(H5706) |
| Comment | Currently not ready. Hybridoma against STK15 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3910 |
| STK15(H5716) |
| Comment | Currently not ready. Hybridoma against STK15 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3911 |
| STK15(H5723) |
| Comment | Currently not ready. Hybridoma against STK15 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3912 |
| STK15(H5725) |
| Comment | Currently not ready. Hybridoma against STK15 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3913 |
| STK15(H5728) |
| Comment | Currently not ready. Hybridoma against STK15 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3914 |
| STK15(H5737) |
| Comment | Currently not ready. Hybridoma against STK15 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3915 |
| STK15(H5743) |
| Comment | Currently not ready. Hybridoma against STK15 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3916 |
| STK15(H5754) |
| Comment | Currently not ready. Hybridoma against STK15 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3917 |
| STK15(H5755) |
| Comment | Currently not ready. Hybridoma against STK15 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3918 |
| TOP1MT(H8602) |
| Comment | Currently not ready. Hybridoma against TOP1MT (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3919 |
| TOP1MT(H8607) |
| Comment | Currently not ready. Hybridoma against TOP1MT (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3920 |
| TOP1MT(H8619) |
| Comment | Currently not ready. Hybridoma against TOP1MT (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3921 |
| TOP1MT(H8624) |
| Comment | Currently not ready. Hybridoma against TOP1MT (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3922 |
| TOP1MT(H8629) |
| Comment | Currently not ready. Hybridoma against TOP1MT (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3923 |
| TOP1MT(H8637) |
| Comment | Currently not ready. Hybridoma against TOP1MT (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3924 |
| TOP1MT(H8638) |
| Comment | Currently not ready. Hybridoma against TOP1MT (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3925 |
| TOP1MT(H8644) |
| Comment | Currently not ready. Hybridoma against TOP1MT (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3926 |
| TOP1MT(H8650) |
| Comment | Currently not ready. Hybridoma against TOP1MT (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3927 |
| TOP1MT(H8655) |
| Comment | Currently not ready. Hybridoma against TOP1MT (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3928 |
| DUSP9(H8901) |
| Comment | Currently not ready. Hybridoma against DUSP9 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3929 |
| DUSP9(H8902) |
| Comment | Currently not ready. Hybridoma against DUSP9 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3930 |
| DUSP9(H8905) |
| Comment | Currently not ready. Hybridoma against DUSP9 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3931 |
| DUSP9(H8913) |
| Comment | Currently not ready. Hybridoma against DUSP9 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3932 |
| DUSP9(H8914) |
| Comment | Currently not ready. Hybridoma against DUSP9 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3933 |
| DUSP9(H8915) |
| Comment | Currently not ready. Hybridoma against DUSP9 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3934 |
| DUSP9(H8921) |
| Comment | Currently not ready. Hybridoma against DUSP9 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3935 |
| DUSP9(H8922) |
| Comment | Currently not ready. Hybridoma against DUSP9 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3936 |
| DUSP9(H8925) |
| Comment | Currently not ready. Hybridoma against DUSP9 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3937 |
| DUSP9(H8942) |
| Comment | Currently not ready. Hybridoma against DUSP9 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3938 |
| TIF2(H8403) |
| Comment | Currently not ready. Hybridoma against TIF2 (2-47 (46aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3939 |
| TIF2(H8407) |
| Comment | Currently not ready. Hybridoma against TIF2 (2-47 (46aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3940 |
| TIF2(H8411) |
| Comment | Currently not ready. Hybridoma against TIF2 (2-47 (46aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3941 |
| TIF2(H8414) |
| Comment | Currently not ready. Hybridoma against TIF2 (2-47 (46aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3942 |
| TIF2(H8424) |
| Comment | Currently not ready. Hybridoma against TIF2 (2-47 (46aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3943 |
| TIF2(H8427) |
| Comment | Currently not ready. Hybridoma against TIF2 (2-47 (46aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3944 |
| SKIP(H8514) |
| Comment | Currently not ready. Hybridoma against SKIP (2-52 (51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3945 |
| SKIP(H8515) |
| Comment | Currently not ready. Hybridoma against SKIP (2-52 (51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3946 |
| SKIP(H8529) |
| Comment | Currently not ready. Hybridoma against SKIP (2-52 (51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3947 |
| SKIP(H8530) |
| Comment | Currently not ready. Hybridoma against SKIP (2-52 (51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3948 |
| SKIP(H8524) |
| Comment | Currently not ready. Hybridoma against SKIP (2-52 (51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3949 |
| SKIP(H8531) |
| Comment | Currently not ready. Hybridoma against SKIP (2-52 (51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3950 |
| TRIP13(H9319) |
| Comment | Currently not ready. Hybridoma against TRIP13 (2-99 (98aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3951 |
| TRIP13(H9341) |
| Comment | Currently not ready. Hybridoma against TRIP13 (2-99 (98aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3952 |
| RCN2(H9757) |
| Comment | Currently not ready. Hybridoma against RCN2 (2-99 (98aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3953 |
| RBP2(H9807) |
| Comment | Currently not ready. Hybridoma against RBP2 (2-99 (98aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3954 |
| PGC1b-2(N5702) |
| Comment | Currently not ready. Hybridoma against PGC1b-2 : PGC1b (52-100(49aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3955 |
| PGC1b-2(N5704) |
| Comment | Currently not ready. Hybridoma against PGC1b-2 : PGC1b (52-100(49aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3956 |
| PGC1b-2(N5708) |
| Comment | Currently not ready. Hybridoma against PGC1b-2 : PGC1b (52-100(49aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3957 |
| PGC1b-2(N5715) |
| Comment | Currently not ready. Hybridoma against PGC1b-2 : PGC1b (52-100(49aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3958 |
| PGC1b-2(N5719) |
| Comment | Currently not ready. Hybridoma against PGC1b-2 : PGC1b (52-100(49aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3959 |
| PGC1b-2(N5720) |
| Comment | Currently not ready. Hybridoma against PGC1b-2 : PGC1b (52-100(49aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3960 |
| PGC1b-2(N5722) |
| Comment | Currently not ready. Hybridoma against PGC1b-2 : PGC1b (52-100(49aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3961 |
| PGC1b-2(N5723) |
| Comment | Currently not ready. Hybridoma against PGC1b-2 : PGC1b (52-100(49aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3962 |
| PGC1b-2(N5739) |
| Comment | Currently not ready. Hybridoma against PGC1b-2 : PGC1b (52-100(49aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3963 |
| gp64(B8109B) |
| Comment | Currently not ready. Hybridoma against gp64 : glycoprotein 64 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3964 |
| gp64(B8121A) |
| Comment | Currently not ready. Hybridoma against gp64 : glycoprotein 64 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3965 |
| gp64(B8137A) |
| Comment | Currently not ready. Hybridoma against gp64 : glycoprotein 64 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3966 |
| gp64(B8140A) |
| Comment | Currently not ready. Hybridoma against gp64 : glycoprotein 64 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3967 |
| gp64(B8147A) |
| Comment | Currently not ready. Hybridoma against gp64 : glycoprotein 64 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3968 |
| mMTMR6(N7705) |
| Comment | Currently not ready. Hybridoma against mMTMR6 : Myotubularin related protein 6 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3969 |
| mMTMR6(N7706) |
| Comment | Currently not ready. Hybridoma against mMTMR6 : Myotubularin related protein 6 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3970 |
| mMTMR6(N7712) |
| Comment | Currently not ready. Hybridoma against mMTMR6 : Myotubularin related protein 6 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3971 |
| mMTMR6(N7715) |
| Comment | Currently not ready. Hybridoma against mMTMR6 : Myotubularin related protein 6 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3972 |
| mMTMR6(N7725) |
| Comment | Currently not ready. Hybridoma against mMTMR6 : Myotubularin related protein 6 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3973 |
| mMTMR6(N7739) |
| Comment | Currently not ready. Hybridoma against mMTMR6 : Myotubularin related protein 6 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3974 |
| SAV-1-N1(Z2011) |
| Comment | Currently not ready. Hybridoma against SAV-1-N1 : Salvador homolog 1 (100-149(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3975 |
| SAV-1-N1(Z2020) |
| Comment | Currently not ready. Hybridoma against SAV-1-N1 : Salvador homolog 1 (100-149(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3976 |
| hPPARα-1(Y1820) |
| Comment | Currently not ready. Hybridoma against PGC1b-2 : PGC1b (52-100(49aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3977 |
| hFRS2β1(Y7607) |
| Comment | Currently not ready. Hybridoma against hFRS2β1 : Fibroblast growth factor receptor substrate 2β (342-392(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3978 |
| hPPARα-1(Y1846) |
| Comment | Currently not ready. Hybridoma against PGC1b-2 : PGC1b (52-100(49aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3979 |
| hRev-erbα-1(Y2313) |
| Comment | Currently not ready. Hybridoma against hRev-erbα-1 : Rev-erbα (2-49 (48)aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3980 |
| hRev-erbα-1(Y2319) |
| Comment | Currently not ready. Hybridoma against hRev-erbα-1 : Rev-erbα (2-49 (48)aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3981 |
| hRev-erbα-1(Y2325) |
| Comment | Currently not ready. Hybridoma against hRev-erbα-1 : Rev-erbα (2-49 (48)aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3982 |
| hRev-erbα-1(Y2336) |
| Comment | Currently not ready. Hybridoma against hRev-erbα-1 : Rev-erbα (2-49 (48)aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3983 |
| hRev-erbα-1(Y2339) |
| Comment | Currently not ready. Hybridoma against hRev-erbα-1 : Rev-erbα (2-49 (48)aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3984 |
| hRev-erbα-1(Y2340) |
| Comment | Currently not ready. Hybridoma against hRev-erbα-1 : Rev-erbα (2-49 (48)aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3985 |
| hRev-erbα-1(Y2347) |
| Comment | Currently not ready. Hybridoma against hRev-erbα-1 : Rev-erbα (2-49 (48)aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3986 |
| DKK1(H2907) |
| Comment | Hybridoma against DKK1 : Dickkopf 1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3987 |
| DKK1(H2910) |
| Comment | Currently not ready. Hybridoma against DKK1 : Dickkopf 1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3988 |
| DKK1(H2913) |
| Comment | Hybridoma against DKK1 : Dickkopf 1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3989 |
| DKK1(H2914) |
| Comment | Currently not ready. Hybridoma against DKK1 : Dickkopf 1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3990 |
| DKK1(H2922) |
| Comment | Hybridoma generated against DKK1 : Dickkopf 1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3991 |
| DKK1(H2927) |
| Comment | Hybridoma against DKK1 : Dickkopf 1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3992 |
| DKK1(H2928) |
| Comment | Currently not ready. Hybridoma against DKK1 : Dickkopf 1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3993 |
| DKK1(H2933) |
| Comment | Currently not ready. Hybridoma against DKK1 : Dickkopf 1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3994 |
| DKK1(H2936) |
| Comment | Currently not ready. Hybridoma against DKK1 : Dickkopf 1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3995 |
| DKK1(H2940) |
| Comment | Currently not ready. Hybridoma against DKK1 : Dickkopf 1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3996 |
| DKK1(H2945) |
| Comment | Currently not ready. Hybridoma against DKK1 : Dickkopf 1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3997 |
| hNDR2C(Z1419) |
| Comment | Currently not ready. Hybridoma against hNDR2C : Nodal-related 2 (365-464(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3998 |
| hNDR2C(Z1440) |
| Comment | Currently not ready. Hybridoma against hNDR2C : Nodal-related 2 (365-464(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB3999 |
| hNDR2C(Y5118) |
| Comment | Currently not ready. Hybridoma against hNDR2C : Nodal-related 2 (365-464(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4000 |
| NFIA1(Y2230) |
| Comment | Currently not ready. Hybridoma against NFIA1 : Nuclear factor I-A1 (256-315(60aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4001 |
| NFIA1(Y2236) |
| Comment | Currently not ready. Hybridoma against NFIA1 : Nuclear factor I-A1 (256-315(60aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4002 |
| NFIA1(Y2238) |
| Comment | Currently not ready. Hybridoma against NFIA1 : Nuclear factor I-A1 (256-315(60aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4003 |
| NFIA1(Y2240) |
| Comment | Currently not ready. Hybridoma against NFIA1 : Nuclear factor I-A1 (256-315(60aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4004 |
| NFIB3(Y2823) |
| Comment | Currently not ready. Hybridoma against NFIB3 : Nuclear factor I-B3 (347-414(68aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4005 |
| NFIB3(Y2833) |
| Comment | Currently not ready. Hybridoma against NFIB3 : Nuclear factor I-B3 (347-414(68aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4006 |
| NFIX1(Y4402) |
| Comment | Currently not ready. Hybridoma against NFIX1 : Nuclear factor I-X1 (258-318(61aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4007 |
| NFIX1(Y4406) |
| Comment | Currently not ready. Hybridoma against NFIX1 : Nuclear factor I-X1 (258-318(61aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4008 |
| NFIX1(Y4418) |
| Comment | Currently not ready. Hybridoma against NFIX1 : Nuclear factor I-X1 (258-318(61aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4009 |
| NFIX1(Y4424) |
| Comment | Currently not ready. Hybridoma against NFIX1 : Nuclear factor I-X1 (258-318(61aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4010 |
| hNRF2-3(Y4902) |
| Comment | Currently not ready. Hybridoma against NFIX1 : hNRF2-3 : Nuclear factor erythroid2-related factor 2 (331-390(60aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4011 |
| Bach1-H1(N9502) |
| Comment | Currently not ready. Hybridoma against NFIX1 : Bach1-H1 : BTB and CNC homology 1 (317-390(74aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4012 |
| Bach1-H1(N9516) |
| Comment | Currently not ready. Hybridoma against NFIX1 : Bach1-H1 : BTB and CNC homology 1 (317-390(74aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4013 |
| Bach1-H2(Y0208) |
| Comment | Currently not ready. Hybridoma against NFIX1 : Bach1-H2 : BTB and CNC homology 1 (637-725(89aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4014 |
| Bach1-M1(N9602) |
| Comment | Currently not ready. Hybridoma against NFIX1 : Bach1-M1 : BTB and CNC homology 1 (318-392(75aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4015 |
| Bach1-M1(N9609) |
| Comment | Currently not ready. Hybridoma against NFIX1 : Bach1-M1 : BTB and CNC homology 1 (318-392(75aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4016 |
| Bach1-M1(N9610) |
| Comment | Currently not ready. Hybridoma against NFIX1 : Bach1-M1 : BTB and CNC homology 1 (318-392(75aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4017 |
| Bach1-M1(N9611) |
| Comment | Currently not ready. Hybridoma against NFIX1 : Bach1-M1 : BTB and CNC homology 1 (318-392(75aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4018 |
| Bach1-M1(N9613) |
| Comment | Currently not ready. Hybridoma against NFIX1 : Bach1-M1 : BTB and CNC homology 1 (318-392(75aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4019 |
| Bach1-M1(N9628) |
| Comment | Currently not ready. Hybridoma against NFIX1 : Bach1-M1 : BTB and CNC homology 1 (318-392(75aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4020 |
| Bach1-M1(N9639) |
| Comment | Currently not ready. Hybridoma against NFIX1 : Bach1-M1 : BTB and CNC homology 1 (318-392(75aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4021 |
| Bach1-M1(N9642) |
| Comment | Currently not ready. Hybridoma against NFIX1 : Bach1-M1 : BTB and CNC homology 1 (318-392(75aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4022 |
| Bach1-M1(N9647) |
| Comment | Currently not ready. Hybridoma against NFIX1 : Bach1-M1 : BTB and CNC homology 1 (318-392(75aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4023 |
| Bach1-M1(N9648) |
| Comment | Currently not ready. Hybridoma against NFIX1 : Bach1-M1 : BTB and CNC homology 1 (318-392(75aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4024 |
| Bach1-M2(Y2103) |
| Comment | Currently not ready. Hybridoma against Bach1-M2 : BTB and CNC homology 1 (640-728(89aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4025 |
| Bach1-M2(Y2117) |
| Comment | Currently not ready. Hybridoma against Bach1-M2 : BTB and CNC homology 1 (640-728(89aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4026 |
| Bach1-M2(Y2133) |
| Comment | Currently not ready. Hybridoma against Bach1-M2 : BTB and CNC homology 1 (640-728(89aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4027 |
| DRPLA-2(N9330) |
| Comment | Currently not ready. Hybridoma against DRPLA-2 : Dentato-rubro-pallido-luysian atrophy (101-200(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4028 |
| DRPLA-2(N9331) |
| Comment | Currently not ready. Hybridoma against DRPLA-2 : Dentato-rubro-pallido-luysian atrophy (101-200(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4029 |
| DRPLA-4(Y0435) |
| Comment | Currently not ready. Hybridoma against DRPLA-4 : Dentato-rubro-pallido-luysian atrophy (1085-1184(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4030 |
| hPTK7-Cyto(Y2040) |
| Comment | Currently not ready. Hybridoma against hPTK7-Cyto : Tyrosine-protein kinase-like 7 (725-795(70aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4031 |
| hPTK7-Extra(Y1927) |
| Comment | Currently not ready. Hybridoma against hPTK7-Extra : Tyrosine-protein kinase-like 7 (31-130 (100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4032 |
| hPTK7-Extra(Y1937) |
| Comment | Currently not ready. Hybridoma against hPTK7-Extra : Tyrosine-protein kinase-like 7 (31-130 (100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4033 |
| MEF2A-3(Y0809) |
| Comment | Currently not ready. Hybridoma against MEF2A-3 : Myocyte-specific enhancer factor 2A (318-403(86aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4034 |
| MEF2A-3(Y0833) |
| Comment | Currently not ready. Hybridoma against MEF2A-3 : Myocyte-specific enhancer factor 2A (318-403(86aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4035 |
| MEF2A-3(Y0834) |
| Comment | Currently not ready. Hybridoma against MEF2A-3 : Myocyte-specific enhancer factor 2A (318-403(86aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4036 |
| MEF2A-3(Y0841) |
| Comment | Currently not ready. Hybridoma against MEF2A-3 : Myocyte-specific enhancer factor 2A (318-403(86aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4037 |
| MEF2A-3(Y0847) |
| Comment | Currently not ready. Hybridoma against MEF2A-3 : Myocyte-specific enhancer factor 2A (318-403(86aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4038 |
| MEF2C-2(Y1728) |
| Comment | Currently not ready. Hybridoma against MEF2C-2 : Myocyte-specific enhancer factor 2C (161-248(88aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4039 |
| MEF2C-2(Y1740) |
| Comment | Currently not ready. Hybridoma against MEF2C-2 : Myocyte-specific enhancer factor 2C (161-248(88aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4040 |
| AFP(B2007C) |
| Comment | Currently not ready. Hybridoma against AFP : Alpha-fetoprotein (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4041 |
| AFP(B2011D) |
| Comment | Currently not ready. Hybridoma against AFP : Alpha-fetoprotein (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4042 |
| AFP(B2015C) |
| Comment | Currently not ready. Hybridoma against AFP : Alpha-fetoprotein (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4043 |
| AFP(B2117C) |
| Comment | Currently not ready. Hybridoma against AFP : Alpha-fetoprotein (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4044 |
| AFP(B2150D) |
| Comment | Currently not ready. Hybridoma against AFP : Alpha-fetoprotein (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4045 |
| AFP(B2151D) |
| Comment | Currently not ready. Hybridoma against AFP : Alpha-fetoprotein (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4046 |
| TFF1(N2306) |
| Comment | Currently not ready. Hybridoma against TFF1 (27-75 (49aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4047 |
| TFF1(N2309) |
| Comment | Currently not ready. Hybridoma against TFF1 (27-75 (49aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4048 |
| TFF1(N2320) |
| Comment | Currently not ready. Hybridoma against TFF1 (27-75 (49aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4049 |
| TFF1(N2325) |
| Comment | Currently not ready. Hybridoma against TFF1 (27-75 (49aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4050 |
| mGCNF-Hinge(N6724) |
| Comment | Currently not ready. Hybridoma against mGCNF-Hinge : Germ cell nuclear factor (160-263(104aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4051 |
| mGCNF-Hinge(N6729) |
| Comment | Currently not ready. Hybridoma against mGCNF-Hinge : Germ cell nuclear factor (160-263(104aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4052 |
| mGCNF-Hinge(N6737) |
| Comment | Currently not ready. Hybridoma against mGCNF-Hinge : Germ cell nuclear factor (160-263(104aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4053 |
| mGCNF-Hinge(N6760) |
| Comment | Currently not ready. Hybridoma against mGCNF-Hinge : Germ cell nuclear factor (160-263(104aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4054 |
| mGCNF-N(N6807) |
| Comment | Currently not ready. Hybridoma against mGCNF-N : Germ cell nuclear factor (2-70(69aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4055 |
| mGCNF-N(N6812) |
| Comment | Currently not ready. Hybridoma against mGCNF-N : Germ cell nuclear factor (2-70(69aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4056 |
| mGCNF-N(N6813) |
| Comment | Currently not ready. Hybridoma against mGCNF-N : Germ cell nuclear factor (2-70(69aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4057 |
| mGCNF-N(N6816) |
| Comment | Currently not ready. Hybridoma against mGCNF-N : Germ cell nuclear factor (2-70(69aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4058 |
| mGCNF-N(N6819) |
| Comment | Currently not ready. Hybridoma against mGCNF-N : Germ cell nuclear factor (2-70(69aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4059 |
| mGCNF-N(N6823) |
| Comment | Currently not ready. Hybridoma against mGCNF-N : Germ cell nuclear factor (2-70(69aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4060 |
| mGCNF-N(N6824) |
| Comment | Currently not ready. Hybridoma against mGCNF-N : Germ cell nuclear factor (2-70(69aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4061 |
| mGCNF-N(N6831) |
| Comment | Currently not ready. Hybridoma against mGCNF-N : Germ cell nuclear factor (2-70(69aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4062 |
| mGCNF-N(N6832) |
| Comment | Currently not ready. Hybridoma against mGCNF-N : Germ cell nuclear factor (2-70(69aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4063 |
| mGCNF-N(N6836) |
| Comment | Currently not ready. Hybridoma against mGCNF-N : Germ cell nuclear factor (2-70(69aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4064 |
| mGCNF-N(N6839) |
| Comment | Currently not ready. Hybridoma against mGCNF-N : Germ cell nuclear factor (2-70(69aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4065 |
| hFOXP3(B8905-6) |
| Comment | Currently not ready. Hybridoma against hFOXP3 : Forkhead box P3 (105-190(86aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4066 |
| hFOXP3(B8916B) |
| Comment | Currently not ready. Hybridoma against hFOXP3 : Forkhead box P3 (105-190(86aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4067 |
| PPARdelta-1(2-45)(C0309A) |
| Comment | Currently not ready. Hybridoma against PPARdelta-1 (2-45) : Peroxisome proliferator-activated receptor delta (2-45(44aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4068 |
| PPARdelta-1(2-45)(C0309B) |
| Comment | Currently not ready. Hybridoma against PPARdelta-1 (2-45) : Peroxisome proliferator-activated receptor delta (2-45(44aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4069 |
| PPARdelta-1(2-45)(C0309C) |
| Comment | Currently not ready. Hybridoma against PPARdelta-1 (2-45) : Peroxisome proliferator-activated receptor delta (2-45(44aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4070 |
| hRev-erbα-2(Y2408) |
| Comment | Currently not ready. Hybridoma against hRev-erbα-2 : Rev-erbα (41-80(40aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4071 |
| hHNF4ɤ-1(Y4602) |
| Comment | Currently not ready. Hybridoma against hHNF4γ-1 : Hepatic nuclear factor 4 γ (78-127(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4072 |
| hHNF4ɤ-1(Y4611) |
| Comment | Currently not ready. Hybridoma against hHNF4γ-1 : Hepatic nuclear factor 4 γ (78-127(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4073 |
| hHNF4ɤ-1(Y4618) |
| Comment | Currently not ready. Hybridoma against hHNF4γ-1 : Hepatic nuclear factor 4 γ (78-127(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4074 |
| hHNF4ɤ-1(Y4621) |
| Comment | Currently not ready. Hybridoma against hHNF4γ-1 : Hepatic nuclear factor 4 γ (78-127(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4075 |
| hHNF4ɤ-1(Y4623) |
| Comment | Currently not ready. Hybridoma against hHNF4γ-1 : Hepatic nuclear factor 4 γ (78-127(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4076 |
| hHNF4ɤ-1(Y4625) |
| Comment | Currently not ready. Hybridoma against hHNF4γ-1 : Hepatic nuclear factor 4 γ (78-127(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4077 |
| hHNF4ɤ-1(Y4626) |
| Comment | Currently not ready. Hybridoma against hHNF4γ-1 : Hepatic nuclear factor 4 γ (78-127(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4078 |
| hHNF4ɤ-1(Y4635) |
| Comment | Currently not ready. Hybridoma against hHNF4γ-1 : Hepatic nuclear factor 4 γ (78-127(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4079 |
| hHNF4ɤ-1(Y4643) |
| Comment | Currently not ready. Hybridoma against hHNF4γ-1 : Hepatic nuclear factor 4 γ (78-127(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4080 |
| Cys-SN2(N3306) |
| Comment | Hybridoma against Cys-SN2 : Cystatin (92-117 (26aa)) antigen. |
|---|
| Comment from the depositor | Cystatin(92-117(26aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4081 |
| Cys-SN2(N3312) |
| Comment | Hybridoma against Cys-SN2 :Cystatin (92-117 (26aa)) antigen. |
|---|
| Comment from the depositor | Cystatin(92-117(26aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4082 |
| Cys-SN2(N3316) |
| Comment | Hybridoma against Cys-SN2 :Cystatin (92-117 (26aa)) antigen. |
|---|
| Comment from the depositor | Cystatin(92-117(26aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4083 |
| Cys-SN2(N3323) |
| Comment | Hybridoma against Cys-SN2 : Cystatin (92-117 (26aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4084 |
| Cys-SN2(N3331) |
| Comment | Hybridoma against Cys-SN2 : Cystatin (92-117 (26aa)) antigen. |
|---|
| Comment from the depositor | Cystatin(92-117(26aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4085 |
| Cys-SN2(N3338) |
| Comment | Hybridoma against Cys-SN2 : Cystatin (92-117 (26aa)) antigen. |
|---|
| Comment from the depositor | Cystatin(92-117(26aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4086 |
| Cys-SN2(N3344) |
| Comment | Hybridoma against Cys-SN2 : Cystatin (92-117 (26aa)) antigen. |
|---|
| Comment from the depositor | Cystatin(92-117(26aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4087 |
| Cys-SN2(N3346) |
| Comment | Currently not ready. Hybridoma against Cys-SN2 : Cystatin (92-117 (26aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4088 |
| Cys-SN2(N3349) |
| Comment | Hybridoma against Cys-SN2 : Cystatin (92-117 (26aa)) antigen. |
|---|
| Comment from the depositor | Cystatin(92-117(26aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4089 |
| Cys-SN2(N3372) |
| Comment | Hybridoma against Cys-SN2 : Cystatin (92-117 (26aa)) antigen. |
|---|
| Comment from the depositor | Cystatin(92-117(26aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4090 |
| TRβ-CT(H9401) |
| Comment | Currently not ready. Hybridoma against TRβ-CT : TRβ (199-227 (29aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4091 |
| TRβ-CT(H9420) |
| Comment | Currently not ready. Hybridoma against TRβ-CT : TRβ (199-227 (29aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4092 |
| TRβ-CT(H9431) |
| Comment | Currently not ready. Hybridoma against TRβ-CT : TRβ (199-227 (29aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4093 |
| TRβ-CT(H9437) |
| Comment | Currently not ready. Hybridoma against TRβ-CT : TRβ (199-227 (29aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4094 |
| mGli2(N7206) |
| Comment | Currently not ready. Hybridoma against mGli2 : GLI family zinc finger 2 (3-49 (47aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4095 |
| mGli2(N7212) |
| Comment | Currently not ready. Hybridoma against mGli2 : GLI family zinc finger 2 (3-49 (47aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4096 |
| mGli2(N7219) |
| Comment | Currently not ready. Hybridoma against mGli2 : GLI family zinc finger 2 (3-49 (47aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4097 |
| mGli2(N7237) |
| Comment | Currently not ready. Hybridoma against mGli2 : GLI family zinc finger 2 (3-49 (47aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4098 |
| mTES101-RP(N6002) |
| Comment | Currently not ready. Hybridoma against mTES101-RP : Testicular germ cell specific antigen101 (194-217(24aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4099 |
| mTES101-RP(N6022A) |
| Comment | Currently not ready. Hybridoma against mTES101-RP : Testicular germ cell specific antigen101 (194-217(24aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4100 |
| mTES101-RP(N6022B) |
| Comment | Currently not ready. Hybridoma against mTES101-RP : Testicular germ cell specific antigen101 (194-217(24aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4101 |
| mTES101-RP(N6035) |
| Comment | Currently not ready. Hybridoma against mTES101-RP : Testicular germ cell specific antigen101 (194-217(24aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4102 |
| mTES101-RP(N6038) |
| Comment | Currently not ready. Hybridoma against mTES101-RP : Testicular germ cell specific antigen101 (194-217(24aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4103 |
| TADA3(B0331A) |
| Comment | Currently not ready. Hybridoma against TADA3 (3-49 (61-160 (100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4104 |
| WBP2(N2617) |
| Comment | Currently not ready. Hybridoma against WBP2 (3-49 (2-101(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4105 |
| WBP2(N2640) |
| Comment | Currently not ready. Hybridoma against WBP2 (3-49 (2-101(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4106 |
| WBP2(N2645) |
| Comment | Currently not ready. Hybridoma against WBP2 (3-49 (2-101(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4107 |
| AI-gp(Y3111) |
| Comment | Currently not ready. Hybridoma against AI-gp : AI (506-555(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4108 |
| AI-gp(Y3123) |
| Comment | Currently not ready. Hybridoma against AI-gp : AI (506-555(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4109 |
| AI-gp(Y3124) |
| Comment | Currently not ready. Hybridoma against AI-gp : AI (506-555(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4110 |
| AI-gp(Y3127) |
| Comment | Currently not ready. Hybridoma against AI-gp : AI (506-555(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4111 |
| AI-gp(Y3147) |
| Comment | Currently not ready. Hybridoma against AI-gp : AI (506-555(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4112 |
| AFP(B5925A) |
| Comment | Currently not ready. Hybridoma against AFP : Alpha-fetoprotein (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4113 |
| AFP(B5937F) |
| Comment | Currently not ready. Hybridoma against AFP : Alpha-fetoprotein (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4114 |
| AFP(B5939D) |
| Comment | Currently not ready. Hybridoma against AFP : Alpha-fetoprotein (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4115 |
| AFP(B5944F) |
| Comment | Currently not ready. Hybridoma against AFP : Alpha-fetoprotein (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4116 |
| AFP(B5955D) |
| Comment | Currently not ready. Hybridoma against AFP : Alpha-fetoprotein (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4117 |
| AFP(B5963D) |
| Comment | Currently not ready. Hybridoma against AFP : Alpha-fetoprotein (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4118 |
| AFP(B5980D) |
| Comment | Currently not ready. Hybridoma against AFP : Alpha-fetoprotein (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4119 |
| CCR5 SP3(Y4108) |
| Comment | Currently not ready. Hybridoma against CCR5 SP3(Y sulfation) : Chemokine receptor 5 (11-19(9aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4120 |
| CCR5 SP3(Y4125) |
| Comment | Currently not ready. Hybridoma against CCR5 SP3(Y sulfation) : Chemokine receptor 5 (11-19(9aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4121 |
| CCR5 SP3(Y4126) |
| Comment | Currently not ready. Hybridoma against CCR5 SP3(Y sulfation) : Chemokine receptor 5 (11-19(9aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4122 |
| mNCoR-1(Y8110) |
| Comment | Currently not ready. Hybridoma against mNCoR-1 : Nuclear receptor corepressor 1 (1817-1879(63aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4123 |
| mNCoR-1(Y8111) |
| Comment | Hybridoma against mNCoR-1 : Nuclear receptor corepressor 1 (1817-1879(63aa)) antigen. |
|---|
| Comment from the depositor | Nuclear receptor corepressor 1 (1817-1879(63aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4124 |
| mNCoR-1(Y8129) |
| Comment | Hybridoma against mNCoR-1 : Nuclear receptor corepressor 1 (1817-1879(63aa)) antigen. |
|---|
| Comment from the depositor | Nuclear receptor corepressor 1 (1817-1879(63aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4125 |
| mNCoR-1(Y8131(A)) |
| Comment | Currently not ready. Hybridoma against mNCoR-1 : Nuclear receptor corepressor 1 (1817-1879(63aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4126 |
| mSRC-1(Y8207) |
| Comment | Currently not ready. Hybridoma against mSRC-1 (626-668(43aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4127 |
| mSRC-1(Y8243) |
| Comment | Currently not ready. Hybridoma against mSRC-1 (626-668(43aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4128 |
| HSMRT(Y9017) |
| Comment | Currently not ready. Hybridoma against HSMRT (1922-2043(122aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4129 |
| HSMRT(Y9033) |
| Comment | Currently not ready. Hybridoma against HSMRT (1922-2043(122aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4130 |
| hRIP140(Y9140) |
| Comment | Currently not ready. Hybridoma against hRIP140 (733-847(115aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4131 |
| hTIF2(Y8917) |
| Comment | Currently not ready. Hybridoma against hTIF2 (733-847(753-804(52aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4132 |
| hTIF2(Y8918) |
| Comment | Currently not ready. Hybridoma against hTIF2 (733-847(753-804(52aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4133 |
| BAP37(Z1131B) |
| Comment | Currently not ready. Hybridoma against BAP37 : B-cell receptor-associated protein 37 (210-249(40aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4134 |
| SOX21 PepT3(Z3001) |
| Comment | Currently not ready. Hybridoma against SOX21 PepT3 : SRY (sex determining region Y)-box 21 (129-176(48aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4135 |
| Epc1AG(Z3703) |
| Comment | Currently not ready. Hybridoma against Epc1AG : Enhancer of polycomb homolog 1 (718-763(46aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4136 |
| Epc1AG(Z3705) |
| Comment | Currently not ready. Hybridoma against Epc1AG : Enhancer of polycomb homolog 1 (718-763(46aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4137 |
| Epc1AG(Z3710) |
| Comment | Currently not ready. Hybridoma against Epc1AG : Enhancer of polycomb homolog 1 (718-763(46aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4138 |
| Epc1AG(Z3714) |
| Comment | Currently not ready. Hybridoma against Epc1AG : Enhancer of polycomb homolog 1 (718-763(46aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4139 |
| Epc1AG(Z3715) |
| Comment | Currently not ready. Hybridoma against Epc1AG : Enhancer of polycomb homolog 1 (718-763(46aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4140 |
| Epc1AG(Z3716) |
| Comment | Currently not ready. Hybridoma against Epc1AG : Enhancer of polycomb homolog 1 (718-763(46aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4141 |
| Epc1AG(Z3725) |
| Comment | Currently not ready. Hybridoma against Epc1AG : Enhancer of polycomb homolog 1 (718-763(46aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4142 |
| Epc1AG(Z3728) |
| Comment | Currently not ready. Hybridoma against Epc1AG : Enhancer of polycomb homolog 1 (718-763(46aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4143 |
| Epc1AG(Z3733) |
| Comment | Currently not ready. Hybridoma against Epc1AG : Enhancer of polycomb homolog 1 (718-763(46aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4144 |
| Epc1AG(Z3741) |
| Comment | Currently not ready. Hybridoma against Epc1AG : Enhancer of polycomb homolog 1 (718-763(46aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4145 |
| Epc1AG(Z3742) |
| Comment | Currently not ready. Hybridoma against Epc1AG : Enhancer of polycomb homolog 1 (718-763(46aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4146 |
| Epc2AG(Z3901) |
| Comment | Currently not ready. Hybridoma against Epc2AG : Enhancer of polycomb homolog 2 (701-779(79aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4147 |
| Epc2AG(Z3906) |
| Comment | Currently not ready. Hybridoma against Epc2AG : Enhancer of polycomb homolog 2 (701-779(79aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4148 |
| Epc2AG(Z3908) |
| Comment | Currently not ready. Hybridoma against Epc2AG : Enhancer of polycomb homolog 2 (701-779(79aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4149 |
| Epc2AG(Z3911) |
| Comment | Currently not ready. Hybridoma against Epc2AG : Enhancer of polycomb homolog 2 (701-779(79aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4150 |
| Epc2AG(Z3921) |
| Comment | Currently not ready. Hybridoma against Epc2AG : Enhancer of polycomb homolog 2 (701-779(79aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4151 |
| Epc2AG(Z3922) |
| Comment | Currently not ready. Hybridoma against Epc2AG : Enhancer of polycomb homolog 2 (701-779(79aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4152 |
| Epc2AG(Z3925) |
| Comment | Currently not ready. Hybridoma against Epc2AG : Enhancer of polycomb homolog 2 (701-779(79aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4153 |
| Epc2AG(Z3931) |
| Comment | Currently not ready. Hybridoma against Epc2AG : Enhancer of polycomb homolog 2 (701-779(79aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4154 |
| Epc2AG(Z3934) |
| Comment | Currently not ready. Hybridoma against Epc2AG : Enhancer of polycomb homolog 2 (701-779(79aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4155 |
| Epc2AG(Z3940) |
| Comment | Currently not ready. Hybridoma against Epc2AG : Enhancer of polycomb homolog 2 (701-779(79aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4156 |
| STK3(Z2801) |
| Comment | Currently not ready. Hybridoma against STK3 : Serine/threonine kinase 3 (382-436(55aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4157 |
| STK3(Z2804) |
| Comment | Currently not ready. Hybridoma against STK3 : Serine/threonine kinase 3 (382-436(55aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4158 |
| STK3(Z2814) |
| Comment | Currently not ready. Hybridoma against STK3 : Serine/threonine kinase 3 (382-436(55aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4159 |
| STK3(Z2816) |
| Comment | Currently not ready. Hybridoma against STK3 : Serine/threonine kinase 3 (382-436(55aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4160 |
| STK3(Z2822) |
| Comment | Currently not ready. Hybridoma against STK3 : Serine/threonine kinase 3 (382-436(55aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4161 |
| STK3(Z2828) |
| Comment | Currently not ready. Hybridoma against STK3 : Serine/threonine kinase 3 (382-436(55aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4162 |
| STK3(Z2829) |
| Comment | Currently not ready. Hybridoma against STK3 : Serine/threonine kinase 3 (382-436(55aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4163 |
| mDAI-3S(Z4401) |
| Comment | Currently not ready. Hybridoma against mDAI-3S : DNA-dependent activator of IFN-regulatory factors (362-411(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4164 |
| mDAI-3S(Z4410) |
| Comment | Currently not ready. Hybridoma against mDAI-3S : DNA-dependent activator of IFN-regulatory factors (362-411(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4165 |
| mDAI-3S(Z4415) |
| Comment | Currently not ready. Hybridoma against mDAI-3S : DNA-dependent activator of IFN-regulatory factors (362-411(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4166 |
| mDAI-3S(Z4420) |
| Comment | Currently not ready. Hybridoma against mDAI-3S : DNA-dependent activator of IFN-regulatory factors (362-411(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4167 |
| mDAI-3S(Z4424) |
| Comment | Currently not ready. Hybridoma against mDAI-3S : DNA-dependent activator of IFN-regulatory factors (362-411(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4168 |
| mDAI-3S(Z4429) |
| Comment | Currently not ready. Hybridoma against mDAI-3S : DNA-dependent activator of IFN-regulatory factors (362-411(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4169 |
| mDAI-3S(Z4402) |
| Comment | Currently not ready. Hybridoma against mDAI-3S : DNA-dependent activator of IFN-regulatory factors (362-411(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4170 |
| mDAI-3S(Z4418) |
| Comment | Currently not ready. Hybridoma against mDAI-3S : DNA-dependent activator of IFN-regulatory factors (362-411(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4171 |
| JHDM2A-3C(Z5507) |
| Comment | Currently not ready. Hybridoma against JHDM2A-3C : Jumonji domain containing gene family of histone demethylase 2A (1151-1224(74aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4172 |
| JHDM2A-4C(Z6316) |
| Comment | Currently not ready. Hybridoma against JHDM2A-4C : Jumonji domain containing gene family of histone demethylase 2A (1089-1138(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4173 |
| HIF1(Z6413) |
| Comment | Currently not ready. Hybridoma against HIF1 : Hypoxia-inducible transcription factor 1 (361-405(45aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4174 |
| HIF1(Z6414) |
| Comment | Currently not ready. Hybridoma against HIF1 : Hypoxia-inducible transcription factor 1 (361-405(45aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4175 |
| HIF1(Z6417) |
| Comment | Currently not ready. Hybridoma against HIF1 : Hypoxia-inducible transcription factor 1 (361-405(45aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4176 |
| HIF1(Z6437) |
| Comment | Currently not ready. Hybridoma against HIF1 : Hypoxia-inducible transcription factor 1 (361-405(45aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4177 |
| HIF2(Z6502) |
| Comment | Currently not ready. Hybridoma against HIF2 : Hypoxia-inducible transcription factor 2 (603-652(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4178 |
| HIF2(Z6526) |
| Comment | Currently not ready. Hybridoma against HIF2 : Hypoxia-inducible transcription factor 2 (603-652(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4179 |
| p65-12(Z6635) |
| Comment | Currently not ready. Hybridoma against p65-12 : p65 (116-168(53aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4180 |
| Mrf2-2(Z7411) |
| Comment | Currently not ready. Hybridoma against Mrf2-2 : Modulator recognition factor 2 (1140-1189(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4181 |
| Mrf2-2(Z7437) |
| Comment | Currently not ready. Hybridoma against Mrf2-2 : Modulator recognition factor 2 (1140-1189(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4182 |
| THRAP3(Z6803) |
| Comment | Currently not ready. Hybridoma against THRAP3 : Thyroid hormone receptor associated protein 3 (457-513(57aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4183 |
| THRAP3(Z6824) |
| Comment | Currently not ready. Hybridoma against THRAP3 : Thyroid hormone receptor associated protein 3 (457-513(57aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4184 |
| THRAP3(Z6832) |
| Comment | Currently not ready. Hybridoma against THRAP3 : Thyroid hormone receptor associated protein 3 (457-513(57aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4185 |
| THRAP3(Z6840) |
| Comment | Currently not ready. Hybridoma against THRAP3 : Thyroid hormone receptor associated protein 3 (457-513(57aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4186 |
| KLF4(Z6902) |
| Comment | Currently not ready. Hybridoma against KLF4 : Kruppel-like factor 4 (26-90(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4187 |
| KLF4(Z6913) |
| Comment | Currently not ready. Hybridoma against KLF4 : Kruppel-like factor 4 (26-90(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4188 |
| KLF4(Z6919) |
| Comment | Currently not ready. Hybridoma against KLF4 : Kruppel-like factor 4 (26-90(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4189 |
| KLF4(Z6928) |
| Comment | Currently not ready. Hybridoma against KLF4 : Kruppel-like factor 4 (26-90(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4190 |
| KLF4(Z6929) |
| Comment | Currently not ready. Hybridoma against KLF4 : Kruppel-like factor 4 (26-90(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4191 |
| KLF4(Z6943) |
| Comment | Currently not ready. Hybridoma against KLF4 : Kruppel-like factor 4 (26-90(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4192 |
| KLF4(Z6944) |
| Comment | Currently not ready. Hybridoma against KLF4 : Kruppel-like factor 4 (26-90(65aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4193 |
| CCR4aN(Y6206) |
| Comment | Hybridoma against CCR4aN : CCR4-NOT transcription complex, subunit 6 (141-190(50aa)) antigen. |
|---|
| Comment from the depositor | CCR4aN : CCR4-NOT transcription complex, subunit 6 (141-190(50aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4194 |
| CCR4bC(Y5601) |
| Comment | Currently not ready. Hybridoma against CCR4bC : CCR4-NOT transcription complex, subunit 6-like (501-555(55aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4195 |
| CCR4bC(Y5606) |
| Comment | Currently not ready. Hybridoma against CCR4bC : CCR4-NOT transcription complex, subunit 6-like (501-555(55aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4196 |
| CCR4bC(Y5657) |
| Comment | Currently not ready. Hybridoma against CCR4bC : CCR4-NOT transcription complex, subunit 6-like (501-555(55aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4197 |
| SETD3(Y2501) |
| Comment | Currently not ready. Hybridoma against SETD3 : SET domain containing 3 (2-139(138aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4198 |
| SETD3(Y2537) |
| Comment | Currently not ready. Hybridoma against SETD3 : SET domain containing 3 (2-139(138aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4199 |
| mSETDB2-1(Y7221) |
| Comment | Currently not ready. Hybridoma against mSETDB2-1 : SET domain, bifurcated 2 (14-129(116aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4200 |
| mSETDB2-1(Y7227) |
| Comment | Currently not ready. Hybridoma against mSETDB2-1 : SET domain, bifurcated 2 (14-129(116aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4201 |
| mSETDB2-1(Y7228) |
| Comment | Currently not ready. Hybridoma against mSETDB2-1 : SET domain, bifurcated 2 (14-129(116aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4202 |
| mSETDB2-1(Y7232) |
| Comment | Currently not ready. Hybridoma against mSETDB2-1 : SET domain, bifurcated 2 (14-129(116aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4203 |
| mSETDB2-1(Y7241) |
| Comment | Currently not ready. Hybridoma against mSETDB2-1 : SET domain, bifurcated 2 (14-129(116aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4204 |
| mSETDB2-1(Y7246) |
| Comment | Currently not ready. Hybridoma against mSETDB2-1 : SET domain, bifurcated 2 (14-129(116aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4205 |
| mSETDB2-1(Y7247) |
| Comment | Currently not ready. Hybridoma against mSETDB2-1 : SET domain, bifurcated 2 (14-129(116aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4206 |
| Prdm6-2(Y7126) |
| Comment | Currently not ready. Hybridoma against Prdm6-2 : PR domain containing 6 (294-392(99aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4207 |
| Prdm16-1(Z0311) |
| Comment | Currently not ready. Hybridoma against Prdm16-1 : PR domain containing 16 (4-103(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4208 |
| Prdm16-1(Z0315) |
| Comment | Currently not ready. Hybridoma against Prdm16-1 : PR domain containing 16 (4-103(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4209 |
| Prdm16-1(Z0324) |
| Comment | Currently not ready. Hybridoma against Prdm16-1 : PR domain containing 16 (4-103(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4210 |
| Prdm16-1(Z0327) |
| Comment | Currently not ready. Hybridoma against Prdm16-1 : PR domain containing 16 (4-103(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4211 |
| Prdm16-1(Z0346) |
| Comment | Currently not ready. Hybridoma against Prdm16-1 : PR domain containing 16 (4-103(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4212 |
| Prdm16-2(Z1301) |
| Comment | Hybridoma against Prdm16-2 : PR domain containing 16 (467-566(100aa)) antigen. |
|---|
| Comment from the depositor | PR domain containing 16 (467-566(100aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4213 |
| Prdm16-2(Z1312) |
| Comment | Currently not ready. Hybridoma against Prdm16-2 : PR domain containing 16 (467-566(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4214 |
| Prdm16-2(Z1322) |
| Comment | Currently not ready. Hybridoma against Prdm16-2 : PR domain containing 16 (467-566(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4215 |
| Prdm2-2(Z0601) |
| Comment | Currently not ready. Hybridoma against Prdm2-2 : PR domain containing 2 (210-309(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4216 |
| Prdm2-2(Z0605) |
| Comment | Currently not ready. Hybridoma against Prdm2-2 : PR domain containing 2 (210-309(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4217 |
| Prdm2-2(Z0626) |
| Comment | Currently not ready. Hybridoma against Prdm2-2 : PR domain containing 2 (210-309(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4218 |
| Prdm2-2(Z0631) |
| Comment | Currently not ready. Hybridoma against Prdm2-2 : PR domain containing 2 (210-309(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4219 |
| Prdm2-2(Z0654) |
| Comment | Currently not ready. Hybridoma against Prdm2-2 : PR domain containing 2 (210-309(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4220 |
| Prdm4-1(Y8328) |
| Comment | Currently not ready. Hybridoma against Prdm4-1 : PR domain containing 4 (161-260(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4221 |
| Prdm4-1(Y8341) |
| Comment | Currently not ready. Hybridoma against Prdm4-1 : PR domain containing 4 (161-260(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4222 |
| COUP TFII-2(Z0504) |
| Comment | Currently not ready. Hybridoma against COUP TFII-2 : Chicken Ovalbumin Upstream Promoter-Transcription Factor II (1-50(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4223 |
| COUP TFII-2(Z0523) |
| Comment | Currently not ready. Hybridoma against COUP TFII-2 : Chicken Ovalbumin Upstream Promoter-Transcription Factor II (1-50(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4224 |
| COUP TFII-2(Z0533) |
| Comment | Currently not ready. Hybridoma against COUP TFII-2 : Chicken Ovalbumin Upstream Promoter-Transcription Factor II (1-50(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4225 |
| methylated budded baculovirus(C4914-2) |
| Comment | Currently not ready. Hybridoma against methylated budded baculovirus (1K,2K,3K) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4226 |
| methylated budded baculovirus(C4930-101) |
| Comment | Currently not ready. Hybridoma against methylated budded baculovirus (1K,2K,3K) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4227 |
| methylated budded baculovirus(C5006-9) |
| Comment | Currently not ready. Hybridoma against methylated budded baculovirus (1K,2K,3K) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4228 |
| methylated budded baculovirus(C5009-33) |
| Comment | Currently not ready. Hybridoma against methylated budded baculovirus (1K,2K,3K) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4229 |
| methylated budded baculovirus(C5032-60) |
| Comment | Currently not ready. Hybridoma against methylated budded baculovirus (1K,2K,3K) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4230 |
| methylated budded baculovirus(C5123-70) |
| Comment | Currently not ready. Hybridoma against methylated budded baculovirus (1K,2K,3K) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4231 |
| ATIP-CT(N4204) |
| Comment | Currently not ready. Hybridoma against ATIP-CT : Angiotensin II receptor type 2-interacting proteins (327-426(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4232 |
| ATIP-CT(N4207) |
| Comment | Currently not ready. Hybridoma against ATIP-CT : Angiotensin II receptor type 2-interacting proteins (327-426(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4233 |
| ATIP-CT(N4235) |
| Comment | Currently not ready. Hybridoma against ATIP-CT : Angiotensin II receptor type 2-interacting proteins (327-426(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4234 |
| ROBO1 Ag1(Y4314) |
| Comment | Currently not ready. Hybridoma against ROBO1 Ag1 : Roundabout 1 (946-1034(89aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4235 |
| ROBO1 Ag2(Y7002) |
| Comment | Currently not ready. Hybridoma against ROBO1 Ag2 : Roundabout 1 (1062-1148(87aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4236 |
| ROBO1 Ag6(Y8411) |
| Comment | Currently not ready. Hybridoma against ROBO1 Ag6 : Roundabout 1 (1458-1555(98aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4237 |
| APE-C(Y1202) |
| Comment | Currently not ready. Hybridoma against APE-C : Akt-phosphorylation enhancer (1786-1845(60aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4238 |
| APE-C(Y1209) |
| Comment | Currently not ready. Hybridoma against APE-C : Akt-phosphorylation enhancer (1786-1845(60aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4239 |
| APE-C(Y1215) |
| Comment | Currently not ready. Hybridoma against APE-C : Akt-phosphorylation enhancer (1786-1845(60aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4240 |
| APE-C(Y1220) |
| Comment | Currently not ready. Hybridoma against APE-C : Akt-phosphorylation enhancer (1786-1845(60aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4241 |
| APE-C(Y1221) |
| Comment | Currently not ready. Hybridoma against APE-C : Akt-phosphorylation enhancer (1786-1845(60aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4242 |
| APE-C(Y1244) |
| Comment | Currently not ready. Hybridoma against APE-C : Akt-phosphorylation enhancer (1786-1845(60aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4243 |
| APE-N1(N9406) |
| Comment | Currently not ready. Hybridoma against APE-N1 : Akt-phosphorylation enhancer (322-372(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4244 |
| APE-N1(N9407) |
| Comment | Currently not ready. Hybridoma against APE-N1 : Akt-phosphorylation enhancer (322-372(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4245 |
| APE-N1(N9426) |
| Comment | Currently not ready. Hybridoma against APE-N1 : Akt-phosphorylation enhancer (322-372(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4246 |
| APE-N1(N9436A) |
| Comment | Currently not ready. Hybridoma against APE-N1 : Akt-phosphorylation enhancer (322-372(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4247 |
| APE-N1(N9436B) |
| Comment | Currently not ready. Hybridoma against APE-N1 : Akt-phosphorylation enhancer (322-372(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4248 |
| APE-N1(N9442) |
| Comment | Currently not ready. Hybridoma against APE-N1 : Akt-phosphorylation enhancer (322-372(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4249 |
| APE-N3(Y0013) |
| Comment | Currently not ready. Hybridoma against APE-N3 : Akt-phosphorylation enhancer (551-601(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4250 |
| APE-N3(Y0026) |
| Comment | Currently not ready. Hybridoma against APE-N3 : Akt-phosphorylation enhancer (551-601(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4251 |
| APE-N3(Y0028) |
| Comment | Currently not ready. Hybridoma against APE-N3 : Akt-phosphorylation enhancer (551-601(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4252 |
| APE-N3(Y0038) |
| Comment | Currently not ready. Hybridoma against APE-N3 : Akt-phosphorylation enhancer (551-601(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4253 |
| hTobC(Y5432) |
| Comment | Hybridoma against hTobC : Transducer of ERBB2, 1 (263-345(83aa)) antigen. |
|---|
| Comment from the depositor | hTobC : Transducer of ERBB2, 1 (263-345(83aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4254 |
| hTobC(Y5443) |
| Comment | Hybridoma against hTobC : Transducer of ERBB2, 1 (263-345(83aa)) antigen. |
|---|
| Comment from the depositor | hTobC : Transducer of ERBB2, 1 (263-345(83aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4255 |
| hTobC(Y5444) |
| Comment | Hybridoma against hTobC : Transducer of ERBB2, 1 (263-345(83aa)) antigen. |
|---|
| Comment from the depositor | hTobC : Transducer of ERBB2, 1 (263-345(83aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4256 |
| hTobC(Y5452) |
| Comment | Hybridoma against hTobC : Transducer of ERBB2, 1 (263-345(83aa)) antigen. |
|---|
| Comment from the depositor | hTobC : Transducer of ERBB2, 1 (263-345(83aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4257 |
| hTobM(Y5807) |
| Comment | Currently not ready. Hybridoma against hTobM : Transducer of ERBB2, 1 (136-236(101aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4258 |
| hTobM(Y5815) |
| Comment | Currently not ready. Hybridoma against hTobM : Transducer of ERBB2, 1 (136-236(101aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4259 |
| p115-C(Y0902) |
| Comment | Currently not ready. Hybridoma against p115-C : p115phoGEF(guanine nucleotide exchange factor) (814-913(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4260 |
| p115-C(Y0912) |
| Comment | Currently not ready. Hybridoma against p115-C : p115phoGEF(guanine nucleotide exchange factor) (814-913(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4261 |
| p115-C(Y0915) |
| Comment | Currently not ready. Hybridoma against p115-C : p115phoGEF(guanine nucleotide exchange factor) (814-913(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4262 |
| p115-C(Y0920) |
| Comment | Currently not ready. Hybridoma against p115-C : p115phoGEF(guanine nucleotide exchange factor) (814-913(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4263 |
| p115-C(Y0921) |
| Comment | Currently not ready. Hybridoma against p115-C : p115phoGEF(guanine nucleotide exchange factor) (814-913(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4264 |
| p115-C(Y0924) |
| Comment | Currently not ready. Hybridoma against p115-C : p115phoGEF(guanine nucleotide exchange factor) (814-913(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4265 |
| p115-C(Y0931) |
| Comment | Currently not ready. Hybridoma against p115-C : p115phoGEF(guanine nucleotide exchange factor) (814-913(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4266 |
| p115-C(Y0945) |
| Comment | Currently not ready. Hybridoma against p115-C : p115phoGEF(guanine nucleotide exchange factor) (814-913(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4267 |
| LARG-C term(Y9601) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1466-1565(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4268 |
| LARG-C term(Y9614) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1466-1565(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4269 |
| LARG-C term(Y9618) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1466-1565(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4270 |
| LARG-C term(Y9619) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1466-1565(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4271 |
| LARG-C term(Y9625) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1466-1565(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4272 |
| LARG-C term(Y9626) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1466-1565(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4273 |
| LARG-C term(Y9627) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1466-1565(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4274 |
| LARG-C term(Y9637) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1466-1565(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4276 |
| ATIP-CT(C1708-1) |
| Comment | Currently not ready. Hybridoma against ATIP-CT : Angiotensin II receptor type 2-interacting proteins (327-426 (100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4277 |
| ATIP-CT(C1717-5) |
| Comment | Currently not ready. Hybridoma against ATIP-CT : Angiotensin II receptor type 2-interacting proteins (327-426 (100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4278 |
| NM6(Y0620) |
| Comment | Currently not ready. Hybridoma against NM6 : Myotubularin related protein 6 (1-100(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4279 |
| NM6s(Y67002) |
| Comment | Hybridoma against NM6s : Myotubularin related protein 6 (1-100(100aa)) antigen. |
|---|
| Comment from the depositor | Myotubularin related protein 6 (1-100(100aa)) was expressed on the surface of baculovirus as the gp64-fusion protein according to the previously described procedure ( J.Immunol,Methods. 234, 123-135, 2000). This hybridoma was generated using the recombinant budded virus as an immunogen. |
|---|
| RCB4280 |
| NM6s(Y67003) |
| Comment | Currently not ready. Hybridoma against NM6s : Myotubularin related protein 6 (1-100(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4281 |
| NM6s(Y67057) |
| Comment | Currently not ready. Hybridoma against NM6s : Myotubularin related protein 6 (1-100(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4282 |
| NM6s(Y67081) |
| Comment | Currently not ready. Hybridoma against NM6s : Myotubularin related protein 6 (1-100(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4283 |
| NM6s(Y67109) |
| Comment | Currently not ready. Hybridoma against NM6s : Myotubularin related protein 6 (1-100(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4284 |
| CM1s(Z1001) |
| Comment | Currently not ready. Hybridoma against CM1s : Myotubular myopathy 1 (555-604(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4285 |
| CM1s(Z1002) |
| Comment | Currently not ready. Hybridoma against CM1s : Myotubular myopathy 1 (555-604(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4286 |
| CM1s(Z1014) |
| Comment | Currently not ready. Hybridoma against CM1s : Myotubular myopathy 1 (555-604(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4287 |
| CM1s(Z1016) |
| Comment | Currently not ready. Hybridoma against CM1s : Myotubular myopathy 1 (555-604(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4288 |
| CM1s(Z1057) |
| Comment | Currently not ready. Hybridoma against CM1s : Myotubular myopathy 1 (555-604(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4289 |
| CM6(Y9506) |
| Comment | Currently not ready. Hybridoma against CM6 : Myotubularin related protein 6 (519-618(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4290 |
| CM6(Y9512) |
| Comment | Currently not ready. Hybridoma against CM6 : Myotubularin related protein 6 (519-618(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4291 |
| CM6(Y9515) |
| Comment | Currently not ready. Hybridoma against CM6 : Myotubularin related protein 6 (519-618(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4292 |
| CM6(Y9517) |
| Comment | Currently not ready. Hybridoma against CM6 : Myotubularin related protein 6 (519-618(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4293 |
| hVir-2(Y1503) |
| Comment | Currently not ready. Hybridoma against hVir-2 : Virilizer (561-611(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4294 |
| hVir-2(Y1513) |
| Comment | Currently not ready. Hybridoma against hVir-2 : Virilizer (561-611(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4295 |
| hVir-2(Y1523) |
| Comment | Currently not ready. Hybridoma against hVir-2 : Virilizer (561-611(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4296 |
| hVir-3(Y1613) |
| Comment | Currently not ready. Hybridoma against hVir-3 : Virilizer (1421-1480(60aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4297 |
| hVir-3(Y1625(4C3)) |
| Comment | Currently not ready. Hybridoma against hVir-3 : Virilizer (1421-1480(60aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4298 |
| hVir-3(Y1639) |
| Comment | Currently not ready. Hybridoma against hVir-3 : Virilizer (1421-1480(60aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4299 |
| WTAP(Y6809) |
| Comment | Currently not ready. Hybridoma against WTAP : Wilms tumor 1 associated protein (6-76(71aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4300 |
| WTAP(Y6828) |
| Comment | Currently not ready. Hybridoma against WTAP : Wilms tumor 1 associated protein (6-76(71aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4301 |
| hFRS2β1(Y7610) |
| Comment | Currently not ready. Hybridoma against hFRS2β1 : Fibroblast growth factor receptor substrate 2β (342-392(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4302 |
| hFRS2β1(Y7612) |
| Comment | Currently not ready. Hybridoma against hFRS2β1 : Fibroblast growth factor receptor substrate 2β (342-392(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4303 |
| hFRS2β1(Y7624) |
| Comment | Currently not ready. Hybridoma against hFRS2β1 : Fibroblast growth factor receptor substrate 2β (342-392(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4304 |
| hFRS2β1(Y7632) |
| Comment | Currently not ready. Hybridoma against hFRS2β1 : Fibroblast growth factor receptor substrate 2β (342-392(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4305 |
| hFRS2β1(Y7641) |
| Comment | Currently not ready. Hybridoma against hFRS2β1 : Fibroblast growth factor receptor substrate 2β (342-392(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4306 |
| hFRS2β1(Y7642) |
| Comment | Currently not ready. Hybridoma against hFRS2β1 : Fibroblast growth factor receptor substrate 2β (342-392(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4307 |
| hFRS2β1(Y7643) |
| Comment | Currently not ready. Hybridoma against hFRS2β1 : Fibroblast growth factor receptor substrate 2β (342-392(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4308 |
| mNFATC-N(Y7402) |
| Comment | Currently not ready. Hybridoma against mNFATC-N : Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (43-143(101aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4309 |
| mNFATC-N(Y7405) |
| Comment | Currently not ready. Hybridoma against mNFATC-N : Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (43-143(101aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4310 |
| mNFATC-N(Y7428) |
| Comment | Currently not ready. Hybridoma against mNFATC-N : Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (43-143(101aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4311 |
| mNFATC-N(Y7445) |
| Comment | Currently not ready. Hybridoma against mNFATC-N : Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (43-143(101aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4312 |
| hEgr1(N8605) |
| Comment | Currently not ready. Hybridoma against hEgr1 : Early growth response 1 (1-99(99aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4313 |
| hEgr1(N8611) |
| Comment | Currently not ready. Hybridoma against hEgr1 : Early growth response 1 (1-99(99aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4314 |
| hEgr1(N8614) |
| Comment | Currently not ready. Hybridoma against hEgr1 : Early growth response 1 (1-99(99aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4315 |
| hEgr1(N8616) |
| Comment | Currently not ready. Hybridoma against hEgr1 : Early growth response 1 (1-99(99aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4316 |
| hEgr1(N8637) |
| Comment | Currently not ready. Hybridoma against hEgr1 : Early growth response 1 (1-99(99aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4317 |
| hEgr1(N8640) |
| Comment | Currently not ready. Hybridoma against hEgr1 : Early growth response 1 (1-99(99aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4318 |
| hEgr3(N8701) |
| Comment | Currently not ready. Hybridoma against hEgr3 : Early growth response 3 (27-82(56aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4319 |
| hEgr3(N8730) |
| Comment | Currently not ready. Hybridoma against hEgr3 : Early growth response 3 (27-82(56aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4320 |
| Prdm8-2(N8501) |
| Comment | Currently not ready. Hybridoma against Prdm8-2 : PR domain containing 8 (265-364(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4321 |
| Prdm8-2(N8506) |
| Comment | Currently not ready. Hybridoma against Prdm8-2 : PR domain containing 8 (265-364(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4322 |
| Prdm8-2(N8508) |
| Comment | Currently not ready. Hybridoma against Prdm8-2 : PR domain containing 8 (265-364(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4323 |
| Prdm8-2(N8513) |
| Comment | Currently not ready. Hybridoma against Prdm8-2 : PR domain containing 8 (265-364(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4324 |
| Prdm8-2(N8520) |
| Comment | Currently not ready. Hybridoma against Prdm8-2 : PR domain containing 8 (265-364(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4325 |
| Prdm8-2(N8526) |
| Comment | Currently not ready. Hybridoma against Prdm8-2 : PR domain containing 8 (265-364(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4326 |
| Prdm8-2(N8533) |
| Comment | Currently not ready. Hybridoma against Prdm8-2 : PR domain containing 8 (265-364(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4327 |
| Aggrecan-1(Y3416) |
| Comment | Currently not ready. Hybridoma against Aggrecan-1 : Aggrecan (2168-2223(56aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4328 |
| Aggrecan-1(Y3428) |
| Comment | Currently not ready. Hybridoma against Aggrecan-1 : Aggrecan (2168-2223(56aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4329 |
| Aggrecan-1(Y3431) |
| Comment | Currently not ready. Hybridoma against Aggrecan-1 : Aggrecan (2168-2223(56aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4330 |
| Aggrecan-1(Y3441) |
| Comment | Currently not ready. Hybridoma against Aggrecan-1 : Aggrecan (2168-2223(56aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4331 |
| Aggrecan-1(Y3446) |
| Comment | Currently not ready. Hybridoma against Aggrecan-1 : Aggrecan (2168-2223(56aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4332 |
| PTX3N46(Z3805(421)) |
| Comment | Currently not ready. Hybridoma against PTX3N46 : Pentraxin3 (18-46(29aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4333 |
| PTX3N46(Z3818-1-19) |
| Comment | Currently not ready. Hybridoma against PTX3N46 : Pentraxin3 (18-46(29aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4334 |
| PTX3N46(Z3821(100)) |
| Comment | Currently not ready. Hybridoma against PTX3N46 : Pentraxin3 (18-46(29aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4335 |
| PTX3N46(Z3825(125)) |
| Comment | Currently not ready. Hybridoma against PTX3N46 : Pentraxin3 (18-46(29aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4336 |
| PTX3N46(Z3829-156) |
| Comment | Currently not ready. Hybridoma against PTX3N46 : Pentraxin3 (18-46(29aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4337 |
| PTX3N46(Z3835-467) |
| Comment | Currently not ready. Hybridoma against PTX3N46 : Pentraxin3 (18-46(29aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4338 |
| PTX3N46(Z3839-590) |
| Comment | Currently not ready. Hybridoma against PTX3N46 : Pentraxin3 (18-46(29aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4339 |
| CBLL1-2(Y6018) |
| Comment | Currently not ready. Hybridoma against CBLL1-2 : Cas-Br-M (murine) ecotropic retroviral transforming sequence-like 1 (430-491(62aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4340 |
| CBLL1-2(Y6026) |
| Comment | Currently not ready. Hybridoma against CBLL1-2 : Cas-Br-M (murine) ecotropic retroviral transforming sequence-like 1 (430-491(62aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4341 |
| CBLL1-2(Y6037) |
| Comment | Currently not ready. Hybridoma against CBLL1-2 : Cas-Br-M (murine) ecotropic retroviral transforming sequence-like 1 (430-491(62aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4342 |
| CBLL1-2(Y6047) |
| Comment | Currently not ready. Hybridoma against CBLL1-2 : Cas-Br-M (murine) ecotropic retroviral transforming sequence-like 1 (430-491(62aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4343 |
| CBLL1-2(Y6048) |
| Comment | Currently not ready. Hybridoma against CBLL1-2 : Cas-Br-M (murine) ecotropic retroviral transforming sequence-like 1 (430-491(62aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4344 |
| CBLL1-1(Y6610) |
| Comment | Currently not ready. Hybridoma against CBLL1-1 : Cas-Br-M (murine) ecotropic retroviral transforming sequence-like 1 (5-70(66aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4345 |
| CBLL1-1(Y6621) |
| Comment | Currently not ready. Hybridoma against CBLL1-1 : Cas-Br-M (murine) ecotropic retroviral transforming sequence-like 1 (5-70(66aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4346 |
| CBLL1-1(Y6641) |
| Comment | Currently not ready. Hybridoma against CBLL1-1 : Cas-Br-M (murine) ecotropic retroviral transforming sequence-like 1 (5-70(66aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4347 |
| PDZ-CS(Y7501) |
| Comment | Currently not ready. Hybridoma against PDZ-CS : Rho guanine nucleotide exchange factor (GEF) 11 (1423-1522(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4348 |
| PDZ-CS(Y7504) |
| Comment | Currently not ready. Hybridoma against PDZ-CS : Rho guanine nucleotide exchange factor (GEF) 11 (1423-1522(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4349 |
| PDZ-CS(Y7505) |
| Comment | Currently not ready. Hybridoma against PDZ-CS : Rho guanine nucleotide exchange factor (GEF) 11 (1423-1522(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4350 |
| PDZ-CS(Y7534) |
| Comment | Currently not ready. Hybridoma against PDZ-CS : Rho guanine nucleotide exchange factor (GEF) 11 (1423-1522(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4351 |
| PDZ-CS(Y7537) |
| Comment | Currently not ready. Hybridoma against PDZ-CS : Rho guanine nucleotide exchange factor (GEF) 11 (1423-1522(100aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4352 |
| Ets-1 Mid(Y8012) |
| Comment | Currently not ready. Hybridoma against Ets-1 Mid : v-ets erythroblastosis virus E26 oncogene homolog 1 (220-304(85aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4353 |
| Ets-1 Mid(Y8020) |
| Comment | Currently not ready. Hybridoma against Ets-1 Mid : v-ets erythroblastosis virus E26 oncogene homolog 1 (220-304(85aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4354 |
| Ets-1 Mid(Y8029) |
| Comment | Currently not ready. Hybridoma against Ets-1 Mid : v-ets erythroblastosis virus E26 oncogene homolog 1 (220-304(85aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4355 |
| prdm 5(C2518A) |
| Comment | Currently not ready. Hybridoma against gp64 fusion prdm 5 : PR domain containing 5 (10-110(101aa)) antigen expressed by baculovirus. |
|---|
| Comment from the depositor | |
|---|
| RCB4356 |
| RGS3T(C6501-4) |
| Comment | Currently not ready. Hybridoma against RGS3T : regular of G protein signaling 3 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4357 |
| Gq(C6604-5) |
| Comment | Currently not ready. Hybridoma against Gq : GNAQ (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4358 |
| Gq(C6611A-11-A2) |
| Comment | Currently not ready. Hybridoma against Gq : GNAQ (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4359 |
| Gq(C6611B-35-18) |
| Comment | Currently not ready. Hybridoma against Gq : GNAQ (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4360 |
| Gq(C6618-81) |
| Comment | Currently not ready. Hybridoma against Gq : GNAQ (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4361 |
| Gq(C6623-18) |
| Comment | Currently not ready. Hybridoma against Gq : GNAQ (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4362 |
| Gα13(C9101-F5-1) |
| Comment | Currently not ready. Hybridoma against Gα13 : GNA12 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4363 |
| Gα13(C9201-B5-4) |
| Comment | Currently not ready. Hybridoma against Gα13 : GNA13 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4364 |
| Gα13(C9202-F9-1) |
| Comment | Currently not ready. Hybridoma against Gα13 : GNA13 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4365 |
| Gα13(C9204-D4-1) |
| Comment | Currently not ready. Hybridoma against Gα13 : GNA13 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4366 |
| Gα13(C9205-F6-4) |
| Comment | Currently not ready. Hybridoma against Gα13 : GNA13 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4367 |
| Gα12(D0901-A1-E11) |
| Comment | Currently not ready. Hybridoma against Gα12 : GNA12 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4368 |
| Gα12(D0902-B12-G11) |
| Comment | Currently not ready. Hybridoma against Gα12 : GNA12 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4369 |
| Gα12(D0904-A6-H2) |
| Comment | Currently not ready. Hybridoma against Gα12 : GNA12 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4370 |
| Gα12(D0906-B10-D6) |
| Comment | Currently not ready. Hybridoma against Gα12 : GNA12 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4371 |
| Gα12(D0907-E2-E8) |
| Comment | Currently not ready. Hybridoma against Gα12 : GNA12 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4372 |
| Gα12(D0908-G5-A6) |
| Comment | Currently not ready. Hybridoma against Gα12 : GNA12 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4373 |
| Gα12(D0910-G5-D10) |
| Comment | Currently not ready. Hybridoma against Gα12 : GNA12 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4374 |
| Gα12(D0911-E6-G1) |
| Comment | Currently not ready. Hybridoma against Gα12 : GNA12 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4375 |
| Gα12(D0912-B5-C9) |
| Comment | Currently not ready. Hybridoma against Gα12 : GNA12 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4376 |
| Gα12(D0914-D5-D4) |
| Comment | Currently not ready. Hybridoma against Gα12 : GNA12 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4377 |
| NFATC-3(Z2705) |
| Comment | Currently not ready. Hybridoma against NFATC-3 : Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (35-107(73aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4378 |
| mOSR-2(Z2914) |
| Comment | Currently not ready. Hybridoma against mOSR-2 : Odd-skipped related 2 (59-157(99aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4379 |
| ATOX1(Z3101) |
| Comment | Currently not ready. Hybridoma against ATOX1 : ATX1 antioxidant protein 1 homolog (68AA) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4380 |
| ATOX1(Z3112) |
| Comment | Hybridoma against ATOX1 : ATX1 antioxidant protein 1 homolog (68AA) antigen. |
|---|
| Comment from the depositor | ATX1 antioxidant protein 1 homolog (68AA) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4381 |
| ATOX1(Z3138) |
| Comment | Currently not ready. Hybridoma against ATOX1 : ATX1 antioxidant protein 1 homolog (68AA) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4382 |
| ATOX1(Z3140) |
| Comment | Currently not ready. Hybridoma against ATOX1 : ATX1 antioxidant protein 1 homolog (68AA) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4383 |
| ATOX1(Z3144) |
| Comment | Currently not ready. Hybridoma against ATOX1 : ATX1 antioxidant protein 1 homolog (68AA) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4384 |
| MAN-1(Z4201) |
| Comment | Currently not ready. Hybridoma against MAN-1 : MAN1 (734-807(74aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4385 |
| MAN-1(Z4202) |
| Comment | Currently not ready. Hybridoma against MAN-1 : MAN1 (734-807(74aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4386 |
| MAN-1(Z4205) |
| Comment | Currently not ready. Hybridoma against MAN-1 : MAN1 (734-807(74aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4387 |
| MAN-1(Z4209) |
| Comment | Currently not ready. Hybridoma against MAN-1 : MAN1 (734-807(74aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4388 |
| MAN-1(Z4221) |
| Comment | Currently not ready. Hybridoma against MAN-1 : MAN1 (734-807(74aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4389 |
| MAN-1(Z4222) |
| Comment | Currently not ready. Hybridoma against MAN-1 : MAN1 (734-807(74aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4390 |
| MAN-1(Z4223) |
| Comment | Currently not ready. Hybridoma against MAN-1 : MAN1 (734-807(74aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4391 |
| MAN-1(Z4237) |
| Comment | Currently not ready. Hybridoma against MAN-1 : MAN1 (734-807(74aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4392 |
| SETDB-1(Z4601) |
| Comment | Hybridoma against SETDB-1 : SET domain, bifurcated 1 (1025-1080(56aa)) antigen. |
|---|
| Comment from the depositor | SET domain, bifurcated 1 (1025-1080(56aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4393 |
| SETDB-1(Z4606) |
| Comment | Hybridoma against SETDB-1 : SET domain, bifurcated 1 (1025-1080(56aa)) antigen. |
|---|
| Comment from the depositor | SET domain, bifurcated 1 (1025-1080(56aa)) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4394 |
| SETDB-1(Z4613) |
| Comment | Currently not ready. Hybridoma against SETDB-1 : SET domain, bifurcated 1 (1025-1080(56aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4395 |
| SETDB-1(Z4630) |
| Comment | Currently not ready. Hybridoma against SETDB-1 : SET domain, bifurcated 1 (1025-1080(56aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4396 |
| mp250GAP(Z4906) |
| Comment | Currently not ready. Hybridoma against mp250GAP : Rho GTPase activating protein 32 (1660-1727(68aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4397 |
| mp250GAP(Z4932) |
| Comment | Currently not ready. Hybridoma against mp250GAP : Rho GTPase activating protein 32 (1660-1727(68aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4398 |
| mp250GAP(Z4937) |
| Comment | Currently not ready. Hybridoma against mp250GAP : Rho GTPase activating protein 32 (1660-1727(68aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4399 |
| mp250GAP(Z4942) |
| Comment | Currently not ready. Hybridoma against mp250GAP : Rho GTPase activating protein 32 (1660-1727(68aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4400 |
| mp250GAP(Z4946) |
| Comment | Currently not ready. Hybridoma against mp250GAP : Rho GTPase activating protein 32 (1660-1727(68aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4401 |
| mp250GAP(Z4947) |
| Comment | Currently not ready. Hybridoma against mp250GAP : Rho GTPase activating protein 32 (1660-1727(68aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4402 |
| SETD5-1(Z5235-36) |
| Comment | Currently not ready. Hybridoma against SETD5-1 : SET domain containing 5 (43-93(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4403 |
| SETD5-1(Z5235-42) |
| Comment | Currently not ready. Hybridoma against SETD5-1 : SET domain containing 5 (43-93(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4404 |
| NFATC1-2(Z5302) |
| Comment | Currently not ready. Hybridoma against NFATC1-2 : Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (134-223(90aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4405 |
| NFATC1-2(Z5321) |
| Comment | Currently not ready. Hybridoma against NFATC1-2 : Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (134-223(90aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4406 |
| GluR1-1(Z6114) |
| Comment | Currently not ready. Hybridoma against GluR1-1 : Glutamate receptor, ionotropic, AMPA 1 (19-68(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4407 |
| GluR1-1(Z6119) |
| Comment | Currently not ready. Hybridoma against GluR1-1 : Glutamate receptor, ionotropic, AMPA 1 (19-68(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4408 |
| GluR1-1(Z6123) |
| Comment | Currently not ready. Hybridoma against GluR1-1 : Glutamate receptor, ionotropic, AMPA 1 (19-68(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4409 |
| GluR1-1(Z6135) |
| Comment | Currently not ready. Hybridoma against GluR1-1 : Glutamate receptor, ionotropic, AMPA 1 (19-68(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4410 |
| GluR1-1(Z6141) |
| Comment | Currently not ready. Hybridoma against GluR1-1 : Glutamate receptor, ionotropic, AMPA 1 (19-68(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4411 |
| GluR1-1(Z6143) |
| Comment | Currently not ready. Hybridoma against GluR1-1 : Glutamate receptor, ionotropic, AMPA 1 (19-68(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4412 |
| SETD5-4(Z5702-3) |
| Comment | Currently not ready. Hybridoma against SETD5-4 : SET domain containing 5 (1241-1291(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4413 |
| SETD5-4(Z5704-209) |
| Comment | Currently not ready. Hybridoma against SETD5-4 : SET domain containing 5 (1241-1291(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4414 |
| SETD5-4(Z5708-71) |
| Comment | Currently not ready. Hybridoma against SETD5-4 : SET domain containing 5 (1241-1291(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4415 |
| SETD5-4(Z5714-114) |
| Comment | Currently not ready. Hybridoma against SETD5-4 : SET domain containing 5 (1241-1291(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4416 |
| SETD5-4(Z5721-234) |
| Comment | Currently not ready. Hybridoma against SETD5-4 : SET domain containing 5 (1241-1291(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4417 |
| PRMT1-N(Z5017) |
| Comment | Currently not ready. Hybridoma against PRMT1-N : Protein arginine methyltransferase 1 (7-56(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4418 |
| PRMT1-N(Z5018) |
| Comment | Currently not ready. Hybridoma against PRMT1-N : Protein arginine methyltransferase 1 (7-56(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4419 |
| PRMT1-N(Z5026) |
| Comment | Currently not ready. Hybridoma against PRMT1-N : Protein arginine methyltransferase 1 (7-56(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4420 |
| NM1S/Tg(Z7332) |
| Comment | Currently not ready. Hybridoma against NM1S/Tg : Myotubular myopathy 1 (1-50(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4421 |
| NM1S/Tg(Z7342) |
| Comment | Currently not ready. Hybridoma against NM1S/Tg : Myotubular myopathy 1 (1-50(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4422 |
| CM3(Z7511) |
| Comment | Currently not ready. Hybridoma against CM3 : Myotubularin related protein 3 (1111-1161(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4423 |
| CM3(Z7528) |
| Comment | Currently not ready. Hybridoma against CM3 : Myotubularin related protein 3 (1111-1161(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4424 |
| CM3(Z7536) |
| Comment | Currently not ready. Hybridoma against CM3 : Myotubularin related protein 3 (1111-1161(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4425 |
| NM3(Z8021) |
| Comment | Currently not ready. Hybridoma against NM3 : Myotubularin related protein 3 (1-50(50aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4426 |
| CM4/Tg(Z8214) |
| Comment | Currently not ready. Hybridoma against CM4/Tg : Myotubularin related protein 4 (909-959(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4427 |
| CM4/Tg(Z8217) |
| Comment | Currently not ready. Hybridoma against CM4/Tg : Myotubularin related protein 4 (909-959(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4428 |
| CM4/Tg(Z8245B) |
| Comment | Currently not ready. Hybridoma against CM4/Tg : Myotubularin related protein 4 (909-959(51aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4429 |
| Fbxl 10-N(Z8310) |
| Comment | Currently not ready. Hybridoma against Fbxl 10-N : F-box and leucine-rich repeat protein 10 (45-92(48aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4430 |
| Fbxl 10-N(Z8312) |
| Comment | Currently not ready. Hybridoma against Fbxl 10-N : F-box and leucine-rich repeat protein 10 (45-92(48aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4431 |
| Fbxl 10-N(Z8320) |
| Comment | Currently not ready. Hybridoma against Fbxl 10-N : F-box and leucine-rich repeat protein 10 (45-92(48aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4432 |
| Fbxl 10-N(Z8327) |
| Comment | Currently not ready. Hybridoma against Fbxl 10-N : F-box and leucine-rich repeat protein 10 (45-92(48aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4433 |
| Fbxl 10-N(Z8345) |
| Comment | Currently not ready. Hybridoma against Fbxl 10-N : F-box and leucine-rich repeat protein 10 (45-92(48aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4434 |
| LARG-C term(D4004-4E2-6) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1304-1544(241aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4435 |
| LARG-C term(D4005-6A6-29) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1304-1544(241aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4436 |
| LARG-C term(D4101-2G11-41) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1304-1544(241aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4437 |
| LARG-C term(D4106-5G1-67) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1304-1544(241aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4438 |
| LARG-C term(D4107-5H2-110) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1304-1544(241aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4439 |
| LARG-C term(D4202-2E6-130) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1304-1544(241aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4440 |
| LARG-C term(D4204-1A10-163) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1304-1544(241aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4441 |
| LARG-C term(D4205-2A9-213) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1304-1544(241aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4442 |
| LARG-C term(D4206-2B8-221) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1304-1544(241aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4443 |
| LARG-C term(D4207-2D10-262) |
| Comment | Currently not ready. Hybridoma against LARG-C-terminal : Leukemia associated Rho guanine nucleotide exchange factor (1304-1544(241aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4444 |
| Emerin Ab-3(D2702-12) |
| Comment | Currently not ready. Hybridoma against Emerin Ab-3 : Emerin (48-110(63aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4445 |
| Emerin Ab-3(D2703-2) |
| Comment | Currently not ready. Hybridoma against Emerin Ab-3 : Emerin (48-110(63aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4446 |
| Emerin Ab-3(D2704-5) |
| Comment | Currently not ready. Hybridoma against Emerin Ab-3 : Emerin (48-110(63aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4447 |
| Emerin Ab-3(D2705-2) |
| Comment | Currently not ready. Hybridoma against Emerin Ab-3 : Emerin (48-110(63aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4448 |
| Emerin Ab-3(D2738-2) |
| Comment | Currently not ready. Hybridoma against Emerin Ab-3 : Emerin (48-110(63aa)) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4449 |
| SR-C3H/He |
| Comment | Ascites sarcoma induced with Rous sarcom. |
|---|
| Comment from the depositor | |
|---|
| RCB4450 |
| SR-DDD |
| Comment | Ascites sarcoma induced with Rous sarcom. |
|---|
| Comment from the depositor | |
|---|
| RCB4451 |
| UPS-1 |
| Comment | Sub-line of CHO-K1 which is defective in the non-endocytic uptake of fluorescent analogs of phosphatidylserine (C6-NBD-PS). |
|---|
| Comment from the depositor | |
|---|
| RCB4452 |
| FL-YB |
| Comment | Mouse follicular dendritic cell line |
|---|
| Comment from the depositor | |
|---|
| RCB4454 |
| SR-CDF1DBT |
| Comment | Mouse brain tumors induced with Rous sarcom. |
|---|
| Comment from the depositor | |
|---|
| RCB4455 |
| PC-9 |
| Comment | Human cell line derived from lung adenocarcinoma cells. Differentiated type. Previous name:PC-14(RCB0446) |
|---|
| Comment from the depositor | |
|---|
| RCB4466 |
| HANK1 |
| Comment | NK/T-cell lymphoma. |
|---|
| Comment from the depositor | |
|---|
| RCB4467 |
| TIG-1 |
| Comment | Human lung-derived adherent cells. The origin is not cancer. 25-35PDL. |
|---|
| Comment from the depositor | |
|---|
| RCB4468 |
| TIG-3 |
| Comment | Human lung-derived adherent cells. The origin is not cancer. 25-35PDL. |
|---|
| Comment from the depositor | |
|---|
| RCB4469 |
| TIG-7 |
| Comment | Human lung-derived adherent cells. The origin is not cancer. 25-35PDL. |
|---|
| Comment from the depositor | |
|---|
| RCB4472 |
| IN-IC |
| Comment | Rat cell line derived from kidney. |
|---|
| Comment from the depositor | |
|---|
| RCB4473 |
| F6B3 |
| Comment | Mouse brain tumors induced with Rous sarcom. |
|---|
| Comment from the depositor | |
|---|
| RCB4474 |
| Ba/F3-CL1 |
| Comment | Mouse pro-B cell line derived from C3H strain. IL-3 dependent. After cloning (RCB0805 Ba/F3). Information |
|---|
| Comment from the depositor | |
|---|
| RCB4475 |
| SMP30/GNL-KO |
| Comment | |
|---|
| Comment from the depositor | Deletion of the ascorbic acid synthesis enzyme gluconolactonase gene, and introduction of the temperature-sensitive SV40T antigen tsA58 gene. |
|---|
| RCB4476 |
| Ba/F3 |
| Comment | Mouse pro-B cell line derived from C3H strain. IL-3 dependent. Information |
|---|
| Comment from the depositor | |
|---|
| RCB4477 |
| ACK2 |
| Comment | Hybridoma cell line producing anti-mouse c-kit (CD117) antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB4478 |
| ACK4 |
| Comment | Hybridoma cell line producing anti-mouse c-kit (CD117) antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB4479 |
| ACK30 |
| Comment | Hybridoma cell line producing anti-mouse c-kit (CD117) antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB4480 |
| ACK45 |
| Comment | Hybridoma cell line producing anti-mouse c-kit (CD117) antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB4481 |
| A7R34 |
| Comment | Hybridoma cell line producing anti-mouse IL-7 Receptor alpha (CD127) antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB4482 |
| APA5 |
| Comment | Hybridoma cell line producing anti-mouse PDGF Receptor alpha (CD140a) antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB4483 |
| APB5 |
| Comment | Hybridoma cell line producing anti-mouse PDGF Receptor beta (CD140b) antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB4484 |
| Avas12 |
| Comment | Hybridoma cell line producing anti-mouse Flk-1/VEGF-Receptor 2 (CD309) antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB4485 |
| A2F10 |
| Comment | Hybridoma cell line producing anti-mouse Flk-2/Flt-3 (CD135) antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB4486 |
| AFS98 |
| Comment | Hybridoma cell line producing anti-mouse c-fms (CD115) antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB4487 |
| ACD1 |
| Comment | Hybridoma cell line producing anti-mouse CDK4 antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB4488 |
| AFL4 |
| Comment | Hybridoma cell line producing anti-mouse VEGF-Receptor 3 antibody.Application consideration |
|---|
| Comment from the depositor | |
|---|
| RCB4489 |
| MB86 |
| Comment | Hybridoma cell line producing anti-mouse IgM(b)/Igh6b antibody. |
|---|
| Comment from the depositor | |
|---|
| RCB4495 |
| BL2-5-8 |
| Comment | |
|---|
| Comment from the depositor | A reporter cell line derived from a mouse hematopoietic cell line, Ba/F3, for identification of proteins that are translocated into or out of the nucleus in response to an extracellular stimulus and other changes in cell status using the inducible translocation trap (ITT) technology. The cell line can also be used for screening of compounds affecting inducible nuclear translocation and nuclear export by ITT. The human CD2 (hCD2) gene is used as reporter gene. |
|---|
| RCB4496 |
| BLG-139-3 |
| Comment | |
|---|
| Comment from the depositor | A reporter cell line derived from a mouse hematopoietic cell line, Ba/F3, for identification of proteins that are translocated into or out of the nucleus in response to an extracellular stimulus and other changes in cell status using the inducible translocation trap (ITT) technology. The cell line can also be used for screening of compounds affecting inducible nuclear translocation and nuclear export by ITT. The green fluorescent protein (GFP) gene is used as reporter gene. |
|---|
| RCB4497 |
| BBLG-50-1 |
| Comment | |
|---|
| Comment from the depositor | A reporter cell line derived from the BB13 cell line for identification of proteins that are translocated into or out of the nucleus in response to an extracellular stimulus and other changes in cell status using the inducible translocation trap (ITT) technology. The cell line can also be used for screening of compounds affecting inducible nuclear translocation and nuclear export by ITT. BB13 is derived from a mouse hematopoietic cell line, Ba/F3, and ectopically expresses epidermal growth factor receptor (EGFR) and the anti-apoptotic Bcl-2 protein. BB13 can survive in the absence of IL-3 if EGF is present. The green fluorescent protein (GFP) gene is used as reporter gene. |
|---|
| RCB4498 |
| NP 2 |
| Comment | Human cell line derived from anaplastic glioma. |
|---|
| Comment from the depositor | |
|---|
| RCB4499 |
| Onda 10 |
| Comment | Human cell line derived from anaplastic glioma. |
|---|
| Comment from the depositor | |
|---|
| RCB4500 |
| Onda 11 |
| Comment | Human cell line derived from glioblastoma. |
|---|
| Comment from the depositor | |
|---|
| RCB4504 |
| NP 3 |
| Comment | Human cell line derived from anaplastic glioma. |
|---|
| Comment from the depositor | |
|---|
| RCB4505 |
| NP 5 |
| Comment | Human cell line derived from anaplastic glioma. |
|---|
| Comment from the depositor | |
|---|
| RCB4515 |
| YACUT |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | |
|---|
| RCB4516 |
| STIM2^(-/-)DT40 |
| Comment | A subline of avian cell line, DT40, lacking STIM2 gene. |
|---|
| Comment from the depositor | |
|---|
| RCB4517 |
| STIM1^(-/-)STIM2^(-/-)DT40 |
| Comment | A subline of avian cell line, DT40, lacking both STIM1 and STIM2 genes. |
|---|
| Comment from the depositor | |
|---|
| RCB4518 |
| Orai1^(-/-)DT40 |
| Comment | A subline of avian cell line, DT40, lacking Orai1 gene. |
|---|
| Comment from the depositor | |
|---|
| RCB4519 |
| Orai2^(-/-)DT40 |
| Comment | A subline of avian cell line, DT40, lacking Orai2 gene. |
|---|
| Comment from the depositor | |
|---|
| RCB4539 |
| MCS-1 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | |
|---|
| RCB4540 |
| MCS-8 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | |
|---|
| RCB4548 |
| PT-r |
| Comment | Rat cell line derived from parathyroid gland. |
|---|
| Comment from the depositor | |
|---|
| RCB4549 |
| RSV-M |
| Comment | Mouse brain tumors induced with Rous sarcom. |
|---|
| Comment from the depositor | |
|---|
| RCB4554 |
| HiDEP-1 |
| Comment | Human erythroid progenitor cell line derived from iPS cells. Expressing fetal type hemoglobin. |
|---|
| Comment from the depositor | |
|---|
| RCB4555 |
| HiDEP-2 |
| Comment | Human erythroid progenitor cell line derived from iPS cells. Expressing fetal type hemoglobin. |
|---|
| Comment from the depositor | |
|---|
| RCB4556 |
| HUDEP-1 |
| Comment | Human erythroid progenitor cell line derived from umbilical cord blood cells. Expressing fetal type hemoglobin. |
|---|
| Comment from the depositor | |
|---|
| RCB4557 |
| HUDEP-2 |
| Comment | Human erythroid progenitor cell line derived from umbilical cord blood cells. Expressing adult type hemoglobin. |
|---|
| Comment from the depositor | |
|---|
| RCB4560 |
| Ham-1 |
| Comment | |
|---|
| Comment from the depositor | Screening of anticancer drug, Transplantable in immunodeficient mice, In vivo model of cholangiocarcinoma. |
|---|
| RCB4561 |
| MOLT-17 |
| Comment | Human cell line derived from T cell leukemia (T-ALL). Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to DSMZ no.:
ACC 36 prior to order. |
|---|
| Comment from the depositor | |
|---|
| RCB4562 |
| HUDEP-3 |
| Comment | Human erythroid progenitor cell line derived from umbilical cord blood cells. Expressing fetal type hemoglobin. |
|---|
| Comment from the depositor | |
|---|
| RCB4563 |
| TSt-4/N-DLL4 |
| Comment | Original murine mesenchymal cell line was derived from fetal thymus tissue. A line Expressing DLL4 gene. |
|---|
| Comment from the depositor | |
|---|
| RCB4566 |
| TEC1C8 |
| Comment | Culture of Thymic Epithelial Cell Lines., Protocol (pdf：120KB) |
|---|
| Comment from the depositor | A mouse thymic cortical epithelial cell. It does not have the ability to present soluble antigen to its antigen specific helper T cells. This cell line is available to analyze the functions of cortical epithelial cells and medullary epithelial cells that control the differentiation and selection of intrathymic T cells. It is also useful for attempts such as thymus reconstruction using these cell lines, aiming at such functional recovery. |
|---|
| RCB4568 |
| TEC2-3 |
| Comment | Culture of Thymic Epithelial Cell Lines., Protocol (pdf：120KB) |
|---|
| Comment from the depositor | A mouse thymic medullary epithelial cell line. It has the ability to present soluble antigen to its antigen specific helper T cells. This cell line is available to analyze the functions of cortical epithelial cells and medullary epithelial cells that control the differentiation and selection of intrathymic T cells. It is also useful for attempts such as thymus reconstruction using these cell lines, aiming at such functional recovery. |
|---|
| RCB4569 |
| TEC3-10 |
| Comment | Culture of Thymic Epithelial Cell Lines., Protocol (pdf：120KB) |
|---|
| Comment from the depositor | A mouse thymic medullary epithelial cell line. It has the ability to present soluble antigen to its antigen specific helper T cells. This cell line is available to analyze the functions of cortical epithelial cells and medullary epithelial cells that control the differentiation and selection of intrathymic T cells. It is also useful for attempts such as thymus reconstruction using these cell lines, aiming at such functional recovery. |
|---|
| RCB4570 |
| MEF(WT) |
| Comment | |
|---|
| Comment from the depositor | The cells are fibroblasts prepared from embryos of the wild type mice (congenic (>96%) to C57BL/6J mice). They were immortalized by transfection with a plasmid encoding the SV40 large T antigen. |
|---|
| RCB4571 |
| MEF(Ngly1-/-) |
| Comment | |
|---|
| Comment from the depositor | The cells are fibroblasts prepared from embryos of the Ngly1-knockout mice (congenic (>96%) to C57BL/6J mice). They were immortalized by transfection with a plasmid encoding the SV40 large T antigen.
|
|---|
| RCB4572 |
| MEF(Engase-/-) |
| Comment | |
|---|
| Comment from the depositor | The cells are fibroblasts prepared from embryos of the Engase -knockout mice (congenic (>96%) to C57BL/6J mice). They were immortalized by transfection with a plasmid encoding the SV40 large T antigen. |
|---|
| RCB4573 |
| MEF(Ngly1-/-Engase-/-) |
| Comment | |
|---|
| Comment from the depositor | The cells are fibroblasts prepared from embryos of the Ngly1 Engase-double knockout mice (congenic (>96%) to C57BL/6J mice). They were immortalized by transfection with a plasmid encoding the SV40 large T antigen. |
|---|
| RCB4582 |
| SEAP/HeLa |
| Comment | |
|---|
| Comment from the depositor | The cell line expresses human secretory alkaline phosphatase. By collecting their culture media, you can measure secretory actlvlty by sensitive enzymatic assay, using Phospha-Light. |
|---|
| RCB4591 |
| Siglec-14/THP-1 |
| Comment | |
|---|
| Comment from the depositor | The cell line was generated by retroviral transduction of human Siglec-14 cDNA into the THP-1 cell line (JCRB0112). Basic properties are similar to those of THP-1. |
|---|
| RCB4592 |
| r/mHM-SFME-1 |
| Comment | |
|---|
| Comment from the depositor | In 1987, D.Loo et al at D.Barnes lab established a pre-glial cell line SFME from Balb/c mouse embryo in serum free condition. C.Rawson et al established a tumorigenic but non-metastatic transformed cell line, ras/mycSFME, by introducing active human cH-ras and mouse c-myc into SFME cells in 1992. T.Nomura et al introduced pSV2neo into ras/mycSFME cells and discovered metastatic cells in syngeneic host lungs. Obtained mtastatic cells no longer showed neomycin resistancy. The r/mHM-SFME-1 cell line, an experimental tumor cell line carrying metastatic ability in immuno-competent Balb/c mouse, was established from the mtastasized lung in 1993 by cloning from soft agar colony,. |
|---|
| RCB4593 |
| CALM WT MEF |
| Comment | CALM non-deficient MEF cells. Tranformed with SV40 large T antigen gene. |
|---|
| Comment from the depositor | |
|---|
| RCB4594 |
| CALM KO MEF |
| Comment | CALM deficient MEF cells. Tranformed with SV40 large T antigen gene. |
|---|
| Comment from the depositor | |
|---|
| RCB4623 |
| Ba/ER |
| Comment | Ba/ER was created by stable transfection of murine pro-B Ba/F3 cells with a murine erythropoietin receptor gene. Ba/ER proliferates dependent on erythropoietin or interleukin-3. |
|---|
| Comment from the depositor | |
|---|
| RCB4624 |
| CHO-DR1000L-4N |
| Comment | |
|---|
| Comment from the depositor | CHO DG44 based recombinant cell line which produce human GM-CSF. Cell line was constructed via gene amplification by transfection of dhfr and GM-CSF genes. |
|---|
| RCB4627 |
| KUP5 |
| Comment | |
|---|
| Comment from the depositor | An immortalized mouse Kupffer cell line established from C57BL/6 strain. The Kupffer cells were proliferated in the mixed primary culture of C57BL/6 adult mouse liver cells, then infected with a replication-deficient retroviral vector containing the human c-myc oncogene and neomycin resistance gene, isolated and selected with G418 (cloned by a limited dilution). No significant production of infectious viral particles from KUP5 cells was confirmed by bioassay using SC-1 cells. |
|---|
| RCB4633 |
| LP5 |
| Comment | Currently not ready. Hybridoma cell line. |
|---|
| Comment from the depositor | anti-mouse CD90 Ab. |
|---|
| RCB4634 |
| Dow2 |
| Comment | Currently not ready. Hybridoma cell line. |
|---|
| Comment from the depositor | Dow2 Ab can induce T cell unresponsiveness in vivo. |
|---|
| RCB4635 |
| #16-15 |
| Comment | Hybridoma cell line producing anti-human BEND3 antibody (rat IgM). |
|---|
| Comment from the depositor | anti-BEND3 Ab. |
|---|
| RCB4636 |
| 20-2b2 |
| Comment | Currently not ready. Hybridoma cell line. |
|---|
| Comment from the depositor | 20-2b2 Ab can induce T cell unresponsiveness in vivo. |
|---|
| RCB4638 |
| M81 |
| Comment | |
|---|
| Comment from the depositor | Anti-human C1s monoclonal antibody producing cell. |
|---|
| RCB4661 |
| Hepa/8F5 |
| Comment | |
|---|
| Comment from the depositor | Hepa/8F5 derived from mouse hepatoma Hepa1-6 [RCB1638] cells was established by introducing doxycycline (Dox)-inducible eight liver-enriched transcription factor (LETF) genes. Upon overexpression of LETF genes by Dox addition, cell proliferation ceases and the cells change the morphology expressing high liver functions. |
|---|
| RCB4662 |
| HCT116 CMV-OsTIR1 |
| Comment | cf.： Kanemaki's Auxin Inducible Degron (AID) System |
|---|
| Comment from the depositor | This is an HCT116 cell line in which CMV-OsTIR1 (pMK232, PURO) was introduced at the both alleles of the AAVS1 locus by using CRISPR/Cas.This parental cell line consitutively express OsTIR1 and can be used for generation of AID mutants. |
|---|
| RCB4664 |
| d5P |
| Comment | |
|---|
| Comment from the depositor | Renal cell carcinoma cell line d5P has established from renal tubule cells of Crlj:WI rat. Moreover this cell line is able to do transplantation for wild type Crlj:WI rat. |
|---|
| RCB4665 |
| d5krm7 |
| Comment | |
|---|
| Comment from the depositor | d5krm7 cell line has established from d5P cell line. Moreover this cell line has highly metastatic activity to lung by intracapsular transplantation. |
|---|
| RCB4666 |
| d5krm3 |
| Comment | |
|---|
| Comment from the depositor | d5krm3 cell line has established from d5P cell line. Moreover this cell line has highly metastatic activity to lung by intracapsular transplantation. |
|---|
| RCB4667 |
| id5P |
| Comment | |
|---|
| Comment from the depositor | Renal cell carcinoma cell line d5P has established from renal tubule cells of Crli:WI rat. Moreover this cell line is able to do transplantation for wild type CrlJ:WI rat. |
|---|
| RCB4668 |
| id5krm7 |
| Comment | |
|---|
| Comment from the depositor | id5krm7 cell line has established from d5P cell line. Moreover this cell line has highly metastatic activity to lung by intracapsular transplantation. |
|---|
| RCB4669 |
| id5krm3 |
| Comment | |
|---|
| Comment from the depositor | id5krm3 cell line has established from d5P cell line. Moreover this cell line has highly metastatic activity to lung by intracapsular transplantation. |
|---|
| RCB4670 |
| KN7 |
| Comment | |
|---|
| Comment from the depositor | KN7 is an anti-idiyotypic antibody for TCRVα5Vβ11 on CD4 T celIs wihich recognize Peptide-25 of A285B from Mycobacterium tuberculosis. |
|---|
| RCB4674 |
| ICH-ERMS-1 |
| Comment | |
|---|
| Comment from the depositor | The cell line has been established from a biopsied sample with an aplastic embryonal rhabdomyosarcoma originating in the pelvis of 5-year-old female. The biopsy revealed TP53 c.733G>A; however, the autopsy and established cell line showed TP53 c.743G>T. |
|---|
| RCB4675 |
| NMuMG/Fucci(CA)2.1 |
| Comment | Important notice regarding nomenclature of Fucci. Research tools : Fucci – Fluorescent Ubiquitination-based Cell Cycle Indicator. |
|---|
| Comment from the depositor | A subline of the NMuMG cell line expressing Fucci(CA)2.1, a cell cycle marker. Cell line name : NMuMG/Fucci(CA)2.1 #2. |
|---|
| RCB4676 |
| HeLa/Fucci(CA)2 |
| Comment | Important notice regarding nomenclature of Fucci. Research tools : Fucci – Fluorescent Ubiquitination-based Cell Cycle Indicator. |
|---|
| Comment from the depositor | A subline of the HeLa cell line expressing Fucci(CA)2, a cell cycle marker. Cell line name : HeLa/Fucci(CA)2 #3. |
|---|
| RCB4679 |
| HepG2-NIAS |
| Comment | A subline of Hep G2 cells that can not only rapidly activate hepatic functions such as albumin secretion, urea synthesis and CYP3A4 activity but also induce the formation of bile canaliculus-like structures by utilizing a collagen vitrigel membrane as a culture substratum. |
|---|
| Comment from the depositor | Hep G2 cells (RCB1648) described as a backup of ECACC 2870 derived from ECACC were conditioned in culture using a DMEM containing 10% heat-inactivated FBS, 20mM HEPES 100U/ml penicillin and 100μg/ml streptomycin. By the use of collagen vitrigel membrane as a culture substratum, hepatic functions such as albumin secretion, urea synthesis and CYP3A4 activity were rapidly activated, and also the formation of bile canaliculus-like structures were induced. |
|---|
| RCB4680 |
| MS-5 |
| Comment | Mouse stromal cell line which supports hematopoietic cells. |
|---|
| Comment from the depositor | |
|---|
| RCB4681 |
| MS-K |
| Comment | Murine cell line derived from sarcoma. |
|---|
| Comment from the depositor | |
|---|
| RCB4683 |
| 6330403Rik |
| Comment | |
|---|
| Comment from the depositor | Anti-6330403k07Rik antibody production hybridoma cell |
|---|
| RCB4684 |
| celf3 |
| Comment | |
|---|
| Comment from the depositor | Anti-Celf3 antibody production hybridoma cell |
|---|
| RCB4685 |
| Dgcr14 |
| Comment | |
|---|
| Comment from the depositor | Anti-Dgcr14 antibody production hybridoma cell |
|---|
| RCB4687 |
| HEK-Dsup |
| Comment | |
|---|
| Comment from the depositor | A subline of the HEK293(RCB1637) cells. Stably expressing Damage suppressor (Dsup). Radio-resistance. Dsup is a tardigrade-unique DNA protection protein. |
|---|
| RCB4688 |
| HEK-DsupKD |
| Comment | |
|---|
| Comment from the depositor | A subline of the HEK293(RCB1637) cells. Expressing shRNA against Dsup in HEK-Dsup celIs. Dsup is a tardigrade-unique DNA protection protein. |
|---|
| RCB4689 |
| HEK-DsupΔC |
| Comment | |
|---|
| Comment from the depositor | A subline of the HEK293(RCB1637) cells. Stably expressing Damage suppressor (Dsup) mutant lacking the C-terminal region. Dsup is a tardigrade-unique DNA protection protein. |
|---|
| RCB4692 |
| HCT116-vim |
| Comment | |
|---|
| Comment from the depositor | Transgenic human cell line derived from colon cancer. This cell line is suitable to observe epithelial- mesenchymal transformation. |
|---|
| RCB4693 |
| ChR2-C2C12 |
| Comment | A subline of the murine C2C12 cell line (RCB0987) which stably expresses channelrhodopsin 2-Venus (ChR2-Venus), one of light-gated cation channels derived from a green alga Chlamydomonas reinhardtii, tagged with a fluorescent protein, Venus. |
|---|
| Comment from the depositor | |
|---|
| RCB4695 |
| GFP-LC3-RFP-LC3ΔG HeLa |
| Comment | |
|---|
| Comment from the depositor | This cell line stablly expresses EGFP-LC3-mRFP-LC3Δ, an autophagic flux probe. Cellular autophagic flux can be evaluated by calculating the ratio of GFP against RFP fluorescent intensity. |
|---|
| RCB4696 |
| GFP-LC3-RFP-LC3ΔG MEF |
| Comment | |
|---|
| Comment from the depositor | This cell line stablly expresses EGFP-LC3-mRFP-LC3Δ, an autophagic flux probe. Cellular autophagic flux can be evaluated by calculating the ratio of GFP against RFP fluorescent intensity. |
|---|
| RCB4699 |
| S-TFE |
| Comment | |
|---|
| Comment from the depositor | S-TFE is established from a rare subtype of Xp11 translocation renal cell carcinoma. The cell line demonstrated definite gene fusion including TFE3 gene located on chromosome X. It showed ASPL-TFE3 type 1 fusion. |
|---|
| RCB4700 |
| A2A12 |
| Comment | |
|---|
| Comment from the depositor | Hybridoma cells producing a monoclonal antibody against plexin-A2. |
|---|
| RCB4701 |
| A4F5 |
| Comment | |
|---|
| Comment from the depositor | Hybridoma cells producing a monoclonal antibody against plexin-A4. |
|---|
| RCB4702 |
| 3A12 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma cells producing a monoclonal antibody against plexin-A2. |
|---|
| RCB4703 |
| 5H1 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma cells producing a monoclonal antibody against plexin-A2. |
|---|
| RCB4704 |
| 6B12 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma cells producing a monoclonal antibody against plexin-A2. |
|---|
| RCB4705 |
| 1D2B |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma cells producing a monoclonal antibody against plexin-A4. |
|---|
| RCB4706 |
| 4F83 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma cells producing a monoclonal antibody against plexin-A4. |
|---|
| RCB4707 |
| 5D83 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma cells producing a monoclonal antibody against plexin-A4. |
|---|
| RCB4708 |
| 5H8B |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma cells producing a monoclonal antibody against plexin-A4. |
|---|
| RCB4709 |
| THL98 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma producing a monoclonal antibody against themolabail hemolysin (TLH) of V. parahaemolyticus. |
|---|
| RCB4710 |
| VP109 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma producing a monoclonal antibody against F0F1 ATP synthase δ-subunit of V. parahaemolyticus. |
|---|
| RCB4711 |
| TRH81 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma producing a monoclonal antibody against thermostable direct hemolysin (TDH)-related hemolysin(TRH) of V. parahaemolyticus. |
|---|
| RCB4712 |
| TRH96 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma producing a monoclonal antibody against thermostable direct hemolysin(TDH)-related hemolysin(TRH) of V. parahaemolyticus. |
|---|
| RCB4713 |
| TRH137 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma producing a monoclonal antibody against thermostable direct hemolysin(TDH)-related hemolysin(TRH) of V. parahaemolyticus. |
|---|
| RCB4714 |
| Betv2-3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma producing a monoclonal antibody against birch pollen allergen profilin (Bet v 2). |
|---|
| RCB4715 |
| Cits2-38 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma producing a monoclonal antibody against orange allergen profilin (Cit s 2). |
|---|
| RCB4716 |
| Cits2-47 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma producing a monoclonal antibody against orange allergen profilin (Cit s 2). |
|---|
| RCB4717 |
| WT(MEF) |
| Comment | |
|---|
| Comment from the depositor | Mouse embryonic fibroblasts immortalized by transfection of SV40 large T antigen in Oyadomari laboratory. |
|---|
| RCB4718 |
| eIF2ak(4KO) |
| Comment | |
|---|
| Comment from the depositor | The eIF2α kinase quadruple knockout cells in which the four known eIF2α kinase genes (Hri, Pkr, Perk, Gcn2) were deleted using the CRISPR/Cas9-mediated genome editing. The parental cell line is the immortalized mouse embryonic fibroblasts established in Oyadomari laboratory. |
|---|
| RCB4719 |
| eIF2ak(4KO+HRI) |
| Comment | |
|---|
| Comment from the depositor | This is an eIF2ak(4KO) RCB4718 MEF cell line in which flag-tagged mouse HRI was reintroduced by retrovirus. |
|---|
| RCB4720 |
| eIF2ak(4KO+PERK) |
| Comment | |
|---|
| Comment from the depositor | This is an eIF2ak(4KO) RCB4718 MEF cell line in which flag-tagged mouse PERK was reintroduced by retrovirus. |
|---|
| RCB4721 |
| eIF2ak(4KO+PKR) |
| Comment | |
|---|
| Comment from the depositor | This is an eIF2ak(4KO) RCB4718 MEF cell line in which flag-tagged mouse PKR was reintroduced by retrovirus. |
|---|
| RCB4722 |
| eIF2ak(4KO+GCN2) |
| Comment | |
|---|
| Comment from the depositor | This is an eIF2ak(4KO) RCB4718 MEF cell line in which flag-tagged mouse GCN2 was reintroduced by retrovirus. |
|---|
| RCB4724 |
| A2A(C2702-B05-52) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4725 |
| A2A(C2704-C07-89) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4726 |
| A2A(C2831-104) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4727 |
| A2A(C2838-190) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4728 |
| A2A(C3007-E6) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4729 |
| A2A(C3019-B-203-B3) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4730 |
| A2A(C3024-43) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4731 |
| A2A(C3025-95) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4732 |
| A2A(C3029A-236) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4733 |
| A2A(C3044-10) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4734 |
| A2A(C3080-145) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4735 |
| A2A(C3138G3(A)) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4736 |
| A2A(C3160-79) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4737 |
| A2A(C3169-214) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4738 |
| A2A(C3978B-D4) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4739 |
| A2A(C3938B-F6) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4740 |
| A2A(C3943B-E3) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4741 |
| A2A(C40006-123) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4742 |
| A2A(C40010-A6) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4743 |
| A2A(C40011-G11) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4744 |
| A2A(C40037-A5) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4745 |
| A2A(C40040-A12) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4746 |
| A2A(C40056-G6) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4747 |
| A2A(C40076-173) |
| Comment | Currently not ready. Hybridoma against A2A (human) : adenosine A2A receptor (1~316 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4748 |
| M2(C1801-A9-16) |
| Comment | Currently not ready. Hybridoma against M2 (human) : muscarinic acetylcholine receptor (delta 224~381 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4749 |
| M2(C1802-B4-42) |
| Comment | Currently not ready. Hybridoma against M2 (human) : muscarinic acetylcholine receptor (delta 224~381 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4750 |
| M2(C1803-C2-74) |
| Comment | Currently not ready. Hybridoma against M2 (human) : muscarinic acetylcholine receptor (delta 224~381 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4751 |
| M2(C1805-E5-95) |
| Comment | Currently not ready. Hybridoma against M2 (human) : muscarinic acetylcholine receptor (delta 224~381 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4752 |
| M2(C1901-C4-152) |
| Comment | Currently not ready. Hybridoma against M2 (human) : muscarinic acetylcholine receptor (delta 224~381 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4753 |
| M2(C3603-D10-1) |
| Comment | Currently not ready. Hybridoma against M2 (human) : muscarinic acetylcholine receptor (delta 224~381 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4754 |
| M2(C4729-H1-3) |
| Comment | Currently not ready. Hybridoma against M2 (human) : muscarinic acetylcholine receptor (delta 224~381 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4755 |
| M2(C4804-3) |
| Comment | Currently not ready. Hybridoma against M2 (human) : muscarinic acetylcholine receptor (delta 224~381 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4756 |
| M2(C4817-1) |
| Comment | Currently not ready. Hybridoma against M2 (human) : muscarinic acetylcholine receptor (delta 224~381 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4757 |
| M2(C4814-E10-3) |
| Comment | Currently not ready. Hybridoma against M2 (human) : muscarinic acetylcholine receptor (delta 224~381 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4758 |
| M2(C5708-1) |
| Comment | Currently not ready. Hybridoma against M2 (human) : muscarinic acetylcholine receptor (delta 224~381 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4759 |
| M2(C5801-3) |
| Comment | Currently not ready. Hybridoma against M2 (human) : muscarinic acetylcholine receptor (delta 224~381 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4760 |
| M2(C5903-1) |
| Comment | Currently not ready. Hybridoma against M2 (human) : muscarinic acetylcholine receptor (delta 224~381 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4761 |
| M2(D0303-12) |
| Comment | Currently not ready. Hybridoma against M2 (human) : muscarinic acetylcholine receptor (delta 224~381 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4762 |
| M2(D0368-63-A1-16) |
| Comment | Currently not ready. Hybridoma against M2 (human) : muscarinic acetylcholine receptor (delta 224~381 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4763 |
| M2(D0403-13) |
| Comment | Currently not ready. Hybridoma against M2 (human) : muscarinic acetylcholine receptor (delta 224~381 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4764 |
| M2(D0423-15) |
| Comment | Currently not ready. Hybridoma against M2 (human) : muscarinic acetylcholine receptor (delta 224~381 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4765 |
| Band3(C4201-A1-10) |
| Comment | Currently not ready. Hybridoma against Band 3 (human) : Band 3 (anion exchanger 1) (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4766 |
| Band3(C4203-D3-26) |
| Comment | Currently not ready. Hybridoma against Band 3 (human) : Band 3 (anion exchanger 1) (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4767 |
| Band3(C4204-C3-48) |
| Comment | Currently not ready. Hybridoma against Band 3 (human) : Band 3 (anion exchanger 1) (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4768 |
| Band3(C4206-G7-90) |
| Comment | Currently not ready. Hybridoma against Band 3 (human) : Band 3 (anion exchanger 1) (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4769 |
| Glut5(C45053-H4) |
| Comment | Currently not ready. Hybridoma against Glut 5 (rat) : glucose transporter 5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4770 |
| Glut5(C45085-F2) |
| Comment | Currently not ready. Hybridoma against Glut 5 (rat) : glucose transporter 5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4771 |
| Glut5(C45107-102) |
| Comment | Currently not ready. Hybridoma against Glut 5 (rat) : glucose transporter 5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4772 |
| Glut5(C45019-3) |
| Comment | Currently not ready. Hybridoma against Glut 5 (rat) : glucose transporter 5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4773 |
| Glut5(C45077-49) |
| Comment | Currently not ready. Hybridoma against Glut 5 (rat) : glucose transporter 5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4774 |
| Glut5(C45106-78) |
| Comment | Currently not ready. Hybridoma against Glut 5 (rat) : glucose transporter 5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4775 |
| Glut5(C45021-34) |
| Comment | Currently not ready. Hybridoma against Glut 5 (rat) : glucose transporter 5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4776 |
| Glut5(C45004-016) |
| Comment | Currently not ready. Hybridoma against Glut 5 (rat) : glucose transporter 5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4777 |
| Glut5(C45008-054) |
| Comment | Currently not ready. Hybridoma against Glut 5 (rat) : glucose transporter 5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4778 |
| Glut5(C45037-101) |
| Comment | Currently not ready. Hybridoma against Glut 5 (rat) : glucose transporter 5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4779 |
| Glut5(C45080-134) |
| Comment | Currently not ready. Hybridoma against Glut 5 (rat) : glucose transporter 5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4780 |
| Glut5(C45081-146) |
| Comment | Currently not ready. Hybridoma against Glut 5 (rat) : glucose transporter 5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4781 |
| Glut5(C45119-160) |
| Comment | Currently not ready. Hybridoma against Glut 5 (rat) : glucose transporter 5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4782 |
| Glut5(C45124-214) |
| Comment | Currently not ready. Hybridoma against Glut 5 (rat) : glucose transporter 5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4783 |
| Glut5(C45125-237) |
| Comment | Currently not ready. Hybridoma against Glut 5 (rat) : glucose transporter 5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4784 |
| Glut5(C45032-73) |
| Comment | Currently not ready. Hybridoma against Glut 5 (rat) : glucose transporter 5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4785 |
| Glut5(C45120-263-A4) |
| Comment | Currently not ready. Hybridoma against Glut 5 (rat) : glucose transporter 5 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4786 |
| v-ATP ase VoV1(C87076-007) |
| Comment | Currently not ready. Hybridoma against v-ATP ase CL : v-ATP ase (CL domain) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4787 |
| v-ATP ase VoV1(C87076-014) |
| Comment | Currently not ready. Hybridoma against v-ATP ase VoV1(E. coli) : v-ATP ase (VoV1 domain) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4788 |
| v-ATP ase VoV1(C87079-067) |
| Comment | Currently not ready. Hybridoma against v-ATP ase VoV1(E. coli) : v-ATP ase (VoV1 domain) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4789 |
| v-ATP ase VoV1(C87119-130) |
| Comment | Currently not ready. Hybridoma against v-ATP ase VoV1(E. coli) : v-ATP ase (VoV1 domain) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4790 |
| v-ATP ase VoV1(C87119-132) |
| Comment | Currently not ready. Hybridoma against v-ATP ase VoV1(E. coli) : v-ATP ase (VoV1 domain) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4791 |
| v-ATP ase VoV1(C87119-148) |
| Comment | Currently not ready. Hybridoma against v-ATP ase VoV1(E. coli) : v-ATP ase (VoV1 domain) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4792 |
| v-ATP ase VoV1(C87160-164) |
| Comment | Currently not ready. Hybridoma against v-ATP ase VoV1(E. coli) : v-ATP ase (VoV1 domain) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4793 |
| v-ATP ase VoV1(C87187-276) |
| Comment | Currently not ready. Hybridoma against v-ATP ase VoV1(E. coli) : v-ATP ase (VoV1 domain) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4794 |
| v-ATP ase VoV1(C87159B-111) |
| Comment | Currently not ready. Hybridoma against v-ATP ase VoV1(E. coli) : v-ATP ase (VoV1 domain) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4795 |
| v-ATP ase VoV1(C9017-349) |
| Comment | Currently not ready. Hybridoma against v-ATP ase VoV1(E. coli) : v-ATP ase (VoV1 domain) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4796 |
| v-ATP ase CL(E72013-2C2-94) |
| Comment | Currently not ready. Hybridoma against v-ATP ase CL : v-ATP ase (CL domain) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4797 |
| HRH1(D2205-A8) |
| Comment | Currently not ready. Hybridoma against HRH1 (human) : histamine receptor H1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4798 |
| HRH1(D2210-C9) |
| Comment | Currently not ready. Hybridoma against HRH1 (human) : histamine receptor H1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4799 |
| HRH1(D2201-D7) |
| Comment | Currently not ready. Hybridoma against HRH1 (human) : histamine receptor H1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4800 |
| HRH1(D2315-H6) |
| Comment | Currently not ready. Hybridoma against HRH1 (human) : histamine receptor H1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4801 |
| HRH1(D2335-A10) |
| Comment | Currently not ready. Hybridoma against HRH1 (human) : histamine receptor H1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4802 |
| HRH1(D2351-H7) |
| Comment | Currently not ready. Hybridoma against HRH1 (human) : histamine receptor H1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4803 |
| HRH1(D2335-F8) |
| Comment | Currently not ready. Hybridoma against HRH1 (human) : histamine receptor H1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4804 |
| HRH1(D2363-H11) |
| Comment | Currently not ready. Hybridoma against HRH1 (human) : histamine receptor H1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4805 |
| HRH1(D2326-G6-F12) |
| Comment | Currently not ready. Hybridoma against HRH1 (human) : histamine receptor H1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4806 |
| HRH1(D2323-H5) |
| Comment | Currently not ready. Hybridoma against HRH1 (human) : histamine receptor H1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4807 |
| HRH1(D2340-67) |
| Comment | Currently not ready. Hybridoma against HRH1 (human) : histamine receptor H1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4808 |
| HRH1(D2401-E6) |
| Comment | Currently not ready. Hybridoma against HRH1 (human) : histamine receptor H1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4809 |
| HRH1(D2503-B5) |
| Comment | Currently not ready. Hybridoma against HRH1 (human) : histamine receptor H1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4810 |
| HRH1(D2510-110) |
| Comment | Currently not ready. Hybridoma against HRH1 (human) : histamine receptor H1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4811 |
| Glut1(D3638-22) |
| Comment | Hybridoma against Glut 1 (human) : glucose transporter 1 (full length) antigen. |
|---|
| Comment from the depositor | Purified full length of human glucose transporter (hGlut1) expressed in the Saccharomyces cerevisiae. was reconstituted into liposomes. This hybridoma was generated using the hGlut1 liposome as an immunogen. |
|---|
| RCB4812 |
| Glut1(D3643-9) |
| Comment | Hybridoma against Glut 1 (human) : glucose transporter 1 (full length) antigen. |
|---|
| Comment from the depositor | Purified full length of human glucose transporter (hGlut1) expressed in the Saccharomyces cerevisiae. was reconstituted into liposomes. This hybridoma was generated using the hGlut1 liposome as an immunogen. |
|---|
| RCB4813 |
| Glut1(D4425-2) |
| Comment | Hybridoma against Glut 1 (human) : glucose transporter 1 (full length) antigen. |
|---|
| Comment from the depositor | Purified full length of human glucose transporter (hGlut1) expressed in the Saccharomyces cerevisiae. was reconstituted into liposomes. This hybridoma was generated using the hGlut1 liposome as an immunogen. |
|---|
| RCB4814 |
| Glut1(D4416-3) |
| Comment | Hybridoma against Glut 1 (human) : glucose transporter 1 (full length) antigen. |
|---|
| Comment from the depositor | Purified full length of human glucose transporter (hGlut1) expressed in the Saccharomyces cerevisiae. was reconstituted into liposomes. This hybridoma was generated using the hGlut1 liposome as an immunogen. |
|---|
| RCB4815 |
| Glut1(D4417-14) |
| Comment | Hybridoma against Glut 1 (human) : glucose transporter 1 (full length) antigen. |
|---|
| Comment from the depositor | Purified full length of human glucose transporter (hGlut1) expressed in the Saccharomyces cerevisiae. was reconstituted into liposomes. This hybridoma was generated using the hGlut1 liposome as an immunogen. |
|---|
| RCB4816 |
| Glut1(D4402-6) |
| Comment | Hybridoma against Glut 1 (human) : glucose transporter 1 (full length) antigen. |
|---|
| Comment from the depositor | Purified full length of human glucose transporter (hGlut1) expressed in the Saccharomyces cerevisiae. was reconstituted into liposomes. This hybridoma was generated using the hGlut1 liposome as an immunogen. |
|---|
| RCB4817 |
| Glut1(D4418-30) |
| Comment | Hybridoma against Glut 1 (human) : glucose transporter 1 (full length) antigen. |
|---|
| Comment from the depositor | Purified full length of human glucose transporter (hGlut1) expressed in the Saccharomyces cerevisiae. was reconstituted into liposomes. This hybridoma was generated using the hGlut1 liposome as an immunogen. |
|---|
| RCB4818 |
| Glut1(D4404-9) |
| Comment | Hybridoma against Glut 1 (human) : glucose transporter 1 (full length) antigen. |
|---|
| Comment from the depositor | Purified full length of human glucose transporter (hGlut1) expressed in the Saccharomyces cerevisiae. was reconstituted into liposomes. This hybridoma was generated using the hGlut1 liposome as an immunogen. |
|---|
| RCB4819 |
| OxlT(D5901-1A08) |
| Comment | Currently not ready. Hybridoma against OxlT(E. coli) : oxalate transport (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4820 |
| OxlT(D5901-1B08) |
| Comment | Currently not ready. Hybridoma against OxlT(E. coli) : oxalate transport (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4821 |
| OxlT(D5904-1D08) |
| Comment | Currently not ready. Hybridoma against OxlT(E. coli) : oxalate transport (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4822 |
| OxlT(D5906-1F04) |
| Comment | Currently not ready. Hybridoma against OxlT(E. coli) : oxalate transport (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4823 |
| OxlT(D5907-1H07) |
| Comment | Currently not ready. Hybridoma against OxlT(E. coli) : oxalate transport (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4824 |
| OxlT(D5908-2B09) |
| Comment | Currently not ready. Hybridoma against OxlT(E. coli) : oxalate transport (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4825 |
| OxlT(D5921-2E03) |
| Comment | Currently not ready. Hybridoma against OxlT(E. coli) : oxalate transport (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4826 |
| OxlT(D5924-2H06) |
| Comment | Currently not ready. Hybridoma against OxlT(E. coli) : oxalate transport (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4827 |
| OxlT(D6205-3B02) |
| Comment | Currently not ready. Hybridoma against OxlT(E. coli) : oxalate transport (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4828 |
| OxlT(D6206-3B05) |
| Comment | Currently not ready. Hybridoma against OxlT(E. coli) : oxalate transport (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4829 |
| OxlT(D6538-3F03) |
| Comment | Currently not ready. Hybridoma against OxlT(E. coli) : oxalate transport (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4830 |
| OxlT(D6541-3G02) |
| Comment | Currently not ready. Hybridoma against OxlT(E. coli) : oxalate transport (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4831 |
| AT2(D5604-006) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4832 |
| AT2(D5614-054) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4833 |
| AT2(D5608-040) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4834 |
| AT2(D5647-129) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4835 |
| AT2(D5655-150) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4836 |
| AT2(D5630-095) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4837 |
| AT2(D5605-011) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4838 |
| AT2(D5640-072) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4839 |
| AT2(D5620-032) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4840 |
| AT2(D5626-060) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4841 |
| AT2(D5711-4A03-B03) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4842 |
| AT2(D5713-4C10-290) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4843 |
| AT2(D5725-3B08-369) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4844 |
| AT2(D5702-1A09-173) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4845 |
| AT2(D5705-1E10-208) |
| Comment | Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | AT2-null mice crossed with gp64 transgenic mice. AT２-null mice were prepared according to the previously described procedure (Nature, 377. 748-750, 1995). Gp64 transgenic mice were prepared according to the previously described procedure ( J.Immunol,Methods. 30: 322(1-2), 114-117, 2007.). |
|---|
| RCB4846 |
| AT2(D5711-2H02-A01) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4847 |
| AT2(D5714A-4D07-334) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4848 |
| AT2(D5706-1F03-149) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4849 |
| AT2(D5709-1H06-187) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4850 |
| AT2(D5711-2H05-229) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4851 |
| AT2(D5701-1A07-116) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4852 |
| AT2(D5712-4A08-236) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4853 |
| AT2(D5707-1G02-158) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4854 |
| AT2(D5722-2D12-202) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4855 |
| AT2(D5701-1A06-100) |
| Comment | Currently not ready. Hybridoma against AT2 ( human) : angiotensin type II receptor (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4856 |
| TACR2(D8116-4C1-1) |
| Comment | Currently not ready. Hybridoma against TACR2 (human) : tachykinin receptor II (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4857 |
| TACR2(D8103-3F12-1) |
| Comment | Currently not ready. Hybridoma against TACR2 (human) : tachykinin receptor II (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4858 |
| TACR2(D8210-5D5-1) |
| Comment | Currently not ready. Hybridoma against TACR2 (human) : tachykinin receptor II (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4859 |
| TACR2(D8213-5A1-3) |
| Comment | Currently not ready. Hybridoma against TACR2 (human) : tachykinin receptor II (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4860 |
| TACR2(D83007-3) |
| Comment | Currently not ready. Hybridoma against TACR2 (human) : tachykinin receptor II (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4861 |
| TACR2(D83010-1) |
| Comment | Currently not ready. Hybridoma against TACR2 (human) : tachykinin receptor II (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4862 |
| TACR2(D83008-1) |
| Comment | Currently not ready. Hybridoma against TACR2 (human) : tachykinin receptor II (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4863 |
| TACR2(D84042-1) |
| Comment | Currently not ready. Hybridoma against TACR2 (human) : tachykinin receptor II (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4864 |
| TACR2(D84048-1) |
| Comment | Currently not ready. Hybridoma against TACR2 (human) : tachykinin receptor II (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4865 |
| TACR2(D84072-1) |
| Comment | Currently not ready. Hybridoma against TACR2 (human) : tachykinin receptor II (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4866 |
| TACR2(D84026-1) |
| Comment | Currently not ready. Hybridoma against TACR2 (human) : tachykinin receptor II (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4867 |
| TACR2(D84083-1) |
| Comment | Currently not ready. Hybridoma against TACR2 (human) : tachykinin receptor II (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4868 |
| TACR2(D84112-1) |
| Comment | Currently not ready. Hybridoma against TACR2 (human) : tachykinin receptor II (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4869 |
| GluR1-2(Z9139) |
| Comment | Currently not ready. Hybridoma against GluR1-2 (mouse) : GluA1 AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptor (236~286 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4870 |
| AQP4(C9401-A3-29) |
| Comment | Currently not ready. Hybridoma against AQP4 (human) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4871 |
| AQP4(D12092-1C3-02) |
| Comment | Currently not ready. Hybridoma against AQP4 (human) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4872 |
| AQP4(D15107-3D7-33) |
| Comment | Hybridoma against AQP4 (human) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | Full length of human aquaporin 4 (hAQP4) M23 isoform was expressed on the surface of baculovirus according to the previously described procedure ( J.Immunol,Methods. 30: 322(1-2), 114-117, 2007). This hybridoma was generated using the recombinant budded virus as an immunogen. |
|---|
| RCB4873 |
| AQP4(E3634-13) |
| Comment | Currently not ready. Hybridoma against AQP4 (human) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4874 |
| AQP4(E3641-70) |
| Comment | Currently not ready. Hybridoma against AQP4 (human) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4875 |
| AQP4(E3635-60-A7) |
| Comment | Currently not ready. Hybridoma against AQP4 (human) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4876 |
| AQP4(E3726A-122) |
| Comment | Currently not ready. Hybridoma against AQP4 (human) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4877 |
| AQP4(E3716-94) |
| Comment | Currently not ready. Hybridoma against AQP4 (human) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4878 |
| AQP4(E3726B-130) |
| Comment | Currently not ready. Hybridoma against AQP4 (human) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4879 |
| AQP4(E5206-1B10-8) |
| Comment | Currently not ready. Hybridoma against AQP4 (mouse) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4880 |
| AQP4(E5209-1C8-22) |
| Comment | Currently not ready. Hybridoma against AQP4 (mouse) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4881 |
| AQP4(E5407-1E6-32) |
| Comment | Currently not ready. Hybridoma against AQP4 (mouse) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4882 |
| AQP4(E5413-1G11-49) |
| Comment | Currently not ready. Hybridoma against AQP4 (mouse) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4883 |
| AQP4(E5415A-1H6-68) |
| Comment | Hybridoma against AQP4 (mouse) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | Full length of mouse aquaporin 4 (ｍAQP4) M23 isoform was expressed on the surface of baculovirus according to the previously described procedure ( J.Immunol,Methods. 30: 322(1-2), 114-117, 2007). This hybridoma was generated using the recombinant budded virus as an immunogen. |
|---|
| RCB4884 |
| AQP4(E5415B-1H7-79) |
| Comment | Hybridoma against AQP4 (mouse) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | Full length of mouse aquaporin 4 (ｍAQP4) M23 isoform was expressed on the surface of baculovirus according to the previously described procedure ( J.Immunol,Methods. 30: 322(1-2), 114-117, 2007). This hybridoma was generated using the recombinant budded virus as an immunogen. |
|---|
| RCB4885 |
| AQP4(E5507-3A1-113) |
| Comment | Currently not ready. Hybridoma against AQP4 (mouse) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4886 |
| AQP4(E5505-3D12-129) |
| Comment | Currently not ready. Hybridoma against AQP4 (mouse) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4887 |
| AQP4(E5504-2G2-105) |
| Comment | Currently not ready. Hybridoma against AQP4 (mouse) : aquaporin (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4888 |
| DP2(D5201-1A5-6) |
| Comment | Currently not ready. Hybridoma against DP2 (mouse) : prostaglandin receptor DP2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4889 |
| DP2(D5203-1D8-31) |
| Comment | Hybridoma against DP2 (mouse) : prostaglandin receptor DP2 (full length) antigen. |
|---|
| Comment from the depositor | Full length of mouse Prostaglandin D2 receptor DP2 was expressed on the surface of BaF3 cells according to the previously described procedure（Nagata et al. PLos One 2017 Apr 10;12(4):e0175452. doi:10.1371/journal.pone.0175452. eCollection 2017. ). This hybridoma was generated using the recombinant mouse DP2 expressed BaF3 cells as an immunogen. |
|---|
| RCB4890 |
| DP2(D5302-3A4-82) |
| Comment | Currently not ready. Hybridoma against DP2 (mouse) : prostaglandin receptor DP2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4891 |
| DP2(D5305-3B3-103) |
| Comment | Currently not ready. Hybridoma against DP2 (mouse) : prostaglandin receptor DP2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4892 |
| DP2(D5502-135) |
| Comment | Currently not ready. Hybridoma against DP2 (mouse) : prostaglandin receptor DP2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4893 |
| DP2(D5513-2-B1) |
| Comment | Currently not ready. Hybridoma against DP2 (mouse) : prostaglandin receptor DP2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4894 |
| DP2(D5516-176) |
| Comment | Currently not ready. Hybridoma against DP2 (mouse) : prostaglandin receptor DP2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4895 |
| DP2(D5517-208-A2) |
| Comment | Currently not ready. Hybridoma against DP2 (mouse) : prostaglandin receptor DP2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4896 |
| DP2(D5524-228) |
| Comment | Currently not ready. Hybridoma against DP2 (mouse) : prostaglandin receptor DP2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4897 |
| DP2(D5531-258) |
| Comment | Currently not ready. Hybridoma against DP2 (mouse) : prostaglandin receptor DP2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4898 |
| DP2(D5534-265) |
| Comment | Currently not ready. Hybridoma against DP2 (mouse) : prostaglandin receptor DP2 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4899 |
| NRF3-2(E9403-D3-A5-1) |
| Comment | Currently not ready. Hybridoma against NRF3-2 (human) : NRF3 (363~415 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4900 |
| NRF3-2(E9405-1) |
| Comment | Currently not ready. Hybridoma against NRF3-2 (human) : NRF3 (363~415 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4901 |
| NRF3-2(E9408-1) |
| Comment | Hybridoma against NRF3-2 (human) : NRF3 (363~415 aa) antigen. |
|---|
| Comment from the depositor | NRF3 (363~415 aa) was expressed on the surface of baculovirus as the gp64 fusion protein according to the previously described procedure (J Atheroscler Thromb. 2002;9:233-242). |
|---|
| RCB4902 |
| NRF3-2(E9413-G1-A3-1) |
| Comment | Currently not ready. Hybridoma against NRF3-2 (human) : NRF3 (363~415 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4903 |
| NRF3-2(E9422-D2-B9-1) |
| Comment | Currently not ready. Hybridoma against NRF3-2 (human) : NRF3 (363~415 aa) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4904 |
| RhoA(E2004-A9-1) |
| Comment | Currently not ready. Hybridoma against Rho A (human) : Rho A (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4905 |
| RhoA(E4402-3A1-12) |
| Comment | Currently not ready. Hybridoma against Rho A (human) : Rho A (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4906 |
| RhoA(E4614-4C9-41) |
| Comment | Currently not ready. Hybridoma against Rho A (human) : Rho A (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4907 |
| DHHC1(D8013-1C11-6) |
| Comment | Currently not ready. Hybridoma against DHHC1 (mouse) : Asp-His-His-Cys motif containing protein 1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4908 |
| DHHC1(D8018-1D10-26) |
| Comment | Currently not ready. Hybridoma against DHHC1 (mouse) : Asp-His-His-Cys motif containing protein 1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4909 |
| DHHC1(D8018-1D10-35) |
| Comment | Currently not ready. Hybridoma against DHHC1 (mouse) : Asp-His-His-Cys motif containing protein 1 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4910 |
| DHHC10(E2601-1C3-2) |
| Comment | Currently not ready. Hybridoma against DHHC10 (mouse) : Asp-His-His-Cys motif containing protein 10 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4911 |
| DHHC10(E2607-1F6-23) |
| Comment | Currently not ready. Hybridoma against DHHC10 (mouse) : Asp-His-His-Cys motif containing protein 10 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4912 |
| DHHC10(E2611-1H2-49) |
| Comment | Currently not ready. Hybridoma against DHHC10 (mouse) : Asp-His-His-Cys motif containing protein 10 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4913 |
| DHHC10(E2614-3B1-69) |
| Comment | Currently not ready. Hybridoma against DHHC10 (mouse) : Asp-His-His-Cys motif containing protein 10 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4914 |
| DHHC10(E2701-2B3-97) |
| Comment | Currently not ready. Hybridoma against DHHC10 (mouse) : Asp-His-His-Cys motif containing protein 10 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4915 |
| DHHC10(E2706-2F7-135) |
| Comment | Currently not ready. Hybridoma against DHHC10 (mouse) : Asp-His-His-Cys motif containing protein 10 (full length) antigen. |
|---|
| Comment from the depositor | |
|---|
| RCB4917 |
| HeLa/Fucci(SA)5#16 |
| Comment | Important notice regarding nomenclature of Fucci. Research tools : Fucci – Fluorescent Ubiquitination-based Cell Cycle Indicator. |
|---|
| Comment from the depositor | a subclone of HeLa.S3 cells provided by Dr. Mikoshiba in 2009. |
|---|
| RCB4919 |
| HeLa/Fucci(CA)5#16 |
| Comment | Important notice regarding nomenclature of Fucci. Research tools : Fucci – Fluorescent Ubiquitination-based Cell Cycle Indicator. |
|---|
| Comment from the depositor | a subclone of HeLa.S3 cells provided by Dr. Mikoshiba in 2009. |
|---|
| RCB4920 |
| PSPA |
| Comment | |
|---|
| Comment from the depositor | A preadipocyte clonal line established from porcine subcutaneous tissue of 85-day fetuses. When appropriately induced by the stimulants, fibroblast-like preadipocytes can differentiate into lipid-filled adipocytes. |
|---|
| RCB4936 |
| CT27 |
| Comment | TS culture protocol, TS culture protocol_V2 |
|---|
| Comment from the depositor | Human trophoblast stem cells were derived from blastocysts or placental cytotrophoblast cells. Human trophoblast stem cells have the potential to differentiate into extravillous cytotrophoblast and syncytiotrophoblast cells. |
|---|
| RCB4937 |
| CT29 |
| Comment | TS culture protocol, TS culture protocol_V2 |
|---|
| Comment from the depositor | Human trophoblast stem cells were derived from blastocysts or placental cytotrophoblast cells. Human trophoblast stem cells have the potential to differentiate into extravillous cytotrophoblast and syncytiotrophoblast cells. |
|---|
| RCB4938 |
| CT30 |
| Comment | TS culture protocol, TS culture protocol_V2 |
|---|
| Comment from the depositor | Human trophoblast stem cells were derived from blastocysts or placental cytotrophoblast cells. Human trophoblast stem cells have the potential to differentiate into extravillous cytotrophoblast and syncytiotrophoblast cells. |
|---|
| RCB4940 |
| bTS5 |
| Comment | TS culture protocol, TS culture protocol_V2 |
|---|
| Comment from the depositor | Human trophoblast stem cells were derived from blastocysts or placental cytotrophoblast cells. Human trophoblast stem cells have the potential to differentiate into extravillous cytotrophoblast and syncytiotrophoblast cells. |
|---|
| RCB4941 |
| bTS11 |
| Comment | TS culture protocol, TS culture protocol_V2 |
|---|
| Comment from the depositor | Human trophoblast stem cells were derived from blastocysts or placental cytotrophoblast cells. Human trophoblast stem cells have the potential to differentiate into extravillous cytotrophoblast and syncytiotrophoblast cells. |
|---|
| RCB4942 |
| BHK/T7-9 |
| Comment | |
|---|
| Comment from the depositor | A hamster kidney-derived BHK cell clone stably expressing T7 RNA polymerase. |
|---|
| RCB4943 |
| NU-RMESO-2 |
| Comment | |
|---|
| Comment from the depositor | Rat malignant mesothelioma induced by crocidolite peritoneal injection. Histology (tissue): epithelioid subtype, tubulopapillary variant. Histology (cell culture on the dish): solid-like. Immunohistochemistry: Podoplanin (-), Mesothelin (+), AE1/AE3 (+). |
|---|
| RCB4944 |
| NU-RMESO-9 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Rat malignant mesothelioma induced by crocidolite peritoneal injection. Histology (tissue): sarcomatoid subtype, fibrosarcomatoid variant with sclerosing. Histology (cell culture on the dish): spindle shape. Immunohistochemistry: Podoplanin (+), Mesothelin (+), AE1/AE3 (-). |
|---|
| RCB4945 |
| NU-RMESO-14 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Rat malignant mesothelioma induced by crocidolite peritoneal injection. Histology (tissue): sarcomatoid subtype, fibrosarcomatoid variant. Histology (cell culture on the dish): spindle shape. Immunohistochemistry: Podoplanin (+), Mesothelin (+), AE1/AE3 (-). |
|---|
| RCB4946 |
| NU-RMESO-20 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Rat malignant mesothelioma induced by crocidolite peritoneal injection. Histology (tissue): subtype, biphasic; variant, adenomatoid (microcystic) 50% + fibrosarcomatoid 50%. Histology (cell culture on the dish): fibroblast-like. Immunohistochemistry: Podoplanin (+), Mesothelin (+), AE1/AE3 (+). |
|---|
| RCB4947 |
| NU-RMESO-40 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Rat malignant mesothelioma induced by crocidolite peritoneal injection. Histology (tissue): sarcomatoid subtype, osteosarcomatoid variant. Histology (cell culture on the dish): spindle shape. Immunohistochemistry: Podoplanin (+), Mesothelin (+), AE1/AE3 (-). |
|---|
| RCB4948 |
| NU-RMESO-26 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Rat malignant mesothelioma induced by crocidolite peritoneal injection. Histology (tissue): subtype, biphasic; variant, deciduoid 30% + fibrosarcomatoid 70%. Histology (cell culture on the dish): short spindle shape . Immunohistochemistry: Podoplanin (+), Mesothelin (+), AE1/AE3 (-). |
|---|
| RCB4949 |
| NU-RMESO-79 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Rat malignant mesothelioma induced by crocidolite peritoneal injection. Histology (tissue): epithelioid subtype, well differentiated variant. Histology (cell culture on the dish): solid-like. Immunohistochemistry: Podoplanin (+), Mesothelin (+), AE1/AE3 (-). |
|---|
| RCB4965 |
| FBD-102b |
| Comment | |
|---|
| Comment from the depositor | Clonal oligodendroglial progenitor cell line established from brain of fetal p53-/- mice. |
|---|
| RCB5003 |
| IWT-1 |
| Comment | |
|---|
| Comment from the depositor | This cell line was established from gastric adenocarcinoma cells in peritonitis carcinomatosa ascites. |
|---|
| RCB5004 |
| CHL-YN |
| Comment | Application consideration |
|---|
| Comment from the depositor | Novel cells derived from female Chinese hamster lung. Cells were immortalized by spontaneous transformation. Cells were adapted in animal component-free chemically defined media and subjected to biosafety testing (BioReliance), in which safety was confirmed by an in vitro assay to detect viral contaminants using 3 detector cell lines, a mycoplasma detection test by real-time PCR, and sterility testing by direct inoculation. |
|---|
| RCB5005 |
| FKH-1 |
| Comment | Acute myeloid leukemia with dek/can chimera mRNA expression. Responding to G-CSF and differentiate. |
|---|
| Comment from the depositor | |
|---|
| RCB5007 |
| MCC138c |
| Comment | |
|---|
| Comment from the depositor | Human cell line derived from poor differentiated lung squamous carcinoma. Transplantable to NOG mice. |
|---|
| RCB5008 |
| MCC148c |
| Comment | |
|---|
| Comment from the depositor | Human cell line derived from poor differentiated lung squamous carcinoma. Transplantable to NOG mice. |
|---|
| RCB5010 |
| D4-ChAT |
| Comment | |
|---|
| Comment from the depositor | Hybridoma cell line producing anti-chicken ChAT antibody (mouse IgG). |
|---|
| RCB5029 |
| NIH3T3 Flp Arl13bCerulean-Fucci2a |
| Comment | Research tools : Fucci – Fluorescent Ubiquitination-based Cell Cycle Indicator. |
|---|
| Comment from the depositor | NIH/3T3 is a fibroblast cell line that was isolated from a mouse NIH/Swiss embryo. These cells were generated by a stable integration of pCDNA5-CAG-Arl13bCerulean-Fucci2a using the Flp-in system they were not cloned but are isogenic. |
|---|
| RCB5030 |
| NIH3T3 Flp Fucci2a |
| Comment | Currently not ready. Research tools : Fucci – Fluorescent Ubiquitination-based Cell Cycle Indicator. |
|---|
| Comment from the depositor | NIH/3T3 is a fibroblast cell line that was isolated from a mouse NIH/Swiss embryo. These cells were generated by a stable integration of pCDNA5-Fucci2a using the Flp-in system they were not cloned but are isogenic. |
|---|
| RCB5036 |
| CMG14-12 |
| Comment | |
|---|
| Comment from the depositor | Mouse M-CSF producing Ltk- cell line, CMG14-12. The mouse M-CSF expression vector was transfected into mouse Ltk- cells, M-CSF high producing cel l line was selected and named ''CMG14-12''. CMG14-12: M-CSF producing cell line |
|---|
| RCB5043 |
| DP002 |
| Comment | |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5044 |
| DP005 |
| Comment | |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5045 |
| DP006 |
| Comment | |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5046 |
| DP007 |
| Comment | |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5047 |
| DP010 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5048 |
| DP011 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5049 |
| DP012 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5050 |
| DP014 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5051 |
| DP015 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5052 |
| DP017 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5053 |
| DP018 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5054 |
| DP025 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5055 |
| DP026 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5056 |
| DP028 |
| Comment | |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5057 |
| DP030 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5058 |
| DP031 |
| Comment | |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5059 |
| DP032 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5060 |
| DP035 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5061 |
| DP038 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5062 |
| DP039 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5063 |
| DP040 |
| Comment | |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5064 |
| DP041 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5065 |
| DP042 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5066 |
| DP044 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5067 |
| DP046 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5068 |
| DP048 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5069 |
| DP049 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5070 |
| DP052 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5071 |
| DP053 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5072 |
| DP054 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5073 |
| DP056 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5074 |
| DP057 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5075 |
| DP060 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5076 |
| DP062 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5077 |
| DP064 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5078 |
| DP065 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5079 |
| DP066 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5080 |
| DP068 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5081 |
| DP069 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5082 |
| DP072 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5083 |
| DP073 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5084 |
| DP083 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5085 |
| DP086 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5086 |
| DP087 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5087 |
| DP092 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5088 |
| DP094 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5089 |
| DP099 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5090 |
| DP100 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Dental pulp cells are derived from human dental pulp. They are characterized with fibroblastic morphology, and contamination of hematopoetic cells is minimal. |
|---|
| RCB5093 |
| KIF13A-KO HeLaM |
| Comment | |
|---|
| Comment from the depositor | KIF13A knockout (KO) HeLaM cells. |
|---|
| RCB5094 |
| KIF13B-KO HeLaM |
| Comment | |
|---|
| Comment from the depositor | KIF13B knockout (KO) HeLaM cells. |
|---|
| RCB5095 |
| KIF13-DKO HeLaM |
| Comment | |
|---|
| Comment from the depositor | KIF13A and KIF13B double knockout (DKO) HeLaM cells. |
|---|
| RCB5096 |
| Rab8-DKO HeLaM |
| Comment | |
|---|
| Comment from the depositor | Rab8A and Rab8B double knockout (DKO) HeLaM cells. |
|---|
| RCB5097 |
| Rab10-KO HeLaM |
| Comment | |
|---|
| Comment from the depositor | Rab10 knockout (KO) HeLaM cells. |
|---|
| RCB5098 |
| Rab22-DKO HeLaM |
| Comment | |
|---|
| Comment from the depositor | Rab22A and Rab22B double knockout (DKO) HeLaM cells. |
|---|
| RCB5099 |
| Rab1A-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5100 |
| Rab1B-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5101 |
| Rab2-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockoutclone ).J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5102 |
| Rab3-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5103 |
| Rab4-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5104 |
| Rab5AB-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5105 |
| Rab5C-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5106 |
| Rab6-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5107 |
| Rab7A-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5108 |
| Rab7B-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5109 |
| Rab8-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5110 |
| Rab9-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5111 |
| Rab10-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5112 |
| Rab11-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5113 |
| Rab12-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-ll cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5114 |
| Rab13-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5115 |
| Rab14-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5116 |
| Rab15-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5117 |
| Rab17-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5118 |
| Rab18-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5119 |
| Rab19-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5120 |
| Rab20-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5121 |
| Rab21-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5122 |
| Rab22-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5123 |
| Rab23-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5124 |
| Rab24-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5125 |
| Rab25-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5126 |
| Rab26-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5127 |
| Rab27-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5128 |
| Rab28-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5129 |
| Rab29-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5130 |
| Rab30-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5131 |
| Rab32/38-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5132 |
| Rab33-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5133 |
| Rab34-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5134 |
| Rab35-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5135 |
| Rab36-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5136 |
| Rab37-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5137 |
| Rab39-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5138 |
| Rab40-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5139 |
| Rab42-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5140 |
| Rab43-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5141 |
| Rab7AB-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5142 |
| Rab7A/9-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5143 |
| Rab11/25-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5144 |
| Rab19/43-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5145 |
| Rab26/37-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5146 |
| Rab34/36-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5147 |
| Rab39/42-KO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (Rab-knockout clone ). J Cell Biol. 2019; 218(6): 2035-2050, Tables S1-S3 (ZIP) |
|---|
| RCB5148 |
| MDCK-II |
| Comment | |
|---|
| Comment from the depositor | MDCK-II cells (parental cells). Rab-knockout clone (RCB5099 - RCB5147). |
|---|
| RCB5257 |
| AS-E2 |
| Comment | |
|---|
| Comment from the depositor | An erythropoietin-dependent human leukemia cell line AS-E2 has been established from bone marrow of pure erythroid leukemia (PEL) patient. AS-E2 cells are strictly dependent on erythropoietin (EPO) for their growth and survival. |
|---|
| RCB5259 |
| ECCD-2 |
| Comment | |
|---|
| Comment from the depositor | Hybridoma which produces the rat monoclonal antibody ECCD-2 that recognizes E-cadherin. |
|---|
| RCB5261 |
| NCD-2 |
| Comment | |
|---|
| Comment from the depositor | Hybridoma which produces the rat monoclonal antibody NCD-2 that recognizes chicken N-cadherin. |
|---|
| RCB5262 |
| PCD-1 |
| Comment | |
|---|
| Comment from the depositor | Hybridoma which produces the rat monoclonal antibody PCD-1 that recognizes mouse P-cadherin. |
|---|
| RCB5263 |
| ATL-1K |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL-1K is a cell line established from peripheral blood of a patient with adult T-cell leukemia (ATL) and can grow without IL-2. ATL-1K cells contain one copy of HTLV-1 proviral DNA per cell. The expression of HTLV-1 antigen is not detected. |
|---|
| RCB5264 |
| ATL-3I |
| Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL-3I is a cell line established from peripheral blood of a patient with adult T-cell leukemia (ATL) and can grow without IL-2. ATL-3I cells are positive for HTLV-1 antigens. |
|---|
| RCB5265 |
| ATL-5S |
| Comment | We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | ATL-5S is a cell line established from peripheral blood of a patient with adult T-cell leukemia (ATL) and can grow without IL-2. ATL-5S cells are positive for HTLV-1 antigens. |
|---|
| RCB5290 |
| BD1B |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Rat/mouse-hybridoma producing anti-mouse-cadherin-17 (BILL-cadherin). |
|---|
| RCB5291 |
| MEF_Hsp47 WT-18 |
| Comment | |
|---|
| Comment from the depositor | Mouse embryonic fibroblasts. Wild type control for Hsp47-deficient cell. |
|---|
| RCB5292 |
| MEF_Hsp47 KO-11 |
| Comment | |
|---|
| Comment from the depositor | Mouse embryonic fibroblasts derived from Hsp47-deficient mouse. |
|---|
| RCB5293 |
| MEF_Hsp47 KO-13 |
| Comment | |
|---|
| Comment from the depositor | Mouse embryonic fibroblasts derived from Hsp47-deficient mouse. |
|---|
| RCB5294 |
| RMM-C |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Cell line established from a rat spontaneous malignant amelanotic melanoma. |
|---|
| RCB5295 |
| RMM-A1 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Neoplastic cloned cell line established from a rat spontaneous malignant amelanotic melanoma. |
|---|
| RCB5296 |
| RMM-CAF |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Non-neoplastic cloned cell line established from a rat spontaneous malignant amelanotic melanoma. |
|---|
| RCB5297 |
| TSD-B4S |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Cloned cell line established from a rat spontaneous malignant teratoma, showing mesenchymal differentiation. |
|---|
| RCB5298 |
| TSD-F9R |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Cloned cell line established from a rat spontaneous malignant teratoma, showing mesenchymal differentiation. |
|---|
| RCB5299 |
| RAP80-TK6 |
| Comment | |
|---|
| Comment from the depositor | RAP80- disrupted TK6 cells ,one of the most commonly used human B lymphocyte-derived cell for cancer research. |
|---|
| RCB5300 |
| RNF8-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | RNF8- disrupted TK6 cells ,one of the most commonly used human B lymphocyte-derived cell for cancer research. |
|---|
| RCB5301 |
| POLβ-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | POLβ- disrupted TK6 cells ,one of the most commonly used human B lymphocyte-derived cell for cancer research. |
|---|
| RCB5302 |
| POLθ-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | POLθ- disrupted TK6 cells ,one of the most commonly used human B lymphocyte-derived cell for cancer research. |
|---|
| RCB5303 |
| PARP1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | PARP1- disrupted TK6 cells ,one of the most commonly used human B lymphocyte-derived cell for cancer research. |
|---|
| RCB5304 |
| 40LB |
| Comment | |
|---|
| Comment from the depositor | A fibroblast cell line, BALB/3T3 A31, stably transfected with expression vectors encoding mouse CD40-ligand (CD40L) and BAFF. Used as feeder cells for B cell culture, they support efficient proliferation and survival of B cells. |
|---|
| RCB5305 |
| NP-2/CD4/EcoVR |
| Comment | |
|---|
| Comment from the depositor | NP-2 is derived from a human glioma cell line. A CD4 and an ecotropic mouse retrovirus receptor (EcoVR) gene are transduced to NP-2 cells. This NP-2/CD4/EcoVR (NP-2/CD4) is resistant to the HIV strains tested. When transduced several HIV co-receptors using an ecotropic mouse retrovirus vector, this cell line become susceptible to HIVs. |
|---|
| RCB5306 |
| NP-2/CD4/EcoVR/CXCR4 |
| Comment | |
|---|
| Comment from the depositor | NP-2 is derived from a human glioma cell line. NP-2/CD4/EcoVR/CXCR4 (NP-2/CD4/CXCR4) cells are transduced with human CD4, ecotropic mouse retrovirus receptor and human CXCR4 genes and expressing cells were cloned. Although NP-2/CD4/EcoVR cell is resistant to HIVs, NP-2/CD4/EcoVR/CXCR4 cells become highly susceptible to HIVs that use CXCR4 as a coreceptor. |
|---|
| RCB5307 |
| NP-2/CD4/EcoVR/CCR5 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | NP-2 is derived from a human glioma cell line. NP-2/CD4/EcoVR/CCR5 (NP-2/CD4/CCR5) cells are transduced with human CD4, ecotropic mouse retrovirus receptor and human CCR5 genes and expressing cells were cloned. Although NP-2/CD4/EcoVR cell is resistant to HIVs, NP-2/CD4/EcoVR/CCR5 cells become highly susceptible to HIVs that use CCR5 as a coreceptor. |
|---|
| RCB5308 |
| NP-2/CD4/EcoVR/APJ |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | NP-2 is derived from a human glioma cell line. NP-2/CD4/EcoVR/APJ (NP-2/CD4/APJ) cells are transduced with human CD4, ecotropic mouse retrovirus receptor and human APJ genes and expressing cells were cloned. Although NP-2/CD4/EcoVR cell is resistant to HIVs, NP-2/CD4/EcoVR/APJ cells become highly susceptible to HIVs that use APJ as a coreceptor. |
|---|
| RCB5309 |
| NP-2/CD4/EcoVR/CCR6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | NP-2 is derived from a human glioma cell line. NP-2/CD4/EcoVR/CCR6 (NP-2/CD4/CCR6) cells are transduced with human CD4, ecotropic mouse retrovirus receptor and human CCR6 genes and expressing cells were cloned. Although NP-2/CD4/EcoVR cell is resistant to HIVs, NP-2/CD4/EcoVR/CCR6 cells become highly susceptible to HIVs that use CCR6 as a coreceptor. |
|---|
| RCB5310 |
| NP-2/CD4/EcoVR/CCR8 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | NP-2 is derived from a human glioma cell line. NP-2/CD4/EcoVR/CCR8 (NP-2/CD4/CCR8) cells are transduced with human CD4, ecotropic mouse retrovirus receptor and human CCR8 genes and expressing cells were cloned. Although NP-2/CD4/EcoVR cell is resistant to HIVs, NP-2/CD4/EcoVR/CCR8 cells become highly susceptible to HIVs that use CCR8 as a coreceptor. |
|---|
| RCB5311 |
| NP-2/CD4/EcoVR/FPRL1 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | NP-2 is derived from a human glioma cell line. NP-2/CD4/EcoVR/FPRL1 (NP-2/CD4/FPRL1) cells are transduced with human CD4, ecotropic mouse retrovirus receptor and human FPRL1 genes and expressing cells were cloned. Although NP-2/CD4/EcoVR cell is resistant to HIVs, NP-2/CD4/EcoVR/FPRL1 cells become highly susceptible to HIVs that use FPRL1 as a coreceptor. |
|---|
| RCB5312 |
| NP-2/CD4/EcoVR/GPR1 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | NP-2 is derived from a human glioma cell line. NP-2/CD4/EcoVR/GPR1 (NP-2/CD4/GPR1) cells are transduced with human CD4, ecotropic mouse retrovirus receptor and human GPR1 genes and expressing cells were cloned. Although NP-2/CD4/EcoVR cell is resistant to HIVs, NP-2/CD4/EcoVR/GPR1 cells become highly susceptible to HIVs that use GPR1 as a coreceptor. |
|---|
| RCB5313 |
| NP-2/CD4/EcoVR/RDC1 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | NP-2 is derived from a human glioma cell line. NP-2/CD4/EcoVR/RDC1 (NP-2/CD4/RDC1) cells are transduced with human CD4, ecotropic mouse retrovirus receptor and humanRDC1 genes and expressing cells were cloned. Although NP-2/CD4/EcoVR cell is resistant to HIVs, NP-2/CD4/EcoVR/RDC1 cells become highly susceptible to HIVs that use RDC1 as a coreceptor. |
|---|
| RCB5314 |
| 53BP1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. 53BP1- disrupted TK6 cells. |
|---|
| RCB5315 |
| 53BP1,BRCA1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. 53BP1, BRCA1- disrupted TK6 cells. |
|---|
| RCB5316 |
| Abraxas-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. Abraxas- disrupted TK6 cells. |
|---|
| RCB5317 |
| ALC1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. ALC1- disrupted TK6 cells. |
|---|
| RCB5318 |
| ALC1,PARP1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. ALC1, PARP1- disrupted TK6 cells. |
|---|
| RCB5319 |
| BLM-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. BLM- disrupted TK6 cells. |
|---|
| RCB5320 |
| CtIP-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. CtIP- disrupted TK6 cells. |
|---|
| RCB5321 |
| DNA-PKcs-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. DNA-PKcs- disrupted TK6 cells. |
|---|
| RCB5322 |
| DNA-PKcs,SMARCAL1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. DNA-PKcs, SMARCAL1- disrupted TK6 cells. |
|---|
| RCB5323 |
| FANCD2-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. FANCD2- disrupted TK6 cells. |
|---|
| RCB5324 |
| LIG4-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. LIG4- disrupted TK6 cells. |
|---|
| RCB5325 |
| LIG4,SMARCAL1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. LIG4, SMARCAL1- disrupted TK6 cells. |
|---|
| RCB5326 |
| MRE11-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. MRE11- disrupted TK6 cells. |
|---|
| RCB5327 |
| MRE11,P53-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. MRE11, P53- disrupted TK6 cells. |
|---|
| RCB5328 |
| MRE11,TDP1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. MRE11, TDP1- disrupted TK6 cells. |
|---|
| RCB5329 |
| MRE11,TDP2-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. MRE11, TDP2- disrupted TK6 cells. |
|---|
| RCB5330 |
| MUS81-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. MUS81- disrupted TK6 cells. |
|---|
| RCB5331 |
| PDIP38-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PDIP38- disrupted TK6 cells. |
|---|
| RCB5332 |
| PDIP38,POLH-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PDIP38, POLH- disrupted TK6 cells. |
|---|
| RCB5333 |
| PDIP38,POLH,XPA-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PDIP38, POLH, XPA- disrupted TK6 cells. |
|---|
| RCB5334 |
| PDIP38,PrimPol-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PDIP38, PrimPol- disrupted TK6 cells. |
|---|
| RCB5335 |
| PIAS1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PIAS1- disrupted TK6 cells. |
|---|
| RCB5336 |
| PIAS1,PIAS4-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PIAS1, PIAS4- disrupted TK6 cells. |
|---|
| RCB5337 |
| PIAS1,PIAS4,POLH-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PIAS1, PIAS4, POLH- disrupted TK6 cells.
|
|---|
| RCB5338 |
| PIAS1,PIAS4,POLH,XPA-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PIAS1, PIAS4, POLH, XPA- disrupted TK6 cells. |
|---|
| RCB5339 |
| PIAS1,PIAS4,XPA-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PIAS1, PIAS4, XPA- disrupted TK6 cells. |
|---|
| RCB5340 |
| PIAS4,XPA-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PIAS4, XPA- disrupted TK6 cells. |
|---|
| RCB5341 |
| RAD54-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. RAD54- disrupted TK6 cells. |
|---|
| RCB5342 |
| RNF168-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. RNF168- disrupted TK6 cells. |
|---|
| RCB5343 |
| SMARCAL1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. SMARCAL1- disrupted TK6 cells. |
|---|
| RCB5344 |
| SMARCAL1,RAD54-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. SMARCAL1, RAD54- disrupted TK6 cells. |
|---|
| RCB5345 |
| TDP1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. TDP1- disrupted TK6 cells. |
|---|
| RCB5346 |
| TDP1,TDP2-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. TDP1, TDP2- disrupted TK6 cells. |
|---|
| RCB5347 |
| TDP2-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. TDP2- disrupted TK6 cells. |
|---|
| RCB5348 |
| XPA-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research.XPA- disrupted TK6 cells. |
|---|
| RCB5349 |
| XRCC1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. XRCC1- disrupted TK6 cells. |
|---|
| RCB5350 |
| XRCC1,XPA-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. XRCC1, XPA- disrupted TK6 cells. |
|---|
| RCB5378 |
| P3-X63-Ag8-U/hEphB6-T49-25 |
| Comment | |
|---|
| Comment from the depositor | Mouse hybridoma cell line producing anti-human Ehph B6 monoclonal antibody. |
|---|
| RCB5379 |
| P3-X63-Ag8-U/hZC3H12D･TFL-21-7G |
| Comment | |
|---|
| Comment from the depositor | Mouse hybridoma cell line producing anti-human ZC3H12D(TFL) monoclonal antibody. |
|---|
| RCB5381 |
| COLO 320DM#3 SIRT1 KO cl.1 |
| Comment | |
|---|
| Comment from the depositor | Human colorectal carcinoma COLO 320DM #3 strain was cloned from the ATCC strain by Von Hoff Laboratory at Texas University around 1990. The strain was used by Shimizu Laboratory at Hiroshima University for development and application of the IR/MAR gene amplification methodology. The strain was further delivered to Mirit I Aladjem Laboratory at US NIH, where the SIRT1 knocked-out clones were isolated. Shimizu Lab in collaboration with Aladjem lab found that the genes amplified in these clones were expressed at very high level. |
|---|
| RCB5382 |
| COLO 320DM#3 SIRT1 KO cl.2 |
| Comment | |
|---|
| Comment from the depositor | Human colorectal carcinoma COLO 320DM #3 strain was cloned from the ATCC strain by Von Hoff Laboratory at Texas University around 1990. The strain was used by Shimizu Laboratory at Hiroshima University for development and application of the IR/MAR gene amplification methodology. The strain was further delivered to Mirit I Aladjem Laboratory at US NIH, where the SIRT1 knocked-out clones were isolated. Shimizu Lab in collaboration with Aladjem lab found that the genes amplified in these clones were expressed at very high level. |
|---|
| RCB5383 |
| COLO 320DM#3 SIRT1 KO cl.3 |
| Comment | |
|---|
| Comment from the depositor | Human colorectal carcinoma COLO 320DM #3 strain was cloned from the ATCC strain by Von Hoff Laboratory at Texas University around 1990. The strain was used by Shimizu Laboratory at Hiroshima University for development and application of the IR/MAR gene amplification methodology. The strain was further delivered to Mirit I Aladjem Laboratory at US NIH, where the SIRT1 knocked-out clones were isolated. Shimizu Lab in collaboration with Aladjem lab found that the genes amplified in these clones were expressed at very high level. |
|---|
| RCB5384 |
| COLO 320DM#3 SIRT1 KO cl.4 |
| Comment | |
|---|
| Comment from the depositor | Human colorectal carcinoma COLO 320DM #3 strain was cloned from the ATCC strain by Von Hoff Laboratory at Texas University around 1990. The strain was used by Shimizu Laboratory at Hiroshima University for development and application of the IR/MAR gene amplification methodology. The strain was further delivered to Mirit I Aladjem Laboratory at US NIH, where the SIRT1 knocked-out clones were isolated. Shimizu Lab in collaboration with Aladjem lab found that the genes amplified in these clones were expressed at very high level. |
|---|
| RCB5385 |
| COLO 320DM#3 SIRT1 KO cl.5 |
| Comment | |
|---|
| Comment from the depositor | Human colorectal carcinoma COLO 320DM #3 strain was cloned from the ATCC strain by Von Hoff Laboratory at Texas University around 1990. The strain was used by Shimizu Laboratory at Hiroshima University for development and application of the IR/MAR gene amplification methodology. The strain was further delivered to Mirit I Aladjem Laboratory at US NIH, where the SIRT1 knocked-out clones were isolated. Shimizu Lab in collaboration with Aladjem lab found that the genes amplified in these clones were expressed at very high level. |
|---|
| RCB5386 |
| COLO 320DM#3 SIRT1 KO cl.6 |
| Comment | |
|---|
| Comment from the depositor | Human colorectal carcinoma COLO 320DM #3 strain was cloned from the ATCC strain by Von Hoff Laboratory at Texas University around 1990. The strain was used by Shimizu Laboratory at Hiroshima University for development and application of the IR/MAR gene amplification methodology. The strain was further delivered to Mirit I Aladjem Laboratory at US NIH, where the SIRT1 knocked-out clones were isolated. Shimizu Lab in collaboration with Aladjem lab found that the genes amplified in these clones were expressed at very high level. |
|---|
| RCB5388 |
| HeLaM |
| Comment | |
|---|
| Comment from the depositor | Human cervical cancer cell line HeLaM (substrain of HeLa). |
|---|
| RCB5389 |
| Rab1-CKO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | Rab1 conditional KO MDCK-II cell line.
|
|---|
| RCB5390 |
| Rab5-CKO MDCK-II |
| Comment | |
|---|
| Comment from the depositor | Rab5 conditional KO MDCK-II cell line. |
|---|
| RCB5391 |
| R52_Spike |
| Comment | |
|---|
| Comment from the depositor | This cell line is a hybridoma producing anti-SARS-CoV-2 Spike antibody (Clone R52). |
|---|
| RCB5392 |
| S1D7_Spike |
| Comment | |
|---|
| Comment from the depositor | This cell line is a hybridoma producing anti-SARS-CoV-2 Spike antibody (Clone S1D7). |
|---|
| RCB5393 |
| S3D8_Spike |
| Comment | |
|---|
| Comment from the depositor | This cell line is a hybridoma producing anti-SARS-CoV-2 Spike antibody (Clone S3D8). |
|---|
| RCB5394 |
| Y-ML-1B |
| Comment | |
|---|
| Comment from the depositor | Large-cell lung cancer cell line producing granulocyte colony-stimulating factor. |
|---|
| RCB5396 |
| KM1978 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Anti human EphB6 monoclonal antibody producing rat hybridoma. |
|---|
| RCB5397 |
| KM2048 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Anti human EphB6 monoclonal antibody producing rat hybridoma. |
|---|
| RCB5398 |
| KM2051 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Anti human EphB6 monoclonal antibody producing rat hybridoma. |
|---|
| RCB5399 |
| PL16B |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Immortalized AAH cell line (RCB5400 PL16T) and human non-neoplastic bronchial epithelial cell line (RCB5399 PL16B) from the same patient by transfection with the gene for SV40 large T antigen. |
|---|
| RCB5400 |
| PL16T |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Immortalized AAH cell line (RCB5400 PL16T) and human non-neoplastic bronchial epithelial cell line (RCB5399 PL16B) from the same patient by transfection with the gene for SV40 large T antigen. |
|---|
| RCB5401 |
| 53BP1,MRE11-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. 53BP1, MRE11- disrupted TK6 cells. |
|---|
| RCB5402 |
| ATM-TK6 |
| Comment | |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. ATM- disrupted TK6 cells. |
|---|
| RCB5403 |
| ATRX-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. ATRX- disrupted TK6 cells. |
|---|
| RCB5404 |
| BLM,MLH1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. BLM, MLH1- disrupted TK6 cells. |
|---|
| RCB5405 |
| BLM,MLH3-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. BLM, MLH3- disrupted TK6 cells. |
|---|
| RCB5406 |
| BLM,MUS81-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. BLM, MUS81- disrupted TK6 cells. |
|---|
| RCB5407 |
| BLM,SMARCAL1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. BLM, SMARCAL1- disrupted TK6 cells. |
|---|
| RCB5408 |
| BLM,XPF-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. BLM, XPF- disrupted TK6 cells. |
|---|
| RCB5409 |
| BRCA1,REV7-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. BRCA1, REV7- disrupted TK6 cells. |
|---|
| RCB5410 |
| CtIP,MRE11-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. CtIP, MRE11- disrupted TK6 cells. |
|---|
| RCB5411 |
| DNA2+/--TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. CtIP, DNA2 +/-- disrupted TK6 cells. |
|---|
| RCB5412 |
| EXO1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. EXO1- disrupted TK6 cells. |
|---|
| RCB5413 |
| EXO1,FAN1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. XO1, FAN1- disrupted TK6 cells. |
|---|
| RCB5414 |
| FAN1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. FAN1- disrupted TK6 cells. |
|---|
| RCB5415 |
| FANCC-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. FANCC- disrupted TK6 cells. |
|---|
| RCB5416 |
| GEN1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. GEN1- disrupted TK6 cells.
|
|---|
| RCB5417 |
| GEN1,MLH3-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. GEN1, MLH3- disrupted TK6 cells. |
|---|
| RCB5418 |
| GEN1,MLH3,PMS2-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. GEN1, MLH3, PMS2- disrupted TK6 cells. |
|---|
| RCB5419 |
| GEN1,MUS81-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. GEN1, MUS81- disrupted TK6 cells. |
|---|
| RCB5420 |
| GEN1,RAD54-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. GEN1, RAD54- disrupted TK6 cells. |
|---|
| RCB5421 |
| LIG4,POLQ-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. LIG4, POLQ- disrupted TK6 cells. |
|---|
| RCB5422 |
| LIG4,POLQ,RAD54-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. LIG4, POLQ, RAD54- disrupted TK6 cells. |
|---|
| RCB5423 |
| LIG4,RAD54-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. LIG4, RAD54- disrupted TK6 cells. |
|---|
| RCB5424 |
| LIG4,RNF8-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. LIG4, RNF8- disrupted TK6 cells. |
|---|
| RCB5425 |
| MLH1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. MLH1- disrupted TK6 cells. |
|---|
| RCB5426 |
| MLH1,MLH3-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. MLH1, MLH3- disrupted TK6 cells. |
|---|
| RCB5427 |
| MLH1,MLH3,PMS2-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. MLH1, MLH3, PMS2- disrupted TK6 cells. |
|---|
| RCB5428 |
| MLH1,MUS81-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. MLH1, MUS81- disrupted TK6 cells. |
|---|
| RCB5429 |
| MLH1,PMS2-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. MLH1, PMS2- disrupted TK6 cells. |
|---|
| RCB5430 |
| MLH3-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. MLH3- disrupted TK6 cells. |
|---|
| RCB5431 |
| MLH3,PMS2-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. MLH3, PMS2- disrupted TK6 cells. |
|---|
| RCB5432 |
| MSH2-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. MSH2- disrupted TK6 cells. |
|---|
| RCB5433 |
| MUS81,PMS2-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. MUS81, PMS2- disrupted TK6 cells. |
|---|
| RCB5434 |
| P53-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. P53- disrupted TK6 cells. |
|---|
| RCB5435 |
| P53,PDIP38-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. P53, PDIP38- disrupted TK6 cells. |
|---|
| RCB5436 |
| P53,POLH-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. P53, POLH- disrupted TK6 cells. |
|---|
| RCB5437 |
| P53,RAD54B-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. P53, RAD54B- disrupted TK6 cells. |
|---|
| RCB5438 |
| PALB2-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PALB2- disrupted TK6 cells. |
|---|
| RCB5439 |
| PARP1,POLB-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PARP1, POLB- disrupted TK6 cells. |
|---|
| RCB5440 |
| PARP1,XRCC1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PARP1, XRCC1- disrupted TK6 cells. |
|---|
| RCB5441 |
| PARP1,XRCC1,ALC1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PARP1, XRCC1, ALC1- disrupted TK6 cells. |
|---|
| RCB5442 |
| PARP2-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PARP2- disrupted TK6 cells. |
|---|
| RCB5443 |
| PMS2-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PMS2- disrupted TK6 cells. |
|---|
| RCB5444 |
| POLD1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. POLD1- disrupted TK6 cells. |
|---|
| RCB5445 |
| POLE-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. POLE- disrupted TK6 cells.
|
|---|
| RCB5446 |
| POLH-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. POLH- disrupted TK6 cells. |
|---|
| RCB5447 |
| POLH,PrimPol-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. POLH, PrimPol- disrupted TK6 cells. |
|---|
| RCB5448 |
| POLH,RAD18,XPA-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. POLH, RAD18, XPA- disrupted TK6 cells. |
|---|
| RCB5449 |
| POLH,XPA-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. POLH, XPA- disrupted TK6 cells. |
|---|
| RCB5450 |
| POLL-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. POLL- disrupted TK6 cells. |
|---|
| RCB5451 |
| PrimPol-TK6 |
| Comment | |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PrimPol- disrupted TK6 cells. |
|---|
| RCB5452 |
| RAD18-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. RAD18- disrupted TK6 cells. |
|---|
| RCB5453 |
| RAD51AP1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. RAD51AP1- disrupted TK6 cells. |
|---|
| RCB5454 |
| RAD51AP1,RAD54-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. RAD51AP1, RAD54- disrupted TK6 cells. |
|---|
| RCB5455 |
| RAD54B-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. RAD54B- disrupted TK6 cells. |
|---|
| RCB5456 |
| REV3-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. REV3- disrupted TK6 cells. |
|---|
| RCB5457 |
| REV7-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. REV7- disrupted TK6 cells. |
|---|
| RCB5458 |
| RNASEH2A-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. RNASEH2A- disrupted TK6 cells. |
|---|
| RCB5459 |
| RPA,SMARCAL1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. RPA, SMARCAL1- disrupted TK6 cells. |
|---|
| RCB5460 |
| SLFN11-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. SLFN11- disrupted TK6 cells. |
|---|
| RCB5461 |
| SLX1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. SLX1- disrupted TK6 cells. |
|---|
| RCB5462 |
| SMARCAD1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. SMARCAD1- disrupted TK6 cells. |
|---|
| RCB5463 |
| SPRTAN-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. SPRTAN- disrupted TK6 cells. |
|---|
| RCB5464 |
| SPRTAN,TDP1,TDP2-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. SPRTAN, TDP1, TDP2- disrupted TK6 cells. |
|---|
| RCB5465 |
| TIR1-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. TIR1- disrupted TK6 cells. |
|---|
| RCB5466 |
| XRCC1,POLB-TK6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. XRCC1, POLB- disrupted TK6 cells. |
|---|
| RCB5467 |
| TTA-1 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Anaplastic thyroid carcinoma. |
|---|
| RCB5468 |
| TTA-2 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Anaplastic Thyroid carcinoma. |
|---|
| RCB5469 |
| TTA-3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Anaplastic Thyroid carcinoma. |
|---|
| RCB5470 |
| KTA-1 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Anaplastic Thyroid Carcinoma. |
|---|
| RCB5471 |
| KTA-2 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Anaplastic Thyroid Carcinoma. |
|---|
| RCB5472 |
| KTA-3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Undifferentiated Thyroid Carcinoma. |
|---|
| RCB5473 |
| KTA-4 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Undifferentiated Thyroid Carcinoma. |
|---|
| RCB5476 |
| hFGFR1b/BaF3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | The FGF receptor-overexpressing cells to be used for the analyses of receptor specificity of the various FGF ligands. These cells are engineered from Ba/F3 cells and stably overexpress one of seven subtypes, as defined in the cell name, of FGF receptors. When a cognate (specific) FGF ligand is added, together with heparin, to the medium of these cells, cell growth is stimulated that can be detected by cell number and/or DNA synthesis. While the parent Ba/F3 cells proliferate only by the stimulation with IL-3. |
|---|
| RCB5477 |
| hFGFR1c/BaF3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | The FGF receptor-overexpressing cells to be used for the analyses of receptor specificity of the various FGF ligands. These cells are engineered from Ba/F3 cells and stably overexpress one of seven subtypes, as defined in the cell name, of FGF receptors. When a cognate (specific) FGF ligand is added, together with heparin, to the medium of these cells, cell growth is stimulated that can be detected by cell number and/or DNA synthesis. While the parent Ba/F3 cells proliferate only by the stimulation with IL-3. |
|---|
| RCB5478 |
| hFGFR2b/BaF3 |
| Comment | |
|---|
| Comment from the depositor | The FGF receptor-overexpressing cells to be used for the analyses of receptor specificity of the various FGF ligands. These cells are engineered from Ba/F3 cells and stably overexpress one of seven subtypes, as defined in the cell name, of FGF receptors. When a cognate (specific) FGF ligand is added, together with heparin, to the medium of these cells, cell growth is stimulated that can be detected by cell number and/or DNA synthesis. While the parent Ba/F3 cells proliferate only by the stimulation with IL-3. |
|---|
| RCB5479 |
| hFGFR2c/BaF3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | The FGF receptor-overexpressing cells to be used for the analyses of receptor specificity of the various FGF ligands. These cells are engineered from Ba/F3 cells and stably overexpress one of seven subtypes, as defined in the cell name, of FGF receptors. When a cognate (specific) FGF ligand is added, together with heparin, to the medium of these cells, cell growth is stimulated that can be detected by cell number and/or DNA synthesis. While the parent Ba/F3 cells proliferate only by the stimulation with IL-3. |
|---|
| RCB5480 |
| hFGFR3b/BaF3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | The FGF receptor-overexpressing cells to be used for the analyses of receptor specificity of the various FGF ligands. These cells are engineered from Ba/F3 cells and stably overexpress one of seven subtypes, as defined in the cell name, of FGF receptors. When a cognate (specific) FGF ligand is added, together with heparin, to the medium of these cells, cell growth is stimulated that can be detected by cell number and/or DNA synthesis. While the parent Ba/F3 cells proliferate only by the stimulation with IL-3. |
|---|
| RCB5481 |
| hFGFR3c/BaF3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | The FGF receptor-overexpressing cells to be used for the analyses of receptor specificity of the various FGF ligands. These cells are engineered from Ba/F3 cells and stably overexpress one of seven subtypes, as defined in the cell name, of FGF receptors. When a cognate (specific) FGF ligand is added, together with heparin, to the medium of these cells, cell growth is stimulated that can be detected by cell number and/or DNA synthesis. While the parent Ba/F3 cells proliferate only by the stimulation with IL-3. |
|---|
| RCB5482 |
| hFGFR4/BaF3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | The FGF receptor-overexpressing cells to be used for the analyses of receptor specificity of the various FGF ligands. These cells are engineered from Ba/F3 cells and stably overexpress one of seven subtypes, as defined in the cell name, of FGF receptors. When a cognate (specific) FGF ligand is added, together with heparin, to the medium of these cells, cell growth is stimulated that can be detected by cell number and/or DNA synthesis. While the parent Ba/F3 cells proliferate only by the stimulation with IL-3. |
|---|
| RCB5483 |
| mFGFR1c/BaF3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | The FGF receptor-overexpressing cells to be used for the analyses of receptor specificity of the various FGF ligands. These cells are engineered from Ba/F3 cells and stably overexpress one of seven subtypes, as defined in the cell name, of FGF receptors. When a cognate (specific) FGF ligand is added, together with heparin, to the medium of these cells, cell growth is stimulated that can be detected by cell number and/or DNA synthesis. While the parent Ba/F3 cells proliferate only by the stimulation with IL-3. |
|---|
| RCB5484 |
| mFGFR2c/BaF3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | The FGF receptor-overexpressing cells to be used for the analyses of receptor specificity of the various FGF ligands. These cells are engineered from Ba/F3 cells and stably overexpress one of seven subtypes, as defined in the cell name, of FGF receptors. When a cognate (specific) FGF ligand is added, together with heparin, to the medium of these cells, cell growth is stimulated that can be detected by cell number and/or DNA synthesis. While the parent Ba/F3 cells proliferate only by the stimulation with IL-3. |
|---|
| RCB5485 |
| mFGFR3b/BaF3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | The FGF receptor-overexpressing cells to be used for the analyses of receptor specificity of the various FGF ligands. These cells are engineered from Ba/F3 cells and stably overexpress one of seven subtypes, as defined in the cell name, of FGF receptors. When a cognate (specific) FGF ligand is added, together with heparin, to the medium of these cells, cell growth is stimulated that can be detected by cell number and/or DNA synthesis. While the parent Ba/F3 cells proliferate only by the stimulation with IL-3. |
|---|
| RCB5486 |
| mFGFR3c/BaF3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | The FGF receptor-overexpressing cells to be used for the analyses of receptor specificity of the various FGF ligands. These cells are engineered from Ba/F3 cells and stably overexpress one of seven subtypes, as defined in the cell name, of FGF receptors. When a cognate (specific) FGF ligand is added, together with heparin, to the medium of these cells, cell growth is stimulated that can be detected by cell number and/or DNA synthesis. While the parent Ba/F3 cells proliferate only by the stimulation with IL-3. |
|---|
| RCB5487 |
| mFGFR4/BaF3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | The FGF receptor-overexpressing cells to be used for the analyses of receptor specificity of the various FGF ligands. These cells are engineered from Ba/F3 cells and stably overexpress one of seven subtypes, as defined in the cell name, of FGF receptors. When a cognate (specific) FGF ligand is added, together with heparin, to the medium of these cells, cell growth is stimulated that can be detected by cell number and/or DNA synthesis. While the parent Ba/F3 cells proliferate only by the stimulation with IL-3. |
|---|
| RCB5503 |
| RAW-D cell |
| Comment | |
|---|
| Comment from the depositor | Sub-clone of RAW-264 cells: Osteoclast precursor cell line efficiently differentiates into multinucleated osteoclasts by the stimulation with RANKL. |
|---|
| RCB5504 |
| Kat1 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma producing Monoclonal antibody against rat osteoclast-specific cell-surface antigen Kat1 antigen. |
|---|
| RCB5505 |
| iKat1-A37 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma producing Monoclonal antibody against rat osteoclast-selective cell-surface antigen iKat1-A37 antigen. |
|---|
| RCB5506 |
| iKat1-C71 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma producing Monoclonal antibody against rat osteoclast-specific cell-surface antigen iKat1-C71 antigen. |
|---|
| RCB5507 |
| iKat1-D34 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma producing Monoclonal antibody against rat osteoclast-specific cell-surface antigen iKat1-D34 antigen. |
|---|
| RCB5509 |
| Nav1.2(466-485)1B6-1C1 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma cell line producing rat monoclonal antibody against Nav1.2 (epitope： 466-485aa, clone： 1B6-1C1). |
|---|
| RCB5510 |
| Navbeta4(209-228)7D7F10 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma cell line producing rat monoclonal antibody against Navbeta4 (epitope： 209-228aa, clone： 7D7F10). |
|---|
| RCB5511 |
| Neuro2a-RXR |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Stably transfected neuro2a cells, which inducibly express N-terminal Htt (exon 1) containing 16Q, 60Q or 150Q fusing EGFP (Neuro2a-tNhtt-EGFP-16Q, Neuro2a-tNhtt-EGFP-60Q, Neuro2a-tNhtt-EGFP-150Q) under control of ponasterone A. Neuro2a-RXR is the parental cell line of Neuro2a-tNhtt-EGFP cell lines before transfection of their expression vectors. |
|---|
| RCB5512 |
| Neuro2a-tNhtt-EGFP-16Q |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Stably transfected neuro2a cells, which inducibly express N-terminal Htt (exon 1) containing 16Q, 60Q or 150Q fusing EGFP (Neuro2a-tNhtt-EGFP-16Q, Neuro2a-tNhtt-EGFP-60Q, Neuro2a-tNhtt-EGFP-150Q) under control of ponasterone A. Neuro2a-RXR is the parental cell line of Neuro2a-tNhtt-EGFP cell lines before transfection of their expression vectors. |
|---|
| RCB5513 |
| Neuro2a-tNhtt-EGFP-60Q |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Stably transfected neuro2a cells, which inducibly express N-terminal Htt (exon 1) containing 16Q, 60Q or 150Q fusing EGFP (Neuro2a-tNhtt-EGFP-16Q, Neuro2a-tNhtt-EGFP-60Q, Neuro2a-tNhtt-EGFP-150Q) under control of ponasterone A. Neuro2a-RXR is the parental cell line of Neuro2a-tNhtt-EGFP cell lines before transfection of their expression vectors. |
|---|
| RCB5514 |
| Neuro2a-tNhtt-EGFP-150Q |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Stably transfected neuro2a cells, which inducibly express N-terminal Htt (exon 1) containing 16Q, 60Q or 150Q fusing EGFP (Neuro2a-tNhtt-EGFP-16Q, Neuro2a-tNhtt-EGFP-60Q, Neuro2a-tNhtt-EGFP-150Q) under control of ponasterone A. Neuro2a-RXR is the parental cell line of Neuro2a-tNhtt-EGFP cell lines before transfection of their expression vectors. |
|---|
| RCB5515 |
| SCEACono2 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Human cell line derived from external auditory canal squamous cell carcinomas. |
|---|
| RCB5649 |
| GM95-CD4 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | |
|---|
| RCB5650 |
| GM95-CXCR4 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | |
|---|
| RCB5651 |
| GM95-CCR5 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | |
|---|
| RCB5652 |
| GM95-CD4-CXCR4 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | |
|---|
| RCB5653 |
| GM95-CD4-CCR5 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | |
|---|
| RCB5654 |
| HOMC-A4 |
| Comment | RCB5654 HOMC-A4, RCB5655 HOMC-B1, RCB5656 HOMC-D4 were derived from the same patient. |
|---|
| Comment from the depositor | Human immortalized mesothelial cell line: Established from mesothelial cells derived from the greater omentum of a human male gastric cancer patient, and immortalized by transfection with human papilloma virus 16 E6/E7 gene and hTERT gene. The HOMC-A4 cell line exhibits an "sarcomatoid" morphology by subcloning. |
|---|
| RCB5655 |
| HOMC-B1 |
| Comment | RCB5654 HOMC-A4, RCB5655 HOMC-B1, RCB5656 HOMC-D4 were derived from the same patient. |
|---|
| Comment from the depositor | Human immortalized mesothelial cell line: Established from mesothelial cells derived from the greater omentum of a human male gastric cancer patient, and immortalized by transfection with human papilloma virus 16 E6/E7 gene and hTERT gene. The HOMC-B1 cell line exhibits an "epithelioid" morphology by subcloning. |
|---|
| RCB5656 |
| HOMC-D4 |
| Comment | RCB5654 HOMC-A4, RCB5655 HOMC-B1, RCB5656 HOMC-D4 were derived from the same patient. |
|---|
| Comment from the depositor | Human immortalized mesothelial cell line: Established from mesothelial cells derived from the greater omentum of a human male gastric cancer patient, and immortalized by transfection with human papilloma virus 16 E6/E7 gene and hTERT gene. The HOMC-D4 cell line exhibits an "intermediate" morphology by subcloning. |
|---|
| RCB5657 |
| 2G11 |
| Comment | |
|---|
| Comment from the depositor | Mesenchymal progenitor cells derived from rat skeletal muscle, with the ability to differentiate into adipocytes and fibroblasts. |
|---|
| RCB5658 |
| HeLa PMP2 KO |
| Comment | |
|---|
| Comment from the depositor | PMP2-knockout HeLa cells were generated with CRISPR/Cas9 gene editing. |
|---|
| RCB5659 |
| HeLa GGA1 KO |
| Comment | |
|---|
| Comment from the depositor | GGA1-knockout HeLa cells were generated with CRISPR/Cas9 gene editing. |
|---|
| RCB5660 |
| HeLa SLC40A1 KO |
| Comment | |
|---|
| Comment from the depositor | SLC40A1-knockout HeLa cells were generated with CRISPR/Cas9 gene editing. |
|---|
| RCB5661 |
| HPL1A |
| Comment | RCB5661 HPL1A、RCB5662 HPL1D were derived from the same patient. |
|---|
| Comment from the depositor | Immortalized human peripheral lung epithelial cell line.The HPL1A and HPL1D lines were established by transfecting the SV40 large T antigen gene from the normal lung of a 74-year-old female donor, who had never smoked and underwent surgery for a small well-demarcated squamous cell carcinoma of the earliest disease stage (pT1N0M0, stage I). Precancerous regions of peripheral lung such as atypical adenomatous hyperplasia were not noted in the lung specimen by the conventional pathological examination. Considering the uniform integration pattern observed for the SV40 large T antigen gene, the HPL1A and HPL1D lines appear to have arisen from a single immortalized cell. |
|---|
| RCB5662 |
| HPL1D |
| Comment | RCB5661 HPL1A、RCB5662 HPL1D were derived from the same patient. |
|---|
| Comment from the depositor | Immortalized human peripheral lung epithelial cell line.The HPL1A and HPL1D lines were established by transfecting the SV40 large T antigen gene from the normal lung of a 74-year-old female donor, who had never smoked and underwent surgery for a small well-demarcated squamous cell carcinoma of the earliest disease stage (pT1N0M0, stage I). Precancerous regions of peripheral lung such as atypical adenomatous hyperplasia were not noted in the lung specimen by the conventional pathological examination. Considering the uniform integration pattern observed for the SV40 large T antigen gene, the HPL1A and HPL1D lines appear to have arisen from a single immortalized cell. |
|---|
| RCB5663 |
| SS-2 |
| Comment | |
|---|
| Comment from the depositor | Neuroendocrine carcinoma cell line derived from a human ascending colon tumor. |
|---|
| RCB5664 |
| Y-MESO-8A |
| Comment | RCB5664 Y-MESO-8A, RCB5665 Y-MESO-8D were derived from the same patient. |
|---|
| Comment from the depositor | Human malignant pleural mesothelioma cell line. The primary tumor is a biphasic (predominantly sarcomatoid) tumor tissue. Subcloned from patient's pleural fluid and shows epithelioid morphology. |
|---|
| RCB5665 |
| Y-MESO-8D |
| Comment | RCB5664 Y-MESO-8A, RCB5665 Y-MESO-8D were derived from the same patient. |
|---|
| Comment from the depositor | Human malignant pleural mesothelioma cell line. The primary tumor is a biphasic (predominantly sarcomatoid) tumor tissue. Subcloned from patient's pleural fluid and shows sarcomatoid morphology. |
|---|
| RCB5666 |
| Y-MESO-9 |
| Comment | |
|---|
| Comment from the depositor | Human malignant pleural mesothelioma cell line. The tumor tissue was epithelial malignant mesothelioma and this cell line was established from the pleural fluid of a patient. This cell line has NF2 and BAP1 gene mutations. |
|---|
| RCB5667 |
| Y-MESO-12 |
| Comment | |
|---|
| Comment from the depositor | Human malignant pleural mesothelioma cell line. This cell line was established from the tumor tissue (epithelioid type MPM) of a patient. This cell line has a homozogous deletion of the NF2 gene. |
|---|
| RCB5668 |
| Y-MESO-14 |
| Comment | |
|---|
| Comment from the depositor | Human malignant pleural mesothelioma cell line. This cell line was established from the tumor tissue (biphasic MPM susp.) of a patient. This cell line has NF2, LATS2 and BAP1 gene mutations. |
|---|
| RCB5669 |
| Y-MESO-22 |
| Comment | |
|---|
| Comment from the depositor | Human malignant pleural mesothelioma cell line. This cell line was established from the tumor tissue (sarcomatoid MPM) of a patient. This cell line has a homozogous deletion of the NF2 gene. |
|---|
| RCB5670 |
| Y-MESO-25 |
| Comment | |
|---|
| Comment from the depositor | Human malignant pleural mesothelioma cell line. This cell line was established from the pleural effusion of epithelioid type MPM of a patient. This cell line has the NF2 gene mutation and the BAP gene homozygous deletion. |
|---|
| RCB5671 |
| Y-MESO-26B |
| Comment | |
|---|
| Comment from the depositor | Human malignant pleural mesothelioma cell line. This cell line was established from the pleural effusion of lymphohistiocytoid type MPM of a patient. This cell line has the NF2 gene homozygous deletion and the NF2 gene mutation. |
|---|
| RCB5672 |
| Y-MESO-27 |
| Comment | |
|---|
| Comment from the depositor | Human malignant pleural mesothelioma cell line. This cell line was established from the pleural effusion of epithelioid type MPM of a patient. |
|---|
| RCB5673 |
| Y-MESO-28 |
| Comment | |
|---|
| Comment from the depositor | Human malignant pleural mesothelioma cell line. This cell line was established from the pleural effusion of epithelioid type MPM of a patient. |
|---|
| RCB5674 |
| Y-MESO-29 |
| Comment | |
|---|
| Comment from the depositor | Human malignant pleural mesothelioma cell line. This cell line was established from the pleural effusion of epithelioid type MPM of a patient. |
|---|
| RCB5675 |
| Y-MESO-30 |
| Comment | |
|---|
| Comment from the depositor | Human malignant pleural mesothelioma cell line. The primary tumor shows epithelioid morphology. |
|---|
| RCB5676 |
| CHK-Q |
| Comment | |
|---|
| Comment from the depositor | A spontaneously immortalized cell line from primary culture of kidney tissue of Chinese hamsters bred as experimental animals. |
|---|
| RCB5677 |
| HepG2/8F_HS |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | A genetically modified human hepatoma cell line in which eight liver-specific transcription factor genes are introduced into human hepatoblastoma HepG2 (RCB1648) cells so as to be expressed by heat stimulation, and many liver functions are induced upon heat treatment (43°C, 30 minutes). |
|---|
| RCB5678 |
| P44D9(1)G4(1)B1#8 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | A hybridoma producing anti-CD271 antibody. |
|---|
| RCB5679 |
| P39G8(1)E1(1)C11#13 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | A hybridoma producing anti-CD271 antibody. |
|---|
| RCB5680 |
| Ba/F3/mIL-31RA/mOSMR |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Ba/F3/mIL-31RA/mOSMR cells were created by transducing mouse IL-31 receptor α (NR10) and mouse OSMR genes. Ba/F3/mIL-31RA/mOSMR cells have acquired mouse IL-31-dependent proliferative response. |
|---|
| RCB5681 |
| Astrocyte(AWT) |
| Comment | |
|---|
| Comment from the depositor | A cultured cell line derived from a strain of primary astrocyte cells isolated from C57BL/6 brain (cerebrum). |
|---|
| RCB5682 |
| Astrocyte(ASD) |
| Comment | |
|---|
| Comment from the depositor | A cultured cell line derived from a strain of primary astrocyte cells isolated from C57BL/6x129sv brain (cerebrum). |
|---|
| RCB5683 |
| ASPS-KY |
| Comment | |
|---|
| Comment from the depositor | Human cell line derived from alveolar soft part sarcoma. |
|---|
| RCB5684 |
| MDS92 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | This cell line was established from the bone marrow of a patient with MDS. MDS92 cells proliferate slowly in the presence of IL-3 and the whole cells consist of immature blastic cell fraction and dysplastic neutrophil-like or macrophage-like differentiated cell fractions. MDS92 is a parental cell line of MDS-L, MDS-L-2007 and MDS-LGF. After a long -term culture, most cells may differentiate into mature cells and proliferate no longer in some cases, while immature cells may begin to expand like as leukemic transition in the other cases. |
|---|
| RCB5685 |
| MDS-L |
| Comment | |
|---|
| Comment from the depositor | MDS-L cell line is a blastic subline originated from MDS92 which was established from the bone marrow of a patient with MDS. MDS-L cells proliferate in the presence of IL-3 and have lost maturing capacity unlike the parental MDS92. MDS-L is a parental cell line of MDS-L-2007 and MDS-LGF. |
|---|
| RCB5686 |
| MDS-L-2007 |
| Comment | |
|---|
| Comment from the depositor | MDS-L-2007 cell line is a blastic subline originated from MDS-L. (MDS-L cell line is a blastic subline derived from MDS92 which was established from the bone marrow of a patient with MDS.) MDS-L-2007 cells proliferate in the presence of IL-3 and have lost maturing capacity. |
|---|
| RCB5687 |
| MDS-LGF |
| Comment | |
|---|
| Comment from the depositor | MDS-LGF cell line is a blastic subline originated from MDS-L. (MDS-L cell line is a blastic subline derived from MDS92 which was established from the bone marrow of a patient with MDS.) MDS-LGF cells proliferate without IL-3 and have lost maturing capacity. |
|---|
| RCB5688 |
| ATG13 WT MEF |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Mouse embryonic fibroblasts. Wild type control for Atg13KO MEF. |
|---|
| RCB5689 |
| ATG13 KO MEF |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Atg13-knockout mouse embryonic fibroblast. |
|---|
| RCB5690 |
| ATG2A/B WT MEF |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Mouse embryonic fibroblasts. Wild type control for Atg2A/B-ＤKO MEF. |
|---|
| RCB5691 |
| ATG2A/B double KO MEF |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Mouse embryonic fibroblast in which Atg2A/B genes were deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5692 |
| ATGs Parental HeLa |
| Comment | |
|---|
| Comment from the depositor | Autophagy related gene knockout HeLa. |
|---|
| RCB5693 |
| ATG5 KO HeLa |
| Comment | |
|---|
| Comment from the depositor | HeLa in which ATG5 gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5694 |
| ATG3 KO HeLa |
| Comment | |
|---|
| Comment from the depositor | HeLa in which ATG3 gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5695 |
| ATG9A KO HeLa |
| Comment | |
|---|
| Comment from the depositor | HeLa in which ATG9A gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5696 |
| FIP200 KO HeLa |
| Comment | |
|---|
| Comment from the depositor | HeLa in which FIP200 gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5697 |
| ATG3 and FIP200 double KO HeLa |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HeLa in which ATG3 and FIP200 genes were deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5698 |
| ATG3 and ATG14L double KO HeLa |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HeLa in which ATG3 and ATG14L genes were deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5699 |
| ATG2A/B double KO HeLa |
| Comment | |
|---|
| Comment from the depositor | HeLa in which ATG2A/B genes were deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5700 |
| ATG2A KO HeLa |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HeLa in which ATG2A gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5701 |
| ATG2B KO HeLa |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HeLa in which ATG2B gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5702 |
| TMEM41A KO HeLa |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HeLa in which TMEM41A gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5703 |
| TMEM41B KO HeLa |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HeLa in which TMEM41B gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5704 |
| TMEM64 KO HeLa |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HeLa in which TMEM64 gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5705 |
| VMP1 KO HeLa |
| Comment | |
|---|
| Comment from the depositor | HeLa in which VMP1 gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5706 |
| SS-GFP-RFP-KDEL HeLa |
| Comment | |
|---|
| Comment from the depositor | HeLa stably expressing GFP-RFP-KDEL. |
|---|
| RCB5707 |
| Parental HEK293T of TMEM41B-KO and VMP1-KO |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Parental cells of TMEM41B-KO and VMP1-KO HEK293T cells. |
|---|
| RCB5708 |
| TMEM41B KO HEK293T |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HEK293T in which TMEM41B gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5709 |
| VMP1 KO HEK293T |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HEK293T in which VMP1 gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5710 |
| Y-MESO-37 |
| Comment | |
|---|
| Comment from the depositor | Human malignant peritoneal mesothelioma cell line. |
|---|
| RCB5711 |
| Y-MESO-43 |
| Comment | |
|---|
| Comment from the depositor | Human malignant pleural mesothelioma cell line, which was initially diagnosed biphasic type. |
|---|
| RCB5712 |
| Y-MESO-45 |
| Comment | |
|---|
| Comment from the depositor | Human malignant pleural mesothelioma cell line. |
|---|
| RCB5714 |
| Y-MESO-61 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Human malignant pleural mesothelioma cell line. Epithelioid type. |
|---|
| RCB5715 |
| Y-MESO-72 |
| Comment | |
|---|
| Comment from the depositor | Human malignant pleural mesothelioma cell line. Epithelioid type. |
|---|
| RCB5716 |
| Y-MESO-76 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Human malignant pleural mesothelioma cell line. Epithelioid type. |
|---|
| RCB5717 |
| HEK-Q37C-798 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | 293T cells (ATCC, CRL-3216) expressing QUEEN-37C, an ATP sensor fluorescent protein. |
|---|
| RCB5718 |
| HL-Q37C-393H8 |
| Comment | |
|---|
| Comment from the depositor | HeLa cells (RIKEN BRC, RCB0007) expressing QUEEN-37C, an ATP sensor fluorescent protein. |
|---|
| RCB5719 |
| HL-Q37C-701G7 |
| Comment | |
|---|
| Comment from the depositor | HeLa cells (RIKEN BRC, RCB0007) expressing QUEEN-37C, an ATP sensor fluorescent protein. |
|---|
| RCB5720 |
| HL-Q37C/GemRFP-801A1 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HeLa cells (RIKEN BRC, RCB0007) expressing QUEEN-37C, an ATP sensor fluorescent protein, and FUCCI (miRFP670-hGem110), a cell cycle marker. Derived from HL-Q37C-701G7. |
|---|
| RCB5721 |
| HL-Q37C/CdtRFP-800 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HeLa cells (RIKEN BRC, RCB0007) expressing QUEEN-37C, an ATP sensor fluorescent protein, and FUCCI (miRFP709-hGem110), a cell cycle marker. Derived from HL-Q37C-701G7. |
|---|
| RCB5722 |
| HT-Q37C-698 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HT-1080細胞 (JCRB, JCRB9113) expressing QUEEN-37C, an ATP sensor fluorescent protein. |
|---|
| RCB5723 |
| JUR-Q37C-752 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Jurkat cell (RIKEN BRC RCB3052) expressing QUEEN-37C, an ATP sensor fluorescent protein. |
|---|
| RCB5724 |
| MC-MitOMQ37C/NucQ37C-839 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MCF7 cell (RIKEN BRC RCB1904) expressing NLS-QUEEN-37C and TOMM-QUEEN-37C. NLS-QUEEN-37C is ATP sensor fluorescent protein QUEEN-37C with localization tag to nucleus. TOMM-QUEEN-37C is ATP sensor fluorescent protein QUEEN-37C with localization tag to outer membrane of mitochondria. |
|---|
| RCB5725 |
| MC-MitOMQ37C-830 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MCF7 cell (RIKEN BRC RCB1904) expressing TOMM-QUEEN-37C, an ATP sensor fluorescent protein with localization tago to outer membrane of mitochondria. |
|---|
| RCB5726 |
| MD-CdtSca-812 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK cells that stably express FUCCI cell cycle marker. |
|---|
| RCB5727 |
| MD-ActpHlu-210A |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing pH sensor fluorescent protein pHluorin with ITPKA, a localization tag to actin filament . |
|---|
| RCB5728 |
| MD-ActQ37C-185 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing ATP sensor fluorescent protein QUEEN-37C fused to ITPKA, a localization tag to actin filament . |
|---|
| RCB5729 |
| MD-ActQ7u-187 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing ATP sensor fluorescent protein QUEEN-7µ fused to ITPKA, a localization tag to actin filament. Since QUEEN-7µ has high affinity to ATP, QUEEN-7µ is always in the ATP-bound state in physiological ATP concentration. For reference of QUEEN-37C ratio. |
|---|
| RCB5730 |
| MD-Sca-841E6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing fluorescent protein mScarlet. |
|---|
| RCB5731 |
| MD-NucpHlu-723A9 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing pH sensor fluorescent protein pHluorin with nuclear localiztaion tag sequence (NLS). |
|---|
| RCB5732 |
| MD-NucQ37C-631H |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing ATP sensor fluorescent protein QUEEN-37C with nuclear localiztaion tag sequence (NLS). |
|---|
| RCB5733 |
| MD-NucQ37C/Q37C-645C1 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)strongly expressing ATP sensor fluorescent protein QUEEN-37C with nuclear localiztaion tag sequence (NLS), and weakly expressing ATP sensor fluorescent protein QUEEN-37C in cytosol. |
|---|
| RCB5734 |
| MD-pHlu/NuciRFP-658 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing pH sensor fluorescent protein pHluorin, and fluorescent protein iRFP fused to nuclear localization tag H2B. |
|---|
| RCB5735 |
| MD-pHlu/pHRed-674 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing pH sensor fluorescent protein pHluorin, and pH sensor fluorescent protein pHRed. |
|---|
| RCB5736 |
| MD-pHlu-209A |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing pH sensor fluorescent protein pHluorin. |
|---|
| RCB5737 |
| MD-Q37C-433 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing ATP sensor fluorescent protein QUEEN-37C. |
|---|
| RCB5738 |
| MD-Q37C-192A1 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing ATP sensor fluorescent protein QUEEN-37C. |
|---|
| RCB5739 |
| MD-Q37C-691D |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing ATP sensor fluorescent protein QUEEN-37C. Expression is low compared to MD-Q37C-192A1. |
|---|
| RCB5740 |
| MD-Q37C/GemRFP-795G1 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing QUEEN-37C, an ATP sensor fluorescent protein, and FUCCI (miRFP670-hGem110), a cell cycle marker. |
|---|
| RCB5741 |
| MD-Q37C/GemRFP/CdtSca-811E4 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing ATP sensor fluorescent protein QUEEN-37C and cell cycle markers FUCCI (miRFP670-hGem110) and FUCCI (mScarlet(i)-hCdt100). |
|---|
| RCB5742 |
| MD-Q37C/CdtRFP-799 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing ATP sensor fluorescent protein QUEEN-37C and cell cycle marker FUCCI (miRFP709-hCdt100). |
|---|
| RCB5743 |
| MD-Q37C/Sca-840D11 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing ATP sensor fluorescent protein QUEEN-37C and fluorescent protein mScarlet. |
|---|
| RCB5744 |
| MD-Q37C/NucSca-792G11 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing ATP sensor fluorescent protein QUEEN-37C and fluorescent protein mScarlet with nuclear localization signal. |
|---|
| RCB5745 |
| MD-Q37C/NucpHlu-722H7 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing ATP sensor fluorescent protein QUEEN-37C and fluorescent pH sensor protein pHluorin with nuclear localization tag sequence. |
|---|
| RCB5746 |
| MD-Q37C/pHRed-667B6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing ATP sensor fluorescent protein QUEEN-37C and fluorescent pH sensor protein pHRed. |
|---|
| RCB5747 |
| MD-MitOMQ37C-188 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | MDCK (ATCC, CCL-34)expressing ATP sensor fluorescent protein QUEEN-37C with localization signal of TOMM20 for mitochondria outer membrane localization. |
|---|
| RCB5748 |
| E14-NucQ37C-653 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | ES cells (RIKEN BRC, AES0135) expressing ATP sensor fluorescent protein QUEEN-37C with nucleus localization tag sequence. |
|---|
| RCB5749 |
| E14-pHlu-234F11 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | ES cells (RIKEN BRC, AES0135) expressing pH sensor fluorescent protein pHluorin. |
|---|
| RCB5750 |
| E14-Q37C-233B6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | ES cells (RIKEN BRC, AES0135) expressing ATP sensor fluorescent protein QUEEN-37C. |
|---|
| RCB5751 |
| EB-Q37C-810C5 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | ES cells (RIKEN BRC, AES0151) expressing ATP sensor fluorescent protein QUEEN-37C. |
|---|
| RCB5752 |
| EB-Q37C/iRFP-842S |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | ES cells (RIKEN BRC, AES0151) expressing ATP sensor fluorescent protein QUEEN-37C. |
|---|
| RCB5753 |
| EB-Q37C/Sca-843S |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | ES cells (RIKEN BRC, AES0151) expressing ATP sensor fluorescent protein QUEEN-37C and fluorescent protein mScarlet. |
|---|
| RCB5754 |
| PC-ActQ37C-167B5 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | PC12 cells (RIKEN BRC, RCB0009) expressing ATP sensor fluorescent protein QUEEN-37C fused to ITPKA, a localization tag to actin filament . |
|---|
| RCB5755 |
| PC-ActQ7u-166G3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | PC12 cells (RIKEN BRC, RCB0009) expressing ATP sensor fluorescent protein QUEEN-7µ fused to ITPKA, a localization tag to actin filament. Since QUEEN-7µ has high affinity to ATP, QUEEN-7µ is always in the ATP-bound state in physiological ATP concentration. For reference of QUEEN-37C ratio. |
|---|
| RCB5756 |
| PC-Q7u-114C |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | PC12 cells (RIKEN BRC, RCB0009) expressing ATP sensor fluorescent protein QUEEN-7µ. Since QUEEN-7µ has high affinity to ATP, QUEEN-7µ is always in the ATP-bound state in physiological ATP concentration. For reference of QUEEN-37C ratio. |
|---|
| RCB5757 |
| PC-Q37C-165F1 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | PC12 cells (RIKEN BRC, RCB0009) expressing ATP sensor fluorescent protein QUEEN-37C. |
|---|
| RCB5759 |
| TD-NucQ37C-827 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | T47D cells (ATCC HTB-133) expressing ATP sensor fluorescent protein QUEEN-37C with nucleus localization tag sequence. |
|---|
| RCB5760 |
| TD-NucQ37C/Q37C-845 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | T47D cells (ATCC HTB-133) expressing ATP sensor fluorescent protein QUEEN-37C with nucleus localization tag sequence and QUEEN-37C without localization. |
|---|
| RCB5761 |
| TD-Q37C-826 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | T47D cells (ATCC HTB-133) expressing ATP sensor fluorescent protein QUEEN-37C. |
|---|
| RCB5924 |
| MELS |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Anorectal melanoma cell line derived from a primary human rectal tumor. It is the world's first melanoma cell line derived from the rectum. |
|---|
| RCB5925 |
| 8C |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2.
|
|---|
| Comment from the depositor | 8C cells were a clonal cell line derived from a feline kidney fibroblast line, CCC, and were transformed by Moloney murine sarcoma virus. |
|---|
| RCB5926 |
| 8C/HTLV-1_2M |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | 8C/HTLV-1_2M cells were HTLV-1 producing cells after cocultivation of 8C cells with lethally irradiated HTLV-1-positive human T-cell line (ATL-2M). Cell-free HTLV-1 prepared from 8C/HTLV-1_2M cells is highly transmissible. |
|---|
| RCB5927 |
| 8C/HTLV-1_MEL5 |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | 8C/HTLV-1MEL5 cells were HTLV-1 producing cells after cocultivation of 8C cells with lethally irradiated HTLV-1-positive human T-cell line (SI-5). |
|---|
| RCB5928 |
| PG-4/HTLV-1_MT-2 |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | PG-4 cells were derived from cat brain G355 cells by transformation with Moloney murine sarcoma virus. PG-4/HTLV-1MT-2 cells were HTLV-1 producing cells after cocultivation of PG-4 cells with lethally irradiated HTLV-1-positive Rabbit T-cell line (Ra-1). |
|---|
| RCB5929 |
| HOS/HTLV-1_MEL5 |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | HOS/HTLV-1MEL5 cells were HTLV-1 producing cells after cocultivation of HOS cells with lethally irradiated HTLV-1-positive human T-cell line (SI-5). |
|---|
| RCB5930 |
| S+L-HOS/HTLV-1_MEL5 |
| Comment | BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
|---|
| Comment from the depositor | S+L-HOS/HTLV-1MEL5 cells were HTLV-1 producing cells after cocultivation of Moloney murine sarcoma virus-positive S+L-HOS cells with lethally irradiated HTLV-1-positive human T-cell line (SI-5). |
|---|
| RCB5931 |
| 50A2 |
| Comment | |
|---|
| Comment from the depositor | Anti-ETNPPL antibody (for immunoprecipitation) producing hybridoma. |
|---|
| RCB5932 |
| 63B2 |
| Comment | |
|---|
| Comment from the depositor | Anti-ETNPPL antibody (for immunohistochemistry) producing hybridoma. |
|---|
| RCB5933 |
| 94A3 |
| Comment | |
|---|
| Comment from the depositor | Anti-ETNPPL antibody (for western blotting) producing hybridoma. |
|---|
| RCB5934 |
| KOG-1 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | KOG-1, was established from ascites fuids isolated from a Japanese woman with pemetrexed-resistant malignant peritoneal mesothelioma. |
|---|
| RCB5935 |
| LLC/luc |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | A mouse lung cancer cell line that stably retains the firefly luciferase gene. |
|---|
| RCB5936 |
| MDA-MB-231/luc |
| Comment | |
|---|
| Comment from the depositor | A human breast cancer cell line that stably retains the firefly luciferase gene. |
|---|
| RCB5937 |
| PC-3/luc |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | A human prostate cancer cell line that stably retains the firefly luciferase gene. |
|---|
| RCB5938 |
| 786-O/luc |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | A human renal cell adenocarcinoma cell line that stably retains the firefly luciferase gene. |
|---|
| RCB5939 |
| 4T1/luc |
| Comment | |
|---|
| Comment from the depositor | A murine breast cancer cell line (derived from the mammary gland tissue of a mouse BALB/c strain) that stably retains the firefly luciferase gene. |
|---|
| RCB5940 |
| MCF7/mKO2-luc2 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Human breast cancer cell line stably retaining Kusabira Orange2 (mKO2) fluorescent protein and firefly luciferase gene |
|---|
| RCB5941 |
| LLC/mKO2-Rluc8.6 |
| Comment | |
|---|
| Comment from the depositor | Mouse lung cancer cell line stably retaining Kusabira Orange2 (mKO2) fluorescent protein and firefly luciferase gene. |
|---|
| RCB5942 |
| HEK293/κB-Fluc |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | A human embryonic kidney cell line that expresses the firefly luciferase gene in an NF-kB activity-dependent manner. |
|---|
| RCB5943 |
| LM8/luc |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | High lung metastasis cell line (isolated from C3H mouse Dan osteosarcoma cell line) expressing firefly luciferase in an NF-kB activity-dependent manner. |
|---|
| RCB5944 |
| LM8-L |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Low lung metastasis subline isolated from LM8/luc tumors by in vivo bioluminescence imaging. |
|---|
| RCB5945 |
| LM8-H |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Highly metastatic lung subline isolated from lung metastases that were incidentally detected after orthotopic transplantation of LM8-L. |
|---|
| RCB5946 |
| LM8‐L/CYGB‐OE |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | LM8-L cells overexpressing Cygb protein. |
|---|
| RCB5947 |
| LM8‐H/Cygb‐KO |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | LM8-H cells with Cygb gene knockout using CRISPR-Cas9 system. |
|---|
| RCB5948 |
| LM8‐H/Lef1‐KO |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | LM8-H cells with Lef-1 gene knockout using CRISPR-Cas9 system. |
|---|
| RCB5950 |
| 2C10 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | 2C10 produces monoclonal antibody which binds to dsDNA, but not to ssDNA. |
|---|
| RCB5951 |
| WB-6 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | WB-6 produces monoclonal antibody which is cross-reactive to cardiolipin-beta2-glycoprotein I, ssDNA and dsDNA. |
|---|
| RCB5953 |
| HeLa.S3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | |
|---|
| RCB5955 |
| HeLa/mClover3-mAID-Lem2 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | A cell line in which the Lem2 gene in the genomic DNA is replaced with the mClover3-mAID-Lem2 gene using HeLa cells as parent cells by genome editing technology using CRISPR/Cas9. All genomic Lem2 genes have been replaced with the mClover3-mAID-Lem2 sequence. The addition of 0.5 mM indole-3-acetic acid (IAA) to the cell culture medium can degrade and eliminate intracellular Lem2 in 30-60 minutes. The degree of degradation can be confirmed by fluorescence microscopy for mClover or western blotting. |
|---|
| RCB5956 |
| hybridoma 1-H3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | A hybridoma that produes mouse anti-human MFG-E8 mAb. |
|---|
| RCB5957 |
| hybridoma 2-8E4A |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | A hybridoma that produces hamster anti-human MFG-E8 mAb. |
|---|
| RCB5958 |
| hybridoma 4-C11 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | A hybridoma that produces anti-mouse ATP11A mAb. |
|---|
| RCB5959 |
| hybridoma Jo2 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | A hybridoma that produces hamster anti-mouse Fas (CD95). |
|---|
| RCB5960 |
| 1G2C1(DrPiwi1) |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | DrPiwi1 protein (Dugesia ryukyuensis) specific monoclonal antibody producing cells . |
|---|
| RCB5961 |
| 3G4G12(DrPiwi2) |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | DrPiwi2 protein (Dugesia ryukyuensis) specific monoclonal antibody producing cells. |
|---|
| RCB5962 |
| HUDEP-2-CY1 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | A derivative cell line of HUDEP-2 in which thalassemia mutations are introduced, i.e., homozygous for the HBB IVSI-110 (G>A) mutation (HGVS name; HBB:c.93-21G>A). |
|---|
| RCB5963 |
| HUDEP-2-CY2 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | A derivative cell line of HUDEP-2 in which thalassemia mutations are introduced, i.e., homozygous for the HBB IVSI-110 (G>A) mutation (HGVS name; HBB:c.93-21G>A). |
|---|
| RCB5964 |
| S-HUDEP2 |
| Comment | |
|---|
| Comment from the depositor | A derivative cell line of HUDEP-2 (RCB4557) carrying a biallelic SCD (sickle cell disease) mutation. |
|---|
| RCB5965 |
| WIPI1 KO HEK293T |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HEK293T in which WIPI1 gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5966 |
| WIPI2 KO HEK293T |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HEK293T in which WIPI2 gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5967 |
| WIPI3 KO HEK293T |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HEK293T in which WIPI3 gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5968 |
| WIPI4 KO HEK293T |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HEK293T in which WIPI4 gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5969 |
| WIPI1 and WIPI2 double KO HEK293T |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HEK293T in which WIPI1 and WIPI2 gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5970 |
| WIPI3 and WIPI4 double KO HEK293T |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HEK293T in which WIPI3 and WIPI4 gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5971 |
| WIPI1-4 quadruple KO HEK293T |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | HEK293T in which WIPI1–4 gene was deleted using CRISPR/Cas9-mediated genome editing. |
|---|
| RCB5972 |
| HepG2-AD13 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | This cell line features a stable clone cell for the antioxidant responsive element (ARE) reporter assay integrated with firefly luciferase. |
|---|
| RCB5973 |
| TKO_NIH3T3 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Three genes (Axl, Tyro3, Gas6) involved in efferocytosis were knocked out using CRISPR/Cas9 technology. The mutant cell line lost the ability to engulf apoptotic cells. |
|---|
| RCB5974 |
| CJ-4B4 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma producing a monoclonal antibody against Campylobacter jejuni. |
|---|
| RCB5975 |
| TDH-3D2 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma producing a monoclonal antibody against thermostabel direct hemolysin produced by Vibrio parahaemolyticus. |
|---|
| RCB5976 |
| TDH-4E5 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | Hybridoma producing a monoclonal antibody against thermostabel direct hemolysin produced by Vibrio parahaemolyticus. |
|---|
| RCB5977 |
| HCT116 CERT1 KO |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | A mutant cell line was developed in the human colon carcinoma-derived HCT 116 cell line, in which the CERT1 gene encoding the ceramide transport protein was disrupted using the CRISPR/Cas9 technology. |
|---|
| RCB5978 |
| HCT116 CERT1 KO/mVenus-CERT WT |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | The parental HCT116 CERT1 KO is a CERT1-disrupted derivative of the HCT 116 cell line, derived from human colon cancer. HCT116 CERT1 KO/mVenus-CERT WT cells represent a batch of HCT116 CERT1 KO-derived cells that stably express mVenus-fused human CERT (wild-type) using the retroviral vector pMXs-IB. This batch consists of a mixture of blasticidin S-resistant cells that were not cloned. |
|---|
| RCB5979 |
| HCT116 CERT1 KO/mVenus-CERT S132L |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | The parental HCT116 CERT1 KO is a CERT1-disrupted derivative of the HCT 116 cell line, derived from human colon cancer. HCT116 CERT1 KO/mVenus-CERT S132L cells represent a batch of HCT116 CERT1 KO-derived cells that stably express mVenus-fused human CERT S132L mutant using the retroviral vector pMXs-IB. This batch consists of a mixture of blasticidin S-resistant cells that were not cloned. |
|---|
| RCB5980 |
| HCT116 CERT1 KO/mVenus-CERT S135P |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | The parental HCT116 CERT1 KO is a CERT1-disrupted derivative of the HCT 116 cell line, derived from human colon cancer. HCT116 CERT1 KO/mVenus-CERT S135P cells represent a batch of HCT116 CERT1 KO-derived cells that stably express mVenus-fused human CERT S135P mutant using the retroviral vector pMXs-IB. This batch consists of a mixture of blasticidin S-resistant cells that were not cloned. |
|---|
| RCB5981 |
| HCT116 CERT1 KO/mVenus-CERT G243R |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | The parental HCT116 CERT1 KO is a CERT1-disrupted derivative of the HCT 116 cell line, derived from human colon cancer. HCT116 CERT1 KO/mVenus-CERT G243R cells represent a batch of HCT116 CERT1 KO-derived cells that stably express mVenus-fused human CERT G243R mutant using the retroviral vector pMXs-IB. This batch consists of a mixture of blasticidin S-resistant cells that were not cloned. |
|---|
| RCB5982 |
| HCT116 CERT1 KO/mVenus-CERT dupAA |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | The parental HCT116 CERT1 KO is a CERT1-disrupted derivative of the HCT 116 cell line, derived from human colon cancer. HCT116 CERT1 KO/mVenus-CERT dupAA cells represent a batch of HCT116 CERT1 KO-derived cells that stably express mVenus-fused human CERT dupAA-frameshift mutant using the retroviral vector pMXs-IB. This batch consists of a mixture of blasticidin S-resistant cells that were not cloned. |
|---|
| RCB5983 |
| sHUDEP-2 |
| Comment | |
|---|
| Comment from the depositor | A derivative cell line of HUDEP-2 (RCB4557) with the genetic mutation in β globin that causes sickle cell anemia. |
|---|
| RCB5984 |
| TK-ST |
| Comment | CITES. Currently not ready. Require import and export permits according to the Convention on International Trade in Endangered Species (CITES). |
|---|
| Comment from the depositor | The cells are infinitely dividing, immortalized by introducing the SV40T antigen gene and the human TERT gene into primary cultured cells derived from the kidney of the common bottlenose dolphin. |
|---|
| RCB5986 |
| AK9 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | This clone produces anti-mouse desmoglein 3 (Dsg3) IgG antibody. |
|---|
| RCB5987 |
| AK18 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | This clone produces anti-mouse desmoglein 3 (Dsg3) IgG antibody. |
|---|
| RCB5988 |
| AK23 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | This clone produces pathogenic anti-mouse desmoglein 3 (Dsg3) IgG antibody that induces acantholysis in vivo. |
|---|
| RCB5989 |
| AK7 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | This clone produces anti-mouse desmoglein 3 (Dsg3) IgG antibody. |
|---|
| RCB5990 |
| AK15 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | This clone produces anti-mouse desmoglein 3 (Dsg3) IgG antibody. |
|---|
| RCB5991 |
| AK19 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | This clone produces anti-mouse desmoglein 3 (Dsg3) IgG antibody. |
|---|
| RCB5992 |
| AK20 |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | This clone produces anti-mouse desmoglein 3 (Dsg3) IgG antibody. |
|---|
| RCB6008 |
| FUHEN |
| Comment | Currently not ready. |
|---|
| Comment from the depositor | This is a non-adherent CD41-positive amphibian thrombocyte cell line established from the long-term bone marrow culture of tree frogs. |
|---|